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Malaria and tuberculosis are listed among the major infectious diseases. They are responsible 
for severe morbidity and mortality especially in resource-poor settings where control 
interventions are inaccessible, unaffordable and plagued by widespread resistance. According 
to current estimates, malaria afflicts over 40% of the world’s population and claims the lives 
of 1-3 million annually. The epidemiology of tuberculosis is just as grim. About one third of 
the world population is reported to be infected with Mycobacterium tuberculosis and it is 
responsible for 2-3 million deaths annually. Of particular interest to this project, is the fact 
that natural products have always been on the frontline in the battle against these diseases, 
that is, most of the clinically used drugs in antimalarial and antitubercular chemotherapy are 
of natural product-origin. In this project we therefore focussed on the design, synthesis, 
characterization and biological evaluation of novel antimalarial and antitubercular agents 
obtained by synthetically hybridizing and decorating scaffolds based on natural products or 
derivatives - with a history in the aforementioned disease models. Scaffolds selected include 
the thiolactone ring system, a key intermediate of the natural product thiolactomycin, the 
non-peptidic natural product isatin and the chalcone scaffold. In this way a series of hybrids 
were constructed which can be subdivided into three main groups: (i) thiolactone-isatin 
hybrids, (ii) β-amino alcohol thiolactone-chalcone and isatin-chalcone hybrids, and (iii) 
dihydroartemisinin-isatin, dihydroartemisinin-chalcones and other miscellaneous hybrids. 
These were evaluated for antiplasmodial activity against the chloroquine resistant (W2) and 
chloroquine sensitive (D10) strains of Plasmodium falciparum as well as for inhibitory 
activity against cysteine proteases. Evaluation of antimycobacterial activity of the 
synthesized compounds against the drug sensitive H37Rv strain of M. tuberculosis was also 
undertaken. 
(i) For the first group of hybrids we used the C-4 hydroxyl group of the thiolactone ring as a 
handle for functionalization by attaching it via a variable, non-hydrolyzable alkyl linker to 
the isatin scaffold. Most striking, is the operational simplicity of the synthesis methodology 
employed and how it led to the discovery of a novel tetracyclic ring system. Identified from 
the latter is the compound 3.8p which is the most active antimalarial from this series with an 
IC50 of 6.92 µM in the W2 strain. Some of the hybrids (3.7 and 3.8) were more active than 
the monomers and the parent drug thiolactomycin, thus demonstrating the potential of 
hybridization as a drug discovery tool. Antimalarial structure activity relationships for the 











the need for increased lipophilicity. Although the antitubercular activity of the hybrids was 
inferior compared to the control drugs, a number of advanced intermediates were identified 
which displayed promising activity against both fast growing and slow-growing, persistent 
forms of M. tuberculosis.  
 
(ii) The second group of hybrids consisted of a 36-member library obtained by the covalent 
linkage of methoxylated chalcones with the thiolactone ring and the isatin scaffold. 
Incorporated in their design is the β-amino alcohol moiety, a known bioactiphore. For the 
synthesis of these hybrids we employed the copper-catalyzed Huisgen 1,3-dipolar 
cycloaddition reaction (also know as “click” chemistry) which in addition to expediting 
structure activity relationship studies yielded the 1,2,3-triazole ring system. The 
antiplasmodial results showed that the thiolactone-chalcones, with IC50s ranging from 0.68 to 
6.08 µM, were more active against the W2 strain than the isatin-chalcones (IC50 = 2.09 - 
14.90 µM). More so, structure activity relationships delineated for the former indicated the 
preference for triOMe substitution on ring A of the chalcone scaffold. The most active 
compound for this series 4.14f [IC50 = 0.68 µM (W2)] is 10-fold less active than chloroquine 
but has a greater efficacy than the parent natural product thiolactomycin. Results obtained for 
cysteine protease activity showed that the isatin-chalcone hybrids inhibited falcipain-2 
activity, whereas the thiolactone-chalcone hybrids were devoid of enzyme inhibitory activity. 
With regard to antitubercular activity, the advanced intermediates were more active than the 
hybrid constructs. The most promising antitubercular agent identified is the acetylenic 
chalcone 4.10f (MIC = 13.1 µM) which is 2-fold more active than one of the controls, 
moxifloxacin (MIC = 31.1 µM) against the slow-growing persistent forms of M. tuberculosis.  
 
(iii) The final group of compounds is a limited series of semi-synthetic artemisinin analogues 
obtained by hybridizing the first generation analogue, dihydroartemisinin with previously 
mentioned scaffolds (isatin, chalcones, thiolactone) and other biologically relevant scaffolds 
such as the 4-aminoquinoline unit and azidovudine (AZT). As with the previous series we 
utilized the ‘click’ reaction to effect the synthesis of these hybrids. The most active 
compound identified is the intermediate 5.4 [IC50 = 6.13 nM (W2)] which is more active than 
the parent natural product artemisinin [IC50 = 10.84 nM (W2)], 16 times more active than 
chloroquine and 2-times less active than dihydroartemisinin. The lack of antitubercular 
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1.1. History of Malaria 
The origin of malaria has been traced to ancient times and the devastating effect it had and is 
still having on mankind is well documented.
1,2
 Ancient Italians coined the term “mal’aria” 
meaning “bad air” in reference to a substance that arose from swamps and marshes and 
which, at the time, was believed to be the cause of malaria. A landmark event in the history 
of malaria is French pathologist Charles Alphonse Laveran’s discovery in 1880 of the 
plasmodial parasite as the causative agent.
1
 This was followed by the groundbreaking work 
of malariologists Ronald Ross and Giovanni Batissta Grassi who identified the Anopheles 
mosquito as the vector of malaria.
3
 These discoveries, although marked by feuds and 
scepticism at their revelation, have made a significant contribution to our current 
understanding of the disease and the development of methods to combat it. 
 
A recent milestone which has become pivotal in the fight against malaria is the completion of 
the Plasmodium falciparum genome sequence by Gardner and co-workers.
4
 The genomic 
data allowed a better understanding of the biochemistry, cellular and molecular biology of 
the parasite, revealed new targets for drug development
4
 and shed light on the molecular 




1.2. Global Distribution and Burden of Malaria 
Malaria is endemic to over 90 countries and affects about 40% of the world’s population. It is 
distributed throughout tropical areas such as sub-Saharan Africa, South East Asia, the Pacific 
islands and Central and South America (fig. 1.1).
6
 Moreover, the disease is reported to have 
spread to regions previously declared malaria-free such as Central Asia and Eastern Europe
7a
 
with clinical cases in the U.S.A, reported to average 1300 per year.
7b
 Over 500 million 
malaria related clinical cases are reported each year, of which 90% are confined to sub-
Saharan Africa.
8
 The severity of the disease is further highlighted by the fact that 2-3 million 
malaria related deaths are reported annually, with most of the casualties being children. 
According to the World Health Organization (WHO) estimates, one child under the age of 5 
















The strong and treacherous link between malaria and poverty has been well documented.
9
 
Indeed, one of the challenges faced by people in resource-poor settings is the difficulty of 
gaining access to health care facilities. This causes them to miss out on an early diagnosis 






Figure 1.1: Global distribution of malaria, 20069c 
 
1.3. Life Cycle of the Malaria Parasite 
The causative agent of malaria is a unicellular, protozoan parasite of the genus Plasmodium. 
It is transmitted from one human host to another through the bite of an infected female 
Anopheles mosquito. There exist 156 species of Plasmodium but only four are known to 
infect humans, that is, P. vivax, P. ovale, P. malariae and P. falciparum of which the latter is 































Figure 1.2: The malaria life cycle11 
 
The malaria parasite reproduces sexually in the mosquito vector and asexually in the human 
host. When an infected female Anopheles mosquito bites a human (1, fig. 1.2) wormlike, 
one-celled parasites called sporozoites are transferred to the bloodstream. These sporozoites 
start the asymptomatic, exo-erythrocytic cycle (A, fig. 1.2) by migrating to the liver of the 
human host where they invade the hepatocytes and undergo rapid multiplication and 
development (2-3, fig. 1.2). After about a week, the hepatocytes rupture and merozoites are 
released into the bloodstream where they infect red blood cells (4-5, fig. 1.2). Recurring 
infection observed with the human malarias P. vivax and P. ovale is attributed to hypnozites, 
a form of the parasite that remains dormant in the hepatocytes. 
 
The erythrocytic parasites (B, fig. 1.2) develop over 48 hours (for P. falciparum, P. vivax and 
P. ovale and 72 hours for P. malariae) from small ring forms to larger more metabolically 
active trophozoites and then to multinucleated schizonts (6, fig. 1.2). The completion of the 
erythrocytic cycle is marked by the rupturing of the schizont-containing erythrocyte and 














manifestation of the disease which is characterized by high fever, convulsions, chills and 
anemia. In the case of severe malaria delirium, metabolic acidosis and multi-organ systems 
failure may occur which, in the absence of timely medical intervention, may result in coma 
and death. 
 
When the erythrocyte ruptures (6, fig. 1.2), it releases merozoites which can infect other 
erythrocytes to generate a new asexual cycle. The parasite proliferates continuously in this 
manner. Some parasites develop into gametocytes (7, fig. 1.2) which can be taken up by 
another mosquito (8, fig. 1.2). In the stomach of the mosquito, the gametocytes develop into 
male and female gametes (C, fig. 1.2) which upon feritilization, produces an oocyst (11, fig. 
1.2). The mature oocyst ruptures to release infectious sporozoites, which migrates to the 
mosquito’s salivary glands (12, fig. 1.2) ready for the next bloodmeal. 
 
1.4. Combating Malaria 
The complexity of malaria as an infectious parasitic disease requires the use of multiple 
approaches for its control. Preventative and curative measures currently employed are 
summarized below:  
(i) Vector control is primarily aimed at reducing the mosquito population density and 
therefore the risk of exposure to infectious mosquitoes. Traditional approaches to 
make residences ‘mosquito-proof’ entail the use of screens and indoor residual 
spraying with pyrethroids, permethrin or deltamethrin. Other personal protective 
measures include the application of insect repellent-containing diethyl toluamide 
(DEET) on exposed skin
6,12a
 and the use of insecticide-treated bed nets (ITNs). 
The efficacy of vector control interventions is hampered by the inconsistent 




(ii) Chemoprophylaxis is a preventative method and has the primary goal of 
prevention and/or suppression of clinical malaria. Antimalarials use in prophylatic 









 These chemprophylatic regimens are 
reported to provide between 75% and 95% protection and are thus not totally 
effective.
12a
 As with vector control, chemoprophylaxis is threatened by resistance. 
(iii) The severity of falciparum malaria requires early diagnosis and the initiation of 














Unfortunately because of this general manifestation the misdiagnosis of malaria is 
common among travellers returning from malaria endemic regions and those 
residing in these regions. 
(iv) Chemotherapy refers to the drug treatment of clinical cases and will be elaborated 
on in section 1.4.1.  
 
1.4.1. Antimalarial Chemotheraphy 
The erythrocytic cycle is the major life cycle target for antimalarials.
14
 Also, there is a 
limited arsenal of antimalarial drugs each with their own set of liabilities. These include 





Several factors need to be considered when choosing an effective and safe antimalarial 
regimen. The species of the malaria parasite and the site of contraction of infection, to 
ascertain the likely pattern of resistance, are important initial requirements.
16
 Effective 
antimalarial treatment also requires an understanding of the clinical manifestations of the 
disease, the different categories of patients and the immune status of the host.
17
 For example, 
treatment of uncomplicated malaria which is commonly found in semi-immune adults differs 
from that for severe malaria which is characterized by anemia and cerebral malaria. Indeed, 
in tropical Africa, people who have acquired partial immunity require less supportive 
antimalarial therapy even with severe parasitaemia.
18
 Immunocompromised patients such as 
pregnant women and young children aged under 5 years, who are at risk of contracting severe 
malaria, require special treatment.
19 
It seems then that there is a need for personalized 
medication in antimalarial chemotherapy which the current arsenal cannot sufficiently 













1.4.1.1. Classification of Antimalarial Drugs 
Antimalarials can be classified according to their structure, life-cycle’s stage specificity and 
their mechanism of action. The commonly used antimalarials (Fig.1.3) can be structurally 
subdivided into five classes of compounds.
6
  
(a) quinolines and aryl aminoalcohols: quinine 1.1, primaquine 1.2, chloroquine 1.3,  
      mefloquine 1.4, lumenfantrine 1.5, halofantrine 1.6, tafenoquine 1.7,  
(b) antifolates: pyrimethamine 1.8, sulfadoxine 1.9, dapsone 1.10, proguanil 1.11,  
      chlorproguanil 1.12,  
(c) hydroxynaphthaquinones: atovaquone 1.13, 
(d) artemisinin derivatives: artemisinin 1.14, dihydroartemisinin 1.15, artemether 1.16,  
     arteether, 1.17, artesunate 1.18, 
(e) antibiotics: tetracycline 1.19, doxycycline 1.20, clindamycin 1.21.  
 
Another method of classifying antimalarials, as mentioned above, is based on their life-
cycle’s stage specificity (fig. 1.2). A blood schizontocide for example, targets the 
erythrocytic stage. Tissue schizontocides kill the liver stage and therefore prevent relapse of 
malaria. It is now widely accepted that P. falciparum is not characterized by recrudescence, 
thus treatment with a blood schizontocidal suffices. Clearance of parasitaemia caused by P. 
vivax and P ovale requires both blood schizontocides and tissue schizontocides; a treatment 
method known as a ‘radical cure’ of malaria.
20
 Gametocidal drugs kill off the non-pathogenic 
gametes. The latter are essential for transmission between hosts and also contributes to the 




1.4.1.2. Clinically Established Antimalarial Drugs 
In this section, some clinically established antimalarial regimens are briefly introduced. The 
emphasis is on their stage or life cycle specificity and their use in curative and/or 
prophylactic therapy. Also covered is their side-effect profiles and other limitations; all of 
which is to demonstrate the constant need for safer, more effective and affordable drugs. A 










































R= H, Dihydroartemisinin 1.15
R = CH3, Artemether 1.16
R = CH2CH3, Arteether 1.17






















































































R = H, Proguanil 1.11
R = Cl, Chlorproguanil 1.12
O
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 is a blood schizontocide with a side-effect profile that includes dysphoria, 
tinnitus and high-tone deafness.
16
 In spite of this it remains the drug of choice and is 
administered intravenously in the treatment of severe malaria. For areas marked by quinine 
resistance the drug is partnered with slow-acting antibiotics such as clindamycin 1.21, 
tetracycline 1.19 or the structurally related doxycycline 1.20. The latter two antibiotics, 
however, are contraindicated in children and pregnant women.
21
 Primaquine 1.2 and 
tafenoquine 1.7 belong to the class of 8-aminoquinolines. The aforementioned drug is an 
effective tissue schizontocide. It kills off P. vivax and P.ovale hypnozoites
16
 but is ineffective 
as a blood schizontocide and thus not ideal for treating P. falciparum infections. Side-effects 
associated with the use of 1.2 include methaemoglobin (MetHb) toxicity and haemolysis in 
glucose-6-phosphate dehydrogenase deficient individuals.
22
 The congener 1.7 is reported to 




The 4-aminoquinoline chloroquine 1.3 is a blood schizontocide which acts on the trophozoite 
stage of the parasite. Although hampered by resistance, most countries in Africa still use it as 
a first line drug.
23
 Mefloquine 1.4, another blood schizontocide is used in the oral treatment 
of uncomplicated malaria and is active against various resistant strains of Plasmodium. Its 
use as a prophylactic stems from its long half-life of 14-21 days.
21
 However, being 
structurally related to quinine it has been implicated in cross-resistance and is also associated 
with various neuropsychiatric side-effects.
24
 Halofantrine 1.6, like mefloquine is an 
expensive drug which is effective in treating chloroquine resistant falciparum malaria, but 
there are doubts about its safety. Common side effects such as abdominal pain, diarrhoea, 
purists and skin rash have been reported.
16
 The combination drug Fansidar
® 
represents a 
cheap first-line treatment in most African countries. It consists of two blood schizontocides 
pyrimethamine 1.8 and sulfadoxine 1.9 and is used for the treatment of uncomplicated 
malaria. Fansidar is reportedly the drug of choice for pregnant women. Malarone, a 
combination of the prodrug proguanil 1.11 and atovaquone 1.13 is used in multi-drug resitant 
malaria and also as a prophylactic in chloroquine resistant areas. A major setback is its high 




                                               














An affordable alternative to Fansidar is the chlorproguanil 1.12 and dapsone 1.10 
combination (Lapdap
®





The most effective and fast-acting class of antimalarials are represented by the sesquiterpene 
lactone peroxides, artemisinin 1.14 and derivatives (dihydroartemisinin 1.15, artemether 
1.16, arteether 1.17 and artesunate 1.18). They are tissue -, blood schizontocidal and 
gametocidal and therefore eliminate all stages of the malarial parasite. To prevent the 
development of resistance, treatment with artemisinin and derivatives is limited to severe 
multidrug resistant falciparum malaria. The therapeutic value of this class is limited by their 
low solubility, neurotoxicity
 26a
 and short half-life which account for the reported 
recrudescence when artemisinin and its derivatives are used in monotherapy. Because of the 
latter and the threat of drug resistance the WHO introduced Artemisinin Combination 
Therapies (ACTs) whereby the artemisinins are partnered with slow-acting antimalarials.
26b
 
One example is the fixed-ratio combination of artemether 1.16 with lumefantrine 1.5, a 
structural analogue to halofantrine 1.6. 
 
1.4.2. Selected Targets for Antimalarial Chemotherapy 
The P. falciparum genome project has been instrumental in the identification of new parasite-
specific targets which are critical to combat emerging resistance. Validated drug targets 
include cytosolic parasite membrane targets, food vacuole targets, mitochondrial targets and 
apicoplast targets.
27,28
 Some of these targets and their location in the malaria parasite are 
shown in fig 1.4. For purposes of this report the discussion of antimalarial drug targets has 
been restricted to fatty acid synthesis which occurs in the apicoplast and the food vacuole 
targets; haemozoin formation and cysteine proteases. Oxidative stress which is mediated by 



























Figure 1.4: Drug targets for antimalarial chemotherapy27 
 
1.4.2.1. The Acidic Food Vacuole 
The intraerythrocytic parasite is highly dependent on the host for nutrients. During the 
intraerythrocytic cycle, the metabolically active trophozoite and early schizont forms
29
 of the 
malaria parasite takes up the cytoplasm of the erythrocyte which is rich in haemoglobin via a 
process known as endocytosis. This entails the invagination of the parasitophorus vacuolar 
membrane or cytosome formation followed by the fusion of (transport) vesicles pinched off 
from the cytosome with the food vacuole.
30
 The digestive, lysosomal food vacuole in P. 
falciparum is a single-membrane organelle with a pH between 5.2-5.6,
31
 which plays host to 
a number of biochemical processes essential for the growth and survival of the parasite. 
These include acidification, peptide transport, haemoglobin degradation and haem 
polymerization. Of these the latter two have been studied more extensively.  
 
1.4.2.1.1. Haemoglobin Degradation Pathway 
The malaria parasite hydrolyses up to 80% of the host haemoglobin to source amino acids for 
protein synthesis,
32a
 to maintain osmotic stability
32b
 and to create space for the growing 
parasite.
33a 
Haemoglobin degradation is catalyzed by proteases such as the aspartic proteases 
[plasmepsins (PM) I, II, IV and histo-aspartic protease (HAP)],
34
 cysteine proteases 
(falcipains-2 and -3)
33





















The highly ordered process of haemoglobin degradation starts with the initial cleavage of 





 demonstrated the substrate specificity of vacuolar proteases 
through in vitro studies. They claimed that the plasmepsins are the only proteases able to 
cleave native haemoglobin. A different view was shared by Gamboa de Dominguez and 
Rosenthal. The isolation of intact native haemoglobin from cultured parasites incubated with 
cysteine proteases, led the authors to conclude that cysteine proteases participate in the 




The further breakdown of globin fragments to peptides consisting of 10-15 amino acids, is 
mediated by falcipains-2 and -3 (fig 1.5). These peptides are then cleaved to smaller peptides 
or oligomers of 6-8 amino acids by the metalloprotease, falcilysin. Interestingly, 
haemoglobin is not degraded to free amino acids in the food vacuole. Instead smaller 
peptides generated by falcilysin are transported from the food vacuole to the cytoplasm of the 
parasite where they are degraded to amino acids by the action of serine proteases.  
 
1.4.2.1.2. Haemozoin Formation as a Target in Antimalarial Chemotherapy 
Large quantities of haem are released during haemoglobin degradation; these are oxidized to 
haematin [aquaferriprotoporphyrin IX or H2O—Fe(III)PPIX)], through an unknown 
process.
39
 Accumulated haematin is toxic to the parasite
40
 and contributes to the formation of 
reactive oxygen intermediates which in turn cause damage to the cellular components of the 
parasite such as lipids and proteins.
30c,41
 The parasite circumvents this problem by 
crystallizing the oxidized ferriprotoporphyrin (FP) into an insoluble, inert crystal known as 
















 It is now accepted that haemozoin formation occurs via a 
biocrystallization process with the end product being a hydrogen bonded network of FP 





Figure. 1.6: Structure of haemozoin with the bonds between iron and the carboxylate group indicated 




1.4.2.1.2. 1. Inhibitors of Haemozoin Formation  
Most of the studies on inhibitors of haemozoin formation were modelled on synthetic 
haematin or β-haematin, a cyclic dimer of ferriprotoporphyrin IX which shows structural and 
chemical similarity to haemozoin.
40,43
 Both the quinolines (quinine 1.1, chloroquine 1.3, 
mefloquine 1.4) and aryl alcohol antimalarials (lumefantrine 1.5, halofantrine 1.6) are 
concentrated in the food vacuole and are thought to exert their activity by forming complexes 
with the haem through π-π stacking of their planar aromatic structures.44 Intriguingly, in a 
recent publication by Egan and co-workers
45
 the crystal structure of the aryl alcohol, 
halofantrine 1.6 complexed with ferriprotoporphyrin IX [Fe(III)PPIX] was presented for the 
first time. The model proposed from the latter revealed, in addition to π-π stacking between 
the phenanthrene and porphyrin ring systems, the coordination of 1.6 through its benzylic 
alcohol to the Fe(III) center and hydrogen bonding between 1.6 and Fe(III)PPIX. These 
interactions provided insight into the mechanism of action of this class of drugs and are 


















All in all, the interaction of the quinolines and aryl alcohol antimalarials with haem prevents 
it from being incorporated into haemozoin. Inhibition of crystal growth subsequently leads to 
the accumulation of toxic haem and thus to the demise of the parasite. 
 
1.4.2.1.3. Oxidative Stress Mediated by the Artemisinins 
The mechanism of action of artemisinin 1.14 and its semisynthetic and synthetic analogues 
(hereon referred to as artemisinins) has been the topic of ongoing and intense debate as 
evidenced by the number of reviews published to date. It is generally accepted that the 
artemisinins undergo a reductive activation which leads to the homolytic cleavage of the 
peroxide bond and the subsequent formation of various cytotoxic radical species. These 
radicals reportedly interact with various biomolecules in the parasite which ultimately results 
in parasite death.
46
 It is also reported that the artemisinins display nanomolar activity against 
the malaria parasite but concentrations in the micromolar range are required for growth 
inhibitory activity against mammalian cells. This selective toxicity has been ascribed to an 
enhanced uptake of artemisinins by the infected erythrocytes compared to normal or 





Despite the plethora of proposed hypotheses, which unfortunately cannot be extensively 
covered in this report, there is a general consensus that the peroxide bridge is essential for the 
antimalarial activity of this class of compounds. Evidence presented in support of this, is the 
observed lack of activity for structural analogues devoid of this moiety (section 5.2). With 
regard to the activation of the latter, one proposal put forth is that activation and the 




 Moreover, the 
alkoxy radicals so generated are believed to undergo rearrangement to form C-centered 
radicals which act as alkylating agents of haem,
47
 essential parasitic proteins
48 
and the P. 
falciparum translationally controlled tumor protein (TCTP).
49
 Evidence presented in support 
of the haem-mediated activation theory, is the isolation of haem-artemisinins adducts from 
parasite cultures treated with pharmacologically relevant doses of the artemisinin.
47c,50a
 The 
fact that these adducts lack in vitro antimalarial activity, contests this theory.
48c,50b
 Studies 
also showed that fluorescent derivatives of artemisinin are distributed throughout the parasite 
and not confined or localized to the acidic food vacuole where the degradation of haemozoin 
takes place (section 1.4.2.1.1).
51
 Other inconsistencies with the haem-hypothesis include the 














parasite which are known to have low concentration of haem
52a,b
 and the discovery of potent 
artemisinin derivatives which cannot chemically react with haem.
52c,d
 Further evidence 
against haem as a source of iron for activation of the endoperoxide bridge
46a
 and the role of 
haem alkylation in the mechanism of action of artemisinins
53a
 has been presented.  
 
Presented as an alternative is the proposal that “exogenous” or free iron(II) may be 
responsible for the reductive cleavage of the peroxide bridge in the artemisinins.
53b-d
 The 
observation that iron chelators, known for their inability to isolate or sequester haem-iron, 
inhibits the parasiticidal effect of artemisinins, supports this proposal.
54a,b
 Further support for 
the iron-mediated activation theory was presented in the study conducted by Eckstein-
Ludwig and coworkers.
51 
More importantly, however, is the convincing evidence they 
presented on the inhibition of PfATP6 - the sarco/endoplasmic reticulum Ca
2+
-transporting 
ATPase (SERCA) of P falciparum - by the artemisinins. In this study, PfATP6 expressed in 
Xenopus laevis oocytes was used to demonstrate the antimalarial equipotency between 
artemisinin 1.14 and thapsigargin, a natural occurring specific inhibitor of mammalian 





Another possible mechanism proposed by Haynes and coworkers is that the artemisinins 
undergo activation after binding to an active site.
52c,53c
 This was based on in vitro studies 
which showed that replacement of the methyl group C-3 of 1.14 (fig 1.3) with sterically 
hindering groups, for example the phenylethyl group, resulted in a reduction of antimalarial 
activity.
54c
 Inhibition of P. falciparum endocytosis
55a
 and interference with mitochondrial 
function
55b,c
 has also been attributed to the action of artemisinins. Furthermore, the inhibition 
of malarial cysteine proteases prevent the parasite from acquiring the essential amino acid 
needed for growth and development, as will be discussed in section 1.4.2.1.4. Of interest 
therefore is the specific inhibition of malarial cysteine proteases by 1.14 as demonstrated by 




As rightfully pointed out by O’Neill and Posner,
46a
 some of the studies conducted to prove or 
disprove the theories proposed to date on the mechanism of action of the artemisinins, need 
to graduate from biomimetic investigations to studies in animal models (malaria parasites) 
whereas some need to be extended from studies in animal forms of the parasite to human 














which is now urgently needed to guide future research and to stem the tide of resistance 
against this valuable class of compounds. Recent developments pertaining to the latter will be 
elaborated on in section 1.5. 
 
1.4.2.1.4. Cysteine Proteases as Targets in Antimalarial Chemotherapy 
As mentioned earlier, cysteine proteases perform critical roles in the erythrocytic life cycle of 
the parasite. These include merozoite release from red blood cells, invasion of red blood cells 
and most importantly the hydrolysis of haemoglobin.
33a
 Although the P. falciparum genome 
codes for other cysteine proteases, the papain-family are the only isolated and extensively 
characterized cysteine proteases. Three papains (or falcipains), are expressed during the 
erythrocytic stages of P. falciparum. It includes the principal cysteine proteases falcipain-2 
and falcipain-3 which show a 68% identity in sequence,
56a
 and are thus homologous. The 
observation that the development of a falcipain-1 knockout malaria parasite is 
uncompromised or comparable to a wild-type parasite led researchers to conclude that the 
structurally distinct falcipain-1 is not important for the growth and survival of the 
intraerythrocytic parasite. Reports about a possible role of falcipain-1 in erythrocyte rupture 
and invasion remain unconfirmed.
56b
 Falcipain-2 and falcipain-3 are critical for the survival 
and growth of the parasite and have been the focus of antimalarial drug discovery efforts. 
 
1.4.2.1.4.1. Mechanism of Proteolysis 
Cysteine proteases are proteolytic enzymes, which utilize the cysteine thiol located at the 
active site as a catalytic nucleophile for peptide bond cleavage.
33a 
The proposed mechanism 
by which they mediate peptide hydrolysis is shown in figure 1.7. It is the imidazole group of 
histidine (His159) - in close proximity to the active site – which polarizes the enzyme 
cysteine thiol group (Cys25) thus allowing for the deprotonation to occur at close to neutral 
pH. This leads to the formation of a highly nucleophilic thiolate/imidazolium ion pair [fig. 
1.7(a)]. Attack of the thiolate anion on the carbonyl carbon of the scissile amide bond, results 
in the formation of a tetrahedral intermediate [fig. 1.7(b)]. This intermediate is reportedly 
stabilized by hydrogen bonding to the NH backbone of Cys25 and to the NH2 group of the 
Gln19 side chain. Acylation of enzyme makes the imidazolium ion acidic allowing for it to 
protonate the nitrogen of the leaving group; release of the first product follows immediately 
[fig. 1.7(b)]. A second tetrahedral intermediate is formed by the base-catalyzed hydrolysis of 
the acyl enzyme [fig. 1.7(c)]. The collapse of the second intermediate results in product 












































































































































1.4.2.1.4.2. Inhibitors of Cysteine Proteases  
In two independent studies Rosenthal and Bailly convincingly demonstrated the role of 
cysteine proteases in haemoglobin degradation by incubating the parasite with a specific 
cysteine proteases inhibitor, E-64 (L-trans-epoxy-succinylleucylamido(4-guanidino)butane). 
The appearance of a swollen, dark-stained food vacuole coupled with the isolation of large 
quantities of undegraded haemoglobin was evidence of the blockage of haemoglobin 
degradation.
33b,57
 These studies also showed that although inhibition of both aspartic and 
cysteine proteases lead to the retardation of haemoglobin hydrolysis, inhibitors of cysteine 
proteases produced a more “specific morphological abnormality”.
33b
 Peptide-based cysteine 







 The therapeutic utility of some of these peptidyl inhibitors is 
however limited by poor bioavailability, instability due to the cleavable nature of the amide 




Molecular modelling studies confirmed that the antimalarial activity of the nonpeptidyl acyl 
hydrazines and chalcones can be attributed to their ability to inhibit cysteine proteases.
61
 
Interest in chalcones as antimalarials was sparked by the discovery of the natural product 
licochalcone A 1.22 [fig. 1.8(a)], an oxygenated chalcone which displayed potent in vitro and 
in vivo antimalarial activity.
62a
 A key structural feature of chalcones is the enone linker which 
is stable at vacuolar pH where cysteine proteases operate.
62b
 More importantly, as a Michael 
acceptor it can undergo conjugate addition with the sulfhydryl group of the cysteine side 
chain [fig.1.8(b)]. Evidence to support the significance of this structural motif for 
antimalarial activity was found in a study conducted by Li and cowokers.
63
 When they 
reduced the double bond of the enone linker they observed a 10 fold decrease in antimalarial 
activity. From this same study it was concluded that antimalarial activity of chalcones cannot 
























Figure 1.8: (a) Chemical structure of licochalcone A, 1.22, (b) Reaction of a representative chalcone 
(Michael acceptor) and a nucleophilic thiol (RSH)
64 
 
Non-peptidyl isatin derivatives have found application as inhibitors of cysteine and serine 
proteases.
65
 Studies undertaken in our laboratory showed the inhibitory activity against 
recombinant falcipain-2 of the N-substituted derivative 1.23 and the thiosemicarbazone 
derivatives 1.24-1.25 (fig. 1.9), with IC50 values less than 10 µM. These were identified from 








R = NO2, 1.24










Figure 1.9: Chemical structure of isatin-derived cysteine protease inhibitors 
 
1.4.2.2. The Apicoplast 
The malaria parasite belongs to the phylum Apicomplexan.
66
 Plasmodium and other 
apicomplexan parasites possess a plastid, an organelle found predominantly in plants and 
algae.
67
 It is thought to have been acquired from an ancestral cyanobacterium (blue-green 
algae) through a process of secondary endosymbiosis. As shown in figure 1.10, primary 
endosymbiosis describes the endosymbiotic relationship between a prokaryote 
(cyanobacteria) and eukaryote (red or green algae). In secondary endosymbiosis the primary 
plastid-containing eukaryote is engulfed by a second heterotrophic eukaryote, for example 
Plasmodium. The presence of extra membranes surrounding the apicoplast lends support to 

































The plastid possesses a 35kb circular genome but most of its proteins are encoded for by 
genes in the nuclear genome of the eukaryotic host (Plasmodium). This is the result of 
evolutionary processes which facilitated the transfer of genes to the host and which stripped 
the engulfed eukaryote from non-essential functions such as photosynthesis.
69
 The plastid is, 
however, indispensable in Plasmodium, having been identified as the site of biosynthetic 
pathways which are essential for parasite growth and survival.
70
 These metabolic pathways 
are specific therapeutic targets by virtue of the prokaryotic origin of the plastid. They include 
the non-mevalonate isoprenoid synthesis, apicoplast DNA replication, transcription, 
translation, fatty acid synthesis and several steps of haeme synthesis.
71
 Of all the metabolic 
pathways occurring in the apicoplast, fatty acid synthesis is reportedly the most well-studied 
function. It is also of particular interest to this project and will be discussed in more detail in 









Figure 1.10: Origin of the plastid72 
 
1.4.2.2.1. Fatty Acid Synthesis 
Fatty acids constitute an important component of cellular and intracellular membranes and 
also function as an energy source. The synthesis thereof is important for living cells. It was 
initially claimed that P. falciparum acquire fatty acids by scavenging them from human host 
cells.
73
 The completion of the P. falciparum genome disproved this long held belief. The de 
novo synthesis of fatty acids in P. falciparum occurs in the apicoplast. Genetic evidence in 
support of this includes the discovery of nucleus-encoded fatty acid synthesis genes such as 
acpP, fabH and fabZ whose translation products - the acyl carrier protein, FabH and 
FabA/FabZ, respectively - are targeted to the apicoplast.
66a,74
 Biochemical studies such as the 
incorporation of 
14
C-labelled acetate CoA and malonyl CoA in fatty acids (C10 and C14) in 

















The organization of the fatty acid synthesis system is essentially the same in all organisms 
and can be divided into two distinct forms called type I and type II. In P. falciparum fatty 
acid synthesis is mediated by the type II fatty acid synthase (FAS
†
) or dissociated pathway.
74
 
The type II pathway which operates in most bacteria, plants and yeast, is distinct from the 
type I or associated pathway.
75a
 The latter is characterized by a single multidomain 
polypeptide located in the cytosol and is found in mammals, fungi and some mycobacteria.
75b 
In contrast, type II FAS is a multienzyme system. These structural differences allows for the 





A recent landmark study conducted by the research groups of Fidock and Kappe showed, that 
type II fas is only necessary for the development of the late liver stage of the malaria 
parasite.
76
 They moreover demonstrated, in the rodent malaria parasite P. yoelli, that type-II 
fas-deficient parasites could not form the infectious exo-erythrocytic merozoites necessary 
for the initiation of the erythrocytic stage. The difference in the number of hepatic merozoites 
(± 40 000
77a
) produced compared to the 8-36 erythrocytic merozoites produced per invasive 
cycle,
77b
 reportedly accounts for the increased demand for fatty acids by the liver stage forms 
of the parasite.
76
 This discovery raises the question as to how the parasite obtains fatty acids 
to sustain the other life cycle stages; more importantly, however, is the new direction it offers 




1.4.2.2.2. Mechanism of Type II Fatty Acid Synthesis  
Fatty acid biosynthesis in E. coli has been extensively studied. As depicted in figure 1.11 it 
comprises two stages - initiation and elongation. In the initiation step acetyl-CoA is 
carboxylated to yield malonyl-CoA. This step is reportedly catalyzed by the biotin containing 
enzyme acetyl-CoA carboxylase (ACC) with bicarbonate acting as the source of the carboxy 
group. Malonyl-CoA is then transferred to the acyl carrier protein (ACP) by the enzyme 
malonyl-CoA:ACP transacylase (FabD).  
 
The elongation step is initiated by the condensation of malonyl-ACP and acetyl-CoA 
catalyzed by the β-ketoacyl-ACP synthase III (FabH). The product so formed, β-ketoacyl-
ACP undergoes a NADPH-dependent reduction catalyzed by the enzyme β-ketoacyl-ACP 
                                               














reductase (FabG) to yield β-hydroxyacyl-ACP. The reduction step is then followed by the 
dehydration of β-hydroxyacyl-ACP by the enzyme β-hydroxyacyl-ACP dehydratase (FabA 
or FabZ). The double bond in the dehydrated product, trans-2-enoylacyl-ACP is reduced by 
enoyl-ACP reductase (FabI) in the presence of NADH to form butyryl-ACP. This product 
then re-enters the elongation cycle catalyzed by either β-ketoacyl-ACP synthase I (FabB) or 
β-ketoacyl-ACP synthase II (FabF). Each cycle of the elongation extends the acyl-ACP 



















Figure 1.11: Type II fatty acid biosynthesis in E. coli78  
 
The type II fas in Plasmodium occurs in an analogous manner to the bacterial type II fas 
discussed above; despite organizational and structural differences in the enzymes. It is 
reported that in addition to other enzymes of type II FAS, plants and bacteria possess three 
KAS enzymes, KAS I, KAS II, and KAS III, with the E.coli equivalents being FabB, FabF 
and FabH, respectively as shown in figure 1.11.
79
 Furthermore, in E.coli the homologous 
FabB and FabF share a 40% identity, but show a poor homology with FabH in spite of the 
similar architecture that they display at the active sites.
79
 In contrast, the P. falciparum 

















































and 31% identity to the FabB and FabF of E. coli, respectively. This enzyme is denoted 
KASI/II or more specifically, pfKASI/II.
80
 The other enzyme, KAS III (or pfKASIII) is 
homologous to the FabH of E.coli. It is reported that the catalytic domain of the former share 




1.4.2.2.3. Inhibitors of Type II Fatty Acid Synthesis 
Studies conducted by Surolia and coworkers revealed that the inhibition of type II fas rapidly 
compromises the growth of the parasite. This is in contrast to the ‘delayed death’ elicited by 
inhibitors of other apicoplast functions such as DNA replication, transcription and 
translation.
81
 To illustrate, comparative studies on the parasiticidal effect of triclosan 1.26 
(inhibitor of type II fas, fig. 1.12) and the antibiotic clindamycin 1.21 (inhibitor of apicoplast 
transcription, fig. 1.3), showed that the latter required a prolonged incubation time (about 72-
84 hours, compared to the 48 hours required for the completion of a life cycle in P. 
falciparum) to exert maximum effect in a P. falciparum growth inhibition assay. This is in 














(+)-Thiolactomycin 1.28  
Figure 1.12: Chemical structures of antimalarial type II fas inhibitors 
 
The bisphenol, 1.26 is a broad-spectrum antibiotic which displays in vitro and in vivo 
growth-inhibitory activity in P. falciparum and specifically targets P. falciparum enoyl 
reductase (FabI in E. coli, fig. 1.11). Although 1.26 inhibits growth of the malaria parasite 
with an IC50 value of ~1 µM,
66b
 it displays poor bioavailability and is also implicated in 
glucoronidation.
82
 Contrary to the findings of Surolia and coworker, a recent study 
demonstrated through gene knockout studies, that FabI is not principal target of 1.26.
76b
 This 
was supported by the findings of Vaughan et al who showed that the FabI enzyme is not 
important for the blood stage development of the P. falciparum.
76a
 Another FAS inhibitor, 
the fungal metabolite cerulenin 1.27 (fig. 1.12) is reported to covalently bind to the active site 
of its primary targets FabB/F (or pfKAS I/II). It furthermore inhibits growth of P. falciparum 
with IC50 values ranging between 10-20 µM.
66b,75a














cerulenin is its ability to irreversibly inhibit both type I fas and type II fas and its instability 
in mammalian systems.
79





A selective reversible inhibitor of type II fas is the natural product (+)-thiolactomycin 1.28 
(fig. 1.12). It is believed to inhibit both FabH and FabB/F by mimicking malonyl-ACP (fig. 
1.11) in its binding site.
84
 Waller and coworkers showed that racemic 1.28 inhibits the 
growth of the multi-drug resistant W2mef strain of P. falciparum with an IC50 value of 50 
µM.
75a
 In a separate study, Prigge and co-workers revealed 1.28 to be a poor inhibitor of 
pfKAS III (IC50 > 330 µM) and attributed the observed inhibitory activity to the 
uncharacterized pfKASI/II enzyme.
80
 The synthesis of derivatives of 1.28 to improve potency 
has been the focus of many investigations. In this endeavour, Price and coworkers solved the 
crystal structure of 1.28 bound to the FabB enzyme in E.coli (fig. 1.13).
84c
 Among the most 
important interactions revealed by the FabB-thiolactomycin model is that: 
• thiolactomycin imitates the transition state adopted by the natural substrate, the 
thiomalonate intermediate; 
• the carbonyl group at C-2 (fig. 1.13) is shown to be hydrogen bonded to two 
histidines (His298 and His333); 
• the isoprenoid moiety at C-5 extends into an incompletely-filled hydrophobic crevice 
in the active site of the enzyme 
• the hydroxyl group at C-4 (fig. 1.13) is housed in an incompletely filled pantetheine 
binding pocket and is stabilized through water–assisted hydrogen bonding interaction 
with the amino acid residues Val270 and Gly305.
84b,c
  
In addition to elucidating the architecture of the KAS active site, the crystal structure 
provided valuable information on enzyme-ligand binding interactions and has greatly 





























(a)        (b)  
 
Figure 1.13: (a) Structure of the FabB-thiolactomycin (TLM) complex showing 1.28 with magenta 
bonds. The hydrophobic residues are shown in green, water molecules in light blue and hydrogen 




1.5. Drug Resistance 




 and the negative effects on public health
10
 caused 
by the increase in drug resistance has been documented. Of the four human plasmodia, 
resistance has been reported only for P. falciparum and P. vivax with particular attention 
given to the former because of its virulence. First reports of the development of resistance to 
quinine 1.1 (fig. 1.3.) surfaced in 1910.
86
 The appearance of the chloroquine resistant (CQR) 
strain of P. falciparum was first reported in the 1950’s in Southeast Asia and South America 
and detected in Africa in the late 1970’s. CQR strains can now be found in most of the 
malaria endemic regions (fig 1.1).
87
 It has consequently been replaced as the first line drug 
with a cheap, alternative, sulfadoxine-pyrimethamine (marketed as Fansidar
®
) in most of 
Africa.
88
 However, resistance to the latter was reported in the late 1980’s in Africa and is 
spreading at an alarming rate.  
 
Increased in vitro IC50s, prolonged clearance of parasitaemia and treatment failure are listed 
as indicators of clinical resistance to the artemisinins.
89a
 A recently conducted clinical study 
involved the treatment of 40 patients [western Cambodia (20) and northwestern Thailand 





    Pocket
Hydrophobic




























 The results obtained (table 1.1) demonstrate the in vivo 
susceptibility to artesunate in the western Cambodia study group, as evidenced by the 
prolonged clearance of parasitaemia. Of interest, however, is the in vitro susceptibility data 
(table 1.1) which appears to be relatively normal for both study groups, when compared to 
the activity against the reference 3D7 strain of P. falciparum. Notwithstanding, results from 
this study serve as an early indication of the emergence of clinical resistance to the 














































 Calculated as a percentage relative to the total (N = 20); 
b
Conducted on parasites from patients in 
study groups; the 3D7 strain was used as reference; cIC50 against 3D7 strain strain: 2.7 nM; 
dIC50 
against 3D7 strain strain: 2.3 nM  
 
1.5.1. Mechanism of Drug Resistance 
The discussion of the mechanism of drug resistance has been limited to the genetic proposals 
put forward to explain the development of resistance against CQ. It was established as early 
as the 1960s that the chloroquine-resistant (CQR) parasite has a significantly lower 
concentration of the drug at the target site, i.e. the food vacuole, compared to chloroquine-
sensitive (CQS) parasites.
90a
 The principal mechanism proposed for verapamil-sensitive CQ 
resistance in P. falciparum involves mutations in the gene, pfcrt. This gene encodes for the 
Plasmodium falciparum chloroquine resistance transporter (PfCRT) an integral membrane 
protein which is located in the lysosome-like food vacuole where CQ exerts its mechanism of 
action.
90
 It is believed that PfCRT brings about changes in the pH of the food vacuole which 
















 Numerous mutations in PfCRT have been reported. The CQ resistant phenotype, 
however, requires a specific mutation which is the replacement of the amino acid threonine 
(T) with lysine (K) at position 76 in PfCRT, also known as the K76T mutation.
90d,92
 The 
complexity of the CQR resistance mechanism makes provision for the consideration of other 











Verapamil 1.29  
Figure 1.14: Chemical structure of verapamil 1.29 
 
The discovery of similarities between multidrug resistance (MDR) in mammalian cancer and 
CQR in P. falciparum suggested a similar mechanism of resistance; both can be reversed by 
the chemosensitizer verapamil 1.29
93a
(fig. 1.14) and both are reportedly linked to the 
overexpression and/or presence of P-glycoproteins (Pgp).
93b,c 
The Pgp is an energy-
dependent, membrane-bounded protein encoded by mdr genes. In P. falciparum the protein 
product of the gene pfmdr1, a mdr homologue, is a P-glycoprotein homologue 1 (Pgh-1) 
which like PfCRT is localized to the membrane of the food vacuole;
93c
 where it actively 
transports chloroquine out of the food vacuole. It is notable that mutations such as increased 
expression of Pgh-1, only account for a low-level drug resistance to chloroquine in P. 
falciparum.
94
 This was supported by the findings of Cowman and coworkers who discovered 
equal amounts of Pgh-1 in both CQS and CQR strains.
93c
 Polymorphism in pfmdr1 has, in 
addition to modulating chloroquine resistance as mentioned above, been implicated in 

















1.5.2. Measures to Manage the Spread of Drug Resistance 
Development of resistance to previously cheap, effective drugs requires the deployment of 
new treatment strategies. One such strategy is the abandoning of monotherapies replacing 
them with effective combination therapies. This strategy is currently being used in the 
treatment of HIV/AIDS, tuberculosis and leprosy.
96
 The combination of two antimalarial 
drugs, each exerting a different mechanism of action or targeting two different metabolic 
pathways of the parasite, retards the development of resistance. The rationale is that for 
resistance to develop against both drugs the occurrence of two independent and simultaneous 
mutations in the same parasite are required which is highly improbable.
88
 Against this 
background, artemisinin-based combination therapies (ACTs) were recommended by the 
WHO in 2001.
26b
 ACTs has been approved in over 40 countries as first or second line 




Another method of slowing down the development of resistance entails the use of resistance 
reversing agents or chemosensitisers such as verapamil 1.29 (fig. 1.14). Reversal of 
resistance is characterized by the reduction of the IC50 value of CQ against the resistant strain 
and the increase of CQ accumulation in the acidic food vacuole of CQR.
98
 It is noteworthy 
that reversal agents identified so far, neither restore CQ levels in the food vacuole nor do 
they restore the IC50 values. These reversal agents only mediate a partial reversal of 




A third measure entails the redesigning of drugs in order to restore their efficacy. A number 
of comprehensive reviews cover the structural changes in the quinoline class of antimalarials. 




According to WHO estimates 8.8 million new cases of TB were reported in 2003 of which 
1.7 million resulted in deaths. The grim reality is that 27% of these cases and 31% of the 
deaths took place in poverty stricken Africa, home to approximately 11% of the world’s 
population.
99a
 The most recent assessment of the TB epidemic puts the estimated new cases 
for 2007 at 9.27 million.
99b















In an attempt to stem a global TB epidemic the WHO launched the “Framework for effective 
TB control” in 1994.
99c
 This entails a five-point strategy which includes the direct 
observation of treatment short-course (DOTS); this protocol involves the provision of drugs 
directly to the patient and requires observing the patient taking the drugs. In spite of the 
adoption of this programme, increases in the incidences of TB has been reported for the 









In sub-Saharan Africa, the continuing increase in the incidence of TB is due to its close 
association with the HIV/AIDS epidemic.
100
 Approximately 12% of the total deaths due to 
TB which occurred in 2000 were attributed to HIV co-infection.
101
 The burden of TB is not 
only compounded by the synergy between TB and HIV/AIDS but also by the emergence of 
multi-drug resistant (MDR) and extensively drug resistant (XDR) forms of the disease. On 
realizing the threat resistance poses and the ease with which it can develop into the virtually 
untreatable XDR-TB, the WHO introduced the DOTS Plus strategy for the control of MDR-
TB. XDR-TB cases have been reported in 45 countries according to a WHO global survey. 
This survey covered the period 2002 to 2006 and included about 90 000 TB patients in 81 
countries.
102
 With limited representative data from Africa, considering that only six countries 
participated in the survey, and the knowledge that most African countries lack the proper 
laboratory infrastructure to perform second line drugs susceptibility testing (DST) a detailed 























Figure 1.16: Electron microscope view of the bacilli of M. tuberculosis 103 
 
The causative agent of tuberculosis (TB) in humans are small, rod-shaped mycobacteria (fig. 
1.16). Of the 85 species in the genus Mycobacterium those commonly affecting humans are 
M. tuberculosis, M. bovis, M. africanum, M. microtti, and M. canetti and are collectively 
known as the Mycobacterium tuberculosis complex.
104
 Tuberculosis is a contagious disease 
generally transmitted from a person with active pulmonary TB in the form of droplets of 
saliva or mucus containing the TB bacilli. This occurs during sneezing or coughing and when 
sharing eating and drinking utensil. Pulmonary tuberculosis represents the contagious form of 
the disease and is characterised by a persistent cough, the coughing of blood, chest pains, 
fatigue, weight loss, fever and night sweats. However, not all TB infections develop into the 
active pulmonary TB. Approximately 90% of all M. tuberculosis infection can be ascribed to 
latent TB infection (LTBI). This asymptomatic, non-contagious form of the disease occurs 
when the bacilli remain dormant in the host after inhalation. The main risk associated with 
latent TB is that 10% of patients diagnosed with it can develop active TB at a later stage, that 
is, the bacilli can become reactivated when the immune system of the host becomes 
compromised. Miliary or disseminated TB is a non-contagious but extreme form of the 
disease and is common in infants and immunocompromised persons.
105
 It occurs when the 
disease spreads from the lungs via the bloodstream to internal organs such as the central 
nervous system (meningitis), the renal and genital tract (genitourinary tuberculosis) and 




1.6.2. Tuberculosis Chemotherapy 
Tuberculosis is a preventable and treatable infectious disease. The WHO-recommended 
multidrug therapy consists of a cocktail of frontline drugs (fig 1.17) initiated by the four-drug 














rifampin) 1.33 or streptomycin 1.34 taken over a period of 2 months. These drugs all exhibit 
bactericidal activity and kill off the fast-growing (replicating) and semi-dormant bacilli.
107
 
The bactericidal phase of the treatment is followed by a course of isoniazid 1.30 and 
rifampicin 1.33 for a further 4-7 months. This constitutes the sterilizing phase of the 






















































Figure 1.17: Chemical structures of the first-line antitubercular drugs 
 
Tuberculosis patients are reported to become non-infectious after the first two weeks of 
treatment; the remainder of 6-9 months of treatment is needed to eradicate the persistent, 
slow-metabolizing and non-growing bacilli and thus prevent relapse. The presence of this 
heterogeneous population of bacilli (actively growing, slow growing and nongrowing) is 
directly responsible for the lengthy treatment and presents additional challenges. For 
example, a consequence of the lengthy course of treatment is patient non-compliance which 
has been implicated in the emergence of resistance.  
 
Failure of treatment with the first line drugs, because of drug resistance or intolerance 
requires treatment with second line drugs (fig. 1.18). This forms part of the DOTS Plus 
programme introduced in 1999 for the treatment of MDR-TB.
109
 These drugs consist of 
ethionamide 1.35 and cycloserine 1.36, para-aminosalicyclic acid 1.37, kanamycin 1.38, 














1.42, levofloxacin 1.43). As would be expected, this treatment regime requires a much longer 
duration (18-24 months) and has a lower success rate than the first line drugs. In addition, 
this cocktail is reported to be more toxic and more expensive.
108 
The treatment outlook is 
poor for both HIV negative and HIV positive TB patients. However, in the case of HIV-
related TB treatment is further challenged by the drug-drug interaction between 




The shortcomings of TB chemotherapy have been identified and incorporated in the 
objectives of the Global Alliance for TB drug development.
111
 These include the shortening 
of treatment regimes from 6-9 months to ≤ 2 months, the development of drugs for treatment 
of MDR-TB, XDR-TB and latent TB. Also included in the objectives is the development of 
drugs which are compatible with antiretrovirals, exert new mechanisms of actions and which 
are low cost by virtue of the association of the disease with poverty. These objectives need to 













































































Kanamycin 1.38   R = NH2







Figure 1.18: Chemical structures of the second-line antitubercular drugs 
 
1.6.3. Drug Resistance 
The emergence of drug resistance in tuberculosis was first noted in the early 1990’s. WHO 
estimates put new infection with the multi-drug resistant strain of tuberculosis at 1.1%.
99b
 
According to the WHO, multidrug-resistance is defined as resistance to rifampicin and 
isoniazid. MDR requires treatment with the less effective second-line drugs (fig. 1.18) which 
incidentally are more expensive, toxic and less accessible especially in Africa.
100
 The 
treatment success rate for MDR-TB stands at 75%. However, in the case of inadequate 
treatment this strain can develop into the highly resistant form of XDR-TB. Extensively 
drug-resistant (XDR) TB is defined as being resistant to at least rifampicin and isoniazid, in 
addition to any fluoroquinolone and at least one injectable second-line agent (kanamycin 
1.38, amikacin 1.39 and capreomycin 1.40, fig. 1.18).
102,112
 The mortality rate for XDR is 
















1.6.4. Type II Fatty Acid Synthesis and Mycolic Acid Biosynthesis as Targets for 
Tuberculosis Chemotherapy 
As was the case with malaria, the completion of the genomic sequence of the H37Rv strain of 
M. tuberculosis in 1998 and the follow-up re-annotation thereof has been instrumental in the 
identification and validation of novel drug targets.
113
 A bulk of the work on the identification 
of genes, and their protein products, essential for M. tuberculosis growth (or “survivasome”) 
was carried out by Sasetti and coworkers.
114
 Among the enzymes identified are those 
responsible for mycolic acid biosynthesis.
114,115
 The latter constitutes a vital component of 
the lipid-rich cell wall and is important in the intracellular survival of the mycobacteria.  
 
Mycolic acids can be subdivided into three main classes (α-mycolates, methoxymycolates 
and ketomycolates) and are structurally characterized as high-molecular weight α-alkyl, β-
hydroxy fatty acids consisting of 60-90 carbon atoms. In mycobacteria, mycolic acid 
synthesis is complex and involves both type I and type II FAS systems.
116 
The eukaryotic 
type I FAS catalyzes the de novo fatty acid synthesis to yield medium chain length (C16,18 or 
C24,26) fatty acids, whereas prokaryotic type II FAS is responsible for the elongation of the 
type I FAS products into long chain mycolic acid precursors.
116c,117
 With most of the enzyme 
activity of the type I FAS restricted to a single polypeptide which shares structural 
similarities with the type I FAS system of the human host, the potential targets for 
antimycobacterial drugs are the enzymes of the type II fas; this has been confirmed by a 
number of researchers.
118
 The type II FAS system in M. tuberculosis include the β-ketoacyl 
reductase (MabA or KAR, FabG in E.coli), trans-2-enoyl reductase (InhA, FabI in E. coli)
119
 
and the condensing enzymes β-ketoacyl-ACP synthases (KAS). The latter category includes 
mtKas A which is responsible for extending the type I fas product (palmitoyl CoA) to C40 
products, mtKas B which extends the mtKas A product to a product of average size C54
118b
 













1.6.4.1. Inhibitors of Type II Fatty Acid Synthesis and Mycolic Acid Biosynthesis 
The frontline antitubercular prodrug isoniazid 1.30 (fig. 1.17) has a remarkable specificity for 
mycobacteria. This was confirmed by the observed minimum inhibitory concentration (MIC) 
of isoniazid which was found to be greater than 500 µg/mL for E.coli whereas as little as 0.05 
µg/mL is required for the inhibition of M. tuberculosis.
120
 The primary target for the active 
form of isoniazid is InhA.
121
 There is existing evidence which implicates the condensing 
enzyme mtKas A as an additional target.
122
 In order to exert its antimycobacterial effect, 
InhA requires activation which is mediated by an endogenous catalase-peroxide, katG.
123
 
Another prodrug ethionamide used in the treatment of MDR-TB also targets InhA. This was 
concluded from the discovery that a single or point mutation in the inhA gene which encodes 
for InhA conferred resistance to both isoniazid and ethionamide.
121
 Triclosan 1.26 (fig. 1.12) 
has been identified as an inhibitor of InhA.
124a
 It displayed in vitro antimycobacterial activity 
against both the isoniazid-resistant and sensitive strains of M. tuberculosis with MIC in the 
range 20-60 µM.
124b
 Parrish and coworkers
125
 recorded minimum inhibitory concentrations 
ranging between 1.5 and 12.5 mg/L for cerulenin 1.27 (fig. 1.12) against various pathogenic 
(M. bovis, H37Rv and multidrug-resistant strains of M. tuberculosis) and non-pathogenic 
mycobacteria species.  
 
A well characterized inhibitor of type II fas, which is of particular interest to this project, is 
the thiolactone containing antibiotic thiolactomycin 1.28 (fig. 1.12). It exerts its 
antimycobacterial activity by inhibiting fatty acid synthesis and mycolic acid 
biosynthesis.
118a
 It is furthermore reported to selectively inhibit the β-ketoacyl synthase 
condensing enzyme mtKas A and mtKas B but appears to be a poor inhibitor of the 
condensing enzyme mtFabH which serves as the link between the type II and type I pathway 
in mycolic acid synthesis. No cross-resistance to other antitubercular agents has been 
reported.
118a,126
 Thiolactomycin analogues with enhanced antimycobacterial activity, include 
the biphenyl based,
127a
 aromatic acetylenic derivatives
127b
 and analogues devoid of the C-5 
isoprene unit.
127c
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2.1. Natural Products (Secondary Metabolites) 
Rollinger and coworkers broadly defined natural products or secondary metabolites as 
“complex extracts and their chemical entities, which are biosynthesized in nature”.
1
 There is 
a general consensus that the boundary between primary and secondary metabolites is blurred. 
Nonetheless, secondary metabolites are believed to be of limited distribution in nature and do 
not directly participate in the growth and development of an organism compared to primary 
metabolites such as carbohydrates, proteins, lipids and nucleic acids. Moreover, these 
metabolites can be sourced from both terrestrial and marine organisms. By virtue of the role 
they play in the survival of organisms (defence, secretion, attraction and signalling) they 
have over the years undergone an evolutionary refinement or natural selection to emerge as 
potent, structurally diverse
2
 and biologically relevant molecules. Secondary metabolites of 
interest to man are dyes, pigments, polymers, drugs, oils, perfumes and flavouring agents to 
name but a few. Relevant to this project and to be discussed from hereon is the utilization of 
natural products in the drug discovery process.  
 
2.2. Natural Products in Drug Discovery  
Throughout the ages, humans exploited nature in sourcing medicine to treat various 
ailments.
3
 The utilization of traditional medicine is still commonplace. In the 19
th
 century, 
technological advances such as spectroscopy contributed significantly to the isolation and 
characterization of bioactive principles from natural resources and thus facilitated the 
transition from plant extracts to single, purified products. Classical natural product research 
is, however, regarded as labour-intensive, time consuming and expensive. Additional 
deterrents to pursuing this route include the difficulties of obtaining an adequate supply of 
the drug from the natural source and securing intellectual property rights.
4
 It was for these 
reasons that the early 1990s witnessed a decline in natural product research with most 
pharmaceutical companies opting for genomics and/or high-throughput-screening of small 
drug-like molecules from combinatorial libraries.
5a
 The counter-productivity of 
deemphasizing natural product research by the major pharmaceutical companies was made 
evident by the observed decline in the number of new chemical entities (NCE).
5c
 This is a 
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development of most of the drugs in clinical use not only preceded the genomic era but also 
originated from, or are, natural products.  
 
Natural products represent a consistent and abundant source of drugs and drug leads. Indeed 
only a small fraction, 5-15% of the about 250 000 species of higher plants have been tested 
for bioactive principles. Additionally, less that 1% of bacterial species and less than 5% of 
fungal species have been explored whereas other sources such as marine life remain virtually 
unexplored.
5
 About 39% of the approximately 520 new drugs approved by the Food and 
Drug Administration (FDA) between 1983 and 1994 are reported to be natural products or 
derivatives thereof.
5c
 The same survey revealed that 60% of the cancer drugs and 75% of 
drugs used in the treatment of infectious diseases were derived from natural products.
5
 It is 
also noteworthy that about 74% of the 119 chemical substances currently considered as 




2.2.1. Natural Products as Drugs and Drug Templates in Non-infectious Diseases 
An example of a natural product turned drug is the anticancer agent Taxol™ 2.1 (paclitaxel, 
fig. 2.1), which was isolated from the bark of the Pacific yew tree, Taxus brevifolia. Its utility 
in cancer chemotherapy includes the treatment of ovarian and breast cancer as well as 
cancers of the head and neck. Analogue synthesis guided by mechanistic and structure 
activity relationship (SAR) studies yielded the analogue taxotere which displayed improved 
selectivity and bioavailability.
7
 Another confirmatory example is the analgesic drug 
morphine 2.2 (fig. 2.1), isolated from the latex of the opium poppy, Papaver somniferum and 
which has revolutionized the treatment of severe pain. It initiated the production of a vast 





Natural products also made significant contributions towards the treatment of non-
communicable diseases, which recently surpassed infectious diseases as the leading cause of 
death globally.
8
 Propanolol 2.3 (fig. 2.1) served as template for the development of a wide 
variety of cardioactive β-adrenoceptor blocking agents (beta-blockers); a class of drugs used 
in the management of hypertension and treatment of other cardiovascular conditions.
7
 The 
discovery of cholesterol lowering agents mevastatin 2.4 and lovastatin 2.5 (fig. 2.1) took the 
pharmaceutical industry by storm.
5a
 Derived from these molecules were a series of analogues 
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rosuvastatin and atorvastatin all of which have surpassed the parent molecule in terms of 
efficacy.
7,9a
 A recent article reported on the superior inhibitory activity of atorvastatin 
compared to other statins against chloroquine-resistant and chloroquine-sensitive strains of P. 
falciparum.
9b
 This serves as a further demonstration of the far reaching effects of natural 





























Mevastatin, R = H  2.4
Lovastatin,  R = Me 2.5
2.1
 
Figure 2.1: Chemical structures of some natural product drugs used in the treatment of non-infectious 
diseases 
 
2.2.2. Natural products as Drugs and Drug Templates in Infectious Diseases 
The greatest concern with infectious diseases is the increasing pace at which resistance 
against established drugs develops. This renders the current arsenal almost ineffective, 
increases the demand for new agents and with the reduced number of NCEs presents a 
precarious situation especially for resource-poor developing countries with high endemicity 
for these diseases. Undoubtedly, for most of these countries traditional medicines still play a 
center-stage role on grounds of accessibility, affordability and efficacy. Among the common 
infectious diseases are malaria and tuberculosis which are the main focus of this project.  
 
2.2.2.1. Natural Products in Antimalarial Chemotherapy 
In the fight against malaria the most typical lead is quinine 1.1 (fig. 2.2) a natural product 
isolated from the bark of the Peruvian Cinchona tree. It represents one of the oldest malaria 
remedies and joined the battle as early as the 1600s.
10
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served as a template for the synthesis of quinoline-containing antimalarials currently in 
clinical use such as chloroquine 1.3 and mefloquine 1.4.
11
 Ethnopharmacological research on 
Chinese herbal remedies led to the discovery of a rare sesquiterpene 1,2,4-trioxane lactone 
with an unusual endoperoxide moiety, artemisinin 1.14 (fig. 2.2). The latter was isolated 
from an extract from the wormwood, Artemisia annua. Using artemisinin as a template, 
semisynthetic derivatives such as dihydroartemisinin 1.15 the oil-soluble artemether 1.16 and 
arteether 1.17 and the water-soluble artesunate 1.18 have been prepared. All these derivatives 
in addition to having enhanced bioavailability are active against the sexual and asexual blood 




Much of the benefit of natural products lies in the fact that by virtue of their origin and thus 
interaction with biological systems, structural information about the target(s) is not a 
requirement in analogue design. Artemisinin 1.14, like various other natural products 
discovered in the pre-genomic era, serves as an example to this effect. As mentioned earlier 
(section 1.4.2.1.3), previous SAR studies identified the endoperoxide bridge as a key 
structural feature which is essential for antimalarial activity.
13
 With this recognition simpler 
and easy to synthesize compounds 2.6 and 2.7 were introduced which in addition to bearing 
the peroxy bridge, still retain nanomolar antimalarial activity.
14
 An exceptional example is 
the 1,2,4-trioxolane derivative OZ277 2.8 (fig. 2.2) designed and synthesized by 
Vennerstrom and coworkers.
15
 Like artemisinin 1.14 it contains a shielded endoperoxide 
bridge but shows increased water solubility, a good toxicity profile and potent in vitro and in 
vivo antimalarial activity which surpasses that of first generation artemisinin analogues 



































Quinine 1.1 Chloroquine 1.3 Mefloquine 1.4
Artemisinin 1.14 Dihydroartemisinin, R = H 1.15
Artemether, R = Me 1.16
Arteether,    R = Et 1.17



























Figure 2.2: Chemical structures of natural product and natural product-derived antimalarials 
 
2.2.2.2. Natural Products in Tuberculosis Chemotherapy  
The global burden of TB, the exacerbation thereof by the HIV pandemic and the ever 
increasing pace at which drug resistance is developing are evidence of the urgent need for 
new classes of anti-TB drugs. Historically, natural product chemistry has contributed 
significantly towards the armamentarium of antitubercular drugs. The search for antibiotics 
from micro-organisms was stimulated by the discovery of the antibiotic penicillin from the 
fungus, Penicillium notatum.
16
 Antimycobacterial drug research was soon after rewarded 
with the discovery of the natural product streptomycin 1.34
17
 (fig. 2.3) which was cultivated 
from cultures of a strain of Streptomyces griseus.
7
 Currently this aminoglycoside antibiotic 
forms part of the frontline antitubercular drugs. Rifamycin, a polyketide produced by cultures 
of Amycolatopsis mediterranei
7,18
 is an important anti-TB drug lead, which aided the 
discovery of the semisynthetic rifampin 1.33 (fig. 2.3), a first-line anti-TB drug. Other 
semisynthetic derivatives of rifamycin, which display enhanced anti-TB activity and 
pharmacological properties include rifapentin, rifametane and rifabutin.
19
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special mention, for its compatibility with antiretrovirals has made it invaluable in the 
treatment of HIV-related TB.
20
 The discovery of p-aminosalicylic acid 1.37 (fig. 2.3) as a 
antitubercular agent in 1949 was an incidental result from the discovery of the rapid 



















































Figure 2.3: Chemical structures of natural product and natural product-derived antitubercular agents 
 
Another streptomycete-derived natural product is the D-alanine mimic, cycloserine 1.36 (fig. 
2.3) which exerts its mechanism of action by inhibiting cell wall biosynthesis in M. 
tuberculosis. It is produced by cultures of Streptomyces orchidaceus and is used clinically as 
a second-line antitubercular agent.
7
 Advances in screening technologies for detection of anti-
TB activity in natural product extracts provided further examples of new classes of natural 
product-derived anti-TB compounds which are undergoing preclinical development. These 
include the capuramycin derivative 2.10
22a
 (fig. 2.4) the oxazolidinone derived linezolid 
2.11
22b
 which is to be used for the treatment of MDR-TB
22c
 as well as the β-
sulfonylcarboxamide derivative 2.12.
22d 
The latter mimics the transition state of the 
condensing enzyme of type II Fas, β-ketoacyl synthase in much the same way as the 



























































Figure 2.4: Chemical structures of natural product antitubercular agents 
 
2.2.3. Natural Product Scaffolds as Templates in the Discovery of Anti-infective Agents 
In rationalizing the use of natural products scaffolds as “blueprints”, Henkel and coworkers
24
 
showed through detailed statistical analysis that natural products, compared to synthetic 
compounds, generally have higher molecular weights and therefore do not always comply 
with Lipinski’s rule of five for oral drugs.
25
 It was also found that these products exhibit a 
different distribution of heteroatoms and are sterically more complex by containing more 
rings and chiral centers.
24
 This chemical and structural diversity coupled with the inherent 





Furthermore, the benefits of incorporating natural product scaffolds or derivatives thereof in 
the synthesis of compound libraries is epitomised by the concept of “privileged structures”.
5a
 
This term was first introduced in the 1988s by Evans and coworkers, after witnessing the 
indiscriminate binding of the 1,4-benzodiazepine-2-one scaffold to various receptors.
27a
 It is 
nowadays used to describe ligands that bind various, unrelated enzymes and receptors with 
high affinity.
27b,c
 By utilizing privileged structures, of which the majority are natural products 
or derivatives thereof, compound libraries can be designed or modelled upon one core 
scaffold and screened against various receptors; several active compounds have been 
obtained in this manner.
27c
 A further expectation is that the incorporation of natural products 
or privileged structures into compound libraries will result in the transfer of favourable, drug-
like properties for example bioactivites and bioavailabilities. This approach is also reputed to 
offer libraries of active compounds with high hit rates at smaller library size compared to 
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In our study we were particularly interested in the natural products thiolactomycin, isatin and 
chalcone. A brief account on the discovery, biological profiles, analogue synthesis and SAR 
studies of each of these scaffolds has therefore been undertaken and is presented below. 
 














1.28 2.13  
Figure 2.5: Chemical structures of thiolactomycin 1.28 and key intermediate thiolactone 2.13 
 
Thiolactomycin ((4S)(2E,5E)-2,4,6-trimethyl-3-hydroxy-2,5,7-octatriene-4-thiolide, 1.28, 
TLM) is a broad-range antibiotic isolated from the fermentation broth of a soil bacteria from 
the genus Nocardia. The structure and antibiotic properties of 1.28 was first reported in 1982 
by Oishi and coworkers.
29
 It displays a number of characteristics which makes it an attractive 
lead in the search for anti-infective agents. These include its low toxicity in mice,
29a
 the fact 
that it is well-absorbed orally and selectively inhibits type II fatty acid synthases (FAS)
30
 
which operates in a number of pathogenic organisms. The diverse biological activity of 1.28 









 and Toxoplasma gondii
33e
 - the causative agent of AIDS-related 
opportunistic infections and congenital birth defects - has been reported. Despite favourable 
properties such as low molecular weight, high water solubility and appropriate 
lipophilicity
32g 
the therapeutic utility of 1.28 is limited by synthetic accessibility and stability 
issues.
34
 These liabilities coupled with the selectivity of 1.28 has attracted the attention of 





 and naturally occurring 1.28.
35d-g
 Also reported are the synthesis and biological 
evaluation of analogues obtained either through modification of 1.28 or the key intermediate 
thiolactone 2.13 (fig. 2.5). Some key structure-activity relationships delineated from these 

















Required. Long chain aliphatic 
substituents tolerated for 
antimalarial activity.33c,d 
Isopreniod,32g biphenyl32d,h or 
acetylenic32e groups tolerated for 
anti-TB activity
Etherification significantly improved 
antimalarial33d and anti-TB32f activity. Tolerance 
for variety of sustituents but requires lipophilic 
substituent at C-5 for antimalarial activity.33c
Required to retain selectivity for 
type II over type I FAS.36 Optimal 
chain lenght of three carbons  to 
retain antimalarial activity.33c
Modification not as 
important as C-3 for 
antimalarial activity.33d
 
Figure 2.6: Summary of structure-activity relationships for thiolactomycin 1.28 
 
The elucidation of the crystal structure of 1.28 bound to E. coli’s FabB (section 1.4.2.2.3) 
revealed important interactions between TLM and the enzyme’s active site. One important 
interaction, is the accommodation of the isoprene group at C-5 of 1.28 in an incompletely 
filled hydrophobic crevice.
23,36
 Most of the synthesis of thiolactomycin analogues focussed 
on the replacement and/or modification of the isopreniod side-chain at C-5, with a bulk of the 
work carried out by Jones and coworkers.
33c
 They initially introduced hydrophobic alkyl 
groups at position C-3 and C-5 and generated a series of racemic analogues which were 
evaluated for in vitro growth inhibitory activity against P. falciparum, T. brucei and T. 
cruzi.
33c
 In order to effect detailed SAR studies (fig 2.6) the authors - in a follow-up study – 
explored, in addition to further derivatization of the C-3 and C-5 position, the replacement of 
the sulfur atom with oxygen and nitrogen as well as alkylation of the hydroxyl group at C-
4.
33d
 The most significant enhancement of antimalarial activity - a 100-fold increase 
compared to 1.28 - was observed for the 4-O-alkylated analogues and in particular 2.14 (fig. 
2.7). All of the analogues synthesized were assessed for inhibitory activity against 
recombinant pfKASIII. However, in failing to correlate antiplasmodial activity with 





Within the context of antitubercular activity, thiolactomycin 1.28 is believed to exert its 
mechanism of action by targeting the β-ketoacyl-acyl-carrier protein synthases; mtKas A, 
mtKas B,
30
 and to a lesser extent mtFabH
32b
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tuberculosis (section 1.6.4). Douglas and coworkers
32c
 synthesized racemic thiolactomycin 
analogues with aliphatic substituents at the C-5 position. These were evaluated for inhibitory 
activity against mycolic acid biosynthesis and type II FAS in extracts of M. smegmatis and 
for in vivo activity against the H37Rv strain of M. tuberculosis. The authors found that 
although 1.28 inhibited both type II Fas and mycolate synthesis, analogues with longer side 
chains showed improved mycolate synthase inhibition but appeared to stimulate type II Fas 
activity.
32c





 substituents at the C-5 position which were screened for 
inhibitory activity against recombinant mtFabH. Tolerance for these functionalities was 
demonstrated by compound 2.15 (fig. 2.7) from the biphenyl-based series which showed a 4-
fold increase in activity compared to 1.28 whereas the most active acetylenic analogue 2.16 
(fig. 2.7) showed a 18-fold increase in activity.  
 
Of particular interest to this project is the thiolactomycin analogues synthesized by Kamal 
and coworkers.
32f
 By etherification of the C-4 hydroxyl group of 2.13 (fig. 2.5) they obtained 
a series of compounds of which the most active 2.17 (fig. 2.7) showed anti-TB activity with 
MICs ranging between 1.0-4.0 µg/mL against drug sensitive and resistant strains of M. 
tuberculosis. Speculatively, the latter study challenges the requirement of an isoprene unit or 
substitution at C-5 in the design of antitubercular thiolactomycin analogues. However, a 
detailed structure-activity relationship study conducted by Kim and coworkers
32g
 confirmed 
the importance of this unit for anti-TB activity. By subjecting the isoprenoid side chain of 
fermentation-derived 1.28 to systematic modification (i.e. selective reduction of the double 
bonds, demethylation and methylation) they obtained a series of analogues which were tested 
for inhibitory activity against mtKas A, mtKas B and mtFabH. Consistent with earlier 
findings they failed to correlate whole-cell activity with enzyme inhibitory activity for some 
of the analogues. Also of importance is the research undertaken by McFadden and co-
workers.
36 
It involved the synthesis of thiolactomycin analogues modified at C-3, C-4, C-5 
and was aimed at sourcing inhibitors for type I Fas or more particularly, cancer and obesity 
treatment. The reason for targeting these two disease models reportedly stem from the higher 
level of type I FAS expressed by cancer and tumour cells compared to normal cells and the 
weight loss resulting from the inhibition of type I FAS activity.
37 
Overall, this study showed 
that a methyl group at C-3 is required for thiolactomycin analogues, to maintain selectivity 
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The comparison of biological activities obtained from different studies as done above may be 
questionable, because of different experimental or assay conditions used. However, the 
intention in this project was to demonstrate the utility and validity of the thiolactomycin 



















 2.14   R1 = -(CH2)6OTBS 2.15
2.16 2.17  
Figure 2.7: Chemical structures of antimalarial and antitubercular thiolactomycin analogues 
 









Figure 2.8: Chemical structure of isatin 2.18 
 
Isatin (1H-indole-2,3-dione or 2,3-dioxindoles, 2.18, fig. 2.8) is widely distributed in nature. 
Sources include the plant genus Isatis, 
38a
 the microbial Alteromones specie, the parotid 
glands of Bufo frogs
38b
 and it has also been identified as a metabolite of adrenaline in 
humans.
38c
 This natural product consists of a pyrrole ring fused to a benzene ring, with 
oxygen substituents at positions 2 and 3 (fig. 2.8). It furthermore represents a versatile 
natural product scaffold with diversity points represented by the ketonic carbonyl at C-3, the 
nitrogen in the five membered ring and the C-5, C-7 positions on the aromatic ring.  
 
Consistent with the privileged status of the isatin scaffold, its derivatives exhibit a wide range 
of biological activity. For example, isatin sulphonamides are selective inhibitors of the 














 whereas N-alkylated-5-isatin carboxamide derivatives inhibits the human 
rhinovirus - causative agent of the common cold.
40
 Also, Schiff and N-Mannich base 






















 activity. The antimalarial activity 
and in particular cysteine protease inhibitory activity of thiosemicarbazone derivatives of 
isatin has been discussed in section 1.4.2.1.4.2. With regards to antitubercular activity, Karali 
and coworkers
41k,42
 designed and synthesized 1H-indole-2,3-dione derivatives of which 5-
nitro-1H-indole-2,3-dione -3-thiosemicarbazones 2.19a-c (fig. 2.9) and 1-morpholinomethyl 
derivatives 2.20a-d showed promising in vitro activity against M. tuberculosis with 90-96% 
























2.19a-c: R2 = cycl-C6H11, 4-CH3C6H4, 4-BrC6H4
2.20a-d: R2 = CH3, cycl-C6H11, 4-CH3C6H4, C6H5  
 
Figure 2.9: Chemical structures of compounds 2.19 and 2.20 
 
The chemistry and synthesis of isatin and its analogues has been extensively studied and 
reported in a number of comprehensive reviews and monographs
43
and because of its 
voluminous nature has not been included in this report. 
 









2.21 1.22  
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Chalcones (1,3-diarylprop-2-en-1-one, 2.21, fig. 2.10) represent a major class of natural 
products which act as precursors in the synthesis of flavonoid derivatives.
7
 Structurally, they 
consist of two aromatic rings joined by a conjugated α,β-unstaurated ketone linker. By 
convention, the aldehyde-derived ring is labelled “A” and the acetophenone–derived ring 
“B”.
44
 Furthermore, they comprise of a class of natural product privileged structures which, 
depending on the substituents on the aromatic rings, displays a wide range of biological 













 and antiTB activity.
51
 With regard to antimalarial activity, 
cysteine protease inhibition is the most likely mode of action by which these derivatives exert 
their antimalarial activity (section 1.4.2.1.4.2). It has also been demonstrated that some 
alkoxylated and hydroxylated chalcones inhibit new permeability pathways (NNP) induced 
by the parasite in the erythrocyte membrane.
50g
 These pathways reportedly allows the 
intracellular parasite access to nutrients, organic and inorganic ions, to which an otherwise 
uninfected erythrocyte is impermeant to.
52
 This study investigated the effect of alkoxylated 
and hydroxylated chalcones on the haemolysis of infected erythrocytes caused by sorbitol 
which entered through parasite-induced channels. The results showed a good correlation 
between antiplasmodial activity and inhibition of parasite-induced channels, especially for 
some mono- and dimethoxychalcones. More interesting is the observation that some of the 
potent chalcones did not inhibit parasite-induced channels which lends support to earlier 
observations that antiplasmodial chalcone derivatives, depending on the substituents and 





Chalcones and derivatives are easily prepared by base-catalyzed Claisen-Schmidt 
condensation of an appropriately substituted acetophenone with an appropriately substituted 
benzaldehyde. Invariable yields obtained for some chalcone derivatives led to the 
modification of the Claisen-Schmidt method and included among others the exploration of 


















 have been reported in the 
literature. Also reported is the utilization of ultrasound and microwave
54
 in facilitating rapid 
SAR studies and the application and limitations of alternative synthesis methodologies such 
as Suzuki coupling
55
























Figure 2.11: Chemical structures of compounds 2.22 and 2.23 
 
The pioneering chalcone antimalarial, licochalcone A (1.22, fig. 2.10) was isolated from the 
roots and rhizomes of Glycyrrhiza inflata also known as the Chinese liquorice.
50a
 
Confirmation of the cysteine protease inhibitory activity of chalcones was obtained via 
computer modelling studies.
50c,f
 The key structural requirement identified for antimalarial 
activity is the conjugated α,β-unsaturated ketone linker which imparts rigidity thus forcing 
the chalcone to adopt an almost planar structure that can fit into the long cleft of the active 
site of the enzyme.
44b,50c
 Antimalarial structure-activity relationship studies showed a 
preference for alkoxylated as opposed to hydroxylated chalcones.
44a 
In a separate study, 
Larsen and coworkers evaluated a series of Z- and E-isomers of chalcones for antiplasmodial 
activity and revealed the thermodynamically stable E-isomer as the bioactive conformer.
50e 
 
Incidentally, 1.22 also served as a model for the design of analogues with antileishmanial and 
anti-TB activity. Friis-Möller and coworkers reported a minimum inhibitory activity (MIC) 
of ≤ 20mg/L for 1.22 against M. tuberculosis, M. bovis, M. kansasii, M. xenophii and M. 
marinum.
51b
 Antitubercular structure-activity relationship studies also showed a preference 
for halogen substituents at the C-3 position (ring A) of 2’-hydroxychalcone as typified by 
compounds 2.22 and 2.23 (fig. 2.11) which showed a 90-92% inhibition at a drug 
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2.2.4. Natural Product and Natural product-like Hybrids as a Source of Leads in Drug 
Discovery 
Hybridization is a strategy long used by nature; it involves the covalent linkage of two or 
more molecules derived from different biosynthetic pathways.
57a
 Apart from being 
structurally diverse, biologically active natural products so derived have been found to 
exhibit enhanced or even new properties compared to the monomers. One example is the 
natural hybrid construct, vincristine 2.24 (fig. 2.12) which has revolutionized the treatment of 
childhood leukaemia. It has been found that the monomeric alkaloids individually do not 
display useful biological activity.
57b
 The strategy of hybrid (chimera) construction has since 
filtered into drug discovery programs. It offers advantages such as (i) a reduced propensity 
for the development of resistance when two scaffolds with different modes of action are 
linked, (ii) improved toxicity and bioavailability profile, (iii) enhanced and/or new properties, 
as will be demonstrated by the examples presented below.  
 
The first example, is the artemisinin-quinine hybrid 2.25 [fig. 2.13(a)] synthesized by Walsh 
and coworkers.
58
 Synthesis of this hybrid entailed the linking of dihydroartemisin 1.15 (fig. 
2.2) to quinine 1.1 via its modified vinylic side chain; whilst retaining functionalities 
necessary for antimalarial activity as guided by previous SAR studies.
59
 Intriguingly, the 
hybrid showed superior antimalarial activity compared to (i) artemisinin 1.14, (ii) 1.1 and 
(iii) a fixed ratio (1:1) combination of 1.1 and 1.14. The authors ascribed the dramatic 
increase in potency to enhanced cellular uptake and anticipated an improved side effect 
profile, that is, compared to the individual drugs.
58
 This approach was further validated by 
the linking of the natural product nostocarboline, a phytotoxic agent with the natural product 
derived antibacterial agent, ciprofloxacin via an aryl linker to yield 2.26 [fig. 2.13(b)]. The 
hybrid 2.26 retained both activities with an MIC of 0.7µM against E. coli and 1 µM against 














































Figure 2.13: Chemical structures of natural product hybrids (a) artemisinin-quinine 2.25, and (b) 
nostocarboline-ciprofloxacin 2.26 
 
Examples of natural product-like hybrids include the Schiff base 2.27 (fig. 2.14), which was 
designed with the aim of sourcing compounds that can suppress HIV-replication and inhibit 
M. tuberculosis activity. The hybrid consisted of lamivudine (3TC) a clinically used 
nucleoside HIV reverse transcriptase inhibitor and 5-fluoro substituted isatin.
61
 In vitro 
antiretroviral studies showed that the hybrid 2.27 displayed anti-HIV activity with a median 
effective concentration (EC50) of 0.0742 µM comparable to that of lamivudine (EC50 = 0.1 
µM) as well as antimycobacterial activity with a 82% inhibition at a drug concentration of 
6.25 µg/mL. This is a promising find in light of the unfavourable drug-drug interaction 




















Figure 2.14: Chemical structure of natural product-like hybrid 2.27  
 
The retardation of resistance development was cited as the main motivation behind the dual-
action concept applied in the synthesis of rifamycin-quinolone hybrids. Identified from a 
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spectrum activity in vitro and a reduced propensity for development of resistance. It is 
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2.3. Aims and Objectives of Study 
The hypothesis formulated for this study is that novel antimalarial and antitubercular agents 
with enhanced activity in vitro can be identified by synthetically hybridizing and 
appropriately decorating scaffolds based on natural products or derivatives thereof. We 
therefore sought to achieve the following aims: 
 
• To synthesize and investigate structure-activity relationships in vitro of natural 
product hybrids and derivatives based on thiolactomycin, chalcone and isatin.  
 
• To demonstrate the potential of ‘click chemistry’ for the generation of compounds 
based on the thiolactomycin, chalcone and isatin scaffolds with hitherto unexplored 
structures. 
 
• To pharmacologically evaluate synthesized compounds in vitro for antimalarial and 
antitubercular activity. 
 
• To gain insight into the mechanism of action of the appropriate (most) potent novel 
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The focus of this chapter is on the design, synthesis and characterization of an exploratory 
series of novel compounds obtained by hybridizing bioactive natural product scaffolds. These 
are the thiolactone and isatin ring systems of the naturally occurring compounds 
thiolactomycin and isatin. The synthetic strategy employed for these natural product-like 
hybrids involved simple standard chemistry, which led to the discovery of novel molecules 
bearing a novel tetracyclic ring system. These structurally intriguing molecules formed the 
basis of a more focused SAR study. All of the analogues synthesized were profiled for in 
vitro antiplasmodial activity against chloroquine resistant (W2) and chloroquine sensitive 
(D10) strains, inhibitory activity against the P. falciparum cysteine protease falcipain-2 and 
antimycobacterial activity against the sensitive H37Rv strain of M. tuberculosis.  
 
3.2. Rationale  
The term pharmacophore was first described by Paul Ehrlich in 1909 as "a molecular 
framework that carries (phoros) the essential features responsible for a drug’s (pharmacon's) 
biological activity”.
1
 Pharmacophore hybridization is believed to be analogous to 
conventional combination therapy with the exception that the two drugs are covalently linked 
and available as a single entity
2
. This strategy renders further appeal in that it facilitates 
expeditious SAR studies since the library so generated is enriched in pharmacophores thus 
precluding the need for large libraries and concomitantly shortens the time needed to identify 
potential leads.
2
 It has been successfully employed in our labs in the design of natural 
product-like hybrids modelled on isatin and the 7-chloroquinoline moiety. Identified from 
this study is the thiosemicarbazone derivative 3.1 (fig. 3.1) which showed promising in vitro 






































Figure 3.1: Chemical structures of compound 3.1, thiolactomycin 1.28 and thiolactone 2.13 
 
With regard to the selection of scaffolds, our first choice fell on thiolactomycin (1.28, fig. 
3.1) which is known for its remarkable selectivity and more so its activity against a wide 
spectrum of pathogenic organisms as discussed in section 2.2.3.1. Additionally, the 
availability of detailed SAR studies on thiolactomycin analogues proved invaluable to our 
drug design effort. Another scaffold selected is the natural product, isatin which is present in 
a number of proprietary molecules and synthetic drugs.
4
 Structurally, the isatin scaffold 
provides a hydrophobic aromatic ring which has the potential of binding to hydrophobic sites 
of target(s). Also, the wide spectrum of pharmacological activity exerted by isatin derivatives 
(section 2.2.3.2) confirms the privileged status of this scaffold and thus renders it worthy for 
inclusion in hybrid construction.  
 
The need to consider cost-effectiveness in the design of drugs for infectious diseases is borne 
of the fact that these diseases are prevalent in poor developing countries.
5
 Due consideration 
was given to the above in designing this series of compounds. The general structure of the 
compounds synthesized is shown in figure 3.2. Although modelled on 1.28 these compounds 
are devoid of the hydrophobic side chain at C-5 which is represented by an isoprenoid moiety 
in thiolactomycin. We hypothesized that these novel hybrids will display improved 
therapeutic properties. Some of the key structural and chemical features targeted for 





















Figure 3.2: Rationale for design of target compounds 
 
(i) It was envisaged that a non-hydrolyzable alkane linker would contribute towards 
enhancing the lipophilicity of the compounds to be synthesized. Lipophilicity, and 
therefore permeability, which refers to the ability of compounds to cross biological 
membranes is of particular importance in antimalarial
6a
 and more so in 
antitubercular
6b
 drug design and was therefore given due consideration in our drug 
design endeavour. SAR studies will probe the effect of the linker length on biological 
activity for this series.  
(ii) The thiolactone ring system (2.13, fig. 3.1) structurally resembles the transition state 
of the thiomalonate intermediate in the chain elongation step of fatty acid 
biosynthesis (section 1.4.2.2.3). As delineated from previous SAR studies, 4-O-





 activity. The synthetic accessibility of C-4 derivatized 
analogues compared to C-5 analogues provides a further incentive, that is, despite the 
fact that synthesis of the latter has been the focus of intense research (section 
2.2.3.1).  
(iii) By incorporating the isatin scaffold, we envisaged the transfer of drug-like properties 
to compounds synthesized. SAR will set out to investigate the substituent effect at C-
5' (fig. 3.2) and would further explore N-alkylation of the scaffold which was shown 
to be a common and rewarding diversification route.
2
  
(iv) Overall it was expected that SAR would reveal regions of the target molecule 
important for retention or improvement of activity.  
Natural product scaffold 
R = H, F, Cl, Br, I, CH3 
Linker 
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3.3. Chemical Synthesis 
3.3.1. Retrosynthetic Analysis  
Scheme 3.1 shows that the target compounds can be obtained by two synthetic pathways. In 
route A synthesis of the target molecules is envisioned from an O-alkylated thiolactone 
intermediate and commercially available isatin/5-substituted isatin. Route B offers access to 
the desired hybrids through the reaction of the N-alkylated isatin/5-substituted isatin 3.6 with 
thiolactone 2.13. The latter can be obtained from a base-mediated cyclization of the thioester 
3.4 which in turn can be prepared from an α-bromo compound 3.3. Further analysis of 3.3 
leads to methyl-2-methyl-3-oxopentanoate 3.2 which can derived from the methylation of the 
commercially available methyl propionyl acetate.  
 
Although both routes can afford the desired hybrids, route B offers several advantages such 
as straightfowardness and the ease of preparation of 3.6. Also no additional base is needed in 
this approach, which is of particular importance considering that alkaline bases reportedly 
contribute towards the hydrolysis (S-acyl cleavage) of the thiolactone ring system.
9a
 More 
importantly, with the benefit of hindsight, this route (B) led to the discovery of an 
unexpected and novel tetracyclic by-product and thus lead to diverse thiolactomycin 
analogues. Further appeal to the use of route B resided in the fact that thiolactone 2.13, which 
is obtained through a laborious 4-step reaction can participate as the limiting reagent and the 

































































Scheme 3.1: Retrosynthesis of the isatin-thiolactone hybrids  
 
3.3.2. Synthesis 
3.3.2.1. Synthesis of Thiolactone  
The thiolactone intermediate 2.13 was prepared using the synthesis methodology developed 
by Benary
10
 and revised by Wang and Salvino.
11
 As outlined in scheme 3.2, it starts with α-
methylation of commercially available methyl propionyl acetate to give 2-methyl-3-oxo-
pentanoic acid methyl ester 3.2 in 70% yield after purification using column 
chromatography. Selective bromination of 3.2 afforded the bromo compound 3.3, which was 
carried through to the next step without purification. The next step involved the treatment of 
3.3 with thiolacetic acid in the presence of triethylamine which afforded the thioester 3.4 in 
60% yield. This was followed by the reaction of the 3.4 with 2 eq of KOH and afforded the 
key intermediate 2.13 as a racemic mixture in 60-80% yield after trituration with DCM, 
EtOAc and hexane. The melting point and spectroscopic data of 2.13 correlated well with 
























Scheme 3.2: Reagents and conditions: (i) K2CO3, THF, reflux, 4 h then CH3I, 0-25°C, 15 h; (ii) Br2, 
CHCl3, 1 h at 0°C and 15 h at 25°C; (iii) CH3COSH, Et3N, CH2Cl2, 0-25°C, 6 h; (iv) KOH, EtOH-
H2O, 25°C, 4 h 
 
3.3.2.1.1. Mechanistic Comments  
The proposed mechanism for ring closure of the thioester intermediate 3.4 is shown in 
scheme 3.3. It involves the chemoselective hydrolysis of the thioester followed by an 
intramolecular acylation of the released thiolate to form the keto-lactone. Base-mediated 
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Figure 3.4: Resonance stabilization of the isatin anion 
 
The synthetic versatility of the isatin scaffold has been the topic of several reviews. As 
mentioned earlier, alkylation and acylation appear to be common reactions and in most 
instances represent the first steps in the synthesis of more complex heterocycles.
3,12
 
Regarding the chemoselectivity of these reactions, it is reported that the treatment of the 
silver salts of isatin with alkylating agents yields the easily hydrolysable C-2 O-alkyl 
derivatives whereas the sodium and potassium salts of isatin generates the more stable N-
alkyl derivatives.
3,12b
 However, in another report the reaction of the sodium salt of isatin with 
the γ-butyrolactone13 and allyl bromide14, respectively yielded the C-2 O-alkylated product as 
by-products. The resonance-stabilized isatide anion (fig. 3.4) can be prepared by basic 
removal of the acidic N-hydrogen in the pyrrole ring. One of the bases commonly used is 
NaH.
15






 in DMF 






Scheme 3.4: Reagents and conditions: (i) NaH, DMF, dibromoalkane, 0-25°C for 1 h, then 60°C for 
24 h 
 
The synthesis of 3.6 involved simple chemistry (scheme 3.4). The sodium salt of the 
commercially available C-5-substituted/unsubstituted isatins was generated in situ using NaH 
in anhydrous DMF followed by treatment with a large excess of the appropriate 
dibromoalkane. Recrystallization from MeOH afforded the intermediates 3.6 in good to 
excellent yields as shown in table 3.1. The spectroscopic data of these intermediates correlate 
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Compound isolated as an oil 
Compound R n Yield(%) m.p. (ºC) 
3.6a H 1 95 128 
3.6b Br 1 92 143-144 
3.6c Cl 1 90 114-116 
3.6d F 1 83 102-104 
3.6e I 1 89 153-154 
3.6f CH3 1 98 117-119 
3.6g H 2 86 85 
3.6h H 3 100 52 
3.6i F 3 63 98 
3.6j Cl 3 76 93 
3.6k Br 3 72 87 
3.6l I 3 61 82-83 
3.6m CH3 3 63 114-115 
3.6n NO2 3 54 260 
3.6o H 4 97 -
a
 
3.6p Cl 4 62 93-95 
3.6q Br 4 78 103 
3.6r I 4 78 89 
3.6s H 5 100 42 
3.6t I 5 75 99-101 
3.6u Cl 5 70 57 
3.6v Br 5 66 64-65 
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3.3.2.3. Thiolactones (Thiotetronic acids) 
The chemical properties of the thiolactone ring system accounts for yields obtained for the 
target molecules synthesized. It was therefore deemed necessary to precede the discussion of 
the synthesis of the latter with a brief account on thiolactones and to extract from literature 
some of the challenges encountered in the synthesis of thiolactomycin analogues. 
Thiolactones (or thiotetronic acids) are described as “internal esters of mercapto-acids”.
9
 
Alpha - and β-thiolactones which represent the 3- and 4-membered rings, respectively, were 
discovered in the 1950s whereas the 5- and 6-membered (or γ- and δ-thiolactones) were more 
extensively investigated by then. Various synthesis methods have been reported for the 
different thiolactones. For this project, however, we were interested in the reactivity and 
stability of γ-thiolactones.  
 
A review by Lin’kova and coworkers
9a
 revealed that hydrolysis of γ- and δ-thiolactones is 
most typically mediated by alkaline reagents such as sodium ethoxide, sodium hyride and 
sodium metal and proceed through cleavage of the S-acyl bond. Reportedly, the same 
cleavage is observed when γ- and δ-thiolactones are subjected to aminolysis and alcoholysis. 
In demonstration, Reppe and coworkers
9b,c
 reacted a saturated γ-thiolactone with a γ-lactones 
in the presence of an alkaline base [fig. 3.5(a)]. A correction of the erroneous interpretation 
made by the authors is that the salt of the mercapto acid generated by cleavage of the S-acyl 
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Substituted unsaturated γ-thiolactones are of particular relevance to the project. In the 1960s 
and early 1970s a series of investigative studies on unsaturated γ-thiolactones were 
undertaken and a bulk of the work focussed on their tautomeric properties.
18,19
 Although 
three tautomeric forms are possible for 5-methyl-2-hydroxythiophene [III, fig. 3.5(b)] earlier 
studies confirmed the presence of only two forms being 5-methyl-3-thiolene-2-one [I, fig. 
3.5(b)] and 5-methyl-4-thiolene-2-one [II, fig. 3.5(b)].
18
 Research into 4-hydroxy-3,5-
dimethylthiophen-2-(5H)-one (γ-thiolactone or thiolactone) 2.13 gained momentum with the 
discovery of its presence in pharmacologically important natural products. Alkylation of 2.13 
appears to be the main synthesis route for the preparation of diverse analogues. 
 









 were among the first to show that alkylation of unsaturated γ-
thiolactone yields an isomeric mixture of compounds. This observation was attributed to the 
resonance stabilization of the thiolate anion as shown in figure 3.6. Douglas et al prepared 
racemic thiolactomycin analogues as potential antitubercular agents by utilizing different 
bases [NaH, lithium bis(trimethylsilyl)amide (LiHMDS), t-BuLi], and base combination 
(NaH/t-BuLi and NaHMDS/t-BuLi) for the deprotonation of 2.13.
20
 Intriguingly, reaction of 
the latter with an alkyl halide in the presence of 1 eq of NaH led to the formation of the 3-
alkyl-3,5-dimethyl-thiophene-2,4-dione [fig. 3.7(a)]. With the base combination, NaH/t-BuLi 
it was found that whilst the relatively milder base NaH removed the more acidic enol proton, 
the stronger base, t-BuLi removed the proton at C-5 to generate the dianion [fig. 3.7 (b)]. The 
more nucleophilic center of the dianion reacted preferentially with appropriately substituted 
alkylating agents and afforded the desired 5-substituted analogues in 11-36% yield.
20
 Kamal 
and coworkers, synthesized O-alkylated thiolactomycin derivatives with different alkane 
linkers using K2CO3 in acetone.
8




























































For the synthesis of their first series of C-3 and C-5 thiolactomycin analogues, Jones and 
coworkers
21
 treated the thiolactone dianion (prepared with the base combination NaH/n-
BuLi) with different halides to afford the analogues in 4-22% yield. In recognition of the 
sensitivity of 2.13 to strongly basic conditions and the contribution thereof to the observed 
low yields, they decided to modify the alkylation procedure by constructing the appropriately 
substituted (thioester) carbon skeleton prior to cyclisation or ‘thiolactonization’.
7
 In another 
study, Takabe and coworkers
22
 attempted O-alkylation of 2.13 using NaH and CH3I at room 
temperature. Although the reaction proceeded regioselectively, only 9% of the product was 
obtained after 144 hours.  
 
Alkylation procedures which yields the 4-alkoxy derivative of 2.13 exclusively, were 
developed by two independent research groups. Wengel and coworkers
23
 reacted a derivative 
of 2.13 with tetrabutylammonium hydroxide (TBAH) and an appropriate dialkyl sulfate 
(phase transfer conditions) whereas Schobert and Siegfried
24
 utilized appropriately 
substituted isourea. To synthesize a 4-alkoxy derivative of 2.13, Shenoy and coworkers
25
 
used the abovementioned procedures. They however, obtained a mixture of 2- and 4-
methoxy-3,5-dimethylthiotetronic acid in ratios of 1:6.4 (with the Wengel method) and 1:2.3 
(with the Schobert method). The first step of the chemoenzymatic synthesis of 1.28 
developed by Takabe and co-workers involved the protection of the C-4 hydroxyl group of 
2.13. They utilized the procedure developed by Wengel and Schobert for the methylation of 
2.13. The reaction proceeded chemoselectively - consistent with the findings of Shenoy - and 
afforded an isomeric mixture (4-methoxy:2-methoxy) in the ratio 82:18.
22 
In another study, 
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derivatives with various alkylating agents in the presence of NaH in DMF.
26
 In a few cases, 
depending on the alkylating agent used, a mixture of products was obtained; these included 
the C-3 C-alkylated, C-2 O-alkylated and the preferred C-4 O-alkylated product, as predicted 











































R = H, n = 1,3
R = H, n = 3-5
R = H, n = 1-5








Scheme 3.5: Reagents and conditions: (i) Dibromoalkane, K2CO3, Acetone, reflux, 16 h, 40-65%, (ii) 
Isatin, NaH, DMF, 60°C, 10-13%, 48 h, (iii) KOH, MeOH-H2O, 25 °C, 4 h, 95-100%, (iv) 3.6, DMF, 
60°C, 48 h, 9-36%. 
 
The two routes explored for the synthesis of 3.7 are shown in scheme 3.5. Our initial attempt 
(route A) involved the reaction of the colourless 4-O-alkylated thiolactone intermediates with 
isatin in the presence of NaH. The former was obtained by refluxing 2.13 and K2CO3 and the 
appropriate dibromoalkane in acetone.
8
 Because of the low-yields obtained for 3.7, 11% for 
the ethyl linked hybrid and 13% for the butyl linked hybrid, route A was not pursued further. 
The alternative route (route B) differs from the former in that the desired hybrids 3.7 can be 
accessed by the reaction of the N-alkylated isatin intermediates 3.6 with 2.13. Attempts to 
further optimize this route entailed exploring bases with varying strengths. The reaction of 
3.6g with 2.13 in the presence of NaH in anhydrous DMF afforded the desired hybrid but the 
yield obtained was still very poor. A second attempt involved replacing the relatively strong 
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4 eq of K2CO3 did not produce the desired hybrid but instead an unidentified product was 
isolated. All efforts were then directed towards the method which utilizes the potassium salt 
of thiolactone 3.5. The latter was obtained in excellent to quantitative yield from the reaction 
of 2.13 with an equimolar amount of aqueous potassium hydroxide in MeOH at room 
temperature. The hygroscopic nature of 3.5 required it to be dried thoroughly prior to its 
reaction with 1.5 eq of 3.6 in anhydrous DMF. The reaction mixture was stirred at room 
temperature under a nitrogen atmosphere, but no noticeable reaction was observed as inferred 
from the thin layer chromatography (tlc) of this red coloured mixture after 24 hours. The 
temperature was then increased to 60°C and tlc confirmed the consumption of the starting 
material after stirring at this temperature for 48 hours. The recrystallized yields obtained for 
the orange coloured products 3.7 (table 3.2) were still disappointingly low but are in 
agreement with previous publications in this area.
7,11,20,27
 It is reasonable to assume that a 
likely contributor to these low yields is the ring-opening polymerization of the thiolactone 
ring under basic conditions (section 3.3.2.3). In fact a significant amount of unidentifiable 
baseline material was isolated during the purification of the crude product mixtures.  
 
Another more likely cause of the low yields is the formation of by-products, as observed 
when the N-alkylated isatin intermediates bearing the n = 3-5 linkers (3.6h, 3.6o and 3.6s) 
were reacted with 3.5. The by-product had a slightly lower Rf than the desired hybrid and on 
tlc (40% EtOAc/Hex) appeared colourless to the naked eye compared to the orange spot 
observed for the desired hybrids. We initially suspected it to be a regioisomer (C-3-alkylated 
or C-2 O-alkylated product, fig. 3.6) because of similarities in the spectral and elemental 
analysis data. It was the single crystal X-ray structure which revealed the tetracyclic nature of 
the by-product 3.8.  
 
Purification of the isomeric mixture obtained for the n = 3-5 linked hybrids presented an 
additional challenge. Repeated column chromatography and at times preparative tlc in 
combination with recrystallization were required to separate the isomers. The contribution of 
this elaborate purification towards the observed low yields can not be ruled out. The yields 
obtained for the yellow crystalline tetracycles 3.8 are shown in table 3.3. Despite the low 
yields sufficient amounts of both the desired hybrids 3.7 and by-product 3.8 were obtained 
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The product distribution for compounds 3.8a-c is shown in Table 3.3. A combined yield of 
45% was obtained for compounds 3.7h and 3.8a, with the latter being the major contributor. 
What is noticeable is the significant change in product distribution on going from the 4-
carbon linker to the 5-carbon linker. A decrease in combined yields with increasing chain 
length was observed for 3.7i and 3.8b (31% ) and 3.7j and 3.8c (21%). The lack of formation 
of 3.8 with the ethyl and propyl linked hybrids (3.7f and 3.7g) and the low yields obtained for 
3.8b and 3.8c will be discussed briefly in section 3.3.3.1. 
Compound R n Yield (%) m.p. (ºC) 
3.7a Br 1 9 168-169 
3.7b Cl 1 13 270-272 
3.7c F 1 14 132-133 
3.7d I 1 10 196 
3.7e CH3 1 26 130 
3.7f H 1 36 54 
3.7g H 2 18 150-151 
3.7h H 3 10 108 
3.7i H 4 22 77-79 
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aRatio of desired hybrid (D) to tetracyclic by-product (T) as determined from recrystallized yield after 
48 hour reaction. 
b
Yields of the tetracyclic compounds only. 
 
3.3.2.4. Tetracyclic By-products 
Interest in the tetracycles 3.8 was sparked by the ease and simplicity of their preparation and 
the novelty of their architecture. Attractive structural features include two vicinal quaternary 
stereogenic centers, the presence of various heteroatoms and a complex, bridged/bicyclic ring 
system (fig. 3.8). The difficulty and failure to name these unique structures according to the 
IUPAC nomenclature
28
 is due to the complexity of the ring system. The bridge fused ring 
system is represented in figure 3.8 by the lactam rings B and C and the amidic carbonyl as 
bridge. Also present is the 3-substituted 3-hydroxyindolin-2-one moiety which features 














Figure 3.8: General structure of the tetracyclic compounds 3.8 
 
A preliminary biological screen showed that some of the tetracycles were more active than 
the corresponding desired hybrids. They therefore formed the basis of a more focussed SAR 
study. Synthesis of the tetracycles 3.8d-p (table 3.4) was preceded by a model study with 3.5 
and the N-alkylated isatin intermediate 3.6h. This study moreover entailed monitoring the 
reaction progress and thus product distribution at regular intervals using 
1
H NMR. An 
observation made is that prolonged reaction times led to an increase in tetracycle product 




 m.p. (ºC) 
3.8a H 3 22:78 35 184-185 
3.8b H 4 84:16 9 214-215 
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formation. Therefore to effect the synthesis of 3.8d-p we employed the same reaction 
conditions shown in scheme 3.4, but increased the reaction duration from 48 hours to 120 
hours. However, in spite of this modification we still obtained poor yields for these 
tetracycles (table 3.4).  
 


















Ratio of desired hybrid (D) to tetracyclic by-product (T) as determined from recrystallized yields after a 120 
hour reaction. 
b
Yields of the tetracyclic compounds only.
 c
Ratio determined from the crude using 
1
H NMR. 





3.8d Br 11:89 14 156-157 
3.8e I 10:90 15 205-206 
3.8f F 19:81 10 157 
3.8g Cl 15:85 14 208-210 
3.8h CH3 33:67 6 170-173 
3.8i NO2 30:70 8 215-217 
3.8j Cl 63:37
c
 5 200-201 
3.8k Br 67:33
 c
 7 203-205 
3.8l I 60:40
 c
 4 189-192 
3.8m Cl 80:20 6 214-215 
3.8n F 69:31 7 212-213 
3.8o Br 73:27 6 211 
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Scheme 3.6: Proposed mechanism for the formation of the tetracycles 3.8 
 
The proposed mechanism for the macrocylization of 3.7 is shown in scheme 3.6. It involves 
an in situ deprotonation of the thiolactone ring in 3.7 at C-5, by the relatively basic 3.5. 
Carbanion formation destroys the original stereogenic center of 3.7. Moreover, this 
intermediate carbanion is stabilized by resonance and by the neighbouring sulfur. This 
stabilizing effect of sulfur on an adjacent carbanion is well known.
30,31
 It reportedly involves 
the delocalization of the negative charge into the σ* orbital of the C-S bond and is in contrast 
to the earlier belief that the negative charge is delocalized into the empty 3d orbital of 
sulfur.
30a
 The flexibility of the alkane tether (for n = 3-5) allows for the proper alignment of 
the orbitals of the reacting groups and thus facilitates the intramolecular addition of the 
nucleophile to the activated ketonic carbonyl of the isatin scaffold. The planar symmetry of 
the isatin scaffold or, more specifically, ketonic carbonyl allows for nucleophilic attack from 
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3.3.2.4.2. Factors Controlling Macrocyclization  
Medium (8-11 ring atoms) and large rings (12 or more ring atoms) are of particular interest in 
synthesis because of their appearance in natural products of biological importance. One of 
the drawbacks of macrocyclization reactions is poor yields which can be ascribed to several 
factors. The key factors which affect the ease of ring closure are ring strain, the entropy 




Most of the information on strain energy originated from the study of cycloalkanes.
31, 32b
 It 
reportedly arises from the combination of transannular, Pitzer and Baeyer strain. 
Transannular strain is commonly found in rings containing 7-13 carbons and arises from the 
repulsive interaction between ring atoms which as a consequence of cyclization are in close 
proximity to each other. Pitzer strain on the other hand, arises when substituents on adjacent 
carbon atoms are forced to adopt an eclipse or partial eclipse conformation to relieve 
transannular strain. Baeyer strain or large-angle strain occurs at the expense of transannular 
and Pitzer strain and is characterized by the distortion of ring bond angles.
31
 Overall, the 
strain energy for medium size rings are reportedly fairly low whereas large rings experience 
little or no strain.
31,32a
 It is conceivable that the lack of formation of 3.8 with the ethyl (n = 1) 
and propyl (n = 2) linked hybrids 3.7 is due to strain at the transition state.  
 
The entropy factor first postulated by Ruzicka in 1935,
33
 refers to the probability of the 
reactive ends of a chain to coincide or merge. This probability reportedly decreases as the 
chain gets longer.
32b
 The trade-off with large rings and to some extent medium rings, is that 
although they experience no or little ring strain the probability of the reactive ends coinciding 
is very poor. It is therefore reasonable to assume that the decrease in yield with increasing 
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3.4. Characterization 
3.4.1. Spectroscopic Analysis  
The spectroscopic data obtained for the desired hybrids 3.7 is consistent with the proposed 
structures. The molecular ion peak observed in the mass spectra of all the compounds in this 
series correlated with their respective molecular weights. Common and characteristic infrared 
bands identified include the ketonic (C-3) and amidic (C-3) carbonyls of the isatin scaffold 
which appeared in the ranges 1732-1743 cm
-1
 and 1600-1620 cm
-1
, respectively - consistent 
with literature data.
2
 The infrared band at 1623-1675 cm
-1
 is in agreement with the carbonyl 
absorption band of the thiolactone ring system.
6





NMR spectra of the representative compound 3.7h. The 
1
H NMR data [fig. 3.9(b)] showed 
some key signals which includes two doublets resonating at δ 1.55 and δ 1.80 each 
integrating for 3 protons which was assigned to the methyl protons H-6” and H-7”, 
respectively. A pair of one-proton multiplets resonating at δ 4.22 and δ 4.35 was assigned to 
the methylene protons H-4’a/b [fig. 3.9(c)]. The observed splitting of these enantiotopic 
protons is most likely due to their proximity to the chiral center at C-5”. The protons of the 
isatin scaffold appeared in the aromatic region of the spectrum. Proton H-7 appeared as an 
unexpected doublet (J 7.8) at δ 6.90 and H-5 as a triplet of doublets (J 0.9, 7.8) at δ 7.13. The 
overlapping signals of H-6 and H-4 appeared at δ 7.60 [fig. 3.9(a)].  
 
1




H COSY experiments revealed mutual coupling 
between the methyl protons H-7” (J 0.9) and the methine proton H-5” at δ 4.14 which 
appeared as a quartet of doublets (J 0.9 and J 6.9). According to a recent publication this 
anomalous, mutual coupling which the authors erroneously referred to as an ‘allylic’ 
coupling is of diagnostic value and can be used to distinguish between the 2- and 4-enol 
(ethers) of the thiolactone.
25
 This ‘allylic’ coupling is reportedly only observed with the 4-




































Figure 3.9: (a) 
1
H NMR spectrum of compound 3.7h in CDCl3 at 300MHz with expanded regions (b) 




C NMR spectrum of compound 3.7h showed 18 non-equivalent signals which 
correlates with the number of carbons expected. Key signals appeared at δ 195.7, δ 183.2 and 
δ 158.3 and were assigned to the carbonyl carbons at C-2”, C-3 and C-2 respectively. 
Another carbon signal of interest is the methine carbon C-5” resonating at 41.9. Confirmation 
of assignment of the 
13
C NMR data was done by comparison with published data for natural 
occurring thiolactomycin
11
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C NMR spectrum of compound 3.7h in CDCl3 at 75MHz 
 
The unambiguous assignment of the structures for the tetracyclic by-products could not be 
done on the basis of spectroscopic data alone. The latter however, revealed some significant 
differences between compound 3.8a and the previously discussed isomer 3.7h. Characteristic 
IR absorptions for compound 3.8a included the carbonyl of the thiolactone and the amidic 
carbonyl of the isatin scaffold observed at 1700 cm
-1
 and 1620 cm
-1
, respectively. The 
presence of a hydroxyl group was inferred from the characteristic broad band at 3311 cm
-1
. 
Figure 3.11 shows the 
1
H NMR spectrum of the representative compound 3.8a. The shielded 
end of the spectrum shows 2 three-proton singlets at δ 1.60 and δ 1.99 which was assigned to 
methyl protons H-6 and H-7, respectively. A signal of interest is the broad, one-proton 
singlet at δ 3.35 which disappeared after D2O-exchange and was assigned to the hydroxyl 
proton. Also noteworthy is the observed splitting of the methylene protons of H-1”and H-4” 
which appeared as 4 one-proton multiplets. HSQC data aided the assignment of the geminal 
coupled protons at H-1” which resonates at δ 3.38 and δ 4.29. In contrast to 3.7h the signal in 
the aromatic region in the 
1
H-NMR spectrum of 3.8a, assignable to the isatin scaffold, are 
well-resolved. The one-proton double doublet (J 1.2 and 7.6) at δ 7.80 was assigned to H-
4’which showed ortho (J 7.6) and meta (J 1.2) coupling to H-5’ and H-6’, respectively. The 
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H-6’ at δ 7.28 (J 1.2, 8.0). The other signal in this region is the one-proton doublet (J 8.0) at 





























C NMR spectrum of 3.8a (fig. 3.12) supplemented with DEPT experiments was used 
to distinguishing between methyl, methylene and quaternary carbons. Key signals are 
represented by the quaternary carbons C-5 and C-3’generated by the cyclization of 3.7h 
































































13C NMR spectrum of compound 3.8a in CDCl3 at 100MHz  
 
3.4.2. Crystallographic Analysis 
The single crystals obtained for compounds 3.8a-c from MeOH at room temperature were 
subjected to crystallographic analysis. Crystal and refinement data obtained is summarized in 
table 3.5. For subsequent discussion we have used the atom numbering scheme of the 
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Table 3.5: Crystal data and structure refinement for compounds 3.8a-c with estimated standard 
deviations in parentheses 
 
Parameter 3.8a 3.8b 3.8c 
Molecular formula C18H19NO4S C19H21NO4S C20H23NO4S 
Formula weight (g/mol) 345.40 359.43 373.45 
Crystal system triclinic monoclinic monoclinic  
Space group P-1 P21/n P21/n 
Unit cell dimensions: a (Å) 9.18680(10) 7.7577(2) 7.9966(3) 
                                     b (Å) 13.60830(10) 13.1299(5) 13.1259(4) 
                                     c (Å) 14.42970(10) 17.2540(6) 17.3410(7) 
                                     α (°) 67.7380(10) 90 90 
                                     β (°) 78.2150(10) 100.819(2) 97.644(2) 
                                     γ (°) 86.5250(10) 90 90 
Volume (Å
3
) 1634.02(2) 1726.22(10) 1803.98(11) 
Z 4 4 4 
Calc. density (Mg/m
3
) 1.404 1.383 1.375 
µ(MoKa) (mm
-1
) 0.220 0.212 0.205 
F (000) 728 760 792 
Temperature (K) 113 213 173 
Wavelength (Å) 0.71073 0.71073 0.71073 
Crystal size (mm) 0.35x0.33x0.25 0.24x0.22x0.21 0.33x0.26x0.22 
Range of θ scanned (°) 3.62 to 25.39 3.09 to 26.72 2.68 to 25.69 
No. of measured 
reflections 
51402 7137 6705 
No. of unique reflections 5962 3654 3432 
R(int) 0.0439 0.0274 0.0330 
No. of parameters 446 233 240 
Goodness-of-fit on F
2
  1.042 1.040 1.033 
R indices (all data) R1 = 0.0402 
wR2 = 0.0768 
R1 = 0.0531 
wR2 = 0.0845 
R1 = 0.0718 
wR2 = 0.1066 
Extinction coefficient 0.0016(9) 0.0026(8) 0.0027(9) 
∆ρ excursions (e.Å
-3
) -0.270,0.271 -0.301, 0.217 -0.378, 0.367 
 
For compounds 3.8a [fig. 3.13(a)], all non-hydrogen atoms were refined anisotropically and 
all hydrogen atoms except the hydroxyl hydrogens were fixed geometrically and were refined 
using a riding model, with C–H = 0.95 – 0.99 Å and Uiso = 1.2 -1.5 x Ueq(C). The hydroxyl 
hydrogens were located in the difference electron density maps and refined with simple bond 
length constraints. The structure was refined successfully with R = 0.0305. Compound 3.8a 
crystallizes in the triclinic unit cell with space group P-1 and contains four molecules per unit 
cell. This centrosymmetric space group confirms the racemic nature of 3.8a. The crystal 
structure furthermore revealed the presence of two non-equivalent molecules which is 
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with the labels A and B in the atom numbering scheme [fig. 3.13 (b)]. Because of similar 











(a)     (b) 
 
Figure 3.13: (a) Molecular structure of 3.8a with probability level = 40%, (b) structure of the dimer 
showing the atomic numbering scheme. All hydrogen atoms are omitted except the hydroxyl 
hydrogens. 
 
In the structure of 3.8a the indole ring is almost planar with C7A and C8A showing 
deviations of -0.0918(10) and +0.0902(11), respectively from the least square plane. The syn 
relationship between the methyl at C5A and the hydroxyl group at C7A was inferred from 
the torsion angle of -65.86º(14) for O4A-C7A-C5A-C6A. Also noted are the dihedral angles 
106.81º (11) and 113.29º (11) for O4A-C7A-C5A and C6A-C5A-C7A, respectively which 
shows a distortion from the expected value (109.47º) for the tetrahedral sp
3
 carbon. It is 
conceivable that this distortion coupled with the bond lengthening of C7A-C5A [1.5783 (19) 
Å] is due to the steric interaction between the relatively bulky hydroxyl group at C7A and the 
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Figure 3.14: Packing diagram of 3.8a with projection viewed along [100]. All hydrogen atoms are 
omitted except the hydroxyl hydrogens  
 
The stabilization effect of the hydrogen bonding for 3.8a is illustrated in the packing diagram 
(fig. 3.14). Hydrogen bond lengths and bond angles are given in table 3.7. 
 
Table 3.6: Selected bond angles (º) and bond lengths (Å) for compounds 3.8a-c 
 3.8a
a
 3.8b 3.8c 
C5A-C7A 1.5783(19) 1.5758(19) 1.572(3) 
C8A-O3A 1.2271(17) 1.2229(16) 1.223(2) 
C7A-O4A 1.4103(16) 1.4179(16) 1.425(2) 
 
C6A-C5A-C7A 113.29(11) 113.96(12) 112.75(17) 
O4A-C7A-C5A 106.81(11) 110.60(10) 109.39(16) 
 
C6A-C5A-C7A-O4A -65.86(14) -70.17(15) -65.3(2) 
O3A-C8A-C7A-C5A -73.33(17) -66.50(17) -64.0(3) 
S1A-C5A-C7A-C8A 177.45(9) 172.63(9) 175.27(14) 
a 
 Parameters for diastereomer A 
 
All the hydrogen atoms for compounds 3.8b-c except the hydroxyl hydrogen H4 were 
included in idealised positions in a riding model with Uiso set at 1.2 or 1.5 times those of the 
parent atoms. The hydroxyl hydrogen H4 was located by difference Fourier methods and 
refined independently. The structure was refined successfully with R = 0.0335 for 3.8b and R 




















(a)        (b)  
Figure 3.15: Molecular structure of (a) 3.8b and (b) 3.8c with ellipsoidal model of probability level = 
35%. 
 
Both compounds crystallized in the racemic monoclinic space group P21/n with 4 molecules 
in the asymmetric unit. Figure 3.15 shows the molecular structure and atom labelling for 3.8b 
and 3.8c. As observed for 3.8a the indole moiety in these compounds is nearly planar with 
the maximum deviation from the least-squares plane for all the nine atoms in the ring at + 
0.045(1) and 0.0412(15) for C-8 in 3.8b and 3.8c, respectively. Important bond angles and 
lengths are summarized in table 3.6. Similar to 3.8a, a stabilizing hydrogen bonding network 
was observed for both compounds exemplified by the packing diagram of 3.8b (fig. 3.16).  
 
Table 3.7: Hydrogen bond distances and bond angles for 3.8a-c 
Code D-H…A D-H(Å) H…A(Å) D…A(Å) DHA(°) 
3.8a
a
 O4A-H4A…O3B 0.9798(10) 1.808(6) 2.7638(14) 164.2(18) 
3.8b O4-H4…O3 0.8500(19) 1.947(19) 2.7723(15) 163.3(18) 
3.8c O4-H4…O3 0.9798(10) 1.894(9) 2.848(2) 164(3) 
a 
















Figure 3.16: Packing diagram of 3.8b with projection viewed along [100]. All hydrogen atoms are 
omitted except the hydroxyl hydrogens H4. The hydrogen bond O4-H4···O3 is shown as a dotted line.
  
 
3.5. Biological Results and Discussion 
Consistent with the objectives of this project compounds 3.7a-j, 3.8a-p and a few advanced 
intermediates 2.13 and 3.6, were evaluated for in vitro growth inhibitory activity against 
chloroquine-resistant (W2) and chloroquine-sensitive (D10) strains of P. falciparum, for 
falcipain-2 inhibitory activity and for growth inhibitory activity of the H37Rv strain of M. 
tuberculosis. 
 
Testing for antiplasmodial activity against the D10 strain of P. falciparum was conducted at 
the Department of Pharmacology, University of Cape Town (UCT). The evaluation of 
compounds for antiplasmodial activity against the W2 strain of P. falciparum and inhibitory 
activity against recombinant-falcipian-2 were conducted at the Department of Medicine, San 
Francisco General Hospital, University of California San Francisco (UCSF). Reference 
compounds used include chloroquine (CQ) for growth inhibition of the D10 and W2 strains 
and E64 for recombinant-falcipain 2 inhibition studies. Experimental details pertaining to the 
above assays are given in the experimental section. The antiplasmodial activities herein 
reported are expressed as a 50% inhibitory concentration (IC50) which describes the 
concentration of a drug necessary to bring about a therapeutic effect such as the inhibition of 
growth or activity in 50% of the test sample. Also determined is the resistance indices (RI) of 
compounds tested against both D10 and W2 strains. It serves as an indication of the 
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falciparum and is used to evaluate whether novel antimalarials have potential activity against 









The calculated log P (c log P) is the physiochemical parameter that describes the lipophilicity 
of a compound and its ability to transverse membranes. The values herein reported were 
calculated using the ChemDraw Ultra 9.0 software.  
 
3.5.1. In vitro Antiplasmodial Activity 
As can be seen from tables 3.8, 3.9 and 3.10, none of the compounds in this series exhibited 
any significant activity against the CQR resistant and CQS strains. In fact, the most active 
compound identified is 3.8p (IC50 = 6.92 µM) which is 100-fold less active than chloroquine 
against the W2 strain. Despite the low activity it is of interest to note that the target 
molecules, with the exception of 3.7e, 3.7g-h and 3.8b, showed enhanced activity compared 
to natural occurring 5R-thiolactomycin 1.28 (Sigma-Aldrich, SA). The results also suggest 
that the tetracycles 3.8 are more active than their precursors 3.7. None of the intermediates 
(table 3.8) were able to inhibit the W2 strain at the highest concentration (20µM) tested. For 
the limited series 3.7, compounds 3.7a, 3.7i and 3.7j show poor growth inhibitory activity 
against the W2 strain with IC50s of 17.40, 15.30 and 12.30 µM, respectively whereas the 
remaining compounds in this series were inactive. A similar trend was observed for the 
tetracycles 3.8. Compounds 3.8m, 3.8o, 3.8p and 3.8c showed moderate activity against the 
W2 strain. 
 
In contrast to the tetracycles 3.8, most of target molecules 3.7 (except 3.7e, 3.7g, 3.7h) 
showed falcipain-2 inhibitory activity albeit weak compared to the control drug, E64. It is 
tempting to speculate that this is due to the presence and/or availability of the ketonic 
carbonyl on the isatin scaffold for interaction with the cysteine thiol of the enzyme. However, 
the results obtained for the tetracycle 3.8k (IC50 = 10.10 µM) argues against the importance 
of this functionality for enzyme inhibition. In fact, identified from this series is compound 
3.8k which displayed the best falcipain-2 inhibitory activity albeit 200-fold less active than 
the standard drug, E64. Furthermore, the inhibition of falcipain-2 activity despite the lack of 
growth inhibitory activity observed for 3.7d may be an indication of the failure of the 
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and/or inadequate solubility. It is therefore safe to assume that poor solubility is the main 
contributor towards the observed low activity for this series of compounds.  
 
Table 3.8: In vitro antiplasmodial activity and falcipain-2 inhibitory activity of intermediates 














Chloroquine - - - 0.06938 0.03823 
E64 - - 0.04733 - - 
1.28 - - >100 >20 >100 
2.13 - - >100 >20 >100 
3.6a H 1 >100 >20 >100 
3.6g H 2 >100 >20 78.29 
3.6h H 3 >100 >20 36.37 
3.6i I 3 >100 >20 11.00 
3.6j Cl 3 >100 >20 9.03 
3.6k Br 3 >100 >20 28.03 
3.6l F 3 >100 >20 63.21 
3.6m CH3 3 >100 >20 36.26 
3.6n NO2 3 11.35 >20 23.02 
3.6o H 4 >100 >20 38.22 
3.6s H 5 >100 >20 >100 
 
Regarding the effect of the substituent (R) at C-5 of the isatin scaffold on the antiplasmodial 
activity for the 3.7 series, the results obtained were inconclusive and no useful trends could 
be delineated. This is in contrast to the trends observed for tetracycles 3.8 which is 
graphically represented in figure 3.17(a). It shows that the unsubstitued isatin derivative (R = 
H) is the least active whereas the derivative bearing a nitro group- a known toxiphore
34 
- is 
the most active for the butyl linked tetracycles. The preference for substitution at C-5 for the 
n = 5 linked hybrids is further demonstrated by the poor activity of unsubstituted isatin 
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RI c log P 
CQ - - - 0.06938 0.03823 1.81 - 
E64 - - 0.04733 - - - - 
1.28 - - >100 >20 >100 - - 
3.7a Br 1 31.70 17.40 42.65 0.41 2.88 
3.7b Cl 1 47.80 >20 32.12 - 2.73 
3.7c F 1 89.60 >20 99.30 - 2.16 
3.7d I 1 17.80 >20 >100 - 3.14 
3.7e CH3 1 >100 >20 66.99 - 2.34 
3.7f H 1 40.20 >20 31.95
b
 - 1.84 
3.7g H 2 >100 >20 37.12 - 2.11 
3.7h H 3 >100 >20 61.09 - 2.16 
3.7i H 4 58.00 15.30 35.61 0.43 2.69 
3.7j H 5 32.00 12.30 26.00 0.47 3.22 
a
Rec-FP-2 = Recombinant Falcipain-2; 
b
Compound tested as a suspension 
 
Lipophilicity is an important property for thiolactomycin analogues; considering that the 
former need to cross multiple membranes to reach their target site (section 1.4.2.2). The 
correlation between c log P and growth inhibitory activity against W2 is clearly evident for 
series 3.7 but is more pronounced for 3.8 [fig. 3.17(b)]. A comparison of the activity of 
unsubstituted isatins (R = H) with increasing chain length (n = 3-5) for the tetracycles (3.8a-
c) reveal a decrease in the activity against the D10 strain whereas the activity against the W2 
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RI c log P 
CQ - - 0.06938 0.03823 1.81 - 
E64 - 0.04733 - - - - 
1.28 - >100 >20 >100 - - 
3.8a H >100 >20 72.67 - 2.12 
3.8b H >100 >20 >100 - 2.68 
3.8c H >100 11.50 >100 - 3.24 
3.8d Br >100 >20 66.41 - 3.12 
3.8e I >100 >20 34.18
c
 - 3.38 
3.8f F >100 >20 21.96
c
 - 2.40 
3.8g Cl >100 >20 56.8 - 2.97 
3.8h CH3 >100 >20 29.46
c
 - 2.62 
3.8i NO2 44.50 >20 18.85
c
 - 2.16 
3.8j Cl >100 >20 9.47 - 3.53 
3.8k Br 10.10 >20 9.93 - 3.68 
3.8l I >100 >20 97.77 - 3.94 
3.8m Cl >100 7.41 9.86 0.75 4.09 
3.8n F >100 14.00 6.46
c
 2.17 3.52 
3.8o Br 83.40 6.93 7.44 0.93 4.24 
3.8p I 48.30 6.92 9.07
c
 0.76 4.50 
a
Rec-FP-2 = Recombinant Falcipain-2; 
b
RI =Resistance Index; 
c
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(a)      (b) 
Figure 3.17: Graph showing (a) the substituent effect on activity against the D10 strain for the n = 3 
linked tetracycles 3.8, and (b) the effect of chain length for the bromo-, iodo- and chloro-substituted 
tetracycle 3.8 on activity against the D10 strain of P. falciparum  
 
3.5.2. In vitro Antitubercular Activity 
The synthesized compounds were evaluated for in vitro antitubercular activity in three 
different assays conducted at two independent laboratories. Testing for activity against the 
drug-sensitive strain of M. tuberculosis, H37Rv using the radiometric BACTEC method, was 
done locally at the Department of Biomedical Sciences, University of Stellenbosch (US). In 
brief, the BACTEC method involves the use of a broth medium containing 
14
C-palmitic acid 
(substrate) as the only source of carbon. The growing mycobacteria consumes the substrate 
with subsequent release of radioactive 
14
CO2 during respiration, which is measured and 
recorded by the BACTEC TB 460 instrument (Becton Dickinson, Sparks, MD USA) as a 
growth index (GI) on a scale of 0-999.
35
 The controls used were drug-free and undiluted with 
the same culture inoculum as used in the drug-containing vials. Because of the high cost of 
BACTEC and its limitation whereas large-scale testing is concerned only two intermediates 
were tested. Moreover, it served as a primary screening tool and as such the actual minimum 
inhibitory concentrations (MICs) of compounds were not determined; instead the percentage 
growth inhibition of the compounds relative to the control were determined and calculated at 
two concentrations (1 µg/mL, 10 µg/mL) using the formula:  
 
% Growth inhibition = 100-((GI of drug treated culture/GI of control culture) X 100).  
All target molecules and advanced intermediates synthesized were evaluated for activity 
against the H37Rv strain of M. tuberculosis in a microplate Alamar Blue assay (MABA) with 
rifampin (RMP), streptomycin (SM), isoniazid (INH), moxifloxacin (MOX) and PA824 as 
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cellular growth. The blue, oxidized non-fluorescent form undergoes reduction to the pink, 
fluorescent form, thus allowing for growth measurements to be made via a visual reading or 
by using either a fluorometer or spectrophotometer.
36
 The challenges presented by the 
heterogeneous population of the bacilli in tuberculosis chemotherapy, has been alluded to in 
section 1.6.2. Of particular concern is the indirect contribution of the slow-growing sub-
populations to the development of resistance and the fact that only a few of the established 
antitubercular agents are active against these nonreplicating persistent forms. Active 
compounds identified from the MABA assay, were therefore further evaluated for activity 
against non-replicating, persistent forms of M. tuberculosis in the luminescence-based low 
oxygen recovery assay (LORA). It is important to point out that the LORA assay was used as 
a secondary screening assay and thus the possibility of test compounds having activity only 
against the slow-growing mycobacteria cannot be ruled out. Both the MABA and the LORA 
assays were conducted at the Institute of Tuberculosis Research, University of Illinois at 
Chicago (UIC). Details pertaining to the above assays are given in the experimental section.  
 
A comparative study of the BACTEC and MABA assays in the screening of 30 validated 
antimicrobial agents, was conducted by Franzblau and coworker. This study showed that the 
results obtained with the BACTEC assay showed a high degree of correlation with those 
obtained with the operational simple, rapid and inexpensive MABA assay.
36
 Consistent with 
their findings, the results obtained for the synthesized compounds (tables 3.11 and 3.12) 
overall showed a reasonable agreement, despite the fact that tests were conducted in two 
independent laboratories and that MICs were determined only for the MABA assay. 
Moreover, in our study the results of both assays (BACTEC and MABA) showed that the 
intermediates (table 3.11) are more efficacious compared to the hybrids (table 3.12). Among 
the intermediates, compounds 3.6i (R = I, n = 3) and 3.6o (R = H, n = 4) are the most 
promising with MABA MICs of 15.5 µM and 23.2 µM, respectively. Also noted is the 
discrepancy in the result obtained for the parent drug thiolactomycin 1.28 - a known 
antimycobacterial (section 2.2.3.1). According to the BACTEC 460 system it exhibits 
moderate activity with a growth inhibition relative to the control of 58.3% at a concentration 
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           (µM) 
c log 
P 
RMP      0.05 96.1 2.4  
INH      0.37 33.2 >128  
MOX      0.29 90.3 31.1  
SM      0.43 ND ND  
PA824      0.16 98.7 3.3  
1.27 - - -3.8 58.6 35 >128 ND ND  
2.13 - - -24.5 -32.8 0 >128 ND ND  
3.6a H 1 ND ND 0 >128 ND ND 1.30 
3.6c Cl 1 ND ND 96 61.3 98.9 43.6 2.19 
3.6f CH3 1 ND ND 32 >128 ND ND 1.80 
3.6g H 2 ND ND 57 >128 ND ND 1.62 
3.6h H 3 ND ND 93 96.5 99.7 28.8 2.00 
3.6i I 3 ND ND 95 15.5 98.1 57.1 3.30 
3.6j Cl 3 ND ND 94 30.5 99.1 30.5 2.90 
3.6k Br 3 ND ND 94 30.5 99.2 37.7 3.04 
3.6l F 3 ND ND 95 123 99.7 53.3 2.32 
3.6m CH3 3 ND ND 96 62.7 101 53.2 2.50 
3.6n NO2 3 ND ND 0 >128 ND ND 2.13 
3.6o H 4 -22.1 34.8 91 23.2 99.6 44.4 2.53 
3.6s H 5 ND ND 94 97.6 97.3 108 3.06 
3.6u Cl 5 ND ND 93 29.7 101 31.0 3.95 
3.6w F 5 ND ND 92 62.3 99.3 31.5 3.38 
a
Calculated using a control growth index of ~ 200; 
b




The MICs of all the target molecules (table 3.12) are greater than the highest concentration 
tested, with the exception of 3.7b (MIC 63.7 µM). This lack of activity is also reflected by 
the BACTEC results. Also noticed is the negative results obtained with the BACTEC 
























 Chapter 3: Design, Synthesis and Characterization of Thiolactone-Isatin Hybrids  
 104 

















































              (µM) 
c log P 
RMP      0.05 96.1 2.4  
INH      0.37 33.2 >128  
MOX      0.29 90.3 31.1  
SM      0.43 ND ND  
PA824      0.16 98.7 3.3  
1.28   -3.8 58.6 35 >128 ND ND - 
3.7b Cl 1 -2.8 9.9 92 63.7 93.1 117.2 2.73 
3.7c F 1 -29 22 0 >128 ND ND 2.16 
3.7d I 1 -3.2 42 82 >128 ND ND 3.14 
3.7e CH3 1 -12 4 14 >128 ND ND 2.34 
3.7f H 1 31.7 34.7 0 >128 ND ND 1.84 
3.7g H 2 -18.5 14.9 0 >128 ND ND 2.11 
3.7h H 3 33.4 42.6 0 >128 ND ND 2.16 
3.7i H 4 34.9 34.0 3 >128 ND ND 2.69 
3.7j H 5 27.7 36.4 14 >128 ND ND 3.22 
3.8a H 3 17.0 18.1 0 >128 ND ND 2.12 
3.8b H 4 21.9 32.6 45 >128 ND ND 2.68 
3.8c H 5 9.4 18.5 2 >128 ND ND 3.24 
3.8d Br 3 -16.2 5.1 3 >128 ND ND 3.12 
3.8e I 3 4.9 19.6 4 >128 ND ND 3.38 
3.8f F 3 4.9 1.3 5 >128 ND ND 2.40 
3.8g Cl 3 13.4 15.3 0 >128 ND ND 2.97 
3.8h CH3 3 -0.6 -4.0 0 >128 ND ND 2.62 
3.8i NO2 3 -3.0 -5.1 11 >128 ND ND 2.16 
3.8j Cl 4 0.0 -15.2 0 >128 ND ND 3.53 
3.8k Br 4 -26.0 -21.1 0 >128 ND ND 3.68 
3.8l I 4 -39.7 -40.7 0 >128 ND ND 3.94 
3.8m Cl 5 -16 -20 19 >128 ND ND 4.09 
3.8n F 5 -35 -28 0 >128 ND ND 3.52 
3.8o Br 5 8.1 -0.5 4 >128 ND ND 4.24 
3.8p I 5 -34 -40 7 >128 ND ND 4.50 
a
Calculated using a control growth index of ~ 200; 
b
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Of all the compounds tested with the LORA assay, the unsubstituted intermediate 3.6h (R = 
H, n = 3) appears to be the most promising. With an MIC of 28.8 µM it is more active than 
the standard drug moxifloxacin (MIC 31.1 µM). Other intermediates of interest are 3.6j, 3.6u 
and 3.6w, which are almost equipotent to moxifloxacin. The hybrid 3.7b appears to be less 
sensitive to the slow-growing mycobacteria with an MIC of 117.2 µM. 
 
3.7. Conclusion  
The antiplasmodial results show that compounds in this series have poor activity compared to 
the control chloroquine but were more active than the parent natural products (1.28 and 
isatin). Although the tetracycles 3.8 were not the compounds we initially envisaged, they 
turned out to be more active compared to their precursors 3.7. Compound 3.8p has been 
identified as the most active compound in this series which inhibits the CQR and CQS strains 
of P. falciparum with IC50s of 6.92 µM and 9.07 µM, respectively. A structure-activity 
relationship derived for the tetracycles 3.8 is the need for substitution at C-5 of the isatin 
scaffold. Also concluded from the results is that falcipain-2 inhibition is not the primary 
mechanism of action for compounds 3.7 and 3.8. It is evident that the alkyl linker contributed 
significantly towards lipophilicity. However, the observed activity for these compounds 
cannot be credited solely to their lipophilicity.  
 
In contrast to the antiplasmodial results, the antitubercular results obtained clearly suggest 
that the intermediates are more efficacious than the hybrids. The lack of activity of the latter 
can most likely be ascribed to poor cell wall permeability or efflux of compounds. In general, 
from the results tabulated it is evident that the hybrids (except 3.7b) do not merit further 
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Chapter four  
 
DESIGN AND SYNTHESIS OF β-AMINO ALCOHOL HYBRIDS 
 
4.1. Introduction  
This chapter describes the design, synthesis and characterization of two novel series of 
natural-product-like hybrids. Incorporated in their design is the β-amino alcohol moiety, a 
known antimalarial pharmacophore, and the activity- and solubility enhancing 1,2,3-triazole 
ring system. Construction of this triazole library required the utilization of ‘click’ chemistry 
to aid the development of rapid SAR studies. All target compounds herein discussed, were 
tested for in vitro antiplasmodial activity against both CQR and CQS strains of P. falciparum 
as well as for anti-TB activity. In an attempt to elucidate the mechanism of action whereby 
these compounds exert their antimalarial activity, the cysteine proteases and in particular 
falcipain-2 inhibitory activity was examined. 
 
4.2. β-Amino Alcohol Thiolactone-Chalcone Hybrids 
4.2.1. Rationale 
We relied on previous SAR studies and the TLM–FabB model (section 1.4.2.2.3) for 
guidance in analogue design and synthesis, because of the ‘uncertainty’ regarding the 
mechanism of action of thiolactomycin analogues (section 2.2.3.1). One of the key drug-
receptor interactions revealed is the presence of an incompletely filled pantetheine pocket 
which houses the C-4 hydroxyl group. Stabilization of the latter is reportedly mediated via 
hydrogen bonding with water molecules present in this pocket.
1
 As mentioned earlier, it has 
been demonstrated that effective antimalarial and antitubercular agents can be sourced from 
the C-4 derivatives of 1.28 and 2.13.
2
 With regard to tuberculosis, it is noteworthy that apart 
from the results reported by Kamal and coworkers,
2a
 modification only of the C-4 hydroxyl 
of 2.13 is a relatively unexplored diversification route. Therefore in our study we set out to 
elaborate the C-4 substituent of 2.13 by introducing functionalities with hydrogen bond 
donors and acceptors to ensure potential increased and favourable interaction with the target 
site(s).  
 
Chalcones 2.34 have been of considerable interest in drug discovery because of their diverse 
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this scaffold allows for the systematic variation of substituents and/or substitution patterns on 
the aromatic rings A and B for SAR investigation. Further appeal to the utilization of this 
scaffold stems from studies undertaken in our laboratories which involved the covalent 
linking of two privileged structures, the chalcone and 7-chloro-4-aminoquinoline moiety. 
Compound 4.1 (fig. 4.1) from this series showed in vitro growth inhibitory activity against 
two different CQR strains of P falciparum with IC50 values of 0.87 µM and 1.64 µM for the 






























Figure 4.1: Chemical structures of thiolactomycin 1.28, thiolactone 2.13, the chalcone template 2.34 
with rings A and B labelled and the chalcone-aminoquinoline hybrid 4.1 
 
By hybridizing thiolactone with chalcones and incorporating pharmacologically relevant 
moieties such as β-amino alcohol and 1,2,3-triazole ring system we envisaged stable 
analogues which could display enhanced therapeutic profiles. To our knowledge hybrids of 
this nature have not been reported in literature. Some of the key structural and chemical 
features targeted for investigation through structure-activity relationship studies are 




























Figure 4.2: Rationale and general structures of the β-amino alcohol thiolactone-isatin hybrids 
 
(a) Previous SAR studies on chalcones revealed that the minimum requirement for 
antimalarial activity is the presence of the enone linker
4
 and for the double bond in this linker 
to have a trans (E)-configuration.
5
 As shown in figure 4.2 these basic structural features were 
retained in the compounds synthesized. Our drug design effort was further guided by a study 
which showed that hydroxylated and alkoxylated chalcones are more important for 
antimalarial activity and that the latter are more potent.
6,7
 With regard to cysteine protease 
inhibition, reports in the literature indicated a preference for electron-withdrawing 
substituents on ring A of the chalcone scaffold (fig. 4.2). This is believed to facilitate 
Michael addition at the α,β-unsaturated carbonyl of the chalcone moiety by nucleophilic 
“cellular thiols”.
4
 However, another study revealed that the in vitro antimalarial activity of 
chalcones was determined by the properties of (or substitution on) the B ring.
6
 To add to the 
confusion, it is now generally accepted that cysteine protease inhibition is not the only mode 
of action by which chalcones exert their antimalarial activity (section 2.2.3.3). 
 
What is noteworthy is that the number and extent of SAR studies exploring the antimalarial 
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In fact, only a few studies have been reported; one study was conducted on a 47-membered 
chalcone library which revealed that halogenated chalcones display superior 
antimycobacterial activity.
8
 With the above considerations and in the interest of developing a 
focussed library from which meaningful SAR can be delineated, our choice of (additional) 
substituents on the chalcone scaffold was limited to the methoxy group.  
 
 β-amino alcohol thiolactone-chalcone  




4-OMe 2,4-diOMe 2,3,4-triOMe 
Meta Para Ortho 
Ring B 
Ortho Meta Para 
Ring A 
4-OMe 2,4-diOMe 2,3,4-triOMe 
 
 
Figure 4.3: Organisation of β-amino alcohol thiolactone-chalcone hybrids  
 
The envisaged 18-membered thiolactone-chalcone hybrid library is organized into two series 
labelled A and B as depicted in figure 4.3. The aromatic ring A of series A has the triazole 
moiety as a substituent attached at either the ortho-, meta- or para-position whereas ring B is 
methoxylated to varying degrees. A similar arrangement holds for series B the only 
difference is that the substituents on rings A and B are interchanged. SAR will set out to 
investigate the effect on antimalarial and antimycobacterial activity of (i) the number of 
methoxy substitutents on ring B and ring A for series A and B, respectively, (ii) the position 
of attachment of the triazolic moiety on ring A and ring B for series A and B, respectively, 
and (iii) the importance of substitution on ring A/B for activity.  
(b) The β-amino alcohol moiety is a pharmacophore which features prominently in 
antimalarial drugs in clinical use such as quinine (1.1, fig. 1.3), mefloquine (1.4, fig. 1.3) and 
halofantrine (1.6, fig. 1.3). A structural requirement for antimalarial activity for these amino 
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amino moiety separated by 2-3 carbon atoms.
9
 This pharmacophore can also be found in 
























Saquinavir 4.2 Nelfinavir 4.3  
 
Figure 4.4: Chemical structures of β- amino alcohol containing anti HIV drugs saquinavir 4.2 and 
nelfinavir 4.3 
 
(c) The 1,2,3-triazole ring system obtained by ‘click’ chemistry has long shed the reputation 
of being a “passive linker”.
10
 Among the attractive properties displayed by this moiety is its 
ability to associate with biological targets through hydrogen-bonding and dipole-dipole 
interactions. The latter is because of the strong dipole moment of this heterocyclic ring 
system.
11
 It reportedly also mimics the atom arrangement and electronic properties of amide 




Pharmacophore hybridization via the copper-catalyzed azide-acetylene cycloaddition 
(‘click’) reaction, offers a quick, reliable and efficient way for drug discovery and 
optimization. In demonstration, a 1,2,3-triazole library consisting of five nor-lapachone 
derivatives were screened for activity against infective bloodstream forms of Trypanosoma 
cruzi, the causative agent of Chagas’ disease. All of the derivatives were more active than the 
natural occurring progenitor, nor-lapachol with 4.4 (figure 4.5) being the most active.
11b
 In 
another example, two focussed 1,2,3-triazole libraries of 50 compounds each based on the 
hydroxyethylamine peptide isostere, were synthesized with the aim of sourcing HIV protease 
inhibitors. Identified from this library is 4.5 (fig. 4.5) which showed inhibitory activity 
against four proteases (wild type HIV-1 and mutants G48V, V82F, V82A) in the low 
nanomolar range.
12
 A more relevant example is the 24-membered library of N-substituted-
phenyl-1,2,3-triazole-4-carbaldehydes which showed an impressive antimycobacterial 
profile. All compounds in this series showed growth inhibitory activity against M. 
tuberculosis. One of the active compounds in this series 4.6 (fig. 4.5) showed 100% growth 






































Figure 4.5: Chemical structures of compounds 4.4, 4.5 and 4.6 
 
In addition to the activities mentioned above, 1,2,3-triazole-containing compounds are also 
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4.2.2. Chemical Synthesis  




































































Scheme 4.1: Retrosynthesis of the β-amino alcohol thiolactone-isatin hybrid for (a) Series A and (b) 
Series B 
 
The retrosynthesis of target molecules 4.11 and 4.14 is shown in scheme 4.1. Synthesis of 
4.11 [scheme 4.1(a)] was envisaged from the 1,3-dipolar cycloaddition reaction of the 
thiolactone azide 4.8 and the acetylenic chalcone 4.10 (4.13 for target molecule 4.14). The 
latter can be obtained from the Claisen-Schmidt condensation of the acetylenic benzaldehyde 
4.9 and commercially available methoxylated acetophenone. Synthesis of 4.8 in turn can be 
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potassium salt of thiolactone 3.5 with commercially available epichlorohydrin. For series B 
[scheme 4.1(a)] synthesis of the acetylenic chalcone 4.13 was envisaged from the acetylenic 
acetophenone 4.12 and commercially available methoxylated benzaldehyde.  
 




























Figure 4.6: Reaction of epichlorohydrin with a nucleophile
17 
 
The versatility of epoxides as intermediates in organic synthesis stem from the polarity and 
strain of the three-membered ring; thus explaining their reactivity towards a wide range of 
nucleophiles, electrophiles, acids, bases as well as oxidizing and reducing agents.
18
 
Nucleophilic attack on epichlorohydrin generally leads to the formation of a new epoxide 
derivative. Moreover, depending on the reaction conditions there are two possible sites where 
nucleophilic attack can occur. Attack at C-1 [fig. 4.6 (a)] represents a direct displacement 
reaction. For an indirect displacement reaction nucleophilic attack occurs at C-3 followed by 
an intramolecular expulsion of the chloride ion by the alkoxide ion with subsequent 
generation of the epoxide (i) [fig. 4.6 (b)]. In the presence of a proton source or polar protic 
solvent the alkoxide intermediate becomes protonated leading to the formation of 
chloroalcohol (ii) in figure 4.6 (b).
17,19a
 In a study conducted by Mclure and coworkers the 
reactivity of epichlorohydrin and other 1-X-2,3-epoxy-propanes (X = MsO, TfO) were 
compared under different conditions, when reacted with para-substituted phenolates.
19
 This 
study showed that the reaction of epichlorohydrin with phenolate in acetone gave the product 
resulting from C-3 attack preferentially, whereas the reaction in DMF led to a 1:1 mixture of 
products resulting from C-1 and C-3 attack. Also reported is the study by Ohishi and 
Nakanishi
20
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2-acetyl-7-hydroxy-benzo[b]furan in DMF; attack occurred predominantly at C-3 as reflected 
by the ratio (5:7).  
 
4.2.2.2.1. Synthesis of the Thiolactone Epoxide 
The synthesis of 4.7 proved to be challenging and most of our earlier attempts were 
unsuccessful. One such attempt involved refluxing 2.13 with 1.2 eq of NaH and 3 eq of 
epichlorohydrin in dry THF in the presence of catalytic amount of tert-butylammonium 
iodide (Bu4NI). A second attempt entailed the reaction of 2.13 with 3 eq epichlorohydrin and 
2 eq of KF-Al2O3 in dry acetonitrile at room temperature. In a third, unsuccessful attempt, 
2.13, epichlorohydrin and 4 eq of K2CO3 was stirred in dry DMF at room temperature for 16 
hours and then for another 18 hours at 60ºC. All of the above procedures gave a similar tlc 
profile and led to the isolation of an unknown product as well as unreacted starting material. 
A final and successful attempt was adopted from a procedure used in our group. It involved 
the synthesis of phthalimide epoxide by reaction of potassium phthalimide and 









Scheme 4.2: Reagents and conditions: (i) (±)-Epichlorohydrin (neat), 130°C, 7 h  
 
Compound 4.7 was therefore synthesized as shown in scheme 4.2. A slurry of 1.00 g of 3.5 
and a large excess of (±)-epichlorohydrin (5 mL) was stirred at 130ºC for 7 hours under an 
inert atmosphere. Isolated from the product mixture was a 50:50 diastereomeric mixture of 




C-NMR data - 
and a bicyclic by-product 4.7b (10% yield). Interestingly enough, a reduction of the 
temperature from 130ºC to 100ºC did not yield the bicyclic byproduct 4.7b and led to a 
concomitant increase in the yield from 75% to 90% for 4.7a. However, the reaction under 
these conditions only went to completion after 12 hours.  
 
We believe the formation of 4.7b proceeds via the mechanism proposed in scheme 4.3. 
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structure (fig. 4.7); it appears that a resonance contributor of the thiolate ion (fig. 3.6) 
undergoes alkylation with racemic epichlorohydrin at C-3. The approach of the incoming 
electrophile is moreover guided by the methyl group at C-6 and the observed syn relationship 
of these methyls (C-6 and C-7) in the epoxide intermediate [scheme 4.3 (i)] is a direct result 
of this. The thermally enhanced nucleophilicity of sulfur allows it to - via its lone pair - 
attack the epoxide in a regioselective manner on the less hindered carbon with subsequent 
formation of the sulfonium ion intermediate [scheme 4.3 (ii)]. To effect lactonization, the 
alkoxide ion generated from the opening of the epoxide needs to have an equatorial-
configuration in the chair transition state. Ring inversion to the high energy boat 
conformation [scheme 4.3 (iii)] brings the alkoxide ion in close proximity to the electrophilic 






































Scheme 4.3: Proposed mechanism for the formation of the racemic by-product 4.7b 
 
The observed formation of 4.7b in low yield and the exclusive formation of 4.7a at reduced 
temperatures led us to hypothesize the existence of a thermodynamic equilibrium between 
the two products, with 4.7a being the thermodynamically stable product. However, in the 
absence of kinetic data and other supporting information the extent and influence of this 
proposed equilibrium on the product distribution cannot be further speculated on.  
 
The proposed structure of the thiolactone epoxide 4.7a was confirmed with spectroscopy 
data. HRMS(ESI) showed a pseudomolecular ion peak at m/z 201.05809 ([M+H]
+
) for 4.7a 
which corresponds to the molecular formula C9H12O3S. Two characteristic absorption bands 
were identified in the IR spectra with the one at 1677cm
-1
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the strong absorption at 1633 cm
-1
 for the vinyl ether functionality. In the 
1
H-NMR spectrum 
of 4.7a the diastereotopic protons next to the oxygen of the thiolactone ring appeared as two, 
one-proton double doublets resonating at δ 4.06 ppm and δ 4.47 ppm. They appear 
significantly more downfield compared to the same protons in epichlorohydrin which appear 
as a two-proton doublet at δ 3.55 ppm. The presence of 4.7a as a diastereomeric mixture was 




C-NMR spectra. Also, 
as mentioned in section 3.3.2.3.1, a common concern with the alkylation of γ-thiolactone is 
the regioselectivity of the reaction. The diagnostic value of the long range “allylic” coupling 
observed between the methyl protons H-7 and the methine protons H-5, has been discussed 
in the previous chapter (section 3.4.1). It provided additional confirmation of the proposed 















































5.14, dd, J 4.8, 8.8, H-1 
3.92, q, J 6.8, H-4 
3.23, dd, J 1.2, 14.4, H-2a/b 
3.03, ddd, J 1.2, 4.8, 14.8, H-2a/b 
2.62, br. d, J 14.4, H-9a/b 
2.40, 1H, ddd, J 1.6, 8.8, 14.4, H-9a/b 
1.49, s, H-10 
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The isomeric relationship between 4.7a and 4.7b was revealed by HR(ESI)MS which showed 
a pseudomolecular ion at m/z 201.05803 ([M+H]
+
) for 4.7b. X-ray crystal structure (fig. 4.7) 
provided the basis for the interpretation of the spectroscopic data obtained. The 
1
H-NMR 
spectrum of 4.7b (fig. 4.5) shows the anomalous splitting patterns for the diastereotopic 
protons of H-9 and H-2, which is most likely due to through space coupling as a consequence 




H COSY and other 2D experiments were invaluable in the 









Figure 4.7: (a) Molecular structure of 4.7b with the atomic numbering scheme and the displacement 
ellipsoids drawn at 40% propability level; (b) chemical structure of 4.7b showing the relative 
stereochemistry inferred from the x-ray crystal structure 
 
4.2.2.3. Azidolysis  
The regioselective opening of the epoxide ring can be perform under neutral, acidic or basic 
conditions. In the presence of an acid the reaction is under electronic control and proceeds 
via a SN1 or “borderline SN2” mechanism [fig. 4.8. (a)]; with the nucleophile attacking the 
more substituted carbon of the epoxide because of its ability to “accommodate” the 
developing positive charge in the transition state. The latter (i.e. the developing positive 
charge) arises from the coordination of the acid to the oxygen of the epoxide ring. Under 
basic and neutral conditions the reaction is under sterric control and proceeds via an SN2 type 




In the case of monosubstituted epoxides, the substituents attached to the epoxide ring also 
govern the outcome of the reaction. For example when R is a phenyl or vinyl group (fig. 4.8) 
which are known for their ability to stabilize the developing positive charge through 
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Figure 4.8: The mechanism of epoxide opening under different conditions 
 
A common ring opening reaction of epoxides utilizes the azide anion as nucleophile 
(azidolysis) to form 2-azido alcohols. The classical azidolysis protocol employs sodium azide 
(NaN3) and NH4Cl in aqueous alcohol at 65-80ºC.
22,23 
However, some of the drawbacks of 
this reaction are the long reaction times and the formation of side products resulting from 
isomerization, epimerization and other product rearrangements.
23
 Various improvements on 
this method have since been reported with most of them involving the combination of NaN3 
















Scheme 4.4: Reagents and conditions: (i) NaN3, NH4Cl, MeOH-H2O (8:1), 25°C, 48 h 
 
In our study, the thiolactone azide 4.8 represented a key precursor. It was therefore deemed 
necessary to invest time in determining optimum conditions for its preparation. To this end, 
various reported procedures and modifications thereof have been attempted with varying 
success rates (table 4.1). The best procedure for the synthesis of 4.8 is a modification of the 
classical, non-chelating conditions (entry 1, table 4.1) which yielded the product in a 










 Chapter 4: Design and Synthesis of β-Amino Alcohol Hybrids  
 122 
from 80°C to room temperature 25°C resulted in a significant improvement of yield from 
38% to 83%.  
In agreement with the literature, the classical method is limited by the long reaction time but 
it proved far superior in terms of yield to other methods such as cerium(III) chloride in 
acetonitrile/H2O (9:1) (entry 2, table 4.1). Low yields (33%) were also obtained when 4.7a 
was reacted with anhydrous LiClO4 in dry acetonitrile at 60ºC instead of the reported 80ºC 
(entry 3, table 4.1). We were also attracted by the easy workup offered by the procedure 
which utilizes 4Å molecular sieves (entry 4, table 4.1), but recovered only starting material 
after a 24 hour reaction. With the combination of SnCl2 and Mg in wet THF (entry 5, table 
4.1) only traces of the product was detected on tlc after 24 hours.  
 
Table 4.1: Isolated yield of 4.8 obtained under various reaction conditions  
Entry Conditions Temperature Duration  Yield 
1 NaN3, NH4Cl, MeOH-H2O (8:1)
22
  80°C 24 h 38% 
 NaN3, NH4Cl, MeOH-H2O (8:1)  25°C 48 h 83% 
2 NaN3,CeCl3.7H2O,CH3CN-H2O (9:1) 
25
 80°C 24 h 29% 
 NaN3,CeCl3.7H2O,CH3CN-H2O (9:1) 25°C 24 h 0%
a
 
3 NaN3, LiClO4, CH3CN
26
  60ºC 19 h 33% 
4 NaN3, 4Å molecular sieves, CH3CN
27
 25°C 24 h 0%
a
 
5 NaN3, SnCl2, Mg, THF-H2O
28
 25ºC 24 h trace 
a
 Recovered only starting material 
 
In the proposed azidolysis mechanism for 4.7a as shown in scheme 4.5, NH4Cl acts as both 
buffer and proton source. The reaction is initiated by the nucleophilic attack of the azide ion 
on the less hindered carbon of the epoxide ring (section 4.2.2.3.1). The intermediate alkoxide 
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Compound 4.8 showed a strong absorption band in the IR spectrum at 2103 cm
-1
 which is 
characteristic for the azide group. Also observed is a broad band at 3428 cm
-1
 which confirms 




C-NMR and LRMS data correlated well with the 
proposed structure.  
 
4.2.2.4. Synthesis of Acetylenic Chalcones 
O












4.9   R = H (91-99%)
4.12 R = CH3 (quant)
4.10
R = H, CH3
 
 
Scheme 4.6: Reagents and conditions (i) Propargyl bromide, K2CO3, DMF, 25ºC, 16 h for 4.9 and 24 
h for 4.12; (ii) Methoxylated acetophenone or benzaldehyde, 3% w/v NaOH, MeOH, 25°C, 16 h 
 
Synthesis of the acetylenic chalcones 4.10 and 4.13 is a two-step procedure as shown in 
scheme 4.6. The first step involved the reaction of variously substituted 
hydroxybenzaldehyde or hydroxyacetophenone with 1.2 eq of propargyl bromide in the 
presence of 1.5 eq of K2CO3 in anhydrous DMF at room temperature. Acetylenes 4.9 and 
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Compound Position Yield m.p. (ºC) 
4.9a ortho quant 68 
4.9b meta quant -
a
 
4.9c para 91% 79-80 
4.12a ortho quant. 38 
4.12b meta quant. 29 
4.12c para quant. 73 
a
Compound isolated as an oil 
 
The second step of the synthesis known as the Claisen-Schmidt condensation, provided 
access to 4.10 and 4.13 using the method reported by Liu et al.
6
 It involved the reaction of 
the acetylenes 4.9 and 4.12 with an equimolar amount of commercially available 
methoxylated acetophenones or benzaldehydes in methanol at room temperature, using 
methanolic NaOH as catalyst. The use of a minimal amount of solvent allowed for most of 
the chalcones to precipitate out of the reaction mixture as pale yellow solids. Workup and 
purification with column chromatography (0-40% EtOAc:Hex) was required for compounds 
4.10c and 4.13a-c thus explaining the higher yields obtained for them (table 4.3). 
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Isolated yield.  
Compound Position R Yield(%) m.p.(ºC) 
4.10a ortho 4-OMe 91 78-79 
4.104b ortho 2,4-diOMe 89 76 
4.10c ortho 2,3,4-triOMe 94
a
 oil 
4.10d meta 4-OMe 78 68-69 
4.10e meta 2,4-diOMe 76 72-73 
4.10f meta 2,3,4-triOMe 76 61-62 
4.10g para 4-OMe 80 135-136 
4.10h para 2,4-diOMe 89 113 
4.10i para 2,3,4-triOMe 83 114 
4.13a ortho 4-OMe 85
a
 oil 
4.13b ortho 2,4-diOMe quant.
a
 oil 
4.13c ortho 2,3,4-triOMe quant.
a
 oil 
4.13d meta 4-OMe 67 83 
4.13e meta 2,4-diOMe 88 132 
4.13f meta 2,3,4-triOMe 74 74 
4.13g para 4-OMe 87 112 
4.13h para 2,4-diOMe 78 76-77 














































Scheme 4.7: Mechanism for the Claisen-Schmidt condensation  
 
The mechanism for the Claisen-Schmidt condensation is depicted in scheme 4.7. It involves 
the base-catalyzed enolization of acetophenone followed by nucleophilic attack of the enolate 
on the benzaldehyde. The β-hydroxy ketone so formed undergoes base catalyzed elimination 
in a E1cB mechanism to yield the α,β-unsaturated chalcone.  
 




C-NMR and low resolution mass 
spectroscopy. The presence of a triple bond was inferred from the weak absorption band 
appearing in the range 2106-2125 cm
-1
 in the IR spectrum for 4.10 and 4.13. In the aromatic 
region of the 
1
H-NMR spectrum the multiplicities or splitting patterns of the signals varied 
depending on the substitution pattern on the aromatic rings A and B. However, two 
characteristic one-proton doublets in the aromatic region were identified for all compounds in 
this series. The one resonating in the range δ 7.26-7.67 ppm was assigned to the alpha proton 
(Hα) of the enone linker whereas the beta proton (Hβ) proton appeared relatively more 
deshielded at δ 7.63-8.07 ppm. The coupling constant J 15.9-16.2 noted for these protons is 
indicative of the trans geometry of the double bond. The remaining spectroscopic data 




4.2.2.5. ‘Click’ Chemistry 
‘Click’ chemistry was coined by Sharpless and coworkers in 2001. It encompasses a series of 
reactions which involve carbon-hetereoatom bond formation.
29
 According to the criteria 
outline by Sharpless et al
30
 these reactions are: modular, high yielding, wide in scope, 
insensitive to oxygen or water, stereospecific and form harmless by-products which can be 
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examples of ‘click’ reactions which include cycloaddition reactions such as the 1,3-dipolar 
and Diels-Alder reactions; the nucleophilic opening of strained rings for example epoxides 





 Within the class of cycloaddition reactions, the most popular - and 
of particular relevance to this project - is the 1,3-dipolar cycloaddition between azides and 
acetylenes which was first introduced by Huisgen in the 1960s.  
 
 




4.2.2.5.1. Huisgen 1,3-Dipolar Cycloaddition Reaction 
The above is characterized by the reaction of a 1,3-dipole with a dipolarophile which leads to 
the formation of a 5-membered heterocyclic ring. Qualifying as 1,3-dipoles are molecules 
which contain one or more heteroatoms and can be described as having at least one 
mesomeric structure represented as a charged dipole (in a 1,3-relation) as shown for the azide 
functionality in figure 4.10(a). 1,3-Dipoles can be subdivided into two categories; the linear 
or propargyl anion-type which includes azides, nitrile oxides and diazoalkanes, whereas 
ozone, azomethine ylides and nitrones falls under the bent or allyl anion-type. The other 
reacting component is called a dipolarophile and contains a double or triple bond; examples 
therefore include alkenes, alkynes, carbonyls, nitriles and imines.
32
 This pericyclic reaction 
moreover involves the concerted
33
 movement of six electrons - 4 π-electrons form the 1,3-
dipole and 2 π-electrons from the dipolarophile – in a suprafacial manner [fig. 4.10(b)] 
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cycloaddition [fig. 4.10(b)]. This notation moreover differs from the commonly and 






















Figure 4.10: (a) Mesomeric forms of the azide 1,3-dipole; (b) Mechanism of the classical Huisgen 
cycloaddition between an azide and an alkene which demonstrates the suprafacial stereospecificity of 
the addition 
 





 of cycloaddition reaction and is based on the interaction of the HOMOs (Highest 
Occupied Molecular Orbital) and LUMOs (Lowest Unoccupied Molecular Orbital) of the 
1,3-dipole and dipolarophile. Stabilization of the resulting complex (or transition state) is 
reportedly brought about by the closeness in energy of the interacting orbitals (HOMO and 
LUMO). The energy of the latter in turn is determined by the electron withdrawing or 
electron-donating ability of the substituent group attached.
35a
 Moreover, the simultaneous 
presence of an electrophilic and nucleophilic site [fig. 4.10 (a)] allows 1,3-dipoles to react 
using either their HOMOs or LUMOs, that is, depending on whether the dipolarophile is 
electron-poor or electron-rich.
32a
 For example, electron-withdrawing groups on the 
dipolarophile favour interaction of the LUMO of the dipolarophile with the HOMO of a 1,3-
dipole and according to the Sustmann classification represents a type I or HOMO-controlled 
interaction which is most typical for nucleophilic 1,3-dipoles such as diazomethane. The 
reverse interaction, also known as a type III or LUMO-controlled interaction, will be 
dominant for electron-rich dipolarophiles and electrophilic 1,3-dipoles such as ozone. A type 
II or HOMO-LUMO-controlled interaction occurs with ambiphilic 1,3-dipoles. The 
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Unsymmetrical dipolarophiles may give rise to two possible regioisomers depending on the 
orientation of the dipole when attacking the dipolarophile as shown in figure 4.11(a). The 
preferred transition state will involve interaction of orbitals with large terminal coefficients 
as shown in figure 4.11(b). Accordingly, knowledge on the relative sizes (coefficients) of the 
interacting orbitals allows the prediction of the regioselectivity of the cycloadduct. It is 
important to note that the regio- and stereoselectivity of 1,3-dipolar cycloaddition reaction is 
influenced by both electronic and steric factors.
36a,b
 Because of the limited scope of the 
project the latter will not be further elaborated on.  
 
 
EDG = electron donating group; EWG = electron withdrawing group 
 
Figure 4.11: Regioselectivity in 1,3-dipolar cycloaddition reaction36c 
 
4.2.2.5.2. The Cu(I) Catalyzed Variant of Huisgen’s 1,3-Dipolar Cycloaddition  
Under thermal conditions the Huisgen’s cycloaddition reaction generates both 1,4- and 1,5- 
regioisomers [fig. 4.12 (a)]. The observed lack of selectivity was ascribed to similar 
activation energies for the concerted process which leads to these two regioisomers.
37
 The 




 showed in two independent studies that the 
addition of Cu(I) in catalytic amounts not only increased the reaction rate but also produced 
the 1,4-regioisomer exclusively [fig. 4.12 (b)]. Since this discovery the reaction has 





















































Figure 4.12: (a) Thermal and (b) Cu catalyzed azide-acetylene cycloaddition reaction42,43  
The most common source of Cu(I) is from the in situ reduction of CuSO4
.
5H2O or Cu(OAc)2 
by sodium ascorbate.
37,42,43
 Other sources of copper include the inorganic Cu(I) salts (CuI 
and CuBr),
44a







comproportionation of Cu(0) and Cu(II)
40a,45
 and Cu(I) stabilized derivatives.
46
 Another 
noteworthy development is the one-pot reaction which affords 1,4-disubstituted 1,2,3-
triazoles derivatives from aromatic and activated aliphatic halides.
47
 The synthetic usefulness 
of this procedure is that it avoids the isolation and handling of potentially explosive organic 
azides.  
 
The mechanism proposed for the copper-catalyzed reaction differs from that depicted in 
figure 4.10(b) and is supported by kinetic studies and density functional theory (DFT) 
calculations.
44a,48
 As shown in scheme 4.8, it is believed to proceed in a stepwise manner and 
is initiated by the formation of a copper-alkyne π-complex. Formation of the latter effectively 
lowers the pKa of the alkyne thus making it acidic enough for deprotonation to occur in 
aqueous media with subsequent formation of the copper(I) acetylide [scheme 4.8 (i)]. In the 
next step a copper-acetylide-azide complex is formed [scheme 4.8 (ii)] which undergoes an 
intramolecular cyclization to generate an unusual six-membered Cu(III) metallocycle 
[scheme 4.8 (iii)]. Ring contraction of the latter generates the 1,2,3-triazole-copper 
intermediate [scheme 4.8 (iv)] which is protonated followed by the release of the 1,4-














































Scheme 4.8: Proposed mechanism for the Cu(I)-catalyzed azide-acetylene cycloaddition43,44 
 
The advantages and scope of click chemistry outweigh its limitations. A common side 
reaction is the copper catalyzed homocoupling of acetylenes.
49-51
 This stems from the similar 
conditions, also known as Hay’s
52
 conditions, employed in the Glaser reaction for the 
oxidative coupling of terminal acetylenes.
49b,c
 To this end the use of nitrogen containing 
bases
46a
 and the exclusion of oxygen from reaction mixtures is recommended whenever 
copper salts are employed as catalysts.
39
 It is plausible that the oxidative dimers or 
bistriazoles identified as (minor) by-products in the copper catalyzed cycloadditions 
undertaken by Angell and coworker
50
 originated from the in situ generated homocoupled 
acetylenes.  
 
Also demonstrated are the structural limitations on acetylenes in the ‘click’ reaction. For 
example, a product mixture consisting of an enol lactone and its hydrolysis product were 
obtained when 4-pentynoic acid was reacted with benzyl azide under aqueous ‘click’ 
chemistry conditions.
53a
 In a separate study, the reaction of sulfonyl substituted azides with 
acetylenes in the presence of Cu(I) and amines yielded only N-sulfonyl amines.
53b
 With 
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type of reactions. However when Bhattacharjya and coworkers
54
 employed the classical 
conditions (1 mol% CuSO4
.
5H2O, 10 mol% sodium ascorbate, in t-BuOH at 25ºC) in the 
synthesis of medium to large ring triazolophanes, they recorded yields in the range 31-35% 
which could not be improved upon by changing solvents or increasing the amount of catalyst. 



























R =  4-methoxy; 2,4-dimethoxy; 2,3,4-trimethoxy
i
 
Scheme 4.9: Reagents and conditions: (i) 4.10 (for 4.11) or 4.13 (for 4.14), CuSO4.5H2O, sodium 
ascorbate, CH2Cl2:H2O(1:1), 25°C, 16 h 
 
4.2.2.5.3. Synthesis of β-Amino Alcohol Thiolactone-Chalcone Hybrids 
As mentioned earlier, the classical ‘click’ conditions utilizes CuSO4.5H2O or Cu(OAc)2 in 
the presence of a reducing agent, sodium ascorbate, at ambient temperature; in water and an 
organic co-solvents such as ethanol, DMSO, THF, tert-butanol, acetonitrile and DCM.
55 
The 
nonpolar nature of the acetylenic and azidic intermediates were considered in the selection of 
a suitable solvent system. Synthesis of target molecules 4.11 and 4.14 (scheme 4.9) was 
therefore achieved using the procedure reported by Lee et al
55
 For the reaction, 1.0 eq of the 
azide 4.8, 1.1 eq of the acetylene 4.10 (4.13 for target molecules 4.14), 5 mol % of 
CuSO4.5H2O and 10 mol % of sodium ascorbate in CH2Cl2/H2O (1:1) was stirred overnight 
at 25°C. Because of the heterogeneous nature of the mixture vigorous stirring was 
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of 4.8 on tlc, a blue colour was observed for the mother liquor and the precipitated product 
was covered with a thin layer of a brown residue. Speculatively, this observation concur with 
literature reports on the thermodynamic instability of Cu (I) and the ease with which it can be 
oxidized and/or disproportionated to Cu(II) (most likely responsible for the blue colour of the 




We anticipated the formation of mixture of diastereomers because of presence of two chiral 
centers in the target molecules. However, thin layer chromatography revealed two new spots; 
one for the product and the other for an unidentified by-product whose 
1
H-NMR hinted at a 
homocoupled chalcone derivative (section 4.2.2.5.2). Purification by column 
chromatography was therefore required to separate the product from excess acetylene and by-
product but also to remove the copper contaminants (brown residue).
43,57
 It is possible that 
the chromatographic purification might have contributed towards product losses. The triazole 
products 4.11 and 4.14 were isolated either as yellow gums or foams and in some instances 
melting points could not be determined. Isolated yields are shown in table 4.4. The yields 
obtained for the target molecules are considerably lower than what is expected for reactions 
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Compound Position R Yield(%) 
4.11a ortho 4-OMe 19 
4.11b ortho 2,4-diOMe 38 
4.11c ortho 2,3,4-triOMe 32 
4.11d meta 4-OMe 20 
4.11e meta 2,4-diOMe 26 
4.11f meta 2,3,4-triOMe 22 
4.11g para 4-OMe 23 
4.11h para 2,4-diOMe 19 
4.11i para 2,3,4-triOMe 43 
4.14a ortho 4-OMe 32 
4.14b ortho 2,4-diOMe 36 
4.14c ortho 2,3,4-triOMe 33 
4.14d meta 4-OMe 23 
4.14e meta 2,4-diOMe 36 
4.14f meta 2,3,4-triOMe 18 
4.14g para 4-OMe 20 
4.14h para 2,4-diOMe 20 
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4.2.2.5.3.1. Characterization 




C-NMR, IR- and 
Mass spectroscopy. The experimentally determined elemental analysis results agreed within 
±0.4% with the calculated values. Identified from the infrared spectrum of these compounds 
are three characteristic bands; a broad band in the range 3393-3418 cm
-1
 assigned to the OH 
group, a weak to medium band at 1625-1633 cm
-1 
which corresponds to the carbonyl of the 
thiolactone ring and medium band at 1600-1604 cm
-1
 for the α,β-unsaturated carbonyl of the 
chalcone. In addition, confirmation of the molecular formula C30H33O8N3S for 4.11i which is 
representative of compounds in this series was done using HREIMS which showed a 




Complete assignment of the 
1





HMQC and HMBC data. Among the key signal identified in the 
1
H-NMR spectrum (fig. 
4.13) is a one proton singlet resonating downfield at δ 7.78 ppm which was assigned to the 
proton of the triazole ring system (H-8’). Further confirmation of the formation of the 
triazole ring system was presented by the change in multiplicity and the downfield shift of 
the methylenic protons H-9’ from δ 4.72 ppm (doublet) for the acetylenic chalcone 4.10i to δ 
5.19 ppm (singlet) in 4.11i. An anomalous splitting pattern was observed for the methyl 
protons H-7, which appeared as a double doublet (and for some compounds the signal 
collapsed to a broad doublet) resonating at δ 1.78 ppm for 4.11i. Speculatively this may be 
due either to some through space coupling or could indicate the diastereomeric nature of 
4.11i. Also of interest was the methine proton at H-2’ appearing as a one-proton multiplet 
sandwiched between the non-equivalent diastereotopic protons of H-1’ and H-3’, 
respectively. Compared to H-1’ the H-3’ protons appeared less deshielded as two multiplets 
at δ 4.29 ppm and δ 4.19 ppm, with  the latter signal overlapping with that of the methine 
proton at H-5. The signals in the aromatic region of the spectra for these series of 
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C-NMR spectrum of 4.11i is shown in figure 4.14. Characteristic signals include the 
two most deshielded quaternary carbons resonating at δ 195.7 and δ 191.1 assignable to C-2 
and the α,β-unsaturated carbonyl of the chalcone, respectively. Other carbons of the enone 
linker Cα and Cβ were found to resonate at δ 124.8 and δ 142.8, respectively. The formation 
of the triazole ring system was also inferred from the presence of a quaternary signal at δ 
142.2 and a protonated carbon at δ 124.6 assigned to C-7’ and C-8’, respectively. No 



















C-NMR spectrum of 4.11i in CDCl3 at 100MHz 
 
4.2.3. Biological Results and Discussion 
4.2.3.1. In vitro Antiplasmodial Activity  
Target molecules 4.11a-i, 4.14a-i and intermediates 4.7a, 4.8, 4.10a-i and 4.13a-i were tested 
for growth inhibitory activity against the CQR (W2) strain in the laboratories of Prof. P.J. 
Rosenthal at the Department of Medicine, San Francisco General Hospital, University of 
California San Francisco (UCSF); growth inhibitory activity against the CQS (D10) strain 
was conducted locally in the laboratories of Prof. P. Smith at the Department of 
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Of all the intermediates listed in table 4.5, the thiolactone epoxide 4.7a with an IC50 of 2.29 
µM against the resistant (W2) strain and 4.10f which displays enzyme inhibitory activity 
(IC50 = 19.0 µM) but no growth inhibitory activity, are worth pointing out. Also noticeable is 
the selective activity of some of the acetylenic chalcones against the sensitive (D10) strain. 
No useful trends with regard to degree of methoxylation and substitution pattern could be 
delineated.  
 
Compared to the thiolactone-isatin hybrids discussed in the previous chapter, the β-amino 
alcohol thiolactone-chalcone hybrids 4.11 and 4.14 showed promising antiplasmodial 
activity. Indeed all of the target molecules showed activity against the W2 (IC50 = 0.68-6.08 
µM) and D10 (IC50 = 0.62-54.6 µM) strain; although relative to chloroquine these activities 
are still poor. The most interesting compound identified is the meta-substituted, 
trimethoxylated derivative 4.14f which is almost equipotent in the two strains [IC50 = 0.68 
(W2) and IC50 = 0.62 (D10)]. The target molecules are more active against the CQR strain 
(IC50 < 7 µM) than the CQS strain as reflected by the RIs (table 4.6). It is also clear that the 
intermediates (except 4.11f) and target molecules (except 4.14h) do not show falcipain-2 
inhibitory activity which is somewhat unexpected considering the association of chalcones 
with cysteine protease inhibition (section 1.4.2.1.4.2). However, reference has been made in 
section 2.2.3.3 to the inhibition of parasite-induced channels or other unknown targets by 
chalcone derivatives.  
 
Furthermore, the results indicate that the growth inhibitory activity against the W2 strain 
increases with the number of methoxy substitutents on the chalcones moiety as shown for 
compounds 4.11a-c and 4.14a-i. This is graphically represented in figure 4.15. It moreover 
confirms the importance of methoxy substituents on chalcones for antimalarial activity 
(section 4.2.1). Moreover, the greater inhibition observed for the series B derivatives as 
shown by 4.14f and 4.14i indicates a preference for methoxy substituents on ring A. Another 
interesting trend observed, is with the attachment of the triazole moiety to the chalcone 
scaffold. It is clear that a meta relationship is preferred as exemplified by compounds 4.11f 
and 4.14f. It is reasonable to conclude from the abovementioned trends, the low micromolar 
activity of the hybrids (4.11, 4.14, table 4.6) against the W2 strain and the fact that the 
chalcone intermediates (4.10, 4.13, table 4.5) are devoid of activity against the W2 strain, 
that thiolactone and chalcones moieties exert a synergistic or rather complementary 
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CQ - - - 0.06938 0.03823 - 
E64 - - 0.04733 - - - 
1.28  - - >100 >20 >100 - 
4.7a - - >100 2.29 43.80 0.94 
4.8 - - >100 >20 >100 1.50 
4.10a ortho 4-OMe >100 >20 >100 4.36 
4.10b ortho 2,4-diOMe >100 >20 8.00 4.45 
4.10c ortho 2,3,4-triOMe >100 >20 50.57 3.74 
4.10d meta 4-OMe >100 >20 11.60 4.36 
4.10e meta 2,4-diOMe >100 >20 7.57 4.45 
4.10f meta 2,3,4-triOMe 19.0 >20 >100 3.74 
4.10g para 4-OMe >100 >20 >100 4.36 
4.10h para 2,4-diOMe >100 >20 54.78 4.45 
4.10i para 2,3,4-triOMe >100 >20 13.34 3.74 
4.13a ortho 4-OMe >100 >20 >100 4.36 
4.13b ortho 2,4-diOMe >100 >20 18.86 4.45 
4.13c ortho 2,3,4-triOMe >100 >20 >100 3.74 
4.13d meta 4-OMe >100 >20 >100 4.36 
4.13e meta 2,4-diOMe >100 >20 >100 4.45 
4.13f meta 2,3,4-triOMe >100 >20 33.03 3.74 
4.13g para 4-OMe >100 >20 16.52 4.36 
4.13h para 2,4-diOMe >100 >20 >100 4.45 
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RI c log P 
CQ - - - 0.06938 0.03823 1.81 - 
E64 - - 0.04733 - - - - 
1.28 - - >100 >20 >100 - - 
4.11a ortho 4-OMe >100 2.31 8.57
c
 0.27 3.32 
4.11b ortho 2,4-diOMe >100 2.08 6.69
c
 0.31 3.41 
4.11c ortho 2,3,4-triOMe >100 1.14 1.48 0.77 2.71 
4.11d meta 4-OMe >100 2.43 3.83 0.63 3.32 
4.11e meta 2,4-diOMe >100 1.64 3.34
c
 0.49 3.41 
4.11f meta 2,3,4-triOMe >100 2.00 1.53
c
 1.31 2.71 
4.11g para 4-OMe >100 3.12 13.1
c
 0.24 3.32 
4.11h para 2,4-diOMe >100 1.54 11.8
c
 0.13 3.41 
4.11i para 2,3,4-triOMe >100 5.04 1.90
c
 2.65 2.71 
4.14a ortho 4-OMe >100 2.64 2.91
c
 0.91 3.32 
4.14b ortho 2,4-diOMe >100 2.14 4.26
c
 0.50 3.41 
4.14c ortho 2,3,4-triOMe >100 1.72 54.6 0.03 2.71 
4.14d meta 4-OMe >100 3.69 16.2
c
 0.23 3.32 
4.14e meta 2,4-diOMe >100 3.51 4.38
c
 0.80 3.41 
4.14f meta 2,3,4-triOMe >100 0.68 0.62 1.10 2.71 
4.14g para 4-OMe >100 6.08 6.93
c
 0.88 3.32 
4.14h para 2,4-diOMe 28.5 3.10 2.63
c
 1.18 3.41 
4.14i para 2,3,4-triOMe >100 0.81 6.18
c
 0.13 2.71 
 
a
Rec-FP-2 = recombinant falcipain-2; 
b
RI = Resistance Index = [IC50(W2)]/[IC50(D10)] 
;
c
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Effect of number of methoxy groups 




















Figure 4.15: Graph showing the effect of number of methoxy groups on activity against the W2 
strain of P. falciparum for ortho-, meta- and para-substituted target molecules 4.14 
 
4.2.3.2. In vitro Antitubercular Activity  
Different in vitro assays were used to screen the synthesized compounds for antitubercular 
activity. The MABA and the LORA assays were conducted in the laboratories of Prof. S.G. 
Franzblau at the Institute of Tuberculosis, University of Illinois, Chicago (UIC) and the 
BACTEC assay at the Biomedical Research Department, University of Stellenbosch in the 
laboratories of Prof. P. Van Helden. 
 
Previous studies indicated the preference for halogenated substituents on chalcones for 
antitubercular activity.
8
 As shown in table 4.7, the BACTEC results showed that the 
combination of methoxy and acetylenic groups can yield chalcone derivatives with promising 
antitubercular activity. Also, from the good to modest activity of the acetylenic chalcones 
4.10 and 4.13, it is reasonable to conclude that they share a common target in M. 
tuberculosis. Activities worth highlighting are those for 4.13h (MABA MIC 31.0 µM), 4.13a 
(MABA MIC 31.1 µM) and the monomethoxylated derivatives 4.10a, 4.10d and 4.13d. With 
the exception of the para-substituted derivatives 4.10g and 4.13g all monomethoxylated 
chalcones display superior antitubercular activity according to the MABA assay. More 
striking is the correlation with the BACTEC results, which show a clear bias towards the 
monomethoxylated chalcones 4.10a, 4.10d, 4.10g, 4.13a, 4.13d and 4.13g; they all showed 
more than 70% mycobacterial growth inhibition at 10 µg/mL. The MABA MICs of all of the 
hybrids (table 4.8) are greater than the highest concentration (128µM) tested. The same trend 
in activity was reflected by the BACTEC results which showed no noticeable growth 
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shows a higher percentage inhibition compared to the parent natural product, thiolactomycin 
1.28. 
 








Calculated using a control growth index of ~ 200; 
b



















             (µM) 
c log 
P 
RMP      0.05 96.1 2.4  
INH      0.37 33.2 >128  
MOX      0.29 90.3 31.1  
SM      0.43 ND ND  
PA 
824 
     0.16 98.7 3.3  
1.28   -3.8 58.6 35 >128 ND ND  
4.7a - - -27.0 -13.2 ND ND ND ND 0.94 
4.8 - - -17.2 -23.5 0 >128 ND ND 1.50 
4.10a ortho 4-OMe 20.1 78.9 99 47.5 99.5 50.7 4.36 
4.10b ortho 2,4-diOMe 4.4 45.6 99 59.1 99.1 14.9 4.45 
4.10c ortho 2,3,4-triOMe ND ND 98 61.9 99.2 28.6 3.74 
4.10d meta 4-OMe 25.5 70.1 100 40.0 94.0 31.7 4.36 
4.10e meta 2,4-diOMe -12.7 13.2 99 54.9 101 26.1 4.45 
4.10f meta 2,3,4-triOMe ND ND 100 54.0 101 13.1 3.74 
4.10g para 4-OMe 17.2 70.6 28 >128 ND ND 4.36 
4.10h para 2,4-diOMe 1.0 29.9 8 >128 ND ND 4.45 
4.10i para 2,3,4-triOMe ND ND 0 >128 ND ND 3.74 
4.13a ortho 4-OMe 28.9 76.0 95 31.1 99.3 56.7 4.36 
4.13b ortho 2,4-diOMe -3.4 36.8 96 53.7 96.3 62.8 4.45 
4.13c ortho 2,3,4-triOMe ND ND 96 98.7 99.5 46.1 3.74 
4.13d meta 4-OMe 69.1 92.6 95 51.2 71.6 >128 4.36 
4.13e meta 2,4-diOMe 3.4 29.9 0 >128 ND ND 4.45 
4.13f meta 2,3,4-triOMe ND ND 97 58.7 99.3 29.7 3.74 
4.13g para 4-OMe 40.2 82.8 43 >128 ND ND 4.36 
4.13h para 2,4-diOMe 5.4 42.6 99 31.0 92.6 108 4.45 


























 Chapter 4: Design and Synthesis of β-Amino Alcohol Hybrids  
 143 











Calculated using a control growth index of ~ 200; 
b















             (µM) 
c log 
P 
RMP      0.05  
INH      0.37  
MOX      0.29  
SM      0.43  
PA824      0.16  
1.28   -3.8 58.6 35 >128  
4.11a ortho 4-OMe 11.9 18.6 62 >128 3.32 
4.11b ortho 2,4-diOMe 13.8 15.7 43 >128 3.36 
4.11c ortho 2,3,4-triOMe -2.4 14.3 39 >128 2.61 
4.11d meta 4-OMe -15 -34 57 >128 3.32 
4.11e meta 2,4-diOMe -43 -17 54 >128 3.36 
4.11f meta 2,3,4-triOMe -44 73 52 >128 2.61 
4.11g para 4-OMe 6.2 29.5 39 >128 3.32 
4.11h para 2,4-diOMe -16 -12 72 >128 3.36 
4.11i para 2,3,4-triOMe -4.3 14.8 60 >128 2.61 
4.14a ortho 4-OMe -2.9 15.7 18 >128 3.32 
4.14b ortho 2,4-diOMe 5.2 10.0 59 >128 3.36 
4.14c ortho 2,3,4-triOMe -2.4 16.7 60 >128 2.61 
4.14d meta 4-OMe -29 10 57 >128 3.32 
4.14e meta 2,4-diOMe 20.5 12.9 67 >128 3.36 
4.14f meta 2,3,4-triOMe -2.9 10.5 56 >128 2.61 
4.14g para 4-OMe 8.1 24.3 44 >128 3.32 
4.14h para 2,4-diOMe 5.2 13.8 61 >128 3.36 
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Figure 4.16: Chemical structures of compound 4.15 and 4.16 
 
The isatin scaffold is of pharmacological importance because of the association of its 
derivatives with diverse biological activity (section 2.2.3.2). Other attractive features include 
its non-peptidic nature and the ease with which it can be synthetically manipulated making it 
the ideal template onto which bioactiphores can be appended. In demonstration, a limited 
series of 1,2,3-triazole-isatin derivatives with varying substituents (H, Cl, CH3, F) at C-5 of 
the isatin scaffold were synthesized in our labs. Structure-activity relationship studies 
revealed compound 4.15 (fig 4.16) to be the most active, with activities against the W2 strain 
of P. falciparum in the low micromolar range (0.920 µM).
58a
 In another comparative study 
from our group the antiplasmodial activity of a β-amino alcohol isatin derivative 4.16 (fig. 
4.16) was compared to a structural analogue devoid of the β-amino alcohol moiety. The 
aforementioned was 11 times more active with an IC50 of 19.2 nM against the CQR of P. 
falciparum.
58b
 Because of the presence of the 7-chloro-4-aminoquinoline moiety and other 
pharmacologically relevant moieties in these structures (fig. 4.16), the contribution of the 5-
chloroisatin scaffold towards the observed activity may not be dominating, nevertheless these 
results collectively demonstrated; (i) the privileged nature of the isatin scaffold, (ii) the 
additive effect on activity exerted by the beta amino alcohol moiety and (iii) the superiority 
of the 5-chloroisatin compared to unsubstituted isatin and other 5-substituted isatins (F, CH3) 
derivatives with regard to antimalarial activity. Indeed, the modulating effect of the chlorine 
atom on the chemical and biological properties of compounds has been reported in 
literature.
59
 Its presence in bioactive natural products and synthetic drugs for example 
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as chloroquine (1.3, fig. 1.3) and related aminoquinolines is noteworthy. In fact with regard 
to the latter, SAR studies showed that the chlorine group was important for inhibition of β-


















































Figure 4.17: Chemical structures of vancomycin 4.17 and griseofulvin 4.18 
 
The hybridization of two drugs or pharmacophores with a similar mode of action as is the 
case with the isatin and chalcone moieties may not be ideal (section 2.2.4). We were however 
hoping for these two privileged, drug-like moieties to exert a synergistic effect which we 
envisaged to be reinforced by the presence of the β-amino alcohol and the triazole 
functionalities. By employing click chemistry we envisaged a rapid and meaningful SAR for 
this novel series which will be comparable with the previously discussed thiolactone-
chalcone hybrids (4.11 and 4.14). For this reason the same methoxylated, acetylenic 
chalcones 4.10a-i and 4.13a-i were used in the synthesis of these hybrids resulting in a 
similar organisation as shown in figure 4.3. The general structure of the target molecules is 






















Figure 4.18:  Rational and general structure of β-amino alcohol isatin-chalcone hybrids molecules  
 
4.3.2. Chemical Synthesis  
4.3.2.1. Retrosynthethic Analysis 
Synthesis of target molecules 4.23 (and 4.24) is a multi-step procedure which includes a 
protection/deprotection step. Synthesis was envisaged from acetylenic chalcone 4.10 (4.13 
for target molecules 4.24 and isatin azide 4.22a (scheme 4.11) via a 1,3-dipolar cycloaddition 
reaction. Preparation of the latter is from a protected azide 4.21a which in turn can be 
obtained by azidolysis of the epoxide 4.20a. Compound 4.19a the precursor of 4.20a can be 
















R" = OMe, diOMe, triOMe








































































Scheme 4.11: Retrosynthesis of the β-amino alcohol isatin-chalcone hybrids represented by target 
molecule 4.23  
 
4.3.2.2. Synthesis of Isatin Azide 
The reactivity of the ketonic carbonyl C-3 of the isatin scaffold is reportedly enhanced by the 
presence of electron withdrawing substituents at C-5. However, to effect changes elsewhere 
in the molecule this carbonyl needs to be blocked. We were therefore compelled to introduce 
a protection/deprotection step in the synthesis of 4.22a. The first step involved protection of 
the ketonic carbonyl as a ketal. Eco-friendly procedures using activated clays under 
microwave radiation
61a
 and heteropolycompounds as catalysts
61b
 for the ketalization of isatin 
and 5-haloisatins have recently been reported. The ketalization protocol we employed 
involved refluxing a mixture of 1 eq of 5-chloroisatin and 30 eq of anhydrous trimethyl 
orthoformate in anhydrous MeOH in the presence of a catalytic amount of para-toluene 
sulfonic acid for 48 hours under a nitrogen atmosphere. The reaction progress was monitored 
by thin layer chromatography (2:3 EtOAc:Hex) and the disappearance of the intense orange 
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chromatography afforded the ketal 4.19a in moderate yield (65%) and an unidentified yellow 


















Scheme 4.12: Reagents and conditions: (i) CH(OMe)3, p-TsOH, MeOH, reflux, 48 h 
 
Spectroscopic data for 4.19a is in agreement with published data.
61a
 The presence of NH was 
inferred from 
1
H NMR which showed a D2O-exchangeable singlet at δ 8.66 ppm. Formation 
of the ketal was also confirm by the presence of singlet at δ 3.58 ppm which integrated for 6 
protons corresponding to the two methoxy groups. The 
13
C-NMR showed the disappearance 
of the ketonic carbonyl signal resonating at δ 185 ppm for 5-chloroisatin and the appearance 
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The mechanism for ketalization is shown in scheme 4.13. Essentially, ketalization is a 
concerted process but for clarification can be viewed as a two-step reaction with the first step 
involving acid-catalyzed hydrolysis of the trimethyl orthoformate by water which results in 
the formation of MeOH and methyl orthoformate [scheme 4.13 (i)]. The methanol generated 
reacts with the oxonium ion intermediate [scheme 4.13 (ii)] in the second, acid-catalyzed 
ketalization step. Deprotonation of the adduct so formed generates a hemiketal [scheme 4.13 
(iii)] which undergoes protonation and subsequent expulsion of water to generate a second 
oxonium ion intermediate [scheme 4.13 (iv)]. The latter reacts with a second molecule of 
MeOH to form an intermediate which losses a proton to give the ketal [scheme 4.13 (v)].  
 
The equilibrium of the hydrolysis step, effectively removes the water generated in the 
































Scheme 4.14: Reagents and conditions: (i) (±)-Epichlorohydrin, KF/Al2O3, DCM, 25ºC, 20 h; (ii) 
NaN3, NH4Cl, MeOH/H2O (8:1), 25ºC, 16 h; (iii) 10% HCl, Acetone, 25ºC, 3 h 
 
With 4.19a in hand, the next step involved synthesis of the epoxide 4.20a. This was achieved 
by the reaction of 4.19a with 5 eq of (±)-epichlorohydrin in the presence of KF-Al2O3 in 
anhydrous DCM under nitrogen at 25ºC. The advantage of using KF-Al2O3 or other solid 
support reagents is the ease with which it can be removed from the product mixture. No 
elaborate workup is required and the reaction progress can be monitored using conventional 
methods, for example tlc.
62
 Accordingly, the reaction proceeded smoothly and was 
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the product mixture by flash chromatography was required to remove the excess 
epichlorohydrin. Formation of isatin epoxide was inferred from the 
1
H-NMR spectrum of 
4.20a which showed the disappearance of the singlet at δ 8.66 ppm assigned to NH for the 
starting material 4.19a.  
 
For the next step in the synthesis (scheme 4.14) we used the azidolysis conditions employed 
for the synthesis of the thiolactone azide 4.8 (scheme 4.4). The epoxide 4.20a was stirred for 
16 hours with NaN3 and NH4Cl in aqueous methanol at room temperature. A clean 
conversion to the azide was observed and the product 4.21a was obtained in excellent yield 
(93%). The appearance of a strong absorption band in the IR spectrum of 4.21a at 2105cm
-1
 
was characteristic for the azide group whereas the broad band at 3457cm
-1
 indicated the 
presence of a hydroxyl group.  
 
The final step toward the isatin azide 4.22a involved an acid hydrolysis of 4.21a. It was 
achieved by treatment of the latter with 10% HCl in acetone at room temperature. A 
noticeable change in colour, that is, from colourless to red was observed for the reaction 
mixture upon addition of HCl; this was evident of the restoration of conjugation in isatin 
scaffold. After workup the product was obtained as red needles in quantitative yield. 
Evidence for removal of the protecting group was obtained from the 
1
H-NMR which showed 
the disappearance of the methoxy signals at δ 3.54 - 3.55 ppm (in 4.21a) and a noticeable 
downfield shift for the aromatic signals in particular those assigned to H-4 and H-6 for 4.22a. 
13
C-NMR confirmed the disappearance of the quaternary ketal carbon and appearance of the 
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Scheme 4.15: Reagents and conditions: (i) 4.10 (for 4.23) or 4.13 (for 4.24), CuSO4.5H2O, sodium 
ascorbate, CH2Cl2:H2O(1:1), 25°C, 3 h 
 
The ligand-free Cu(I) catalyzed 1,3-cycloaddition protocol reported by Lee et al
55
 was used 
in the synthesis of the target molecules 4.23 and 4.24. As shown in scheme 4.15, the azide 
4.22a was treated with the acetylene 4.10 in the presence of 5 mol% of CuSO4.H2O and 10 
mol % of sodium ascorbate in 4 mL DCM:H2O (1:1) at room temperature. Synthesis of 4.24 
proceeded in a similar fashion with the acetylenic chalcone 4.13. The reactions proceeded 
cleanly and no by-products were detected on tlc. Additionally, for all reactions the product 
precipitated out after continuous stirring for 3 hours as a red or orange solid which was 
recovered from the reaction mixture via simple filtration. Consecutive washing of the filtrate 
with water and DCM was made to remove any adhering impurities. Target molecules were 
obtained in moderate to good yield (table 4.9). It is clear that the above reaction met the 
criteria of ‘click’ reaction (section 4.2.2.5); at least where high yields and the redundancy of 
chromatographic purification are concerned. Also the yields recorded for this series of 
compounds were significantly higher compared to those of the previously discussed 
thiolactone-chalcone hybrids. It is therefore reasonable to conclude that this discrepancy in 
yields for two different azide inputs (4.8 and 4.22a) is a further demonstration of the 
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Compound Position R Yield (%) m.p.(ºC) 
4.23a ortho 4-OMe 58 178-180 
4.23b ortho 2,4-diOMe 61 189 
4.23c ortho 2,3,4-triOMe 64 93 
4.23d meta 4-OMe 60 186 
4.23e meta 2,4-diOMe 51 76 
4.23f meta 2,3,4-triOMe 54 127-128 
4.23g para 4-OMe 70 203-205 
4.23h para 2,4-diOMe 48 126-128 
4.23i para 2,3,4-triOMe 60 143-145 
4.24a ortho 4-OMe 84 93-94 
4.24b ortho 2,4-diOMe 54 97-98 
4.24c ortho 2,3,4-triOMe 83 96 
4.24d meta 4-OMe 70 180 
4.24e meta 2,4-diOMe 54 162 
4.24f meta 2,3,4-triOMe 52 149-150 
4.24g para 4-OMe 65 199-202 
4.24h para 2,4-diOMe 80 185-187 
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4.3.2.3.1. Characterization 
The IR spectra of the target molecules 4.23a-i and 4.24a-i displayed characteristic 
absorptions in the region 3367-3489 cm
-1
 (OH), 1744-1753 cm
-1
 (C3=O), 1646-1662 (α,β-
unsaturated C=O) and 1598-1611(C2=O). The molecular formula of 4.23i, which is 
representative of other compounds in this series, was confirmed to be C32H29ClN4O8 by 






H-NMR spectrum of 4.23i (fig. 4.19) was invaluable in confirming the proposed 
structure, despite the poor resolution. The intactness of the amino alcohol moiety was 
inferred from the presence of the methine proton H-2’ appearing as a broad singlet at δ 4.23 
ppm as oppose to a multiplet. The signal for the methylene protons at H-1’ appear relatively 
more upfield at δ 3.76 ppm as a two-proton multiplet which overlaps partially with the 




H-COSY experiments aided the assignment of the two 
non-equivalent methylene protons of H-3’ which appear as a geminal coupled (J = 13.2) 
double doublet and a broad doublet  at δ 4.40 ppm and δ 4.59 ppm, respectively. A signal 
appearing relatively downfield at δ 5.22 ppm as a two-proton singlet was assigned to H-9’. 
The proton of the hydroxyl group at C-2 resonates at δ 5.47 ppm (fig. 4.19). Key signals in 
the aromatic region include the one-proton singlet at δ 8.16 ppm assigned to H-8’ of the 
triazole ring system. The characteristic Hβ, a one-proton doublet (J = 16.2), appears at δ 7.50 


















































C-NMR spectrum of 4.23i (figure 4.20) shows 32 signals of which the most important 
are the quaternary signals at δ 190.1 ppm, δ 182.1 ppm and δ 159.9 ppm assignable to the 
α,β-unsaturated carbonyl of the chalcone unit, C-3 and C-2 respectively. Also of interest are 
the sp
2
-hybridized carbons of the triazole ring system with the quaternary C-7’ appearing at δ 



























































H-3A & H-5A 
Hα, H-7, H-6B 































C-NMR spectrum of compound 4.23i in DMSO-d6 at 75MHz 
 
4.3.3. Biological Results and Discussion 
Biological evaluation of compounds in this series were conducted in the same laboratories as 
mentioned in section 4.2.3.1 for antiplasmodial activity and section 4.2.3.2 for antitubercular 
activity. 
 
4.3.3.1. In vitro Antiplasmodial Activity  
According to table 4.10 the most active compound in this series, represented by 4.24b (IC50 
2.09 µM) is 21 times less efficacious than chloroquine. Also, there are no noticeable trends 
regarding the effect of the number of methoxy groups or substitution patterns on activity. In 
addition, the compounds appear more active in the sensitive D10 strain than in the resistant 
W2 strain of P. falciparum. It is of interest to note that all compounds in this series show 
falcipain-2 inhibitory activity albeit weak. In fact a fairly good correlation between falcipain-
2 inhibition and antimalarial activity against the D10 strain can be discerned when excluding 
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RI c log P 
CQ    0.0694 0.0382   
E64   0.04733     
4.22a   >100 >20 >20 -  
4.23a ortho 4-OMe 25.44 >20 2.15 - 3.64 
4.23b ortho 2,4-diOMe 15.58 >20 2.11 - 3.67 
4.23c ortho 2,3,4-triOMe 90.47 6.10 3.27 1.86 2.93 
4.23d meta 4-OMe 10.29 5.75 1.97
c
 2.92 3.64 
4.23e meta 2,4-diOMe 6.80 3.17 1.99
c
 1.59 3.67 
4.23f meta 2,3,4-triOMe 11.49 2.18 2.07
c
 1.05 2.93 
4.23g para 4-OMe 10.84 10.61 6.72 1.58 3.64 
4.23h para 2,4-diOMe ND 9.73 4.10 2.37 3.67 
4.23i para 2,3,4-triOMe 16.62 10.98 2.53 4.34 2.93 
4.24a ortho 4-OMe 15.96 7.79 2.34 3.33 3.64 
4.24b ortho 2,4-diOMe 15.04 2.09 1.92 1.09 3.67 
4.24c ortho 2,3,4-triOMe 15.33 6.21 2.42 2.57 2.93 
4.24d meta 4-OMe 9.91 3.57 1.41
c
 2.53 3.64 
4.24e meta 2,4-diOMe 10.61 2.95 0.99
c
 2.98 3.67 
4.24f meta 2,3,4-triOMe 16.73 2.57 1.85
c
 1.39 2.93 
4.24g para 4-OMe 15.89 14.90 5.62 2.65 3.64 
4.24h para 2,4-diOMe 18.28 14.52 5.14 2.82 3.67 
4.24i para 2,3,4-triOMe 25.06 >20 3.49 - 2.93 
a
rec-FP-2 = recombinant falcipain-2; 
b
RI = Resistance Index = [IC50(W2)]/[IC50(D10)]; 
c
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4.3.3.2. In vitro antitubercular activity  
Compounds in this series were not evaluated with the BACTEC method. The MABA assay 
revealed that all the hybrids are inactive, with the exception of compound 4.24a, which 
showed 82% growth inhibition at 128 µM,  
 






































             (µM) 
c log P 
RMP    0.05  
INH    0.37  
MOX    0.29  
SM    0.43  
PA824    0.16  
4.22a   0 >128  
4.23a ortho 4-OMe 0 >128 3.64 
4.23b ortho 2,4-diOMe 23 >128 3.67 
4.23c ortho 2,3,4-triOMe 13 >128 2.93 
4.23d meta 4-OMe 6 >128 3.64 
4.23e meta 2,4-diOMe 2 >128 3.67 
4.23f meta 2,3,4-triOMe 11 >128 2.93 
4.23g para 4-OMe 5 >128 3.64 
4.23h para 2,4-diOMe 0 >128 3.67 
4.23i para 2,3,4-triOMe 0 >128 2.93 
4.24a ortho 4-OMe 82 >128 3.64 
4.24b ortho 2,4-diOMe 67 >128 3.67 
4.24c ortho 2,3,4-triOMe 68 >128 2.93 
4.24d meta 4-OMe 26 >128 3.64 
4.24e meta 2,4-diOMe 3 >128 3.67 
4.24f meta 2,3,4-triOMe 3 >128 2.93 
4.24g para 4-OMe 7 >128 3.64 
4.24h para 2,4-diOMe 6 >128 3.67 
4.24i para 2,3,4-triOMe 0 >128 2.93 
a
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4.4. Conclusions  
When comparing the antiplasmodial activity of the thiolactone-chalcone and isatin –chalcone 
hybrids it is clear that the former is more efficacious compared to the latter. However, with 
regard to enzyme inhibitory activity, all of the isatin-derived hybrids are active whereas the 
thiolactone-chalcone hybrids are practically devoid of cysteine protease inhibitory activity. 
This demonstrates the contribution and importance of the isatin scaffold for falcipian-2 
inhibition; considering that the acetylenic chalcones, with the exception of 4.10f are devoid 
of enzyme inhibitory activity. Failure to correlate falicpain-2 inhibitory activity with growth 
inhibitory activity led us to conclude that the thiolactone-chalcone hybrids do not exert their 
parasiticidal effect via inhibition of falcipain-2. Despite the enzyme inhibitory activity of the 
isatin-chalcones, the aforementioned cannot be considered as their primary mode of action. 
The most active compound from this 36-membered library, is 4.14f which showed 
submicromolar activity (IC50 = 0.62 µM) in the resistant strain. Overall the hybrids are much 
more active than the intermediates which again demonstrate the potential of pharmacophore 
hybridization as drug discovery tool in this case.  
 
In contrast to the antiplasmodial activity, the antitubercular activity of the hybrids was poor 
compared to the intermediates. In fact, of the 36 hybrids synthesized only compounds 4.11h 
and 4.24a showed significant activity at the highest concentration tested (128 µM) according 
to the MABA assay. Identified among the intermediates is 4.13h a para-sustituted, 
dimethoxylated acetylenic chalcones which according to the MABA MIC (31.0 µM) showed 
the highest efficacy against the fast growing, replicating mycobacteria; whereas 4.10f a meta-
substituted, trimethoxylated acetylenic chalcones is more efficacious against the slow-
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This chapter describes the design, synthesis, characterization and biological evaluation of an 
exploratory library of semi-synthetic artemisinin analogues which are hybrid constructs of 
dihydroartemisinin with isatin, thiolactone, chalcone and other natural product derived 
scaffolds. With the focus still on malaria and tuberculosis as disease models, the hybrids 
synthesized were tested for growth inhibitory activity against (i) the CQR and CQS of P. 
falciparum and (ii) the drug-sensitive H37Rv strain of M. tuberculosis. Attempts to elucidate 
a possible antimalarial mode of action involved testing their cysteine protease inhibitory 
activity.  
 









R= H, Dihydroartemisinin 1.15
R = CH3, Artemether  1.16
R = CH2CH3, Arteether  1.17




















Figure 5.1: Chemical structures of artemisinin 1.14 and the first generation analogues 1.15-1.18  
 
Artemisinin 1.14 (fig. 5.1) has since its discovery in the 1970s became the focus of a 
concerted research effort.
1
 As mentioned in section 1.4.2.1.3, the mechanism of action of 
artemisinin and analogues differs from other antimalarials in clinical use. They are active 





 Also, the efficaciousness of artemisinins in parasitic 




 Schistosoma mansoni and 
Schistosoma japanicum
4c
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impaired by its low solubility in water and oil,
5a
 and its short half-life.
5b
 With regard to the 
latter, two remedial strategies are currently employed one being the utilization of 
combination therapy which is advocated by WHO because of the pending risk of resistance 
development (section 1.5.2.). The other strategy ties in with our project objectives and 
involves the synthesis of analogues with enhanced activity.  
 
Structural modification of 1.14 is an active field of research judging from the number of 
research papers, patents and reviews.
1,6
 Moreover, there is a large volume of SAR data 
generated from semi-synthetic analogues obtained by the modifications of 1.14 at C-16, C-
10, C-9, C-3, C-4, O-11 and O-13.
1
 Some key structural-activity relations revealed by 
previous studies are summarized in figure 5.2. Despite the huge demand for 1.14 only a small 
amount can be extracted from the plant material. The preparation of synthetic peroxide 
analogues such as 1,2,4-trioxanes, 1,2,4,5-tetraoxanes and 1,2,4-trioxolanes (fig 5.3) was 
therefore explored. They are all modelled on the pharmacophore traced in red on the 
artemisinin scaffold (fig. 5.2). Some of these analogues showed exceptional activity profiles, 





















Replacement of O-13 with carbon
afforded 13-carbaartemisinin 
derivatives. These analogues are 
less active than 1.14.12
Replacement of O-11 with nitrogen 
afforded 11-azaartemisinin
derivatives. These analogues have 
activities greater than or equal to 
1.14.13
The C-10 carbonyl group is not  important for 
antimalarial activity as confirmed by the 
enhanced activity of 10-deoxodihydroartemisinin 
and derivatives.8
O-glycosides including the first generation 
analogues 1.15-1.18 show enhanced activity 
compared to 1.14,5,9but are susceptible to 
oxidative metabolism
N-glycosides
10 and C-glycosides11 offered 
metabolically stable analogues with activities 
equal to or superior to the first generation 
analogues.
Removal of O-2 afforded deoxyartemisinin 
which is devoid of antimalarial activity; 
concluded from this study is that the peroxide 
bridge is important for antimalarial activity.7
1
Replacement of methyl
group with bulky groups
































MeO HR = F, COOH
 
Figure 5.3: Chemical structures of synthetic analogues of artemisinin 1.14 
 
Of interest to this project are the C-10 semi-synthetic derivatives of dihydroartemisinin (1.15, 
DHA) which can be further subdivided into O-glycosides, N-glycosides and C-glycosides. 
Counted among the C-10 O-glycosides are the first generation analogues which were 
obtained by the sodium borohydride reduction of 1.14 to give 1.15 (fig. 5.1). The latter in 
turn served as a precursor for the oil-soluble artemether 1.16, arteether 1.17 and the water-
soluble artesunate 1.18 (fig. 5.1). Although they displayed enhanced activity in vitro 
compared to 1.14 these analogues are reported to be neurotoxic
14 
and display poor 
bioavalability.
15
 More specifically, it is reported that 1.16 and 1.17 undergo an oxidative 
dealkylation mediated by the action of cytochrome P450 (scheme 5.1). It is believed to 
proceed via a monohydroxylated derivative or hemiacetal. The latter decomposes to the 
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The introduction of minor structural changes at C-10 as observed with 1.16 and 1.17, resulted 
in a significant enhancement in the antimalarial activity. This prompted many researchers to 
explore C-10 modification of 1.15. However, the challenge was - and still is - to synthesize 
analogues which are not susceptible to oxidative dealkylation (scheme 5.1) and thus possess 
negligible neurotoxicity. The metabolic stabilization of C-10 ether derivatives was achieved 
by the introduction of the trifluoromethyl (CF3) group directly at C-10 as undertaken in the 
preparation of the trifluoromethyl analogues of 1.16-1.18 by Bonnet-Delpon and 
coworkers.
18
 Another approach towards more stable analogues was explored by O’Neill and 
coworkers.
17
 It entailed the replacement of the O-alkyl group in first generation analogues 
with an O-phenoxy group. They managed a further increase in stability for these analogues 
by introducing a fluoro- or trifluoromethyl group at the para position of the phenyl ring. 
Introduction of a carboxylic acid group at the meta position proved advantageous in 
enhancing the water solubility of these 10-β-aryl ethers of 1.15.
17,19
 A more common 
structural modification route explored, involves the replacement of the oxygen at C-10 with 
carbon to furnish the chemical and hydrolytic stable C-10 C-glycosides or deoxoartemisinins 
(fig. 5.2).
11
 Hydrolytically stable analogues were also found among C-10 N-glycosides. 






Coartem™ is an example of a combination therapy where artemether 1.16 a fast acting 
antimalarial is partnered with the longer half lived, arylaminoalcohol lumefantrine 1.5 (fig. 
1.3). As an alternative to this strategy, hybridization - the drug discovery ‘tool’ we have used 
throughout this project - has been applied in artemisinin analogue synthesis. In section 2.2.4 
we cited the example of the artemisinin-quinine hybrid 2.25 (fig. 2.13) but other dimeric 





Also, the application of the ADME (absorption, distribution, metabolism and excretion) 
approach in artemisinin analogue design has come to the fore because of increasing concerns 
regarding the link between lipophilicity and neurotoxicity.
10a,17,20
 Reportedly analogues with 
log P >3.5 are neurotoxic by virtue of their ability to cross the blood-brain-barrier.
20b
 
Utilizing the ADME approach, Haynes and coworkers developed artemisone 5.1 (fig 5.4) a 
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favourable bioavailability and negligible neurotoxicity.
21
 It should be pointed out that there 
are contradictory findings in the literature regarding the neurotoxicity of first generation alkyl 
ethers. For example, a study reported that the intramuscular administration of a high dose of 
artemether 1.16 showed a lack of neuronal death in patients.
22
 However, a comparative study 














Figure 5.4: Chemical structure of artemisone 5.1 
 
The investigation of the antitubercular activity of artemisinins, to the best of our knowledge, 
is a relatively unexplored field. The publications we managed to trace, reported on the 
screening of mixed steroidal 1,2,4,5-tetraoxanes for activity against the M. tuberculosis 
H37Rv strain.
23
 These analogues showed inhibitory activity with MICs as low as 4.73 µM.
23a 
On the basis of these considerations and the promising results obtained with the β-amino 
alcohol hybrids discussed in the previous chapter, we reasoned that the covalent linkage, via 
‘click’ chemistry, of isatin, chalcone, zidovudine (AZT) and the 7-chloroquinoline moiety 
with 1.15 will lead to analogues with potentially enhanced therapeutic profiles. Incidentally, 
a recent paper reported on a 10-membered library of 1,4-substituted 1,2,3-triazole artemisinin 
analogues obtained via Huisgen’s 1,3-dipolar cycloaddition reaction. These compounds 
however were not tested for antimalarial activity but for cell proliferation inhibition activity 












 Chapter 5: Design, Synthesis and Characterization of Artemisinin Analogues  
 169 
The limited series of compounds designed and synthesized can be subdivided into three 
groups:  
(i) The first group shown in figure 5.5 (i) represent the hybrid construct between 1.15 and a 
β-amino alcohol isatin derivative. We envisaged improved metabolic stability and aqueous 
solubility for these analogues which is to be facilitated by the β-amino alcohol group and the 
1,2,3-triazole ring. Speculatively, the chemical stability and more so strong dipole moment of 
the latter (section 4.2.1) and its proximity to the acetal function (C-10) make these analogues 
electronically different from the easily hydrolysable acetyl-analogues. Also, the calculated 
log P values or lipophilicity for these compounds are relatively low ranging from 2.07 to 
3.37. Structure-activity relationship studies will investigate the effect of different substituents 















      (i)                                                                              (ii) 
Figure 5.5: Rationale for design of target molecules 
 
(ii) The design and synthesis of the second group of compounds [fig. 5.5 (ii)] was motivated 
in part, by the endoperoxide cysteine protease inhibitor (ECPI) prodrug model pioneered by 
O’Neil and coworkers.
25
 Prodrugs, as defined by Adrien Albert, describes compounds which 
need to undergo biotransformation before they can elicit a pharmacological effect.
26
 The 
masked prodrug 5.2 [(fig. 5.6 (a)], a structural analogue to the synthetic ART analogue, 
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for cysteine protease inhibition (section 1.4.2.1.4.2) to the acidic food vacuole after a ferrous-
mediated unmasking [fig. 5.6 (b)]. The active carbon centered radical species formed as a by-
product in this reaction, is believe to exert a mechanism of action similar to that postulated 







































Figure 5.6: (a) Chemical structure of generic prodrug 5.2 and arteflene 5.3; (b) Ferrous-catalyzed 




Two recent independent studies utilized the isobologram method
27
 to investigate the 
interaction of 1.14 and licochalcone A 1.22 (fig. 2.10)
28a
 and the interaction of 1.14 with 
three synthetic chalcone azole derivatives,
28b
 respectively. These studies collectively showed 
that fixed ratio combinations of 1.14 and chalcones displayed a synergistic or additive effect 
when evaluated for in vitro antiplasmodial activity. Some of the benefits of incorporating 
chalcones in hybrid constructs have been discussed in the previous chapter. The cost-
effectiveness and simplicity of their preparation however, needs to be emphasized. Also 
because of the lack of stereogenic centers in the chalcone moiety there is no risk of hybrid 
formation leading to complex diastereomeric mixtures as was observed with some previously 
reported chimeras,
19
 thereby ensuring interpretable SAR. The c log P values (5.87 - 6.31) and 
molecular weights (645.7 g/mol to 673.8 g/mol) of the envisaged compounds are in clear 
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of the variable alkyl linker on activity; for this reason, substitution was restricted to a para-

































Figure 5.7: Rationale for design of target molecules 
 
(iii) The third group of analogues (fig. 5.7) consists of structurally unrelated hybrids of 1.15 
with thiolactone 2.13 (fig. 3.1), 7-chloro-4-aminoquinoline and AZT. The rationale for 
choosing 2.13 as a monomer in the construction of hybrids has been discussed in previous 
chapters. The nucleoside analogue, AZT is an antiretroviral drug which has found use in 
antimalarial drug design. There exist extensive reports on the efficacy and toxicity of AZT. 
Counted among the attractive properties is its ability to cross cell membranes via passive 
diffusion.
29
 It is envisaged that the hybrid generated by the covalent linkage of AZT and 1.15 
will display an improved toxicity profile whilst retaining nanomolar antimalarial activity.  
 
Reference has been made to the privileged status of the 7-chloro-4-aminoquinoline moiety. 
Previous studies identified this moiety as being important for the inhibition of haemozoin 
formation (section 1.4.2.1.2.1). The presence of a protonable nitrogen reportedly aids 
accumulation of the drug in the acidic food vacuole via pH trapping. This phenomenon 
describes the diffusion of the free base via a pH-gradient into the acidic food vacuole where 
the quinoline nitrogen gets protonated. In this way the compound (now positively charged) 
gets trapped and accumulates inside the food vacuole. It is expected that the aforementioned 
properties of the aminoquinoline moiety will complement those of the radical alkylating 
properties associated with 1.15 for the envisaged hybrid. Moreover, the utility of the 7-
chloro-4-aminoquinoline moiety in hybrid construct is demonstrated by the trioxaquines 
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the synthetic artemisinin analogue, 1,2,4-trioxane. Identified from this series are derivatives 
with potent in vitro activity against the W2 strain of P. falciparum with IC50 values of the 




It is worth mentioning that we do not envisage the delineation of meaningful SAR from these 
miscellaneous hybrids. However, their synthesis and biological evaluation was deemed 
important in validating the strategy of hybridizing natural product derived scaffolds to source 
potential anti-infective agents and to make a contribution albeit mediocre, towards 
demonstrating the scope of ‘click’ chemistry.  
 
5.4. Chemical Synthesis  
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As shown in scheme 5.2, synthesis of the target molecules 5.5 is envisaged from the Huisgen 
1,3-dipolar cycloaddition reaction of the acetylenic intermediate 5.4 and the isatin azide 4.22 
(scheme 5.2). The acetylene 5.4 can be easily obtained from condensation of 
dihydroartemisinin 1.15 and commercially available propargyl alcohol. The retrosynthetic 
analysis of 4.22 has been discussed in chapter 4 (section 4.3.2.1) and will therefore not be 
further elaborated on. 
 
5.4.1.1. Literature Review on the Synthesis of C-10 Ethers (O-glycosides) of 1.15  
Dihydroartemisinin 1.15 is structurally characterized by the presence of ketal, acetal, and 
lactol functional groups. Each of these groups have varying sensitivities to or 
incompatibilities with acidic, alkaline or redox conditions. Also in view of the importance of 
the peroxide group for antimalarial activity, the preservation of this moiety is a priority in 
analogue synthesis and thus requires a judicious selection of reaction conditions. As alluded 
to earlier, the C-10 of 1.15 is comparable to the anomeric hydroxyl group of a pyranose ring 
in terms of chemical property and reactivity.
31
 With this recognition, various synthetic 
methodologies have been developed for the synthesis of C-10 ether derivatives.  
 
The most commonly used method affords the β-isomer of DHA ether derivatives 
predominantly and involves the reaction of 1.15 with alcohols in the presence of BF3
.
EtO2 in 
anhydrous diethyl ether or DCM at room temperature.
5a,9,32
 This reaction as shown in scheme 
5.3, reportedly proceeds via an oxonium ion intermediate. Consequently, a common side 
reaction is the deprotonation of this reactive intermediate with subsequent formation of 9,10-
dehydrodeoxoartemisinin (anhydroartemisinin). The latter is reported to be formed 
preferentially, when sterically hindered secondary or tertiary alcohols are used
9a,32b
 or as the 
group of Bonnet-Delphon
33







































Scheme 5.3: Demonstration of the intermediacy of the oxonium ion in the aldol-type, acid catalyzed 




The formation of α- and β-isomers is further proof of the intermediacy of the oxonium ion. 
More interesting however, is the preferential formation of the β-isomers under Lewis acid-
catalyzed conditions, which reportedly stems from the anomeric effect. The latter describes 
the tendency of electronegative substituents on a pyranose ring to adopt the axial-
configuration at the anomeric center (C-1 carbon) as opposed to the sterically less hindered 
equatorial-configuration.
34
 In accordance, the axial configuration of the hemisuccinyl side 
chain in the chair pyranose ring for the β-isomer of 1.18 was confirmed by means of X-ray 
crystallographic analysis and 
1
H-NMR data. A relative large coupling constant (J = 9.2) 
confirmed the trans-diaxial relationship between the vicinal H-9 and H-10 for the α-isomer 
[fig. 5.8 (a)] whereas a smaller coupling constant (J = 3.3) was indicative of the cis-
equatorial-axial relationship between these protons in the β-isomer [fig. 5.8 (b)].
35
 Bulky 
substituents at C-10 reportedly cause the pyran ring of derivatives of 1.15 to adopt a twist-




   
Figure 5.8: Partial structure of 1.18 showing the relationship between H-9 and H-10 in the (a) α-
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The use of chlorotrimethylsilane (TMSCl) instead of BF3
.
OEt2 for the synthesis of C-10 
ethers of dihydroartemisinin has also been reported.
36
 However, when the Bonnet-Delphon 
group used this method they isolated the (α- and β) epimers and a by-product which was 
identified as an isomerized ether. From this observation they concluded that under these 
conditions, the formation of anhydroartemisinin from the oxonium ion (scheme 5.3) is a 
reversible process with protonation at C-9 occurring either from the re or si face of the 
double bond.
33
 Activation of the hydroxyl group of 1.15 followed by nucleophilic 
substitution reportedly also furnished the β-isomer under Schmidt–Hofmann
37
 conditions 
(trichloroacetonitrile, DBU, SnCl2); the application of this synthesis protocol is discussed in 






















Scheme 5.4. Reagents and conditions: (i) Propargyl alcohol, BF3
.
OEt2, DCM, 25ºC, 10 h  
 
For the synthesis of 5.4 a procedure reported by Li et al
38
 was used (scheme 5.4). 
Dihydroartemisinin 1.15 was reacted with 4 eq of propargyl alcohol in 10 mL of dry DCM in 
the presence of 5 drops of BF3
.
Et2O at 25ºC; the reaction progress was monitored by tlc with 
anisaldehyde spray reagent for detection. The product was obtained in excellent yield (96%) 
as a 21:79 mixture of the α:β-isomers which was separated using conventional column 
chromatography (EtOAc:Hex 0-20%). No dehydration product (anhydroartemisinin) was 
isolated and the reaction is very easy to scale-up.  
 
As mentioned earlier, the β-isomer of O-glycosidic derivatives of 1.15 is formed 
preferentially under acid catalyzed conditions. It has also been reported that for some of these 
derivatives, the α-isomers display superior antimalarial activity compared to the former.
9c
 For 
this study however, we chose to prepare β-configured ether derivatives and therefore only the 










 Chapter 5: Design, Synthesis and Characterization of Artemisinin Analogues  
 176 
isomers upstream, i.e. at the intermediate stage, as opposed to after the synthesis of the target 
compounds, was to avoid the formation of complex diastereomeric mixtures considering the 








































Scheme 5.5. Proposed mechanism for the condensation of 1.15 and propargyl alcohol 
 
The postulated mechanism for the formation of 5.4 is shown in scheme 5.5. The 
condensation reaction is believed to proceed via an SN1 mechanism and starts with the 
coordination of the Lewis acid, BF3 to the hydroxyl group of 1.15 thereby generating a good 
leaving group. Expulsion of the leaving group is facilitated by the lone pair of electrons on 
the adjacent oxygen and leads to the reactive intermediate oxonium ion. The nucleophile 
(propargyl alcohol) attacks the oxonium ion preferentially on the β- face as suggested by the 
product distribution (21:79) for α:β isomers. Deprotonation of the adduct formed, leads to an 




H-NMR spectrum of the crude in CDCl3 (fig. 5.9) highlighted the key spectroscopic 
difference between the α- and β-isomer for compound 5.4. The anomeric proton (H-10) of 
the α-isomer appear as a doublet resonating at δ 4.68 ppm (J = 9.3).
36
 A characteristic small 
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which appeared as a doublet resonating at δ 4.95 ppm. This is ascribed to the gauche 
relationship between H-10 and H-9. Other key signals for 5.4 include the one assigned to H-
12 - a one-proton singlet resonating downfield at δ 5.19 ppm. The assignment of the methyl 
protons at H-14, H-15 and H-16, were straightforward. In the shielded end of the 
1
H-NMR 
spectrum, H-14 appeared as a three-proton singlet at δ 1.41 ppm whereas H-15 and H-16 
appeared as doublets resonating at δ 0.91 ppm (J = 7.2) and δ 0.93 ppm (J = 6.0), 
respectively. Protons of the acetylenic moiety such as H-1’ appeared as a two-proton doublet 
at δ 4.29 ppm and H-3’ overlapped with a peak assignable to a proton of the DHA nucleus in 
the region δ 2.40-2.30 ppm. Assignment of the remaining signals proved challenging and as 



















H-NMR spectrum of an epimeric mixture of 5.4 in CDCl3 at 300MHz  
 
5.4.1.1.2. Synthesis of the Isatin/5-substituted Isatin Azide Intermediates 
The synthesis and characterization of 4.22a and its intermediates (4.19a, 4.20a, 4.21a) have 
been discussed in detail in section 4.3.2.2. For the synthesis of 4.22b-f we employed the 
same reaction conditions and identified similar spectral features to confirm the proposed 
structures (section 4.3.2.2). Subsequent discussion will therefore focus on the yields obtained 





























H-3’ & a proton of 
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The isolated yields for 4.19a-f were moderate (48-65%, scheme 5.6) with the products 
obtained as variously coloured crystalline solids. In contrast, the epoxide intermediates 4.20 
were isolated as colourless to light yellow oils in good to excellent yield (81-93%) after the 
chromatographic removal of excess epichlorohydrin. The azidohydrins 4.21 were obtained as 
colourless oils in moderate to excellent yield (50-93%) and the deketalization proceeded 
smoothly to afford the bright red coloured azide 4.22 in quantitative yield. It is worth 
mentioning that the deprotection step could have preceded the azidolysis as it is unlikely for 
the azide to react with the ketonic carbonyl in the following step. However, deprotection of 


































a. R = Cl,  65%
b. R = Br, 45%
c. R = F, 48%
d. R = I, 51%
e. R = CH3, 55%
f.  R = H, 54%
a. R = Cl, 85%
b. R = Br, 89%
c. R = F, 87%
d. R = I, 81%
e. R = CH3, 95%
f.  R = H, 93%
a. R = Cl, 93%
b. R = Br, 50%
c. R = F, 50%
d. R = I, 88%
e. R = CH3, 90%
f.  R = H, 92%
4.22
a. R = Cl, 97%
b. R = Br, 86%
c. R = F, 98%
d. R = I, 93%
e. R = CH3, 90%
f.  R = H, quant.  
 
Scheme 5.6: Reagents and conditions: (i) CH(OMe)3, p-TsOH, MeOH, reflux, 48 h; (ii) (±)-
Epichlorohydrin, KF-Al2O3, DCM, 25ºC, 20 h; (iii) NaN3, NH4Cl, MeOH/H2O (8:1), 25ºC, 16 h; (iv) 
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Scheme 5.7. Reagents and conditions: (i) CuSO4.5H2O, sodium ascorbate, CH2Cl2:H2O(1:1), 25°C, 6 
h 
 
Because of the redox susceptibility of the peroxide bridge our initial concern was the stability 
of this functional group under ‘click’ chemistry conditions. This was fuelled by reports on 
the degradation of some biological scaffold mediated by copper or sodium ascorbate.
39
 A 
small-scale reaction complemented by a published report on the synthesis of the 1,2,3-
triazole artemisinin library using the CuSO4/sodium ascorbate catalyst system
24
 proved these 
concerns to be invalid. Synthesis of target molecule 5.5 was therefore achieved using the 
conditions outlined in scheme 5.7. The reaction was completed in 6 hours as indicated by tlc 
with detection aided by the highly coloured nature of the isatins. Purification with column 
chromatography (EtOAc: Hex 20-80%) afforded the pure target molecules as orange foams 
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Compound R Yield (%) m.p. (ºC) 
5.5a Cl 52 99-101 
5.5b F 31 101-103 
5.5c H 48 92 
5.5d CH3 45 103-105 
5.5e I 42 112-115 




H-NMR spectrum representative for compounds in this series, is shown for 5.5d in 
figure 5.10. Due to the proximity of H-9'' to chiral centers of the dihydroartemisinin moiety, 
the two methylene protons are non-equivalent and appeared as one proton doublets at δ 4.79 
ppm and δ 4.56 ppm; each with a large geminal coupling constant (J = 12.4-12.8). The signal 
at δ 4.85 ppm has the appearance of a broad doublet and was assigned to H-10. The coupling 
constant for the latter (J = 3.6) confirmed the β-configuration of 5.5d. Also, the anomalous 
splitting pattern observed for H-12 which appear as a doublet at δ 5.44 ppm is either due to 
through space coupling or may indicate that 5.5d exists as a diastereomeric mixture which is 
expected because of the chiral center at C-2''. Further support of the latter stems from the 
multiplicity of the methyl protons H-16 at δ 0.91ppm, which appeared as a doublet of 
doublets (J = 2.8 and 6.0) instead of the expected doublet. The signal at δ 5.51 ppm 
disappeared after being shaken with D2O and was therefore assigned to the proton of the 
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which appeared as a singlet resonating downfield at δ 8.06 ppm confirmed the formation of 





























C-NMR spectrum (fig. 5.11) shows no duplication of signals the possibility 
that 5.5d exists as a mixture of diastereomers cannot be ruled out. Nevertheless, 30 non-
equivalent signals were detected. The carbon signals worth pointing out are the acetal 
carbons C-10 and C-3 resonating at δ 100.6 ppm and δ 125.3 ppm, respectively. Signals of 
interest in the sp
2
 region include those for C-7'' (δ 144.3 ppm) and C-8'' (δ 125.3 ppm) of the 
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Scheme 5.8: Retrosynthetic analysis of 5.9 
 
Synthesis of the triazole linked hybrid 5.9 is envisaged from the acetylene 5.4 and 
azidochalcone 5.8 as shown in scheme 5.8. The latter can be obtained by the azidation of 5.7. 
Synthesis of 5.7 is similar to the previously discussed chalcones (chapter 4) and can be 
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R = Br , n = 1 : 76%
             n = 2 : 70%
             n = 3 : quant.
R = N3 , n = 1 : quant.
              n = 2 : 74%
              n = 3 : quant.
i ii
iii
 n = 1 : 73%
 n = 2 : 68%





Scheme 5.9: Reagents and conditions: (i) Dibromoalkane, K2CO3, DMF, 25ºC, 48 h; (ii) 4-
Methoxybenzaldehyde, 3% w/v NaOH, MeOH, 25ºC, 8 h; (iii) NaN3, DMF, 25ºC, 18 h 
 
Synthesis of the azidochalcones 5.8 is a straightforward 3-step reaction, which starts with the 
O-alkylation of commercially available 4-hydroxyacetophenone with excess dibromoalkane 
in the presence of K2CO3. The product 5.6 was condensed with an equimolar amount of 4-
methoxybenzaldehyde using the conditions shown in scheme 5.9 to generate 5.7. Reaction of 





C-NMR and IR data of 5.8 is consistent with the proposed structure. 
 




























Scheme 5.10. Reagents and conditions (i) CuSO4.5H2O, sodium ascorbate, DCM:H2O (1:1), 25ºC, 6h 
 
Synthesis of the target molecule 5.9 is depicted in scheme 5.10. Purification of the crude 
product mixtures using column chromatography (0-2.5% MeOH:DCM) afforded the pure 
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obtained in moderate yields as shown in table 5.2. A one-pot reaction of 5.7 and 5.4 to 
improve yields, may be worthwhile exploring for this series of compounds.  
 














Compound n Yield (%) m.p. (ºC) 
5.9a 1 38 -
a
 
5.9b 2 65 145-146 
5.9c 3 55 -
a
 
   
a




H-NMR spectrum of 5.9c (fig. 5.12) displayed key signals such as the one assigned to 
H-12 which appear as a one proton singlet resonating at δ 5.39 ppm. The proton H-10 
appeared as a doublet at δ 4.90 ppm (J = 4.8) overlapping with one of the diastereotopic 
protons of H-10’ (δ 4.67 ppm). The latter shows geminal coupling (J = 12.0) with the signal 
at δ 4.91 ppm. Protons of the alkyl linker include H-4’ and H-1’which appeared as two-
proton triplets at δ 4.05 ppm and δ 4.44 ppm, respectively. The protons H-2’ and H-3’ 
overlapped with peaks assignable to protons of the dihydroartemisinin moiety, in the shielded 
region of the spectra. Identified in the aromatic region is the two AA’BB’ systems for the 
aromatic rings of the chalcone moiety and the protons of the enone linker. The latter 
appeared as doublets at δ 7.40 ppm (J = 15.6) and δ 7.75 ppm (J = 15.6) assigned to Hα and 
Hβ, respectively. The number of carbon signals in the 
13
C-NMR spectrum correlates with 

































Figure 5.12: 1H-NMR spectrum of 5.9c in CDCl3 at 300MHz 
 
5.4.3. Retrosynthesis, Synthesis and Characterization of Dihydroartemisinin-
Thiolactone Hybrid 
As shown in scheme 5.11, compound 5.12 can be obtained by reaction of the potassium salt 
of thiolactone 3.5 with the mesylate 5.11. Further analysis of 5.11 leads to the alcohol 5.10, 
























































































































Scheme 5.11: Retrosynthetic analysis of 5.12 
 
Synthesis of 5.12 was initiated by the reaction of 1 eq of 1.15 with 2 eq of ethylene glycol in 
the presence of a catalytic amount of BF3 etherate in anhydrous DCM at room temperature 
(scheme 5.12). 
1
H-NMR analysis of the crude colourless gel obtained after workup revealed 
traces of the elimination product anhydroartemisinin in addition to a 10:90 (α:β) isomeric 
mixture of 5.10. Purification by column chromatography yielded the β-isomer 5.10 as light 
green prisms in 74% yield. For the mesylation, 5.10 was reacted with 1.5 eq of 
methanesulfonyl chloride in dry DCM in the presence of 1.1 eq of Et3N at 0ºC for 3 hours. 
The mesylate 5.11 was found to be unstable at room temperature as evidenced by a colour 
change from colourless to dark brown. The crude was therefore used in subsequent steps 
without purification. The potassium salt of thiolactone 3.5 was added to 1.2 eq of the crude 
mesylate 5.11 in anhydrous DMF under an inert atmosphere. After stirring at room 
temperature for 24 hours no reaction was detected (tlc). The reaction was therefore repeated 
with freshly prepared 5.11, which and after stirring for 20 hours at 60ºC followed by the 
purification of the crude product mixture with column chromatography (0-40% EtOAc:Hex), 
















































Scheme 5.12: Reagents and conditions: (i) BF3
.
OEt2, DCM, Ethylene glycol, 25ºC, 19 h; (ii) 
methanesulfonyl chloride, Et3N, DCM, 0ºC, 2 h; (iii) 3.5, DMF, 60ºC, 20 h 
 
We observed no changes in the physical appearance or 
1
H-NMR profile of 5.12, after storing 
it undisturbed in the dark at ambient temperature over a period of 1 month. Following this 
period, we noticed the gel-like product 5.12 changed colour from light yellow to dark brown 
after repeated exposure to light. Further confirmation of the light sensitive nature of 5.12 was 
obtained from 
1
H-NMR which showed a complex spectrum for the decomposed product. It 
was for this reason that 5.12 was not submitted for biological evaluation. Moreover, the 
formation of “breakdown” products from chemically and thermally unstable artemisinin 











































Figure 5.13. Chemical structure of  5.12 
 




C-NMR analysis. Identified in the shielded end of the 
1
H-NMR spectrum are the methyl 
signals of the dihydroartemisinin nucleus, H-15 and H-16, which appeared as unresolved 
multiplets in the region δ 0.85-0.93 ppm. This observation coupled with anomalous splitting 
patterns of the methyl protons H-6” and H-7” at δ 1.57 ppm and δ 1.79 ppm, respectively 
indicated that 5.12 exist as a mixture of diastereomers. Other key signals include the methine 
proton H-5” of the thiolactone ring system which appeared as a characteristic quartet of 
doublets (J = 1.2 and 6.8) at δ 4.20 ppm. The coupling constant (J = 3.2) of H-10 at δ 4.80 
ppm indicated the β-isomer. Consistent with the 
1
H-NMR data, the 
13
C-NMR spectra of 5.12 
showed a duplication of signals, and thus confirmed 5.12 to be a mixture. 
 
5.4.4. Retrosynthesis, Synthesis and Characterization of Dihydroartemisinin-
Aminoquinoline Hybrid 
The retrosynthesis of 5.14 involves a two-step disconnection (scheme 5.13). Formation of the 
target molecule 5.14 is envisaged from 5.4 and the azido derivative 5.13 via a 1,3-dipolar 


































Scheme 5.13: Retrosynthetic analysis of 5.14 
 
For the preparation of the azide 5.13, commercially available 4,7 dichloroquinoline was 
stirred with NaN3 in DMF for 10 hours at 60ºC (scheme 5.14). Ice-cold water was added to 
the reaction mixture which led to the precipitation of the crude product. Recrystallization of 
the crude product from DCM afforded 5.13 as light green needles in 92% yield. With 5.13 in 
hand, the ‘click’ reaction followed. Purification of the crude residue obtained after a 16 hour 



















Scheme 5.14: Reagents and conditions: (i) NaN3, DMF, 60ºC 10 h;(ii) 5.4, CuSO4.5H2O, Sodium 
ascorbate, DCM/H20 (1:1), 25ºC, 16 h 
 
Quinolines are structurally characterized as benzo-fused pyridine heterocycles. The reactivity 
of the latter reportedly matches that of the benzene and pyridine rings. For example, 
electrophilic substitution generally occurs at the electron rich benzene whereas nucleophilic 
substitution is favoured by the pyridine ring. The nitrogen in the quinoline ring enhances 
reactivity towards nucleophilic substitution of particularly, the C-2 and C-4 position by 
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position is further enhanced by the presence of electron withdrawing (chloro) group and the 
close proximity of the nitrogen atom. As shown in scheme 5.15 the nucleophilic azide ion 
attacks the quinoline ring regioselectively at C-4 with the quinoline nitrogen acting as an 



















































Figure 5.14: Chemical structures of  5.14 
 
Identified in the aromatic region of the 
1
H-NMR spectrum of 5.14 (fig. 5.14) is the well-
resolved signals of the quinoline ring system with their expected splitting patterns. The one-
proton doublet resonating downfield at δ 9.03 ppm was assigned to H-2'' which couples (J = 
4.2-4.5) to H-3'' at δ 7.48 ppm. Also observed is the proton H-5'', a one-proton doublet (J = 
9.3) at δ 7.96 ppm which show ortho-coupling to H-6'' at δ 7.56 ppm. The latter in turn is 
meta-coupled to H-8'' at δ 8.22 ppm. The signal for the triazole proton, H-5' resonates at δ 
7.96 ppm. Confirmation of the β-configuration of H-10 was obtained from the coupling 
constant (J = 4.5) for the signal at δ 4.97 ppm. As observed with the previous triazole 
products, the methylene protons (H-6’) on the carbon α to the ether oxygen of the 
dihydroartemisinin moiety, are non-equivalent and appeared as two one-proton doublets with 
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Scheme 5.16: Retrosynthetic analysis of 5.19 
 
Scheme 5.16 shows that 5.15 can be accessed via a 1,3-dipolar cycloaddition reaction 

































Scheme 5.17: Reagents and conditions: (i) CuSO4.5H2O, Sodium ascorbate, DCM/H20 (1:1), 25ºC, 
24 h  
 
For the synthesis of 5.15, as depicted in scheme 5.17, commercially available AZT was 
reacted with 1.1 eq of 5.4 under classical ’click’ conditions. Purification of the crude 
afforded the desired product 5.15 as a light green foam in 45% yield.  
 
Noticeable in the 
1
H-NMR spectrum of 5.15 (fig. 5.15) is the broadening of peaks in the non-
polar CDCl3. This is reflected in the splitting patterns of signals assigned to the furan ring; 
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expected multiplicities are given in brackets. However, these signals appeared as broad one-
proton singlets at δ 6.24 ppm, δ 4.43 ppm and δ 5.46 ppm, respectively. The unresolved 
signal at δ 3.00 ppm, a two-proton broad singlet, was assigned to the methylene protons at H-
2”. The non-equivalent protons of H-5” appeared as two geminal–coupled (J = 11.2-11.6), 
one-proton doublets instead of double doublets at δ 3.81 ppm and δ 4.02 ppm. Other peaks 
assignable to the AZT scaffold include the signal resonating downfield at δ 7.46 ppm which 
















Figure 5.15: 1H-NMR spectrum of 5.15 in CDCl3 at 400 MHz 
 
5.5. Biological Results and Discussion 
As was the case with the previously discussed compounds, antiplasmodial testing against the 
W2 strain of P. falciparum and falcipain-2 inhibitory activity of the hybrids (5.5, 5.9, 5.14, 
5.15) and their advanced intermediates, were conducted in the laboratories of Prof. P. J. 
Rosenthal at the University of California San Francisco (UCSF). Evaluation of compounds 
for growth inhibitory activity against the CQS strain of P. falciparum was conducted locally 
in the laboratories of Prof. P. Smith at the Department of Pharmacology (UCT). The controls 
used include chloroquine (CQ), artemisinin (1.14, ART). A sample of the dihydroartemisinin 
(1.15, DHA), used as starting material in the synthesis of the abovementioned hybrids - 
kindly donated by Cipla (India) –
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5.5.1. In vitro Antiplasmodial Activity 
Although the hybrids 5.5 and 5.9 are less active than the natural product artemisinin (ART), 
they still retained nanomolar activity as shown in table 5.3. The most active compound 
identified from this series is the intermediate 5.4 (IC50 6.13 nM) which is more active than 
artemisinins (IC50 10.84 nM) against the CQR strain. It is also two-fold less active than the 
first generation analogue DHA, but 16 times more active than chloroquine. Results obtained 
for the limited isatin-derived series 5.5, showed a need for substitution at C-5’ of the isatin 
scaffold. This was inferred from the activity of the unsubstituted isatin derivative 5.5c (IC50 
73.68 nM) relative to the substituted derivatives 5.5a-b and 5.5d-f. The promising activities 
of 5.9a-c against the W2 strain, lend support to earlier findings on the synergism between 
ART and chalcones derivatives (section 5.3). The most active compound of the three DHA-
chalcone hybrids is the propyl-linked 5.9b (n = 2, IC50 33.00 nM).  
 
The inhibition of falcipain-2 and falcipain-3 activity by artemisinin, as reported by Pandey 
and coworkers,
41
 is comparable to the cysteine protease inhibitor E64. For this reason 
compounds 5.5 and 5.9 were evaluated for falcipain-2 inhibitory activity. The hybrids 
showed poor to moderate enzyme inhibitory activity which coupled with the lack of 
falcipain-2 inhibitory activity of the most active analogue 5.4, is indicative that cysteine 
protease inhibition is not the primary, or the only mode of action for artemisinin analogues 
(section 1.4.2.1.3). The 7-chloro aminoquinoline unit is a validated antimalaria 
pharmacophore, as mentioned in section 5.3. However, the results in table 5.4 show that the 
quinoline based derivative 5.14 (IC50 286.5 µM) is three fold less active than chloroquine 
(IC50 97.31 nM). Instead the AZT-derivative 5.15 (IC50 76.46 nM) appears to have a higher 
efficacy. The equipotency of ART and DHA against the CQR and CQS strains of P. 
falciparum has been reported.
42
 Our results show that these two drugs are 4-fold more active 
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ART  - >100000 10.84 40.66 0.27 2.72 
DHA  - >100000 2.56 11.01 0.23 2.45 
CQ  - ND 97.31 29.48 3.30 - 
E64  - 49.43 ND ND - - 
5.4  - >100000 6.13 7.82 0.78 3.51 
4.22a  Cl ND >20000 >20000 - 1.82 
4.22b  Br ND >20000 ND - 1.97 
4.22c  F ND >20000 ND - 1.25 
4.22d  I ND >20000 ND - 2.23 
4.22e  CH3 ND >20000 ND - 1.42 
4.22f  H ND >20000 ND - 0.92 
5.5a  Cl 80715 25.24 127.25 0.20 2.96 
5.5b  F 57425 31.96 379.01 0.084 2.39 
5.5c  H 96415 73.68 123.65 0.60 2.07 
5.5d  CH3 27050 29.82 120.40 0.25 2.57 
5.5e  I 17705 25.04 81.73 0.31 3.37 
5.5f  Br ND 26.23 134.21 0.20 3.11 
5.8a 1  ND >20000 >100000 - 4.96 
5.8b 2  ND 9160 >100000 - 5.09 
5.8c 3  ND 5951 >100000 - 5.62 
5.9a 1  45450 85.46 467.68 0.18 5.87 
5.9b 2  65805 33.00 91.55 0.36 6.18 
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RI c log P 
ART >100000 10.84 40.66 0.27 2.72 
DHA >100000 2.56 11.01 0.23 2.45 
CQ - 97.31 29.48 3.30 - 
E64 49.43 - - - - 
5.4 >100000 6.13 7.82 0.78 3.51 
AZT ND 14615 >100000 - 0.0435 
5.13 ND 1666 9970 0.17 3.98 
5.14 85635 286.5 816.00 0.35 5.73 
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5.5.2. In vitro Antitubercular Activity  
All target molecules and advanced intermediates synthesized were evaluated for 
antitubercular activity at the Institute of Tuberculosis Research, College Pharmacy, 
University of Illinois at Chicago (UIC); using the microplate Alamar Blue assay (MABA) 
and the low oxygen recovery assay (LORA)  
 
The iron-mediated activation of the peroxide-bond of artemisinin analogues is now generally 
accepted. More so it has been postulated, as alluded to in section 1.4.2.1.3, that the peroxide 
bond requires activation either by haeme released during the breakdown of haemoglobin or 
by “free” iron in the infected red blood cell.
19,43
 This iron-dependent mechanism of the 
artemisinins has been cited as the reason behind the antimalarial specificity of this class of 
compounds.
44
 The antitubercular results obtained for the intermediates and hybrids as shown 
in tables 5.5. and 5.6, agrees with this finding. Most of the compounds tested, with the 
exception of 5.5e, 5.5f and 5.14, are inactive at the highest concentration tested (128 µM). A 
comparison of the MABA MICs and LORA MICs of the active compounds show that they 
have a higher efficacy against fast growing replicating mycobacteria. The observed activity 
of 5.14 (MABA MIC 109.4 µM) deserves special mention. From published reports on the 
antitubercular activity of quinoline based compounds,
45
 it is reasonable to conclude that the 
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            (µM) 
c log 
P 
RMP    0.05 96.1 2.4  
INH    0.37 33.2 >128  
MOX    0.29 90.3 31.1  
SM    0.43 ND ND  
PA824    0.16 98.7 3.3  
ART   15 >128   2.72 
DHA   41 >128   2.45 
5.4   56 >128   3.51 
4.22a  Cl 0 >128   1.82 
4.22b  Br 0 >128   1.97 
4.22c  F 0 >128   1.25 
4.22d  I 24 >128   2.23 
4.22e  CH3 0 >128   1.42 
4.22f  H 0 >128   0.92 
5.5a  Cl 87 >128   2.96 
5.5b  F 62 >128   2.39 
5.5c  H 51 >128   2.07 
5.5d  CH3 77 >128   2.57 
5.5e  I 92 96.7 64.2 >128 3.37 
5.5f  Br 90 62.4 74.0 >128 3.11 
5.9a 1  83 >128   4.96 
5.9b 2  84 >128   5.09 
5.9c 3  43 >128   5.62 
5.9a 1  52 >128   5.87 
5.9b 2  11 >128   6.18 
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            (µM) 
c log P 
RMP  0.05 96.1 2.4  
INH  0.37 33.2 >128  
MOX  0.29 90.3 31.1  
SM  0.43 ND ND  
PA824  0.16 98.7 3.3  
ART 15 >128   2.72 
DHA 41 >128   2.45 
5.4 56 >128   3.51 
AZT 1 >128   0.0435 
5.13 42 >128   3.98 
5.14 95 109.4 73.2 >128 5.73 
5.15 2 >128   1.27 
a
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5.6. Conclusion  
Of all the advanced intermediates and target molecules tested, 5.4 proved to be the most 
promising for this limited series of compounds. Most of the target molecules showed 
nanomolar antiplasmodial activity, which implicates the artemisinin moiety as the main 
contributor to the observed activity. From the lack of correlation of antiplasmodial activity 
and falcipain-2 inhibition activity as demonstrated by 5.4, it is safe to assume that the 
inhibition of cysteine protease is not the primary target for this series of compounds. 
Moreover, the lack of, and in some cases poor antitubercular activity observed for the 
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SUMMARY, CONCLUSION AND RECOMMENDATIONS FOR FUTURE WORK 
 
6.1. General 
We have successfully synthesized novel hybrids modelled on the isatin, chalcone and 
thiolactone scaffolds with promising activity profiles against the disease models under 
investigation. More importantly, the results obtained reiterate the importance and benefits of 
using natural products in drug discovery. This is to be seen in the context of the number of 
active compounds identified from the relatively small library of compounds synthesized and 
the SAR delineated from this study. As mentioned earlier, the hybrids showed superior 
antiplasmodial activity compared to the (advanced) intermediates thus lending support to the 
potential of hybridization as a drug discovery tool. Of particular interest was the observed 
antimalarial specificity of the synthesized hybrids, that is, they displayed moderate to good 
antimalarial activity but showed relatively poor, and in some cases were devoid of, 
antitubercular activity. This lack of antitubercular activity may be an indication of the 
inability of the hybrids to penetrate the unusual lipid-rich cell wall of mycobacteria, but may 
also be indicative of a lack of broad range activity which is an attractive feature for any 
potential drug insofar as limiting off-target activity is concerned. Confirmation of the latter 
will require further testing of the synthesized compounds in other disease models. 
 
6.2. Click chemistry 
One of the aims of this project was to further demonstrate the utility of ‘click’ chemistry in 
drug discovery. To this end, different types of ‘click’ reactions were employed in the course 
of this project. These include the nucleophilic ring opening of epoxides 4.7 and 4.20 to yield 
the corresponding β-amino alcohol derivatives 4.8 and 4.21. Also listed among the ‘click’ 
reactions is the “protecting group” or carbonyl group chemistry which we employed in the 
ketalization of isatin and its derivatives 4.23. The Huisgen 1,3-dipolar cycloaddition reaction 
was used in chapters 4 and 5 for the synthesis of the β-amino alcohol hybrids. The reaction 
which led to the triazole-linked β-amino alcohol thiolactone-chalcone hybrids, however, 
deserves special mention. The product mixture of this reaction required elaborate 
chromatographic purification and afforded the product in low yields (section 4.2.2.5.3) and 
therefore does not fulfil the requirements of a ‘click’ reaction (section 4.2.2.5). Nonetheless, 
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mechanism of action. Also demonstrated, is the tolerability of the classical ‘click’ conditions 
for various functional groups in the artemisinin hybridization reaction; the combined 
presence of relatively sensitive functional groups, that is, the peroxy, ketal, acetal and lactone 
moieties was an initial concern (section 5.4.1.1.3). Overall the results obtained are in full 
support of the fact that ‘click’ chemistry is a powerful and indispensable synthesis tool in 
drug discovery. 
 
6.3. Thiolactone-Isatin Hybrids 
As mentioned earlier, the advancement of thiolactomycin analogues to drug candidates is 
hindered by the difficulty of developing viable synthesis routes. The less than desirable 
yields obtained for the hybrids 3.7 and 3.8, albeit via a simple and straightforward synthesis 
route, attest to this. Nonetheless a novel tetracyclic ring system 3.8 was discovered, whose 
bioactive ‘calling’ is still to be revealed. Contrary to our expectations, the antiplasmodial 
activity of compounds 3.7 and 3.8 ranged from poor to moderate when compared to 
chloroquine which incidentally, exert its antimalarial effect via a different mode of action. 
Also, the antitubercular activity of the hybrids were not very promising, instead the 
intermediates and in particular compounds 3.6i and 3.6o were more active. 
 
Speculatively, the fact that the tetracycles 3.8 are more active than their precursors 3.7, hint 
at the need for substitution at C-5 of the thiolactone ring for antimalarial and more so 
antitubercular activity. Further studies are however needed, to make a meaningful 
contribution to the ongoing debate on the importance of the isoprenoid moiety (or 
substitution at C-5), or more specifically, to identify the essential antimalarial/antitubercular 
pharmacophore of thiolactomycin (section 2.2.3.1). Future studies may also explore viable 
synthesis routes for thiolactomycin analogues. In this regard, one of the optimization 
conditions which we did not explore in the synthesis of the tetracycles 3.8 is the high dilution 
technique. The dilution principle advocates the use of low concentration of reactants in ring 
formation reactions so that ring closure is favoured over polymerization or oligomerization. 
The rationale is that by isolating the reacting molecules, as in the case of a diluted solution, 
intramolecular cyclization (as opposed to the intermolecular reaction) can take place 
preferentially. The application of this principle in cyclization reactions has been reported
1
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The discovery that type II fatty acid synthesis is non-essential in the symptomatic blood stage 
but important for the development of the late liver stage forms of the malaria parasite was 
discussed in section 1.4.2.2.1. It is therefore reasonable to assume, that the hybrids (3.7, 3.8) 
may display an improved activity profile when tested in in vitro assays on the liver stage 
forms of the malaria parasite. These results will not only complement the in vitro data on the 
blood stage forms of the parasite presented in this report, but may also contribute towards 
elucidating the mode of action of the hybrids.  
 
6.4. β-Amino Alcohol Hybrids 
As mentioned earlier, for the synthesis of the β-amino alcohol hybrids we employed the click 
reaction which afforded the thiolactone-chalcones (4.11 and 4.14) in low yields and the 
isatin-chalcones (4.23 and 4.24) in moderate to high yields. In essence, compounds in this 
series consist of four structural units: 1,2,3-triazole ring, β-amino alcohol unit, chalcone 
moiety and the thiolactone or isatin moiety; with the triazole and β-amino alcohol unit 
functioning as a linker. It may be worthwhile to investigate the contribution of each of these 
units to the observed antiplasmodial activity. Moreover, the poor antiplasmodial activity of 
the acetylenic chalcones (4.10 and 4.13, table 4.4) and the moderate to good activity of the 
hybrids (4.11, 4.14, table 4.5 and 4.23, 4.24, table 4.9) support the strategy of hybridization 
in antimalarial drug discovery for this series of compounds 
 
Reference has also been made to the low solubility of compounds in this series and the fact 
that the enhancement thereof may lead to improved activity (section 4.3.3.1). Future studies 
on the isatin-chalcone hybrids may include the condensation of the ketonic carbonyl on the 
isatin scaffold with (thio)semicarbazide. We envisaged that the Schiff-base derivatives so 
generated will have enhanced solubility and activity profiles.  
 
6.5. Semi-synthetic Artemisinin Analogues 
Of all the compounds synthesized in this project, the most active were found among the 
semi-synthetic analogues of artemisinins. Our efforts towards the synthesis of hydrolytically 
stable acetyl type analogues of artemisinin entailed the introduction of polar groups such as 
the hydroxyl group and the triazole ring system. Metabolic studies on the hybrids 5.5, 5.9, 
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All commercially available chemicals used in this project were purchased either from Sigma-
Aldrich or Merck in South Africa. With the exception of DMF and MeOH, which were 
purchased as anhydrous solvents, all commonly used solvents were purified and dried as 
described in literature.
1
 Tetrahydrofuran (THF) and diethyl ether were dried over and 
distilled from sodium wire with benzophenone as indicator. Triethylamine was dried over 
and distilled from CaH2 and stored over potassium hydroxide pellets whereas 
dichloromethane (DCM) was distilled from phosphorous pentoxide prior to use. Reactions 
were monitored by thin layer chromatography (tlc) using Merck F254 aluminium-backed 
silica gel 60 coated plates. Detection and visualization of spots were done using (a) the naked 
eye (visible region) especially for the highly coloured isatin derivatives, (b) ultraviolet light 
(254 nm/ 366 nm), (c) iodine vapours and (d) anisaldehyde spray reagent. Column 
chromatography and preparative layer chromatography were carried out on silica gel (Merck 
Kieselgel 60) and used in the purification of samples. 
 
Proton nuclear magnetic resonance (
1
H NMR) spectra were recorded in deuterochloroform 
(CDCl3), deuteromethanol (CD3OD) or deuterodimethylsulfoxide ((CD3)2SO) on a Varian 
Gemini (300 MHz) or Varian Unity Spectrometer (400 MHz) with tetramethylsilane (TMS) 
as internal standard. All chemical shifts (δ) are given in ppm and coupling constants (J), 
rounded off to one decimal place, are given in Hz. Carbon-13 nuclear magnetic resonance 
(
13
C NMR) spectra were recorded on the same instruments at 75 MHz or 100 MHz and in the 
same deuterated solvents with TMS as internal standard. The format used for recording 
13
C 
NMR data is accepted by most international journals. In this format chemical shift values are 
listed without specific assignment to carbon atoms. 
 
Melting points were determined using a Reichert-Jung Thermovar hot stage microscope and 
are uncorrected. Infrared (IR) spectra were recorded on a Thermo Nicolette FTIR instrument 
in the 3800 cm
-1
 – 900 cm
-1
 range as chloroform solutions, KBr pellets or as thin films on 
NaCl discs. Microanalyses were performed on a Fisons EA 1108 CHNS-O instrument. Low 
resolution mass spectrometry (LRMS) analysis was conducted at the Department of 
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spectrometry (HRMS) was performed on a VG70-SEQ (in EI and ESI mode) at the 
University of Witwatersrand (SA) and on a Waters API QTOF Ultima apparatus with a 
Waters UPLC system (Waters, Milford, MA, USA) at the University of Stellenbosch. 
 
7.2. Experimental details pertaining to chapter 3 
2-Methyl-3-oxo-pentanoic acid methyl ester, 3.2 
 
Anhydrous K2CO3 (17.0 g, 122.9 mmol, 4.0 eq) was added to a solution 
of commercially available methyl propionyl acetate (4.0 g, 30.7 mmol, 
1.0 eq) in dry THF (50 mL). The mixture was refluxed for 4 hours under nitrogen and 
thereafter cooled to 0°C. MeI (6.54 g, 46.1 mmol, 1.5 eq) was added and stirring continued 
for a further 2 hours at the same temperature (0°C). The reaction mixture was then allowed to 
warm to 25°C and left to stir at this temperature for 15 hours. Upon completion, the mixture 
was filtered on a celite pad. Evaporation of the solvent in vacuo followed by chromatography 
(eluent EtOAc:Hex 1:9) afforded a colourless oil (2.8 g, 70%); Rf (EtOAC:Hex 1:20) 0.19; 
δH (300MHz, CDCl3) 3.70 (3H, s, H-7), 3.45 (1H, q, J 7.3, H-4), 2.54 (2H, q, J 7.3, H-2), 
1.32 (3H, d, J 7.3, H-5), 1.05 (3H, t, J 7.1, H-1); δC (75MHz, CDCl3) 206.3, 171.1, 52.4, 
52.3, 34.6, 12.8, 7.6. 
 
4-Bromo-2-Methyl-3-oxo-pentanoic acid methyl ester, 3.3 
 
Bromine (2.4 g, 15.1 mmol, 1.0 eq) in chloroform was added dropwise 
over a period of 1 hour, to a solution of compound 3.2 (2.2 g, 15.1 mmol, 
1.0 eq) in chloroform at 0°C. The resulting mixture was left to stir at 25°C for a period of 15 
hours. Upon completion, a stream of air was passed through the reaction mixture. The latter 
was then dried over anhydrous Na2SO4 and the solvent evaporated under reduced pressure to 
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4-Acetylsufanyl-2-methyl-3-oxo-pentanoic acid methyl ester, 3.4 
 
Dry dichloromethane was added to the crude bromo compound 3.3 (3.0 
g, 13.4 mmol, 1.0 eq). The resulting mixture was added dropwise over 
a period of 30 minutes to a mixture of thiolacetic acid (1.22 g, 16.0 mmol, 1.2 eq) and dry 
Et3N (2.03 g, 20.0 mmol, 1.5 eq) in dry dichloromethane at 0ºC. The mixture so obtained was 
stirred at room temperature (25ºC) under an inert atmosphere for a period of 6 hours. Upon 
completion, water was added to the reaction mass. The resulting mixture was extracted with 
DCM and the combined organic layer washed with saturated NaCl solution. The organic 
layer was dried over anhydrous Na2SO4, concentrated and the resulting crude residue purified 
by column chromatography (eluent EtOAc:Hex 1:4) to afforded 3.4 as an orange oil (1.8 g, 
60%); Rf (EtOAc:Hex 1:5) 0.49; δH (300MHz, CDCl3) 4.52 (1H, q, J 7.2, H-2), 3.84 (1H, q, 
J 7.5, H-6), 3.71 (3H, s, H-9), 2.35 (3H, s, H-4), 1.41 (3H, d, J 7.1, H-1), 1.32 (3H, d, J 7.1, 




A 10% KOH solution (1.4 g, 25.6 mmol, 2.0 eq) was added to a stirred 
solution of thioester 3.4 (2.8 g, 12.8 mmol, 1.0 eq) in 16 mL ethanol at 
0°C. The reaction mixture was stirred at room temperature for 4 hours. The solvent was then 
evaporated under reduced pressure, and the residue taken up in water. The resulting mixture 
was extracted with diethyl ether and the ether layer discarded. The aqueous layer was 
acidified to pH 1 with 10% HCl and extracted with EtOAc. The combined organic layer was 
washed with saturated brine solution and dried over anhydrous Na2SO4. Evaporation of the 
solvent under reduced pressure gave a crude product mixture. Recrystallization from DCM 
gave the thiolactone as an off-white solid (1.7 g, 60%); Rf (EtOAc:Hex 1:10) 0.36; m.p. 130-
131°C (lit. m. p. 128-130°C)2; δH (300MHz, CD3OD) 4.12 (1H, q, J 7.1, H-5), 1.66 (3H, s, 
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4-Hydroxy-3,5-dimethyl-5H-thiophen-2-one, potassium derivative, 3.5 
 
A 2.5% KOH solution (390 mg, 6.94 mmol, 1.0 eq) was added to 2.13 
(1.00 g, 6.94 mmol, 1.0 eq) in 10 mL MeOH. The resulting mixture was 
stirred at 25°C for 4 hours. Evaporation of the solvent under reduced pressure afforded an 
off-white hygroscopic solid (954 mg, 95%); m.p. >300°C; δH (300MHz, CD3OD) 4.12 (1H, 
q, J 7.1, H-5), 1.66 (3H, s, H-7), 1.56 (3H, d, J 7.1, H-6); δC (75 MHz, CD3OD) 194.9, 188.6, 
95.2, 45.4, 20.0, 9.2  
 
A. General procedure for preparation of compounds 3.6a-w 
Sodium hydride, 60% suspended in mineral oil (10.2 mmol, 1.5 eq) was added to 
commercially available isatin/5-substituted isatin (6.8 mmol, 1.0 eq) in 10 mL of anhydrous 
DMF at 0°C. The dibromoalkane (27.2 mmol, 4.0 eq) was added and the resulting mixture 
slowly warmed to 25°C. Stirring was continued for 1hour at this temperature. The 
temperature was then increased to 60°C and the reaction mixture stirred for 24 hours at this 
temperature. Ice-cold water was added to the orange coloured reaction mixture and the 
precipitate that formed was filtered, washed with water and recrystallized from MeOH.  
 
1-(2-Bromo-ethyl)- 1H-indole-2,3-dione, 3.6a  
 
The conditions employed for the preparation of this compound were 
those described in general procedure A. However 6.80 mmol of isatin 
and 27.2 mmol of 1,2-dibromoethane was used. The product was 
obtained as an orange crystalline solid (1.64 g, 95%); m.p. 128°C; Rf (EtOAc:Hex 1:1) 0.61; 
IRνmax(KBr)/cm
-1
 1735 (C3=O), 1612 (C2=O), 1472 (Ar C=C); δH (300MHz, CDCl3) 7.61 
(2H, m, H-4 and H-6), 7.14 (1H, td, J 0.9 and 7.2, H-5), 6.99 (1H, d
*
, J 7.8, H-7), 4.14 (2H, t, 
J 6.9, H-2’), 3.61 (2H, t, J 6.9, H-1’); δC (75MHz, CDCl3) 183.0, 158.2, 150.4, 138.4, 125.6, 
124.0, 117.6, 110.2, 27.0, 41.9; LRMS(ESI) found m/z 254.0 (54%, [M+H]
+
) requires 253.0 
for C10H8O2NBr.  
                                               
*
 H-7 of the isatin scaffold consistently appeared as a doublet instead of the expected doublet of doublet for all 



































The conditions employed for the preparation of this compound were 
those described in general procedure A. However 4.42 mmol of 5-
bromoisatin and 17.7 mmol of 1,2-dibromoethane was used. The 
product was obtained as an orange solid (1.35 g, 92%); m.p. 143-144°C; Rf (EtOAc:Hex 1:1) 
0.78; IRνmax(KBr)/cm
-1
 1736 (C3=O), 1603 (C2=O), 1470 (Ar C=C); δH (300MHz, CDCl3) 
7.72 (2H, m, H-4 and H-6), 6.93 (1H, d, J 7.5, H-7), 4.14 (2H, t, J 6.9, H-2’), 3.61 (2H, t, J 
6.9, H-1’); δC (75MHz, CDCl3) 183.1, 157.5, 149.2, 140.6, 128.4, 118.8, 116.9, 112.0, 42.2, 
27.1; LRMS(ESI) found m/z 331.4 (28%, [M+H]
+
) requires 330.9 for C10H7O2NBr2.  
 
1-(2-Bromo-ethyl)-5-chloro-1H-indole-2,3-dione, 3.6c  
 
The conditions employed for the preparation of this compound were 
those described in general procedure A. However 5.51 mmol of the 5-
chloroisatin and 22.0 mmol of 1,2-dibromoethane was used. The 
product was obtained as an orange solid (1.43 g, 90%); m.p. 114-116°C; Rf (EtOAc:Hex 1:1) 
0.74; IRνmax(KBr)/cm
-1
 1738 (C3=O), 1605 (C2=O), 1471 (Ar C=C); δH (300MHz, CDCl3) 
7.57 (2H, m, H-4 and H-6), 6.98 (1H, d, J 7.8, H-7), 4.14 (2H, t, J 6.9, H-2’), 3.61 (2H, t, J 
6.9, H-1’); δC (75MHz, CDCl3) 183.6, 158.2, 150.4, 137.7, 129.9, 125.5, 117.6, 111.6, 42.2, 
27.1; LRMS(ESI) found m/z 288.0 (26%, [M+H]
+
) requires 286.9 for C10H7O2NBrCl.  
 
1-(2-Bromo-ethyl)-5-fluoro-1H-indole-2,3-dione, 3.6d  
 
The conditions employed for the preparation of this compound were 
those described in general procedure A. However 6.06 mmol of 5-
fluoroisatin and 24.2 mmol of 1,2-dibromoethane was used. The 
product was obtained as an orange-red crystalline solid (1.37 g, 83%); m.p. 102-104°C; Rf 
(EtOAc:Hex 1:1) 0.54; IRνmax(KBr)/cm
-1
 1736 (C3=O), 1617 (C2=O), 1485 (Ar C=C); δH 
(300MHz, CDCl3) 7.32 (2H, m, H-4 and H-6), 6.99 (1H, dd, J 3.9 and 9.6, H-7), 4.14 (2H, t, 
J 6.9, H-2’), 3.61 (2H, t, J 6.9, H-1’); δC (75MHz, CDCl3) 183.8, 161.0, 157.7, 146.6, 129.9, 
124.7, 112.6, 111.5, 42.1, 27.1; LRMS(ESI) found m/z 272.2 (42%, [M+H]
+
) requires 270.9 
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1-(2-Bromo-ethyl)-5-iodo-1H-indole-2,3-dione, 3.6e  
 
The conditions employed for the preparation of this compound were 
those described in general procedure A. However 3.66 mmol of the 5-
iodoisatin and 14.7 mmol of 1,2-dibromoethane was used. The 
product was obtained as an orange solid (1.24 g, 89%); m.p. 153-154°C; Rf (EtOAc:Hex 1:1) 
0.84; IRνmax(KBr)/cm
-1
 1733 (C3=O), 1600 (C2=O), 1467 (Ar C=C); δH (300MHz, CDCl3) 
7.90 (2H, m, H-4 and H-6), 6.82 (1H, d, J 8.7, H-7), 4.13 (2H, t, J 6.9, H-2’), 3.60 (2H, t, J 
6.9, H-1’); δC (75MHz, CDCl3) 183.8, 160.0, 150.0, 146.3, 134.1, 119.1, 112.4, 86.2, 42.1, 
27.1; LRMS(ESI) found m/z 380.4 (26%, [M+H]
+
) requires 378.9 for C10H7O2NBrI.  
 
1-(2-Bromo-ethyl)-5-methyl-1H-indole-2,3-dione, 3.6f  
 
The conditions employed for the preparation of this compound were 
those described in general procedure A. However 6.21 mmol of the 5-
methylisatin and 24.8 mmol of 1,2-dibromoethane was used. The 
product was obtained as an orange solid (1.63 g, 98%); m.p. 117-119°C; Rf (EtOAc:Hex 1:1) 
0.80; IRνmax(KBr)/cm
-1
 1738 (C3=O), 1621 (amidic C2=O), 1490 (Ar C=C); δH (300MHz, 
CDCl3) 7.40 (2H, m, H-4 and H-6), 6.88 (1H, d, J 8.1, H-7), 4.11 (2H, t, J 6.9, H-2’), 3.59 
(2H, t, J 6.9, H-1’), 2.34 (3H, s, H-8); δC (75MHz, CDCl3) 183.0, 158.3, 150.0, 138.8, 133.9, 
126.0, 117.6, 110.0, 41.9, 27.1, 20.6; LRMS(ESI) found m/z 268.0 (75%, [M+H]
+
) requires 
267.0 for C10H7O2NBrI.  
 
1-(3-Bromo-propyl)-1H-indole-2,3-dione, 3.6g  
 
The conditions employed for the preparation of this compound were 
those described in general procedure A. However 6.80 mmol of isatin 
and 27.2 mmol of 1,3-dibromopropane was used. The product was 
obtained as an orange crystalline solid (1.57 g, 86%); m.p. 85°C; Rf 
(EtOAc:Hex 1:1) 0.66; IRνmax(KBr)/cm
-1
 1740 (C3=O), 1615 (C2=O), 1470 (Ar C=C); δH 
(300MHz, CDCl3) 7.60 (2H, m, H-4 and H-6), 7.12 (1H, td, J 1.2 and 7.8, H-5), 7.01 (1H, d, 
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δC (75MHz, CDCl3) 183.0, 158.3, 150.7, 138.5, 125.6, 123.9, 117.6, 110.0, 38.8, 30.3, 30.0; 
LRMS(ESI) found m/z 268.0 (69%, [M+H]
+
) requires 267.0 for C11H10O2NBr.  
 
1-(4-Bromo-butyl)-1H-indole-2,3-dione, 3.6h  
 
The conditions employed for the preparation of this compound were 
those described in general procedure A. However 6.80 mmol of isatin 
and 27.2 mmol of 1,4-dibromobutane was used. The product was 
obtained as an orange solid (1.92 g, quant.); m.p. 52°C; Rf 
(EtOAc:Hex 1:1) 0.75; IRνmax(KBr)/cm
-1
 1727 (C3=O), 1609 (C2=O), 1472 (Ar C=C); δH 
(300MHz, CDCl3) 7.58 (2H, m, H-4 and H-6), 7.10 (1H, td, J 0.9 and 7.2, H-5), 6.92 (1H, d, 
J 7.8, H-7), 3.74 (2H, t, J 6.9, H-4’), 3.44 (2H, t, J 6.9, H-1’), 1.97-1.86 (4H, m, H-2’ and H-
3’); δC (75MHz, CDCl3) 183.2, 158.1, 150.6, 138.4, 125.4, 123.7, 117.5, 110.1, 39.1, 32.7, 
29.5, 25.6; LRMS(ESI) found m/z 282.3 [M+H]
+
 requires 281.0 for C12H12O2NBr.  
 
1-(4-Bromobutyl)-5-fluoroindoline-2,3-dione, 3.6i  
 
The conditions employed for the preparation of this compound 
were those described in general procedure A. However 12.1 mmol 
of 5-fluoroisatin and 48.4 mmol of 1,4-dibromobutane was used. 
The product was obtained as an orange solid (2.30 g, 63%); m.p. 
98°C; Rf (EtOAc:Hex 1:1) 0.70; IR νmax(KBr)/cm
-1
 1727 (C3=O), 1621 (C2=O), 1486 (Ar 
C=C); δH (400MHz, CDCl3) 7.33 (2H, m, H-4 and H-6), 6.91 (1H, m, H-7), 3.77 (2H, t, J 
6.8, H-4’), 3.47 (2H, t, J 6.4, H-1’), 1.98-1.88 (4H, m, H-2’ and H-3’); δC (100MHz, CDCl3) 
182.3, 160.6, 158.1, 146.7, 124.7, 118.3, 112.6, 111.3, 39.4, 32.7, 29.5, 25.6; LRMS(ESI) 
found m/z 300.4 (89%, [M+H]
+
) requires 299.0 for C12H11O2NBrF.  
 
1-(4-Bromobutyl)-5-chloroindoline-2,3-dione, 3.6j  
 
The conditions employed for the preparation of this compound 
were those described in general procedure A. However 11.0 mmol 
of 5-chloroisatin and 44.1 mmol of 1,4-dibromobutane was used. 
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93°C; Rf (EtOAc:Hex, 1:1) 0.75; IRνmax(KBr)/cm
-1
 1735 (C3=O), 1604 (C2=O), 1474 (Ar 
C=C); δH (400MHz, CDCl3) 7.58 (2H, m, H-4 and H-6), 6.91 (1H, d, J 8.8, H-7), 3.78 (2H, t, 
J 6.8, H-4’), 3.47 (2H, t, J 6.4, H-1’), 1.97-1.88 (4H, m, H-2’ and H-3’); δC (100MHz, 
CDCl3) 182.3, 157.7, 149.0, 137.7, 129.7, 125.5, 118.5, 111.4, 39.4, 32.6, 29.5, 25.6; 
LRMS(ESI) found m/z 316.2 (66%, [M+H]
+
) requires 315.0 for C12H11O2NBrCl.  
 
5-Bromo-1-(4-bromobutyl)indoline-2,3-dione, 3.6k  
 
The conditions employed for the preparation of this compound 
were those described in general procedure A. However 8.85 mmol 
of 5-bromoisatin and 35.4 mmol of 1,4-dibromobutane was used. 
The product was obtained as an orange solid (2.30 g, 72%); m.p. 
87°C; Rf (EtOAc:Hex 1:1) 0.73; IRνmax(KBr)/cm
-1
 1735 (C3=O), 1601 (C2=O), 1471 (Ar 
C=C); δH (400MHz, CDCl3) 7.72 (2H, m, H-4 and H-6), 6.86 (1H, d, J 8.8, H-7), 3.77 (2H, t, 
J 6.8, H-4’), 3.47 (2H, t, J 6.0, H-1’), 1.97-1.89 (4H, m, H-2’ and H-3’); δC (100MHz, 
CDCl3) 182.1, 157.5, 149.4, 140.6, 128.3, 118.8, 116.7, 111.8, 39.2, 32.6, 29.5, 25.6; 
LRMS(ESI) found m/z 360.0 (59%, [M+H]
+
) requires 358.9 for C12H11O2NBr2.  
 
1-(4-Bromobutyl)-5-iodoindoline-2,3-dione, 3.6l  
 
The conditions employed for the preparation of this compound 
were those described in general procedure A. However 7.33 mmol 
of 5-iodoisatin and 29.3 mmol of 1,4-dibromobutane was used. 
The product was obtained as an orange solid (1.81 g, 61%); m.p. 
82-83°C; Rf (EtOAc:Hex 1:1) 0.82; IRνmax(KBr)/cm
-1
 1726 (C3=O), 1600 (C2=O), 1469 (Ar 
C=C); δH (400MHz, CDCl3) 7.90 (2H, m, H-4 and H-6), 6.76 (1H, d, J 8.8, H-7), 3.76 (2H, t, 
J 6.8, H-4’), 3.47 (2H, t, J 6.4, H-1’), 1.976-1.86 (4H, m, H-2’ and H-3’); δC (100MHz, 
CDCl3) 181.9, 157.2, 150.0, 146.5, 134.0, 119.2, 112.2, 86.0, 39.4, 32.6, 29.5, 25.6; 
LRMS(ESI) found m/z 408.1 (89%, [M+H]
+
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1-(4-Bromobutyl)-5-methylindoline-2,3-dione, 3.6m  
 
The conditions employed for the preparation of this compound 
were those described in general procedure A. However 12.4 mmol 
of 5-methylisatin and 49.6 mmol of 1,4-dibromobutane was used. 
The product was obtained as an orange solid (2.31 g, 63%); m.p. 
114-115°C; Rf (EtOAc:Hex 1:1) 0.69; IRνmax(KBr)/cm
-1
 1738 (C3=O), 1621 (C2=O), 1491 
(Ar C=C); δH (400MHz, CDCl3) 7.42 (2H, m, H-4 and H-6), 6.83 (1H, d, J 8.0, H-7), 3.76 
(2H, t, J 6.8, H-4’), 3.47 (2H, t, J 6.4, H-1’), 2.35 (3H, s, H-8), 1.98-1.87 (4H, m, H-2’ and 
H-3’); δC (100MHz, CDCl3) 183.7, 156.8, 148.5, 138.8, 133.7, 125.9, 117.7, 109.9, 39.2, 
32.7, 29.6, 25.7, 20.6; LRMS(ESI) found m/z 296.3 (84%, [M+H]
+
) requires 295.0 for 
C13H14O2NBr.  
 
1-4-Bromobutyl)-5-nitroindoline-2,3-dione, 3.6n  
 
The conditions employed for the preparation of this compound 
were those described in general procedure A. However 10.4 mmol 
of 5-nitroisatin and 41.6 mmol of 1,4-dibromobutane was used. 
The product was obtained as a yellow solid (1.85 g, 54%); m.p. 
260°C; Rf (EtOAc:Hex 1:1) 0.55; IRνmax(KBr)/cm
-1
 1746 (C3=O), 1610 (C2=O), 1477 (Ar 
C=C), 1520/1336 (Asym./sym. NO2 str.); δH (400MHz, DMSO-d6) 8.49 (1H, dd, J 2.4 and 
8.5, H-6), 8.22 (1H, d, J 2.4, H-4), 7.42 (1H, d, J 8.4, H-7), 3.78 (2H, t, J 6.4, H-4’), 3.56 
(2H, t, J 6.4, H-1’), 1.76-1.68 (4H, m, H-2’ and H-3’); δC (100MHz, DMSO-d6) 181.1, 158.8, 
154.9, 142.8, 132.8, 119.0, 117.9, 111.0, 39.6, 34.5, 29.3, 25.5; LRMS(ESI) found m/z 327.0 
[M+H]
+
 requires 326.0 for C12H11O4N2Br.   
 
1-(5-Bromo-pentyl)-1H-indole-2,3-dione, 3.6o  
 
The conditions employed for the preparation of this compound 
were those described in general procedure A. However 6.80 
mmol of isatin and 27.2 mmol of 1,5-dibromopentane was used. 
The product was obtained as an orange oil (1.95 g, 97%); Rf 
(EtOAc:Hex 1:1) 0.78; IRνmax(film)/cm
-1






























































 Chapter 7: Experimental  
 218 
(C2=O), 1470 (Ar C=C); δH (300MHz, CDCl3) 7.56 (2H, m, H-4 and H-6), 7.08 (1H, td, J 0.9 
and 7.5, H-5), 6.88 (1H, d, J 8.4, H-7), 3.70 (2H, t, J 6.9, H-5’), 3.36 (2H, t, J 6.9, H-1’), 1.86 
(2H, quint, J 6.9, H-4’), 1.63 (2H, quint, J 6.9, H-2’), 1.51 (2H, quint, J 7.2, H-3’); δC (75 
MHz, CDCl3) 183.3, 158.1, 150.7, 138.3, 125.3, 123.6, 117.4, 110.0, 39.8, 33.1, 32.0, 26.3, 
25.3; LRMS(ESI) found m/z 296.1 (100%, [M+H]
+
) requires 295.0 for C13H14O2NBr.   
 
1-(5-Bromopentyl)-5-chloroindoline-2,3-dione, 3.6p  
 
The conditions employed for the preparation of this compound 
were those described in general procedure A. However 11.0 
mmol of 5-chloroisatin and 44.1 mmol of 1,5-dibromopentane 
was used. The product was obtained as a red crystalline solid 
(2.27 g, 62%); m.p. 93-95°C; Rf (EtOAc:Hex 2:3) 0.69; δH (400MHz, CDCl3) 7.58-7.55 (2H, 
m, H-4 and H-6), 6.87 (1H, d, J 8.0, H-7), 3.75 (2H, t, J 7.6, H-5’), 3.41 (2H, t, J 6.4, H-1’), 
1.93 (2H, quint, J 7.2, H-4’), 1.74 (2H, quint, J 7.2, H-2’), 1.57 (2H, quint, J 7.6, H-3’); δC 
(100MHz, CDCl3) 182.1, 158.0, 149.2, 137.8, 129.9, 125.2, 118.0, 111.3, 40.1, 33.1, 32.0, 
26.4, 25.4; LRMS(ESI) found m/z 330.2 (74%, [M+H]
+
) requires 329.0 for C13H13O2NBrCl.  
 
5-Bromo-1-(5-bromopentyl)indoline-2,3-dione, 3.6q  
 
The conditions employed for the preparation of this compound 
were those described in general procedure A. However 8.85 
mmol of 5-bromoisatin and 35.4 mmol of 1,5-dibromopentane 
was used. The product was obtained as an orange crystalline 
solid (2.58 g, 78%); m.p. 103°C; Rf (EtOAc:Hex 2:3) 0.65; δH 
(400MHz, CDCl3) 7.73-7.70 (2H, m, H-4 and H-6), 6.82 (1H, d, J 8.8, H-7), 3.74 (2H, t, J 
7.2, H-5’), 3.41 (2H, t, J 6.8, H-1’), 1.93 (2H, quint, J 7.2, H-4’), 1.74 (2H, quint, J 7.2, H-
2’), 1.57 (2H, quint, J 7.6, H-3’); δC (100MHz, CDCl3) 182.2, 157.5, 149.6, 140.6, 128.3, 
118.8, 116.6, 111.7, 40.1, 33.1, 32.0, 26.4, 25.4; LRMS(ESI) found m/z 374.1 (58%, 
[M+H]
+














































 Chapter 7: Experimental  
 219 
1-(5-Bromopentyl)-5-iodoindoline-2,3-dione, 3.6r  
 
The conditions employed for the preparation of this compound 
were those described in general procedure A. However 7.32 
mmol of 5-iodoisatin and 29.3 mmol of 1,5-dibromopentane was 
used. The product was obtained as a red crystalline solid (2.41 g, 
78%); m.p. 89°C; Rf (EtOAc:Hex 2:3) 0.68; δH (400MHz, CDCl3) 7.91-7.89 (2H, m, H-4 and 
H-6), 6.72 (1H, d, J 8.8, H-7), 3.73 (2H, t, J 7.2, H-5’), 3.41 (2H, t, J 6.4, H-1’), 1.92 (2H, 
quint, J 7.2, H-4’), 1.73 (2H, quint, J 7.2, H-2’), 1.54 (2H, quint, J 7.6, H-3’); δC (100MHz, 
CDCl3) 182.2, 157.2, 150.2, 146.4, 134.0, 119.2, 112.2, 85.9, 40.1, 33.1, 32.0, 26.4, 25.4; 
LRMS(ESI) found m/z 422.3 (100%, [M+H]
+
) requires 420.9 for C13H13O2NBrI.   
 
1-(6-Bromo-hexyl)-1H-indole-2,3-dione, 3.6s  
 
The conditions employed for the preparation of this compound 
were those described in general procedure A. However 6.80 mmol 
of isatin and 27.2 mmol of 1,6-dibromohexane was used. The 
product was obtained as a red crystalline solid (2.11 g, quant); 
m.p. 42°C; Rf (EtOAc:Hex 1:1) 0.77; IRνmax(KBr)/cm
-1
 1740 
(C3=O), 1611 (C2=O), 1471 (Ar C=C); δH (300MHz, CDCl3) 7.57 (2H, m, H-4 and H-6), 
7.10 (1H, td, J 0.9 and 7.8, H-5), 6.88 (1H, d, J 8.4, H-7), 3.71 (2H, t, J 6.9, H-6’), 3.38 (2H, 
t, J 7.2, H-1’), 1.82 (2H, quint, J 6.9, H-2’), 1.65 (2H, quint, J 7.2, H-5’), 1.54-1.36 (4H, m, 
H-3’ and H-4’); δC (75 MHz, CDCl3) 183.4, 158.1, 150.9, 138.3, 125.4, 123.6, 117.6, 110.0, 
40.0, 33.6, 32.4, 27.6, 27.0, 26.0; LRMS(ESI) found m/z 310.0 (95%, [M+H]
+
) requires 
309.0 for C14H16O2NBr.  
 
1-(6-Bromohexyl)-5-iodoindoline-2,3-dione, 3.6t  
 
The conditions employed for the preparation of this compound 
were those described in general procedure A. However 7.32 
mmol of 5-iodoisatin and 29.3 mmol of 1,6-dibromohexane was 
used. The product was obtained as an orange crystalline solid 
(2.41 g, 75%); m.p. 99-101°C; Rf (EtOAc:Hex 1:1) 0.82; IRνmax(KBr)/cm
-1
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1601 (C2=O), 1468 (Ar C=C); δH (300MHz, CDCl3) 7.87 (2H, m, H-4, H-6), 6.70 (1H, d, J 
8.7, H-7), 3.70 (2H, t, J 7.2, H-6’), 3.39 (2H, t, J 6.6, H-1’), 1.85 (2H, quint, J 6.9, H-5’), 
1.70 (2H, quint, J 7.2, H-2’), 1.55-1.36 (4H, m, H-3’, H-4’); δC (75MHz, CDCl3) 182.2, 
157.1, 150.2, 146.3, 133.9, 119.2, 112.2, 85.8, 40.1, 33.5, 32.4, 27.6, 27.0, 26.0; LRMS(ESI) 
found m/z 436.2 (96%, [M+H]
+
) requires 434.9 for C14H15O2NBrI.   
 
1-(6-Bromohexyl)-5-chloroindoline-2,3-dione, 3.6u  
 
The conditions employed for the preparation of this compound 
were those described in general procedure A. However 11.0 
mmol of 5-chloroisatin and 44.1 mmol of 1,6-dibromohexane 
was used. The product was obtained as an orange crystalline 
solid (2.66 g, 70%); m.p. 57°C; Rf (EtOAc:Hex 1:1) 0.75; 
IRνmax(KBr)/cm
-1
 1731 (C3=O), 1606 (C2=O), 1474 (Ar C=C); δH (300MHz, CDCl3) 7.54 
(2H, m, H-4 and H-6), 6.85 (1H, d, J 8.7, H-7), 3.71 (2H, t, J 7.2, H-6’), 3.38 (2H, t, J 6.9, H-
1’), 1.84 (2H, quint, J 6.9, H-5’), 1.70 (2H, quint, J 7.2, H-2’), 1.54-1.36 (4H, m, H-3’, H-
4’); δC (75MHz, CDCl3) 182.4, 157.6, 149.1, 137.6, 129.5, 125.3, 118.4, 111.3, 40.2, 33.5, 
32.4, 27.6, 27.0, 26.0; LRMS(ESI) found m/z 344.4 (75%, [M+H]
+
) requires 343.0 for 
C14H15O2NClBr.   
 
5-Bromo-1-(6-bromohexyl)indoline-2,3-dione, 3.6v  
 
The conditions employed for the preparation of this compound 
were those described in general procedure A. However 8.84 
mmol of 5-bromoisatin and 35.4 mmol of 1,6-dibromohexane 
was used. The product was obtained as an orange crystalline 
solid (2.26 g, 66%); m.p. 64-65°C; Rf (EtOAc:Hex 1:1) 0.85; 
IRνmax(KBr)/cm
-1
 1753 (C3=O), 1606 (C2=O), 1472 (Ar C=C); δH (300MHz, CDCl3) 7.68 
(2H, m, H-4, H-6), 6.80 (1H, d, J 9.3, H-7), 3.71 (2H, t, J 7.2, H-6’), 3.38 (2H, t, J 6.9, H-1’), 
1.84 (2H, quint, J 6.9, H-5’), 1.70 (2H, quint, J 7.2, H-2’), 1.52-1.36 (4H, m, H-3’, H-4’); δC 
(75MHz, CDCl3) 182.3, 157.4, 149.6, 140.5, 128.2, 118.8, 116.4, 111.8, 40.2, 33.5, 32.4, 
27.6, 27.0, 26.0; LRMS(ESI) found m/z 388.1 (58%, [M+H]
+
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1-(6-Bromohexyl)-5-fluoroindoline-2,3-dione, 3.6w  
 
The conditions employed for the preparation of this compound 
were those described in general procedure A. However 12.1 
mmol of 5-fluoroisatin and 48.4 mmol of 1,6-dibromohexane 
was used. The product was obtained as an orange crystalline 
solid (2.25 g, 57%); m.p. 36°C; Rf (EtOAc:Hex 1:1) 0.74; 
IRνmax(KBr)/cm
-1
 1736 (C3=O), 1620 (C2=O), 1485 (Ar C=C); δH (300MHz, CDCl3) 7.26-
7.32 (2H, m, H-4 and H-6), 6.85 (1H, dd, J 3.3 and 9.0, H-7), 3.71 (2H, t, J 7.5, H-6’), 3.39 
(2H, t, J 6.9, H-1’), 1.84 (2H, quint, J 7.2, H-5’), 1.71 (2H, quint, J 6.9, H-2’), 1.53-1.37 (4H, 
m, H-3’, H-4’); δC (75MHz, CDCl3) 182.0, 157.6, 146.9, 124.6, 118.2, 112.5, 111.2, 40.2, 
33.5, 32.4, 27.6, 27.0, 26.0; LRMS(ESI) found m/z 328.3 (11%, [M+H]
+
) requires 327.0 for 
C14H15O2NFBr.   
 
B. General procedure for preparation of compounds 3.7 a-j 
The appropriate N-alkylated isatin/5-substituted isatin 3.6a-h,o,s (4.11 mmol, 1.5 eq) and 3.5 
(2.74 mmol, 1.0 eq) was dissolved in 3 ml anhydrous DMF. The resulting mixture was stirred 
at 60°C for 48 hours under a N2 atmosphere. When the reaction was completed, ice-cold 
water was added to the dark red product mixture. The precipitate so obtained was filtered, 
washed with water and purified using column chromatography (eluent EtOAc:Hex 3:2). 
When no precipitate formed upon the addition of ice-cold water, the product mixture was 
extracted with EtOAc. The combined organic layer was then washed with deionized water to 
remove DMF and subsequently dried over anhydrous Na2SO4. Concentration under reduced 
pressure afforded the crude product mixture which was subjected to column chromatography 
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5-Bromo-1-[2-(2,4-dimethyl-5-oxo-2,5-dihydro-thiophen-3-yloxy)-ethyl]-indole-2,3-
dione, 3.7a (RBrn2O) 
 
Orange solid (97.7 mg, 9%), m.p. 168-169°C; Rf (EtOAc:Hex 1:1) 0.28; 
IRνmax(KBr)/cm
-1
 1748 (C3=O), 1624 (C2”=O), 1603 (C2=O); δH 
(400MHz, CDCl3) 7.73 (2H, m, H-4 and H-6), 6.95 (1H, d, J 7.5, H-7), 
4.57 (1H, m, H-2’a/b), 4.46 (1H, m, H-2’a/b), 4.08 (3H, m, H-5” and H-
1’), 1.76 (3H, d
†
, J 1.6, H-7”), 1.49 (3H, d, J 6.8, H-6”); δC (100MHz, 
CDCl3) 194.5, 182.0, 176.4, 157.7, 149.5, 140.5, 128.5, 118.8, 117.1, 
115.3, 112.0, 68.2, 41.7, 40.5, 19.7, 9.1; HRMS(EI) found m/z 394.98277 for 
C16H14O4NSBr, requires 394.98269; Anal. Calc. for C16H14O4NSBr: C, 48.50%; H, 3.56%; 
N, 3.53%; S, 8.09%. Found: C, 48.40%; H, 3.45%; N, 3.70%; S, 7.70%.  
 
5-Chloro-1-[2-(2,4-dimethyl-5-oxo-2,5-dihydro-thiophen-3-yloxy)-ethyl]-1H-indole-2,3-
dione, 3.7b (RCln2O)  
 
Orange solid (125 mg, 13%); m.p. 270-272°C; Rf (EtOAc:Hex 1:1) 0.23; 
IRνmax(KBr)/cm
-1
 1743 (C3=O), 1633 (C2”=O), 1610 (C2=O); δH 
(400MHz, CDCl3) 7.58 (2H, m, H-6 and H-4), 7.00 (1H, d, J 8.0, H-7), 
4.56 (1H, m, H-2’a/b), 4.46 (1H, m, H-2’a/b), 4.08 (3H, m, H-5” and H-
1’), 1.76 (3H, d, J 1.2, H-7”), 1.25 (3H, d, J 7.2, H-6”); δC (100MHz, 
CDCl3) 195.1, 181.5, 176.4, 157.8, 149.1, 137.7, 130.1, 125.6, 118.4, 115.3, 111.7, 68.2, 
41.7, 40.5, 19.7, 9.1; HRMS(EI) found m/z 350.99468, C16H14O4NSCl, requires 351.03321; 
Anal. Calc. for C16H14O4NSCl: C, 54.62%; H, 4.01%; N, 3.98%; S, 9.11%. Found: C, 
54.41%; H, 3.88; N, 3.80%; S, 8.89%. 
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1-[2-(2,4-Dimethyl-5-oxo-2,5-dihydro-thiophen-3-yloxy)-ethyl]-5-fluoro-1H-indole-2,3-
dione, 3.7c (RFn2O) 
 
Orange solid (129 mg, 14%), m.p. 132-133°C; Rf (EtOAc:Hex 1:1) 0.19; 
IRνmax(KBr)/cm
-1
 1740 (C3=O), 1641 (C2”=O), 1620 ( C2=O); δH 
(400MHz, CDCl3) 7.34 (2H, m, H-4 and H-6), 7.02 (1H, dd, J 4.0 and 
9.6, H-7), 4.57 (1H, m, H-2’a/b), 4.46 (1H, m, H-2’a/b), 4.09 (3H, m, H-
5” and H-1’), 1.76 (3H, d, J 1.2, H-7”), 1.49 (3H, d, J 6.8, H-6”); δC 
(100MHz, CDCl3) 195.1, 181.9, 176.5, 160.7, 158.2, 146.8, 124.7, 118.3, 115.3, 112.7, 
111.6, 68.2, 41.7, 40.5, 19.7, 9.0; HRMS(EI) found m/z 335.06248 for C16H14O4NSF, 
requires 335.06276; Anal. Calc. for C16H14O4NF: C, 57.30%; H, 4.21%; N, 4.18%; S, 9.56%. 
Found: C, 57.13%; H, 4.06%; N, 3.72%; S, 9.22%. 
 
1-[2-(2,4-Dimethyl-5-oxo-2,5-dihydro-thiophen-3-yloxy)-ethyl]-5-iodo-1H-indole-2,3-
dione, 3.7d (RIn2O) 
 
Orange solid (121 mg, 10%); m.p. 196°C; Rf (EtOAc:Hex 1:1) 0.26; 
IRνmax(KBr)/cm
-1
 1740 (C3=O), 1623 (C2”=O), 1600 (C2=O); δH (400MHz, 
CDCl3) 7.92 (2H, m, H-4 and H-6), 6.84 (1H, d, J 8.8, H-7), 4.56 (1H, m, 
H-2’a/b), 4.45 (1H, m, H-2’a/b), 4.08 (3H, m, H-5” and H-1’), 1.77 (3H, d, 
J 1.2, H-7”), 1.49 (3H, d, J 7.2, H-6”); δC (100MHz, CDCl3) 195.1, 182.5, 
178.4, 169.2, 157.4, 150.1, 146.3, 134.2, 119.1, 112.4, 86.4, 68.2, 41.7, 40.4, 19.7, 9.1; 
HRMS(EI) found m/z 442.97039, C16H14O4NSI, requires 442.96883; Anal. Calc. for 
C16H14O4NSI: C, 43.35%; H, 3.18%; N, 3.16%; S, 7.23%. Found: C, 42.95%; H, 3.29%; N, 
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1-[2-(2,4-Dimethyl-5-oxo-2,5-dihydro-thiophen-3-yloxy)-ethyl]-5-methyl-1H-indole-2,3-
dione, 3.7e (RCH3n2O) 
 
Orange solid (236 mg, 26%), m.p. 130°C; Rf (EtOAc:Hex 1:1) 0.23; 
IRνmax(KBr)/cm
-1
 1740 (C3=O), 1643 (C2”=O), 1619 (C2=O); δH 
(400MHz, CDCl3) 7.41 (2H, m, H-6 and H-4), 6.91 (1H, d, J 8.0, H-7), 
4.56 (1H, m, H-2’a/b), 4.46 (1H, m, H-2’a/b), 4.07 (3H, m, H-5” and H-
1’), 2.35 (3H, s, H-8), 1.76 (3H, d, J 1.6, H-7”), 1.48 (3H, d, J 6.8, H-
6”); δC (100MHz, CDCl3) 195.3, 182.8, 176.6, 158.6, 148.6, 138.7, 134.1, 126.0, 117.6, 
115.0, 110.1, 68.2, 41.7, 40.3, 20.6, 19.6, 9.0; HRMS(EI) found m/z 331.08822 for 
C17H17O4NS requires 331.08783; Anal. Calc. for C17H17O4NS: C, 61.61%; H, 5.17%; N, 





Orange solid (258 mg, 36%); m.p. 54°C; Rf (EtOAc:Hex 1:1) 0.18; 
IRνmax(KBr)/cm
-1
 1740 (C3=O), 1644 (C2”=O), 1611 (C2=O); δH 
(400MHz, CDCl3) 7.62 (2H, m, H-4 and H-6), 7.16 (1H, td, J 0.9 and 7.8, 
H-5), 7.03 (1H, d, J 7.8, H-7), 4.58 (1H, m, H-2’a/b), 4.47 (1H, m, H-
2’a/b), 4.09 (3H, m, H-5” and H-1’), 1.75 (3H, d, J 1.5, H-7”), 1.48 (3H, 
d, J 6.6, H-6”); δC (100MHz, CDCl3) 195.2, 182.5, 176.6, 158.4, 150.8, 138.3, 125.7, 124.2, 
117.6, 115.1, 110.3, 68.2, 41.8, 40.3, 19.6, 9.0; HRMS(EI) found m/z 317.0722 for 
C16H15O4NS requires 317.07218; Anal Calc. for C16H15O4NS: C, 60.55%; H, 4.76%; N, 




























































Orange solid (161 mg, 18%); m.p. 150-151°C; Rf (EtOAc:Hex 1:1) 
0.24; IRνmax(KBr)/cm
-1
 1736 (C3=O), 1663 (C2”=O), 1612 (C2=O); 
δH (400MHz, CDCl3) 7.62 (2H, m, H-6 and H-4), 7.15 (1H, td, J 0.9 
and 7.6, H-5), 6.92 (1H, d, J 7.6, H-7), 4.39 (1H, m, H-3’a/b), 4.27 
(1H, m, H-3’a/b), 4.15 (1H, qd, J 1.2 and 7.2, H-5”), 3.93 (2H, t, J 
6.8, H-1’), 2.18 (2H, m, H-2’), 1.82 (3H, d, J 1.2, H-7”), 1.57 (3H, d, J 7.2, H-6”); δC 
(100MHz, CDCl3) 195.5, 183.0, 177.3, 158.4, 150.6, 138.5, 125.7, 124.0, 117.7, 114.8, 
109.7, 68.3, 41.9, 37.0, 28.0, 19.8, 9.0; HRMS(EI) found m/z 331.08695 for C17H17O4NS 
requires 331.08783; Anal Calc. for C17H17O4NS: C, 61.67%; H, 5.17%; N, 4.23%; S, 9.68%. 





Orange solid (91.6 mg, 10%); m.p. 108°C; Rf (EtOAc:Hex 1:1) 
0.18; IRνmax(KBr)/cm
-1
 1733 (C3=O), 1639 (C2”=O), 1606 
(C2=O); δH (300MHz, CDCl3) 7.60 (2H, m, H-6 and H-4), 7.13 
(1H, td, J 0.9 and 7.8, H-5), 6.90 (1H, d, J 7.8, H-7), 4.35 (1H, 
m, H-4’a/b), 4.22 (1H, m, H-4’a/b), 4.14 (1H, qd, J 0.9 and 6.9, 
H-5”), 3.81 (2H, t, J 6.9, H-1’), 1.86 (4H, m, H-2’ and H-3’), 1.80 (3H, d, J 0.9, H-7”), 1.55 
(3H, d, J 6.9, H-6”); δC (75MHz, CDCl3) 195.7, 183.2, 177.7, 158.3, 150.6, 138.3, 125.6, 
123.9, 117.6, 114.5, 109.9, 70.2, 41.9, 39.5, 27.1, 23.6, 19.8, 9.0; HRMS(EI) found m/z 
345.1029 for C18H19O4NS requires 345.10348; Anal Calc. for C18H19O4NS: C, 62.59%; H, 































































Orange solid (217 mg, 22%); m.p. 77-79°C; Rf (EtOAc:Hex 1:1) 
0.36; IRνmax(KBr)/cm
-1
 1732 (C3=O), 1670 (C2”=O), 1620 (C2=O); 
δH (400MHz, CDCl3) 7.59 (2H, m, H-6 and H-4), 7.12 (1H, td, J 
0.9 and 7.6, H-5), 6.89 (1H, d, J 8, H-7), 4.30 (1H, m, H-5’a/b), 
4.13 (2H, m, H-5’a/b and H-5”), 3.77 (2H, t, J 7.2, H-1’), 1.80 (7H, 
m, H-7”, H-2’ and H-4’), 1.54, (5H, m, H-6” and H-3’); δC 
(100MHz, CDCl3) 195.4, 183.3, 177.9, 158.2, 150.8, 138.3, 125.6, 
123.8, 117.6, 114.3, 110.0, 70.8, 41.9, 39.8, 29.4, 26.9, 23.1, 19.8, 9.0; HRMS(EI) found m/z 
359.11842 for C19H21O4NS requires 359.11913; Anal Calc. for C19H21O4NS: C, 63.49%; H, 





Orange oil (154 mg, 15%); Rf (EtOAc:Hex 1:1) 0.31; 
IRνmax(CHCl3)/cm
-1
 1739 (C3=O), 1675 (C2”=O), 1611 (C2=O); δH 
(300MHz, CDCl3) 7.57 (2H, m, H-4 and H-6), 7.09 (1H, td, J 0.9 and 
7.4, H-5), 6.88 (1H, d, J 7.8, H-7), 4.27 (1H, m, H-6’a/b), 4.13 (2H, m, 
H-6’a/b and H-5”), 3.72 (2H, t, J 7.5, H-1’), 1.79 (3H, d, J 0.9, H-7”), 
1.76-1.68 (4H, m, H-2’ and H-5’), 1.54 (3H, d, J 6.6, H-6”), 1.41-1.50 
(4H, m, H-3’ and H-4’); δC (75MHz, CDCl3) 195.7, 183.4, 178.0, 
158.1, 150.8, 138.2, 125.4, 123.6, 117.5, 114.0, 110.0, 71.0, 41.9, 39.9, 29.7, 27.1, 26.4, 25.3, 
19.8, 9.0;  HRMS(EI) found m/z 373.1346 for C20H23O4NS requires 373.13478; Anal. Calc. 
for C20H23O4NS: C, 64.32%; H, 6.21%; N, 3.75%; S, 8.59%. Found: C, 63.64%; H, 6.46%; 
N, 3.65%; S, 7.24%.  
 
The conditions employed for the preparation of compound 3.8a-p are those described in 
general procedure B. However, the reaction duration for compounds 3.8d-p was increased 
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Compound 3.8a (RHn4Y) 
 
Yellow crystalline solid (333 mg, 35%); m.p. 184-185°C; Rf 
(EtOAc:Hex 1:1) 0.29; IRνmax(KBr)/cm
-1
 3311 (OH), 1700 (C2=O), 
1620 (C2’=O), 1468 (Ar C=C); δH (400MHz, CDCl3) 7.80 (1H, dd, J 
1.2 and 7.6, H-4’), 7.28 (1H, td, J 1.2 and 8.0, H-6’), 6.96 (1H, td, J 
0.8 and 7.6, H-5’), 6.78 (1H, d, J 8.0, H-7’), 4.59 (1H, m, H-4”a/b), 4.29 (1H, m, H-1”a/b), 
3.55 (1H, m, H-4”a/b), 3.38 (1H, dt, J 3.6 and 14.4, H-1”a/b), 3.35 (1H, s, OH), 2.08-1.86 
(4H, m, H-2” and H-3”), 1.99 (3H, s, H-7), 1.60 (3H, s, H-6); δC (100MHz, CDCl3) 195.3, 
176.3, 175.4, 141.7, 130.3, 127.5, 125.8, 122.5, 110.9, 108.4, 78.8, 74.4, 66.1, 39.4, 28.3, 
26.7, 19.5, 9.3; HRMS(EI) found m/z 345.1030 for C18H19O4NS requires 345.10348; Anal 
Calc. for C18H19O4NS: C, 62.59%; H, 5.54%; N, 4.06%; S, 9.28%. Found: C, 62.48%; H, 
5.09%; N, 3.70%; S, 9.01%.  
 
Compound 3.8b (RHn5Y) 
 
Light yellow crystalline solid (85.3 mg, 9%); m.p. 214-215°C; Rf 
(EtOAc:Hex 1:1) 0.38; IRνmax(KBr)/cm
-1
 3380 (OH), 1695 (C2=O), 
1622 (C2’=O), 1471 (Ar C=C); δH (400MHz, CDCl3) 7.80 (1H, dd, J 
1.2 and 7.6, H-4’), 7.28 (1H, td, J 1.2 and 8.0, H-6’), 6.96 (1H, td, J 
0.8 and 7.6, H-5’), 6.78 (1H, d, J 8.0, H-7’), 4.59 (1H, m, H-5”a/b), 4.29 (1H, m, H-1”a/b), 
3.45 (1H, m, H-5”a/b), 3.29 (1H, br. s, OH), 3.26 (1H, dt, J 3.2 and 14.0, H-1”a/b), 1.96 (3H, 
s, H-7), 1.91–1.72 (4H, m, H-2” and H-4”), 1.60 (3H, s, H-6), 1.44 (2H, m, H-3”); δC 
(100MHz, CDCl3) 195.7, 176.3, 175.2, 142.3, 130.5, 127.8, 125.4, 122.9, 110.8, 107.9, 78.3, 
67.7, 66.0, 40.8, 28.5, 23.2, 19.7, 19.5, 9.7; HRMS(EI) found m/z 359.1186 for C19H21O4NS 
requires 359.11913; Anal Calc. for C19H21O4NS: C, 63.49%; H, 5.89%; N, 3.90%; S, 8.92%. 
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Compound 3.8c (RHn6Y) 
 
Yellow crystalline solid (61.4 mg, 6%); m.p.198°C; Rf (EtOAc:Hex 
1:1) 0.40; IRνmax(KBr)/cm
-1
 3412 (OH), 1697 (C2=O), 1630 (C2’=O), 
1471 (Ar C=C); δH (300MHz, CDCl3) 7.86 (1H, dd, J 1.5 and 7.8, H-
4’), 7.28 (1H, td, J 1.2 and 7.8, H-6’), 6.94 (1H, td, J 0.9 and 7.8, H-
5’), 6.83 (1H, d, J 7.8, H-7’), 4.26-4.10 (3H, m, H-1”a/b and H-6”), 3.28 (1H, m, H-1”a/b), 
3.18 (1H, br. s, OH), 2.04 (3H, s, H-7), 1.98-1.81 (3H, m, H-2”a/b and H-5”), 1.67 (3H, s, H-
6), 1.62-1.30 (5H, m, H-2”a/b, H-3” and H-4”); δC (75MHz, CDCl3) 195.6, 176.2, 175.2, 
144.0, 130.5, 127.2, 125.1, 122.6, 111.7, 108.4, 77.4, 72.5, 65.4, 39.2, 26.0, 24.1, 23.8, 22.6, 
21.2, 9.7; HRMS(EI) found m/z 373.1341 for C20H23O4NS requires 373.13478; Anal Calc. 
for C20H23O4NS: C, 64.32%; H, 6.21%; N, 3.75%; S, 8.59%. Found: C, 64.31%; H, 6.13%; 
N, 3.70%; S, 8.66%.  
 
Compound 3.8d (RBrn4Y) 
 
Off-white amorphous powder (158 mg, 14%); m. p. 156-157°C; Rf 
(EtOAc:Hex, 1:1) 0.27; IR νmax(KBr)/cm
-1
 3416 (OH), 1705 (ester 
C=O), 1618 (amidic C=O), 1482 (Ar C=C); δH (400MHz, CDCl3) 
7.93 (1H, d, J 1.8, H-4’), 7.43 (1H, dd, J 2.1 and 8.4, H-6’), 6.67 
(1H, d, J 8.4, H-7’), 4.63 (1H, m, H-4”a/b), 4.32 (1H, m, H-1”a/b), 3.59 (1H, m, H-4”a/b), 
3.40 (1H, dt, J 3.6 and 14.4, H-1”a/b), 3.18 (1H, br. s, OH), 2.08-1.87 (4H, m, H-2” and H-
3”), 2.00 (3H, s, H-7), 1.68 (3H, s, H-6); δC (100MHz, CDCl3) 194.4, 185.1, 175.0, 156.0, 
133.2, 129.4, 129.2, 115.2, 111.1, 109.7, 78.7, 74.5, 65.9, 39.5, 28.3, 26.7, 19.8, 9.5; 
HRMS(ESI) found m/z 424.02123 [M+H]
+
 for C18H18O4NSBr requires 423.01399; Anal 
Calc. for C18H18O4NSBr: C, 50.95%; H, 4.28%; N, 3.30%; S, 7.56%. Found: C, 50.36%; H, 
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Compound 3.8e (RIn4Y) 
 
Light yellow solid (188 mg, 15%); m.p. 205-206°C; Rf 
(EtOAc:Hex 1:1) 0.29; IRνmax(KBr)/cm
-1
 3439 (OH), 1715 (C2=O), 
1631 (C2’=O), 1480 (Ar C=C); δH (400MHz, CDCl3) 8.09 (1H, d, J 
2.0, H-4’), 7.62 (1H, dd, J 2.0 and 8.4, H-6’), 6.58 (1H, d, J 8.4, H-
7’), 4.62 (1H, m, H-4”a/b), 4.27 (1H, m, H-1”a/b), 3.55 (1H, m, H-4”a/b), 3.48 (1H, br. s, 
OH), 3.36 (1H, dt, J 3.2 and 14.8, H-1”a/b), 2.07-1.84 (4H, m, H-2” and H-3”), 1.97 (3H, s, 
H-7), 1.66 (3H, s, H-6); δC (100MHz, CDCl3) 194.4, 175.8, 175.1, 141.4, 139.1, 134.6, 
129.8, 111.1, 110.3, 84.8, 78.7, 74.5, 65.9, 39.5, 28.3, 26.7, 19.8, 9.5; HRMS(ESI) found m/z 
472.00759 [M+H]
+
 for C18H18O4NSI requires 471.00013; Anal Calc. for C18H18O4NSI: C, 
45.87%; H, 3.85%; N, 2.97%; S, 6.80%. Found: C, 45.62%; H, 3.34%; N, 2.06%; S, 6.66%.  
 
Compound 3.8f (RFn4Y) 
 
Light yellow solid (95.2 mg, 10%); m.p. 157°C; Rf (EtOAc:Hex 
1:1) 0.26; IRνmax(KBr)/cm
-1
 3306 (OH), 1701 (C2=O), 1625 
(C2’=O), 1489 (Ar C=C); δH (400MHz, CDCl3) 7.59 (1H, dd, J 
2.8 and 8.0, H-4’), 7.01 (1H, ddd, J 2.4, 8.6 and 8.8, H-6’), 6.73 
(1H, dd, J 4.0 and 8.4, H-7’), 4.63 (1H, m, H-4”a/b), 4.31 (1H, m, H-1”a/b), 3.57 (1H, m, H-
4”a/b), 3.45 (1H, br. s, OH), 3.39 (1H, dt, J 3.2 and 14.4, H-1”a/b), 2.09-1.83 (4H, m, H-2” 
and H-3”), 1.99 (3H, s, H-7), 1.66 (3H, s, H-6); δC (100MHz, CDCl3) 194.4, 177.2, 175.1, 
159.8, 147.1, 137.6, 116.7, 114.6, 111.0, 108.9, 78.8, 74.5, 66.0, 39.6, 28.4, 26.7, 19.7, 9.4; 
HRMS(ESI) found m/z 364.10153 [M+H]
+
 for C18H18O4NSF requires 363.09406; Anal Calc. 
for C18H18O4NSF: C, 59.49%; H, 4.99%; N, 3.85%; S, 8.82%. Found: C, 59.37%; H, 4.88%; 
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Compound 3.8g (RCln4Y) 
 
Light yellow solid (151 mg, 14%); m.p. 208-210°C; Rf 
(EtOAc:Hex 1:1) 0.24; IRνmax(KBr)/cm
-1
 3415 (OH), 1707 (C2=O), 
1618 (C2’=O), 1484 (Ar C=C); δH (400MHz, DMSO-d6) 7.54 (1H, 
d, J 2.4, H-4’), 7.37 (1H, dd, J 2.4 and 8.8, H-6’), 7.04 (1H, d, J 
8.4, H-7’), 6.86 (1H, br. s, OH), 4.65 (1H, br. dd, J 4.0 and 10.0, H-4”a/b), 4.07 (1H, m, H-
1”a/b), 3.53 (1H, m, H-4”a/b), 3.46 (1H, m, H-1”a/b), 1.98-1.59 (4H, m, H-2” and H-3”), 
1.89 (3H, s, H-7), 1.56 (3H, s, H-6); δC (100MHz, DMSO-d6) 193.8, 175.8, 175.1, 140.6, 
130.3, 129.6, 125.1, 124.8, 110.2, 109.8, 77.7, 74.7, 65.6, 48.5, 27.8, 25.9, 19.8, 8.8; 
HRMS(ESI) found m/z 380.07214 [M+H]
+
 for C18H18O4NSCl requires 379.06451; Anal 
Calc. for C18H18O4NSCl: C, 56.91%; H, 4.78%; N, 3.69%; S, 8.44%. Found: C, 55.91%; H, 
4.68%; N, 3.49%; S, 8.37%.  
 
Compound 3.8h (RCH3n4Y) 
 
Light yellow solid (55.5 mg, 6%); m.p. 170-173°C; Rf 
(EtOAc:Hex 1:1) 0.31; IRνmax(KBr)/cm
-1
 3377 (OH), 1700 
(C2=O), 1613 (C2’=O), 1494 (Ar C=C); δH (400MHz, CDCl3) 7.63 
(1H, d, J 1.6, H-4’), 7.09 (1H, dd, J 1.6 and 7.6, H-6’), 6.68 (1H, 
d, J 8, H-7’), 4.61 (1H, m, H-4”a/b), 4.28 (1H, m, H-1”a/b), 3.56 (1H, m, H-4”a/b), 3.38 (1H, 
dt, J 3.6 and 14.4, H-1”a/b), 3.34 (1H, br. s, OH), 2.28 (3H, s, H-8’), 2.08-1.85 (4H, m, H-2” 
and H-3”), 2.00 (3H, s, H-7), 1.63 (3H, s, H-6); δC (100MHz, CDCl3) 193.4, 176.3, 175.5, 
139.2, 132.1, 130.5, 127.5, 126.8, 111.0, 108.1, 78.9, 74.5, 66.1, 39.4, 28.4, 26.8, 21.2, 19.6, 
9.4; HRMS(ESI) found m/z 360.12638 [M+H]
+
 for C19H21O4NS requires 359.11913; Anal 
Calc. for C19H21O4NS: C, 63.49%; H, 5.89%; N, 3.90%; S, 8.92%. Found: C, 63.45%; H, 
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Compound 3.8i (RNO2n4Y) 
 
Light yellow crystalline solid (83.5 mg, 8%); m.p. 215-217°C; Rf 
(EtOAc:Hex 1:1) 0.14; IRνmax(KBr)/cm
-1
 3293 (OH), 1739 
(C2=O), 1605 (C2’=O), 1523 (Ar C=C), 1335/1523 (Asym./sym. 
NO2 str.); δH (400MHz, DMSO-d6) 7.54 (1H, d, J 2.4, H-4’), 
7.37 (1H, dd, J 2.4 and 8.8, H-6’), 7.04 (1H, d, J 8.4, H-7’), 6.86 (1H, br. s, OH), 4.65 (1H, 
m, H-4”a/b), 4.07 (1H, m, H-1”a/b), 3.53 (1H, m, H-4”a/b), 3.46 (1H, m, H-1”a/b), 2.01-1.61 
(4H, m, H-2” and H-3”), 1.89 (3H, s, H-7), 1.56 (3H, s, H-6); δC (100MHz, DMSO-d6) 
193.4, 175.9, 175.3, 148.0, 141.3, 129.1, 127.0, 119.6, 109.9, 109.1, 77.2, 74.8, 65.5, 39.3, 
27.8, 26.0, 19.8, 8.8; HRMS(ESI) found m/z 391.09609 [M+H]
+
 for C18H18O6N2S requires 
390.08856; Anal Calc. for C18H18O6N2S: C, 55.38%; H, 4.86%; N, 7.18%; S, 8.21%. Found: 
C, 55.74%; H, 4.86%; N, 6.29%; S, 8.45%.  
 
Compound 3.8j (RHH145A) 
 
Light yellow solid (57.8 mg, 5%); m.p. 200-201°C; Rf (EtOAc:Hex 
2:3) 0.32; IRνmax(KBr)/cm
-1
 3287 (OH), 1701 (C2=O), 1607 
(C2’=O), 1482 (Ar C=C); δH (300MHz, CDCl3) 7.85 (1H, d, J 2.1, 
H-4’), 7.29 (1H, dd, J 2.4 and 8.4, H-6’), 6.74 (1H, d, J 8.1, H-7’), 
4.51 (1H, m, H-5”a/b), 4.17 (1H, m, H-1”a/b), 3.50 (1H, m, H-5”a/b) 3.33 (1H, br. s, OH), 
3.26 (1H, dt, J 3.0 and 14.1, H-1”a/b), 1.98 (3H, s, H-7), 1.96–1.71 (4H, m, H-2” and H-4”), 
1.68 (3H, s, H-6), 1.45 (2H, m, H-3”); δC (75MHz, CDCl3) 194.9, 175.7, 174.8, 140.9, 130.4, 
129.4, 128.4, 126.0, 112.1, 108.7, 78.2, 67.8, 65.8, 41.0, 28.4, 23.1, 19.8, 19.5, 9.8; 
HRMS(ESI) found m/z 394.08725 [M+H]
+
 for C19H20NO4SCl requires 393.08016; Anal 
Calc. for C19H20NO4SCl: C, 57.94%; H, 5.12%; N, 3.56%; S, 8.14%. Found: C, 57.45%; H, 
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Compound 3.8k (RHH145D) 
 
Light yellow solid (88.6 mg, 7%); m.p. 203-205°C; Rf (EtOAc:Hex 
2:3) 0.34; IRνmax(KBr)/cm
-1
 3321 (OH), 1706 (C2=O), 1604 
(C2’=O), 1476 (Ar C=C); δH (300MHz, CDCl3) 7.98 (1H, d, J 2.4, 
H-4’), 7.44 (1H, dd, J 1.8 and 8.1, H-6’), 6.69 (1H, d, J 8.1, H-7’), 
4.50 (1H, m, H-5”a/b), 4.15 (1H, m, H-1”a/b), 3.46-3.54 (2H, m, H-5”a/b and OH), 3.25 (1H, 
dt, J 3.0 and 14.0, H-1”a/b), 1.97 (3H, s, H-7), 1.95–1.71 (4H, m, H-2” and H-4”), 1.68 (3H, 
s, H-6), 1.46 (2H, m, H-3”); δC (75MHz, CDCl3) 194.8, 175.9, 174.8, 141.4, 133.3, 129.7, 
128.6, 115.5, 112.1, 109.2, 78.2, 67.8, 65.8, 40.9, 28.4, 23.1, 19.8, 19.5, 9.8; HRMS(ESI) 
found m/z 438.03618 [M+H]
+
 for C19H20NO4SBr requires 437.02964; Anal Calc. for 
C19H20NO4SBr: C, 52.06%; H, 4.60%; N, 3.20%; S, 7.32%. Found: C, 51.88%; H, 4.11%; N, 
3.01%; S, 7.22%.  
 
Compound 3.8l (RHH145E) 
 
Light yellow solid (47.8 mg, 4%); m.p. 189-192°C; Rf (EtOAc:Hex 
2:3) 0.35; IRνmax(KBr)/cm
-1
 3378 (OH), 1709 (C2=O), 1601 
(C2’=O), 1482 (Ar C=C); δH (300MHz, DMSO-d6) 7.90 (1H, d, J 
1.8, H-4’), 7.41 (1H, dd, J 1.8 and 8.1, H-6’), 6.41 (1H, d, J 8.4, H-
7’), 6.17 (1H, br. s, OH), 4.31 (1H, m, H-5”a/b), 3.96 (1H, m, H-1”a/b), 3.30 (1H, m, H-
5”a/b), 3.04 (1H, dt, J 2.7 and 14.4, H-1”a/b), 1.82 (3H, s, H-7), 1.80-1.55 (4H, m, H-2” and 
H-4”), 1.48 (3H, s, H-6), 1.25 (2H, m, H-3”); δC (75MHz, DMSO-d6) 195.0, 175.2, 174.8, 
141.7, 138.2, 133.5, 130.6, 111.3, 109.2, 83.9, 78.6, 67.3, 65.7, 40.1, 27.9, 22.6, 19.6, 19.0, 
9.3; HRMS(ESI) found m/z 486.02280 [M+H]
+
 for C19H20NO4SI requires 485.01577; Anal 
Calc. for C19H20NO4SI: C, 47.02%; H, 4.15%; N, 2.89%; S, 6.61%. Found: C, 46.98%; H, 
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Compound 3.8m (RHH146A) 
 
Yellow crystalline solid (65.5 mg, 6%); m.p. 214-215°C; Rf 
(EtOAc:Hex 1:1) 0.48; IRνmax(KBr)/cm
-1
 3367 (OH), 1699 (C2=O), 
1611 (C2’=O), 1478 (Ar C=C); δH (400MHz, CDCl3) 7.87 (1H, d, J 
2.4, H-4’), 7.28 (1H, dd, J 2.4 and 8.4, H-6’), 6.78 (1H, d, J 8.4, H-
7’), 4.29-4.14 (3H, m, H-1”a/b and H-6”), 3.30 (1H, br. s, OH), 3.26 (1H, m, H-1”a/b), 2.05 
(3H, s, H-7), 1.98-1.84 (3H, m, H-2”a/b and H-5”), 1.74 (3H, s, H-6), 1.64-1.30 (5H, m, H-
2”a/b, H-3” and H-4”); δC (100MHz, CDCl3) 194.8, 175.9, 175.0, 142.6, 130.5, 128.9, 125.7, 
125.0, 112.0, 109.3, 77.4, 72.6, 65.2, 39.5, 26.0, 24.1, 23.7, 22.6, 21.5, 9.8; HRMS(EI) found 
m/z 407.09528 for C20H22O4ClNS requires 407.09581; Anal Calc. for C20H22O4ClNS: C, 
58.89%; H, 5.44%; N, 3.43%; S, 7.86%. Found: C, 58.85%; H, 5.42%; N, 3.38%; S, 7.89% 
 
Compound 3.8n (RHH146C) 
 
Light yellow crystalline solid (74.5 mg, 7%); m. p.212-213°C; Rf 
(EtOAc:Hex 1:1) 0.45; IRνmax(KBr)/cm
-1
 3358 (OH), 1699 (C2=O), 
1614 (C2’=O), 1491 (Ar C=C); δH (400MHz, CDCl3) 7.40 (1H, dd, J 
2.8 and 8.8, H-4’), 6.78 (1H, ddd, J 2.8, 8.4 and 8.8, H-6’), 6.57 
(1H, dd, J 4.0 and 8.4, H-7’), 4.08-3.97 (3H, m, H-1”a/b and H-6”), 3.06 (1H, m, H-1”a/b), 
2.52 (1H, br. s, OH), 1.89 (3H, s, H-7), 1.78-1.66 (3H, m, H-2”a/b and H-5”), 1.54 (3H, s, H-
6), 1.43-1.24 (5H, m, H-2”a/b, H-3” and H-4”); δC (100MHz, CDCl3) 195.5, 176.3, 175.0, 
159.4, 157.0, 139.9, 129.8, 116.0, 113.2, 111.2, 108.4, 76.5, 72.2, 65.4, 39.0, 25.8, 23.7, 23.5, 
22.4, 21.6, 9.7; HRMS(EI) found m/z 391.12484 for C20H22O4FNS requires 391.12536; Anal 
Calc. for C20H22O4FNS: C, 61.36%; H, 5.66%; N, 3.58%; S, 8.19%. Found: C, 60.92%; H, 
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Compound 3.8o (RHH146D) 
 
Yellow crystalline solid (68.9 mg, 6%); m.p. 211°C; Rf (EtOAc:Hex 
1:1) 0.55; IRνmax(KBr)/cm
-1
 3370 (OH), 1698 (C2=O), 1609 (C2’=O), 
1478 (Ar C=C); δH (400MHz, CDCl3) 8.00 (1H, d, J 2.0, H-4’), 7.44 
(1H, dd, J 2.0 and 8.4, H-6’), 6.73 (1H, br. d, J 8.4, H-7’), 4.29-4.15 
(3H, m, H-1”a/b and H-6”), 3.27 (2H, m, H-1”a/b and OH), 2.05 (3H, s, H-7), 1.96-1.85 (3H, 
m, H-2”a/b and H-5”), 1.75 (3H, s, H-6), 1.63-1.31 (5H, m, H-2”a/b, H-3” and H-4”); δC 
(100MHz, CDCl3) 194.7, 175.8, 174.8, 143.1, 133.4, 129.2, 128.4, 115.3, 112.0, 109.8, 76.7, 
72.6, 65.2, 39.4, 26.0, 24.1, 23.7, 22.6, 21.5, 9.9; HRMS(EI) found m/z 451.04475 for 
C20H22O4FNS requires 451.04529; Anal Calc. for C20H22O4BrNS: C, 53.10%; H, 4.90%; N, 
3.10%; S, 7.09%. Found: C, 53.19%; H, 4.89%; N, 2.94%; S, 6.97%. 
 
Compound 3.8p (RHH146E) 
 
Yellow crystalline solid (90.8 mg, 7%); m.p.214-215°C; Rf 
(EtOAc:Hex 1:1) 0.45; IRνmax(KBr)/cm
-1
 3365 (OH), 1697 (C2=O), 
1604 (C2’=O), 1481 (Ar C=C); δH (400MHz, CDCl3) 7.99 (1H, d, J 
1.6, H-4’), 7.46 (1H, dd, J 2.0 and 8.0, H-6’), 6.49 (1H, d, J 8.0, H-
7’), 4.15-4.02 (3H, m, H-1”a/b and H-6”), 3.10 (1H, m, H-1”a/b), 2.40 (1H, br. s, OH), 1.94 
(3H, s, H-7), 1.84-1.70 (3H, m, H-2”a/b and H-5”), 1.61 (3H, s, H-6), 1.51-1.15 (5H, m, H-
2”a/b, H-3” and H-4”); δC (100MHz, CDCl3) 195.1, 176.0, 174.4, 143.5, 138.5, 133.5, 130.2, 
111.2, 109.8, 83.9, 76.2, 72.1, 65.2, 38.8, 25.6, 23.7, 23.3, 22.2, 21.3, 9.5; HRMS(EI) found 
m/z 499.03088 for C20H22O4INS requires 499.03142; Anal Calc. for C20H22O4INS: C, 
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7.3. Experimental details pertaining to Chapters 4 and 5 
 
3,5-Dimethyl-4-oxiranylmethoxy-5H-thiophen-2-one, 4.7a  
 
The potassium salt of thiolactone 3.5 (1.00 g, 5.48 mmol, 1.0 eq) was 
added to 5 mL of (±)-epichlorohydrin. The reaction mixture was refluxed 
under nitrogen at 130°C for 7 hours. The product mixture was then cooled 
to room temperature and filtered over a celite pad. The filtrate was 
concentrated and the residue purified using column chromatography (eluent EtOAc:Hex 2:3) 
to afford 4.7a as a colourless oil (823.0 mg, 75%); Rf (EtOAc:Hex 2:3) 0.58; 
IRνmax(film)/cm
-1
 1677 (C=O), 1633 (C=C
_
O vinyl ether); δH (400MHz, CDCl3) (50:50 
diastereomeric mixture) 4.56/4.47 (1H, dd, J 2.8 and 11.2, H-1’a/b), 4.21/4.19 (1H, m, H-5), 
4.17/4.06 (1H, dd, J 6.4 and 11.2, H-1’a/b), 3.27 (1H, m, H-2’), 2.89/2.88 (1H, dd, J 1.6 and 
4.0, H-3’a/b), 2.71/2.70, (1H, dd, J 2.4 and 4.4, H-3’a/b), 1.83 (3H, d, J 1.2, H-7), 1.58/1.57 
(3H, d, J 6.8, H-6); δC (100MHz, CDCl3) 195.7, 177.4 (177.5), 115.3 (115.7), 71.3 (71.7), 
50.0 (50.1), 44.1, 41.8 (41.9), 19.6, 8.9. Chemical shift values given in brackets represent 
those of the other diastereomer; HRMS (ESI) found m/z 201.05809 [M+H]
+
 for C9H12O3S 
requires 200.05071; Anal. Calc. for C9H12O3S: C, 53.98%; H, 6.04%; S, 16.01%. Found: C, 
53.88%; H, 7.22%; S, 15.02%.  
 
4,6-Dimethyl-8-oxa-3-thiabicyclo[4.2.1]nonane-5,7-dione, 4.7b  
 
The potassium salt of thiolactone 3.5 (1.00g, 5.48 mmol, 1.0 eq) was added 
to 5 mL of (±)-epichlorohydrin. The reaction mixture was refluxed under 
nitrogen at 130°C for 7 hours. The product mixture was then cooled to room 
temperature and filtered over a celite pad. The filtrate was concentrated and the residue 
purified using column chromatography (eluent EtOAc:Hex 3:2) to afford the by-product 4.7b 
as a colourless crystalline solid (109.7 mg, 10%); m.p. 164°C; Rf (EtOAc:Hex 2:3) 0.14; 
IRνmax(KBr)/cm
-1
 1762 (C7=O), 1699 (C5=O), 1350 (C1-O); δH (400MHz, CDCl3) 5.14 (1H, 
dd, J 4.8 and 8.8, H-1), 3.92 (1H, q, J 6.8, H-4), 3.23 (1H, dd, J 1.2 and 14.4, H-2a/b), 3.03 
(1H, ddd, J 1.2, 4.8 and 14.8, H-2a/b), 2.62 (1H, br. d, J 14.4, H-9a/b), 2.40 (1H, ddd, J 1.6, 
8.8 and 14.4, H-9a/b), 1.49 (3H, s, H-10), 1.34 (3H, d, J 6.8, H-11); δC(100MHz, CDCl3) 





































 for C9H12O3S requires 200.05071; Anal Calc. for C9H12O3S: C, 53.98%; H, 6.04%; 
S, 16.01%. Found: C, 53.99%; H, 6.03%; S, 16.10%. 
 
4-(3-Azido-2-hydroxy-propoxy)-3,5-dimethyl-5H-thiophen-2-one, 4.8  
 
Sodium azide (34.1 mmol, 5.0 eq) was added to a stirred solution 
of the thiolactone epoxide 4.7a (6.81 mmol, 1.0 eq) and NH4Cl 
(20.4 mmol, 3.0 eq) in 10 mL of MeOH:H2O (8:1). The resulting 
mixture was stirred at 25°C for 48 hours. The reaction mixture 
was then diluted with water, extracted with Et2O and the combined organic layer washed 
with water, brine and dried over anhydrous Na2SO4. Evaporation of the solvent under 
reduced pressure followed by purification with column chromatography (eluent EtOAc:Hex 
3:2) afforded a colourless oil (1.38 g, 83%); Rf (MeOH:DCM 1:39) 0.28; IRνmax(film)/cm
-1
 
3428 (OH), 2103 (N3), 1626 (C2=O); δH (300MHz, CDCl3) 4.33-4.16 (3H, m, H-1’and H-5), 
4.08 (1H, m, H-2’), 3.48 (2H, m, H-3’), 3.22 (1H, br. s, OH), 1.79 (3H, d, J 1.8, H-7), 1.57 
(3H, d, J 6.9, H-6); δC (75MHz, CDCl3) 196.3, 177.5, 115.3, 71.7, 69.3, 53.0, 41.8, 19.6, 8.8; 
LRMS(EI) found m/z 242.9 for C9H13N3O3S requires 243.0; Anal. Calc. for C9H13N3O3S: C, 
44.43%; H, 5.39%; N, 17.27%; S, 13.18%. Found C, 44.37%; H, 5.28%; N, 16.99%; S, 
13.00%. 
 
C. General procedure for preparing compounds 4.9a-c 
Anhydrous K2CO3 (1.70 g, 12.3 mmol, 1.5 eq) was added to hydroxybenzaldehyde (1.0 g, 
8.19 mmol, 1.0 eq) dissolved in 5 mL anhydrous DMF. Propargyl bromide, 80% in toluene, 
(1.17 g, 9.83 mmol, 1.2 eq) was added to the mixture. The resulting mixture was stirred for 
16 hours at 25°C. After consumption of the starting material, as indicated by tlc, ice-cold 
water was added to the reaction mixture. The precipitate so obtained was filtered, washed 
with water and recrystallized from MeOH to afford the pure product in excellent yield. If no 
precipitate formed upon addition of ice-cold water, the product mixture was extracted with 
EtOAc and the combined organic layer washed with water to remove DMF. This was 
followed with the drying of the resulting organic layer over anhydrous Na2SO4 and the 
subsequent concentration thereof under reduced pressure. The crude was then subjected to 
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2-Prop-2-ynyloxy-benzaldehyde, 4.9a  
Off-white crystalline solid (1.38 g, quant); m.p. 68°C; Rf (EtOAc:Hex 3:7) 
0.72; IRνmax(CHCl3)/cm
-1
 2125 (C≡C), 1688 (C=O); δH (300MHz, CDCl3) 
10.5 (1H, s, CHO), 7.85 (1H, dd, J 2.0 and 7.6, H-6), 7.55 (1H, m, H-4), 
7.12-7.05 (2H, m, H-3, H-5), 4.82 (2H, d, J 2.4, H-1’), 2.56 (1H, t, J 2.4, H-
3’); δC (75MHz, CDCl3) 189.4, 159.7, 135.6, 128.5, 125.5, 121.7, 113.2, 
77.6, 76.4, 56.4 
  
3-Prop-2-ynyloxy-benzaldehyde, 4.9b  
Yellow oil (1.37 g, quant); Rf (EtOAc:Hex 3:7) 0.66; IRνmax(CHCl3)/cm
-1
 
2125 (C≡C), 1701 (C=O); δH (400MHz, CDCl3) 9.95 (1H, s, CHO), 7.49-
7.42 (3H, m, H-2, H-5, H-6), 7.22 (1H, ddd, J 2.4, 2.8 and 8.0, H-4), 4.73 
(2H, d, J 2.4, H-1’), 2.54 (1H, t, J 2.4, H-3’); δC (100MHz, CDCl3) 190.8, 
158.1, 137.8, 130.2, 124.0, 122.0, 113.7, 78.0, 76.2, 56.0  
 
4-Prop-2-ynyloxy-benzaldehyde, 4.9c  
Off-white crystalline solid (1.20 g, 91%) m.p. 79-80°C; Rf (EtOAc:Hex 3:7) 
0.59; IRνmax(CHCl3)/cm
-1
 2125 (C≡C), 1691 (C=O); δH (400MHz, CDCl3) 9.90 
(1H, s, CHO), 7.85 (2H, d, J 8.7, H-2, H-6), 7.08 (2H, d, J 8.7, H-3, H-5), 4.77 
(2H, d, J 2.4, H-1’), 2.56 (1H, t, J 2.4, H-3’); δC (100MHz, CDCl3) 190.7, 
162.4, 131.8 (x2), 130.6, 115.2 (x2), 77.5, 76.3, 55.9  
 
 
D. General procedure for preparing compounds 4.12a-c 
Anhydrous K2CO3 (3.04 g, 22.0 mmol, 1.5 eq) was added to hydroxyacetophenone (2.0 g, 
14.7 mmol, 1.0 eq) dissolved in 5 mL anhydrous DMF. Propargyl bromide, 80% in toluene, 
(2.62 g, 17.6 mmol, 1.2 eq) was added to the mixture. The resulting mixture was stirred for 
24 hours at 25°C. Upon completion ice-cold water was added to the reaction mixture. The 
precipitate so obtained was filtered and washed with water. Recrystallization from MeOH 










































 Chapter 7: Experimental  
 238 
1-(2-(Prop-2-ynyoloxy)phenyl)ethanone, 4.12a  
Off-white crystalline solid (2.45 g, quant); m.p. 38°C; Rf (EtOAc:Hex 
3:7) 0.64; δH (400MHz, CDCl3) 7.75 (1H, dd, J 1.6 and 7.6, H-6), 
7.48 (1H, m, H-4), 7.09-7.04 (2H, m, H-3, H-5), 4.81 (2H, d, J 2.4, H-
1’), 2.65 (3H, s, H-8), 2.56 (1H, t, J 2.4, H-3’); δC (100MHz, CDCl3) 
31.9, 56.3, 76.1, 77.9, 113.1, 121.6, 129.2, 130.5, 133.4, 156.8, 199.6 
 
1-(3-(Prop-2-ynyloxy)phenyl)ethanone, 4.12b  
Off-white crystalline solid (2.41 g, quant); m.p. 29°C; Rf (EtOAc:Hex 3:7) 
0.65; δH (400MHz, CDCl3) 7.60-7.56 (2H, m, H-6 and H-2), 7.39 (1H, t, J 
8.4, H-5), 7.18 (1H, ddd, J 2.4, 2.8 and 8.4, H-4), 4.74 (2H, d, J 2.4, H-1’), 
2.59 (3H, s, H-8), 2.55 (1H, t, J 2.4, H-3’); δC (100MHz, CDCl3) 197.6, 
157.8, 138.6, 129.7, 121.9, 120.3, 113.8, 78.1, 75.9, 56.0, 26.7 
 
1-(4-(Prop-2-ynyloxy)phenyl)ethanone, 4.12c  
White crystalline solid (2.76 g, quant); m.p. 73°C; Rf 
(EtOAc:Hex 3:7) 0.58; δH (400MHz, CDCl3) 7.95 (2H, d, J 8.8, 
H-2, H-6), 7.02 (2H, d, J 8.8, H-3, H-5), 4.76 (2H, d, J 2.4, H-
1’), 2.56 (4H, m, H-3’, H-8); δC (100MHz, CDCl3) 196.6, 
161.3, 131.1, 130.5 (2xC), 114.6 (2xC), 77.8, 76.1, 55.9, 26.3 
 
E. General procedure for preparation of compounds 4.10 a-i  
To a solution of the acetylenic aldehyde 4.9a-c (6.25 mmol, 1.0 eq) in MeOH was added 5 
mL of methanolic NaOH (3% w/v). The resulting mixture was stirred at 25°C for 30 minutes. 
A methanolic solution of the commercially available, substituted acetophenone (6.25 mmol, 
1.0 eq) was added drop-wise and the mixture stirred overnight at the same temperature. A 
precipitate was formed which was filtered and washed with cold MeOH. Recrystallization 
from MeOH afforded the pure product. For the reactions in which no precipitation occurred, 
the product mixture was diluted with H2O, neutralized with 10% HCl and extracted with 
EtOAc. The combined organic layer was dried and concentrated. The crude product was then 
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1-(4-Methoxy-phenyl-3-(2-prop-2-ynyloxy-phenyl)-propenone, 4.10a  
 
Light yellow amorphous solid (1.67 g, 91%); m. p. 78-
79°C; Rf (EtOAc:Hex 1:4) 0.24; IRνmax(CHCl3)/cm
-1
 2125 
(C≡C), 1657 (C=O); δH (300MHz, CDCl3) 8.07 (1H, d, J 
16.2, Hβ), 8.04 (2H, d, J 8.7, H-2B, H-6B), 7.67 (1H, d, J 
15.6, Hα), 7.64 (1H, dd, J 1.5 and 7.2, H-6A), 7.36 (1H, m, 
H-4A), 7.05, (2H, m, H-3A, H-5A), 6.97 (2H, d, J 8.7, H-3B, H-5B), 4.80 (2H, d, J 2.4, H-
1’), 3.88 (3H, s, OMe), 2.55 (1H, t, J 2.4, H-3’); δC (75MHz, CDCl3) 189.2, 163.3, 156.7, 
139.1, 131.3, 131.2, 130.2 (x2), 129.5, 124.8, 123.3, 121.7, 113.7 (x2), 112.8, 78.2, 75.9, 
55.2, 55.4; LRMS(ESI) found m/z 293.1 (100%; [M+H]
+
) for C19H16O3 requires 292.1; Anal 
Calc. for C19H16O3: C, 78.06%; H, 5.52%. Found: C, 77.66%; H, 5.52%  
 
1-(2,4-Dimethoxy-phenyl)-3-(2-prop-2-ynyloxy-phenyl)-propene, 4.10b  
 
Light yellow amorphous solid (1.76 g, 89%); m. p. 76°C; 
Rf (EtOAc:Hex 1:4) 0.16; IR νmax(CHCl3)/cm
-1
 2125 
(C≡C), 1652 (C=O); δH (400MHz, CDCl3) 7.99 (1H, d, J 
16, Hβ), 7.75 (1H, d, J 8.4, H-6B), 7.62 (1H, dd, J 1.6 and 
7.6, H-6A), 7.55 (1H, d, J 16, Hα), 7.34 (1H, m, H-4A), 7.06-7.00 (2H, m, H-3A, H-5A), 
6.56 (1H, dd, J 2.4 and 8.4, H-5B), 6.49 (1H, d, J 2.4, H-3B), 4.77 (2H, d, J 2.4, H-1’), 3.89 
(3H, s, OMe), 3.86 (3H, s, OMe), 2.51 (1H, t, J 2.4, H-3’); δC (100MHz, CDCl3) 190.9, 
164.0, 160.4, 156.5, 137.1, 132.8, 130.9, 128.7, 128.1, 125.2, 122.5, 121.6, 112.8, 105.1, 
98.7, 78.3, 75.8, 56.1, 55.7, 55.5; LRMS(ESI) found m/z 322.8 (100%, [M+H]
+
) for 
C20H18O4 requires 322.1; Anal Calc. for C20H18O4: C, 74.52%; H, 5.63%. Found: C, 74.36%; 
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3-(2-Prop-2-ynyloxy-phenyl)-1-(2,3,4-trimethoxy-phenyl)-propene, 4.10c  
 
Yellow oil (1.25 g, 94%); Rf (EtOAc:Hex 1:4) 0.22; 
IRνmax(CHCl3)/cm
-1
 2125 (C≡C), 1651 (C=O); δH 
(300MHz, CDCl3) 8.00 (1H, d, J 15.9, Hβ), 7.65 (1H, dd, J 
2.1 and 7.8, H-6A), 7.52 (1H, d, J 15.9, Hα), 7.47 (1H, d, J 
8.7, H-6B), 7.36, (1H, m, H-4A), 7.04 (2H, m, H-3A, H-5A), 6.74 (1H, d, J 9.0, H-5B), 4.78 
(2H, d, J 2.4, H-1’), 3.89 (3H, s, OMe), 3.91 (3H, s, OMe), 3.92 (3H, s, OMe), 2.51 (1H, t, J 
2.4, H-3’); δC (75MHz, CDCl3) 191.4, 156.9, 156.5, 153.7, 142.2, 138.1, 131.2, 128.8, 127.5, 
127.1, 125.7, 124.9, 121.7, 112.9, 107.3, 78.3, 75.9, 62.1, 61.0, 56.2, 56.1; LRMS(ESI) found 
m/z 353.0 (100%, [M+H]
+
) for C21H20O5 requires 352.1; Anal Calc. for C21H20O5: C, 
71.58%; H, 5.72%. Found: C, 71.19%; H, 5.74% 
 
1-(4-Methoxy-phenyl-3-(3-prop-2-ynyloxy-phenyl)-propenone, 4.10d  
 
Light yellow amorphous solid (1.42 g, 78%); m.p. 68-
69°C; Rf (EtOAc:Hex 1:4) 0.28; IRνmax(CHCl3)/cm
-1
 
2125 (C≡C), 1660 (C=O); δH (400MHz, CDCl3) 8.03 
(2H, d, J 8.8, H-2B, H-6B), 7.72 (1H, d, J 15.6, Hβ), 
7.51 (1H, d, J 15.6, Hα), 7.34 (1H, t, J 8.0, H-5A), 7.28-
7.23 (2H, m, H-2A, H-6A), 7.02 (1H, ddd, J 2.4, 2.6 and 8.4, H-4A), 6.97 (2H, d, J 8.8, H-
3B, H-5B), 4.74 (2H, d, J 2.4, H-1’), 3.88 (3H, s, OMe), 2.55 (1H, t, J 2.4, H-3’); δC 
(100MHz, CDCl3) 188.6, 163.5, 158.0, 143.6, 136.6, 131.1, 130.8 (x2), 129.9, 122.5, 121.8, 
116.9, 114.6, 113.9 (x2), 78.3, 75.9, 56.0, 55.5; LRMS(ESI) found m/z 293.1 (100%, 
[M+H]
+
) for C19H16O3 requires 292.1; Anal Calc. for C19H16O3: C, 78.06%; H, 5.52%. 
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1-(2,4-Dimethoxy-phenyl)-3-(3-prop-2-ynyloxy-phenyl)-propene, 4.10e  
 
Light yellow amorphous solid (1.50 g, 76%); m.p. 72-
73°C; Rf (EtOAc:Hex, 1:4) 0.18; IRνmax(CHCl3)/cm
-1
 
2125 (C≡C), 1652 (C=O); δH (400MHz, CDCl3) 7.76, 
(1H, d, J 8.8, H-6B), 7.63 (1H, d, J 15.6, Hβ), 7.50 (1H, 
d, J 15.6, Hα), 7.32 (1H, t, J 8.0, H-5A), 7.22 (2H, m, 
H-2A, H-6A), 7.00 (1H, ddd, J 2.4, 2.7 and 8.0, H-4A), 6.57 (1H, dd, J 2.0 and 8.4, H-5B), 
6.50 (1H, d, J 2.4, H-3B), 4.73 (2H, d, J 2.4, H-1’), 3.90 (3H, s, OMe), 3.87 (3H, s, OMe), 
2.54 (1H, t, J 2.4, H-3’); δC (100MHz, CDCl3) 190.3, 164.3, 160.5, 157.9, 141.6, 137.1, 
132.9, 129.8, 127.8, 122.2, 121.9, 116.6, 114.4, 105.3, 98.7, 78.4, 75.8, 55.9, 55.8, 55.6; 
LRMS(ESI) found m/z 323.4 (59%, [M+H]
+
) for C20H18O4 requires 322.1; Anal Calc. for 
C20H18O4: C, 74.52%; H, 5.63%. Found: C, 74.32%; H 5.56% 
 
3-(3-Prop-2-ynyloxy-phenyl)-1-(2,3,4-trimethoxy-phenyl)-propene, 4.10f  
 
Light yellow amorphous solid, (998 mg, 76%); m.p. 61-
62°C; Rf 0.19 (EtOAc:Hex 1:4); IRνmax(KBr)/cm
-1
 2106 
(C≡C), 1654 (C=O); δH (400MHz, CDCl3) 7.63 (1H, d, 
J 15.6, Hβ), 7.48 (1H, d, J 9.0, H-6B), 7.47 (1H, d, J 
15.6, Hα), 7.32, (1H, t, J 7.6, H-5A), 7.24-7.21 (2H, m, 
H-2A, H-6A), 7.00 (1H, ddd, J 2.4, 2.8 and 8.0, H-4A), 6.75 (1H, d, J 9.2, H-5B), 4.72 (2H, 
d, J 2.0, H-1’), 3.91 (3H, s, OMe), 3.91(3H, s, OMe), 3.89 (3H, s, OMe), 2.53 (1H, t, J 2.4, 
H-3’); δC (100MHz, CDCl3) 190.7, 157.9, 157.1, 153.8, 142.5, 142.2, 136.8, 129.9, 127.1, 
126.7, 125.8, 121.9, 116.8, 114.4, 107.4, 78.3, 75.8, 62.1, 61.0, 56.1, 55.9; LRMS(ESI) found 
m/z 353.0 (100%, [M+H]
+
) for C20H18O4 requires 352.1; Anal Calc. for C21H20O5: C, 
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1-(4-Methoxy-phenyl-3-(4-prop-2-ynyloxy-phenyl)-propenone, 4.10g  
 
Light yellow amorphous solid (1.46 g, 80%); m.p. 135-
136°C; Rf (EtOAc:Hex 1:4) 0.34; IRνmax(CHCl3)/cm
-1
 
2126 (C≡C), 1657 (C=O); δH (300MHz, CDCl3) 8.02 
(2H, d, J 9.3, H-2B, H-6B), 7.76 (1H, d, J 15.6, Hβ), 
7.60 (2H, d, J 8.1, H-2A, H-6A), 7.43 (1H, d, J 15.6, Hα), 7.00-6.97 (4H, m, H-3B, H-5B, H-
3A, H-5A), 4.73 (2H, d, J 3.2, H-1’), 3.88 (3H, s, OMe), 2.55 (1H, t, J 3.2, H-3’); δC 
(75MHz, CDCl3) 188.7, 163.3, 159.3, 143.5, 131.3(x2), 130.7(x2), 130.0, 128.7, 120.1, 115.3 
(x2), 113.8 (x2), 78.0, 75.9, 55.8, 55.4; LRMS(ESI) found m/z 293.0 (100%, [M+H]
+
) for 
C19H16O3 requires 292.1; Anal Calc. for C19H16O3: C, 78.06%; H, 5.52%. Found: C, 77.86%; 
H, 5.44%  
 
1-(2,4-Dimethoxy-phenyl)-3-(4-prop-2-ynyloxy-phenyl)-propene, 4.10h  
 
Light yellow amorphous solid (1.75 g, 89%); m.p. 113-
114°C; Rf (EtOAc:Hex 1:4) 0.17; IRνmax(CHCl3)/cm
-1
 
2126 (C≡C), 1653 (C=O); δH (300MHz, CDCl3) 7.74 
(1H, d, J 9.0, H-6B), 7.64 (1H, d, J 16.2, Hβ), 7.55 
(2H, d, J 8.7, H-2A, H-6A), 7.39 (1H, d, J 15.6, Hα), 6.98 (2H, d, J 8.7, H-3A, H-5A), 6.55 
(1H, dd, J 2.4 and 9.0, H-5B), 6.49 (1H, d, J 2.4, H-3B), 4.72 (2H, d, J 3.2, H-1’), 3.89 (3H, 
s, OMe), 3.86 (3H, s, OMe), 2.54 (1H, t, J 2.7, H-3’); δC (75MHz, CDCl3) 190.5, 164.0, 
160.3, 159.0, 141.7, 132.7, 129.8, 129.0 (x2), 125.5, 122.4, 115.2 (x2), 105.2, 98.7, 78.1, 
75.8, 55.8, 55.7, 55.5; LRMS(ESI) found m/z 323.4 (100%, [M+H]
+
) for C20H18O4 requires 
322.1; Anal Calc. for C20H18O4: C, 74.52%; H, 5.63%. Found: C, 74.59%; H, 5.58%  
 
3-(4-Prop-2-ynyloxy-phenyl)-1-(2,3,4-trimethoxy-phenyl)-propene, 4.10i  
 
Light yellow amorphous solid (1.10 g, 83%); Rf 
(EtOAc:Hex 1:4) 0.17; m.p. 113-114°C; 
IRνmax(CHCl3)/cm
-1
 2125 (C≡C), 1653 (C=O); δH 
(400MHz, CDCl3) 7.64 (1H, d, J 16, Hβ), 7.57 (2H, d, 
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3A, H-5A), 6.74 (1H, d, J 9.2, H-5B ), 4.72 (2H, d, J 2.0, H-1’), 3.91 (3H, s, OMe), 3.91 (3H, 
s, OMe), 3.90 (3H, s, OMe), 2.54 (1H, t, J 2.4, H-3’); δC (100MHz, CDCl3) 190.9, 159.3, 
156.9, 153.7, 142.7, 142.2, 130.0(x2), 128.8, 127.0, 125.7, 124.9, 115.3(x2), 107.4, 78.1, 
75.9, 62.1, 61.0, 56.1, 55.9; LRMS(ESI) found m/z 353.0 (100%, [M+H]
+
) for C20H18O4 
requires 352.1; Anal Calc. for C21H20O5: C, 71.58%; H, 5.72%. Found: C, 71.51%; H, 5.63%  
 
F. General procedure for preparation of compounds 4.13 a-i 
To a solution of the acetylenic acetophenone 4.12a-c (6.25 mmol, 1.0 eq) in MeOH was 
added 5 mL of methanolic NaOH (3% w/v). The resulting mixture was stirred at 25°C for 30 
minutes. A methanolic solution of the commercially available, substituted aldehyde (6.25 
mmol, 1.0 eq) was added drop-wise and the mixture stirred for a period of 16 hours at the 
same temperature. A precipitate was formed which was filtered and washed with cold 
MeOH. Recrystallization from MeOH afforded the pure product. For the reactions in which 
no precipitation occurred, the product mixture was diluted with H2O, neutralized with 10% 
HCl and extracted with EtOAc. The combined organic layer was dried over anhydrous 
NaSO4 and concentrated under reduced pressure. The crude so obtained was subjected to 
recrystallization from MeOH to afford the acetylenic chalcones in good to excellent yields. 
 
3-(4-Methoxy-phenyl-1-(2-prop-2-ynyloxy-phenyl)-propenone, 4.13a  
 
Yellow oil (1.44 g, 85%); Rf (30% EtOAc:Hex 3:7) 0.60; 
IRνmax(film)/cm
-1
 2121 (C≡C), 1655 (C=O); δH (400MHz, 
CDCl3) 7.61 (1H, dd, J 2.0 and 8.0, H-6B), 7.56 (1H, d, J 
15.6, Hβ), 7.53 (2H, d, J 8.8, H-2A, H-6A), 7.45 (1H, m, 
H-4B), 7.26 (1H, d, J 16, Hα), 7.10-7.05 (2H, m, H-3B, H-5B), 6.89 (2H, d, J 8.8, H-3A, H-
5A), 4.76 (2H, d, J 2.4, H-1’), 3.82 (3H, s, OMe), 2.50 (1H, t, J 2.4, H-3’); δC (100MHz, 
CDCl3) 192.7, 161.5, 155.9, 143.6, 132.4, 132.0, 130.4, 130.2(x2), 127.9, 125.0, 121.8, 
114.4(x2), 113.5, 78.2, 76.0, 56.5, 55.4; LRMS(ESI) found m/z 293.3 (100%, [M+H]
+
) for 
C19H16O3 requires 292.1; Anal Calc. for C19H16O3: C, 78.06%; H, 5.52%. Found: C, 77.86%; 
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3-(2,4-Dimethoxy-phenyl)-1-(2-prop-2-ynyloxy-phenyl)-propene, 4.13b  
 
Yellow oil (1.86 g, quant); Rf (EtOAc:Hex 3:7) 0.47; 
IRνmax(film)/cm
-1
 2121 (C≡C), 1653 (C=O); δH (400MHz, 
CDCl3) 7.86 (1H, d, J 16, Hβ), 7.59 (1H, dd, J 2.0 and 7.6, 
H-6B), 7.52 (1H, d, J 8.8, H-6A), 7.43 (1H, m, H-4B), 7.35 
(1H, d, J 16, Hα), 7.11-7.04 (2H, m, H-3B, H-5B), 6.49 
(1H, dd, J 2.4 and 8.4, H-5A), 6.43 (1H, d, J 2.4, H-3A), 4.75 (2H, d, J 2.4, H-1’), 3.84 (3H, 
s, OMe), 3.82 (3H, s, OMe), 2.49 (1H, t, J 2.4, H-3’); δC (100MHz, CDCl3) 193.2, 162.9, 
160.3, 155.8, 139.3, 132.0, 130.8, 130.6, 130.4, 125.3, 121.7, 117.3, 113.6, 105.4, 98.4, 78.3, 
75.9, 55.56, 55.5, 55.5; LRMS(ESI) found m/z 323.0 (100%, [M+H]
+
) for C20H18O4 requires 
322.1; Anal Calc. for C20H18O4: C, 74.52%; H, 5.63%. Found: C, 74.58%; H, 5.64% 
 
1-(2-Prop-2-ynyloxy-phenyl)-3-(2,3,4-trimethoxy-phenyl)-propene, 4.13c  
 
Yellow oil (2.05 g, quant.); Rf (EtOAc:Hex 1:4) 0.44; 
IRνmax(film)/cm
-1
 2121 (C≡C), 1654 (C=O); δH (300MHz, 
CDCl3) 7.81 (1H, d, J 16.2, Hβ), 7.60 (1H, dd, J 1.8 and 
7.5, H-6B), 7.45 (1H, m, H-4B), 7.35 (1H, d, J 8.7, H-6A), 
7.35 (1H, d, J 15.9, Hα), 7.08 (2H, m, H-3B, H-5B), 6.68 
(1H, d, J 8.7, H-5A), 4.76 (2H, d, J 2.4, H-1’), 3.90 (3H, s, OMe), 3.88 (3H, s, OMe), 3.86 
(3H, s, OMe), 2.51 (1H, t, J 2.4, H-3’); δC (75MHz, CDCl3) 192.9, 155.7, 155.6, 153.7, 
142.4, 138.8, 132.2, 130.5, 130.3, 126.1, 123.5, 122.1, 121.7, 113.4, 107.6, 78.2, 76.0, 60.8, 
61.4, 56.5, 56.0; LRMS(ESI) found m/z 353.3 (100%, [M+H]
+
) for C21H20O5 requires 352.1; 
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3-(4-Methoxy-phenyl-1-(3-prop-2-ynyloxy-phenyl)-propenone, 4.13d  
 
Light yellow powder (1.13 g, 67%); m.p. 83°C; Rf 
(EtOAc:Hex, 3:7) 0.61; IRνmax(KBr)/cm
-1
 2124 (C≡C), 
1650 (C=O); δH (300MHz, CDCl3) 7.78 (1H, d, J 15.6, 
Hβ), 7.59-7.64 (4H, m, H-2A, H-6A, H-2B, H-6B), 7.42 
(1H, t, J 8.4, H-5B), 7.37 (1H, d, J 15.6, Hα), 7.19 (1H, 
ddd, J 2.4, 2.7 and 8.1, H-4B), 6.94 (2H, d, J 8.7, H-3A, H-5A), 4.77 (2H, d, J 2.1, H-1’), 
3.86 (3H, s, OMe), 2.54 (1H, t, J 2.4, H-3’); δC (75MHz, CDCl3) 190.1, 161.7, 157.8, 144.8, 
140.0, 130.2(x2), 129.6, 127.6, 121.8, 119.8, 119.7, 114.4(x2), 114.2, 78.1, 75.9, 56.0, 55.4; 
LRMS(ESI) found m/z 293.1 (100%, [M+H]
+
) for C19H16O3 requires 292.1; Anal Calc. for 
C19H16O3: C, 78.06%; H, 5.52%. Found: C, 77.64%; H, 5.55%  
 
3-(2,4-Dimethoxy-phenyl)-1-(3-prop-2-ynyloxy-phenyl)-propene, 4.13e  
 
Light yellow amorphous solid (1.60 g, 88%); m.p. 
132.°C; Rf (EtOAc:Hex 1:4) 0.53; IRνmax(KBr)/cm
-1
 
2123 (C≡C), 1653 (C=O); δH (400MHz, CDCl3) 8.05 
(1H, d, J 15.6, Hβ), 7.63 (2H, m, H-2B, H-6B), 7.56 
(1H, d, J 8.4, H-6A), 7.51 (1H, d, J 15.6, Hα), 7.41 (1H, 
t, J 8.1, H-5B), 7.17 (1H, ddd, J 2.4, 2.7 and 8.1, H-4B), 6.53 (1H, dd, J 2.7 and 8.4, H-5A), 
6.47 (1H, d, J 2.7, H-3A), 4.76 (2H, d, J 2.4, H-1’), 3.90 (3H, s, OMe), 3.85 (3H, s, OMe), 
2.54,(1H, t, J 2.4, H-3’);  δC (100MHz, CDCl3) 190.7, 163.1, 160.5, 157.7, 140.7, 140.4, 
131.0, 129.5, 121.8, 120.4, 119.5, 117.2, 114.2, 105.5, 98.5, 78.3, 75.8, 56.0, 55.6, 55.5; 
LRMS(ESI) found m/z 323.3 (100%, [M+H]
+
) for C20H18O4 requires 322.1; Anal Calc. for 
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1-(3-Prop-2-ynyloxy-phenyl)-3-(2,3,4-trimethoxy-phenyl)-propene, 4.13f  
 
Light yellow amorphous solid (1.49 g, 74%); m.p. 74°C; 
Rf (EtOAc:Hex 1:4) 0.49; IRνmax(KBr)/cm
-1
 2113 
(C≡C), 1653 (C=O); δH (300MHz, CDCl3) 7.99 (1H, d, 
J 15.6, Hβ), 7.63 (2H, m, H-2B, H-6B), 7.52 (1H, d, J 
15.6, Hα), 7.43 (1H, d, J 8.4, H-6A), 7.38 (1H, t, J 8.7, 
H-5B), 7.18 (1H, ddd, J 2.4, 2.7 and 8.1, H-4B), 6.71 (1H, d, J 9.0, H-5A), 4.76 (2H, d, J 2.4, 
H-1’), 3.94 (3H, s, OMe), 3.90 (3H, s, OMe), 3.88 (3H, s, OMe), 2.54 (1H, t, J 2.7, H-3’); δC 
(75MHz, CDCl3) 190.3, 157.7, 155.8, 153.8, 142.5, 140.3, 140.0, 129.5, 123.9, 122.0, 121.8, 
121.3, 119.6, 114.2, 107.6, 78.2, 75.8, 61.4, 60.9, 56.1, 56.0; LRMS(ESI) found m/z 353.2 
(100%, [M+H]
+
) for C21H20O5 requires 352.1; Anal Calc. for C21H20O5: C, 71.58%; H, 
5.72%. Found: C, 71.20%; H, 5.78% 
 
3-(4-Methoxy-phenyl-1-(4-prop-2-ynyloxy-phenyl)-propenone, 4.13g  
 
Light yellow amorphous solid (1.55 g, 87%); m.p. 
112°C; Rf (EtOAc:Hex 3:7) 0.60; IRνmax(KBr)/cm
-1
 
2111 (C≡C), 1651 (C=O); δH (400MHz, CDCl3) 8.02 
(2H, d, J 8.8, H-2B, H-6B), 7.76 (1H, d, J 15.6, Hβ), 
7.58 (2H, d, J 8.8, H-2A, H-6A), 7.40 (1H, d, J 15.6, Hα), 7.04 (2H, d, J 8.8, H-3A, H-5A), 
6.92 (2H, d, J 8.8, H-3B, H-5B), 4.67 (2H, d, J 2.4, H-1’), 3.84 (3H, s, OMe), 2.54 (1H, t, J 
2.0, H-3’); δC (100MHz, CDCl3) 188.8, 161.5, 161.0, 144.0, 132.2, 130.6(x2), 130.1(x2), 
121.8, 119.5, 114.7 (x2), 114.4 (x2), 77.8, 76.0, 55.9, 55.4; LRMS(ESI) found m/z 293.3 
(100%, [M+H]
+
) for C19H16O3 requires 292.1; Anal Calc. for C19H16O3: C, 78.06%; H, 
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3-(2,4-Dimethoxy-phenyl)-1-(4-prop-2-ynyloxy-phenyl)-propene, 4.13h  
 
Light yellow amorphous solid (1.42 g, 78%); m.p. 76-
77°C; Rf (EtOAc:Hex 1:4) 0.48; IRνmax(KBr)/cm
-1
 
2123 (C≡C), 1652 (C=O); δH (300MHz, CDCl3) 8.01-
8.06 (3H, m, H-2B, H-6B, Hβ), 7.56 (1H, d, J 8.4, H-
6A), 7.54 (1H, d, J 15.6, Hα), 7.05 (2H, d, J 9.0, H-3B, H-5B), 6.53 (1H, dd, J 2.4 and 8.4, 
H-5A), 6.48 (1H, d, J 2.4, H-3A), 4.77 (2H, d, J 3.2, H-1’), 3.90 (3H, s, OMe), 3.85 (3H, s, 
OMe), 2.55 (1H, t, J 2.4, H-3’); δC (75MHz, CDCl3) 189.4, 162.9, 160.9, 160.4, 139.9, 132.5, 
130.9, 130.6(x2), 120.3, 117.3, 114.6(x2), 105.4, 98.5, 78.0, 76.0, 55.9, 55.6, 55.5; 
LRMS(ESI) found m/z 323.1 (100%, [M+H]
+
) for C20H18O4 requires 322.1; Anal Calc. for 
C20H18O4: C, 74.52%; H, 5.63%. Found: C, 74.27%; H, 5.66% 
 
1-(4-Prop-2-ynyloxy-phenyl)-3-(2,3,4-trimethoxy-phenyl)-propene, 4.13i  
 
Light yellow amorphous solid (1.43 g, 71%); m.p. 97-
98°C; Rf (EtOAc:Hex 1:4) 0.43; IRνmax(KBr)/cm
-1
 
2126 (C≡C), 1655 (C=O); δH (300MHz, CDCl3) 8.03 
(2H, d, J 9.0, H-2B, H-6B), 7.97 (1H, d, J 15.6, Hβ), 
7.55 (1H, d, J 16.2, Hα), 7.36 (1H, d, J 8.7, H-6A), 7.05 (2H, d, J 8.7, H-3B, H-5B), 6.71 
(1H, d, J 8.7, H-5A), 4.76 (2H, d, J 2.4, H-1’), 3.94 (3H s, OMe), 3.90 (3H, s, OMe), 3.88 
(3H, s, OMe), 2.55 (1H, t, J 2.4, H-3’); δC (75MHz, CDCl3) 189.1, 161.0, 155.6, 153.7, 
142.5, 139.5, 132.2, 130.6(x2), 123.8, 122.2, 121.2, 114.6 (x2), 107.6, 77.8, 76.1, 61.3, 60.9, 
56.1, 55.8; LRMS(ESI) found m/z 353.1 (100%, [M+H]
+
) for C21H20O5 requires 352.1; Anal 
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G. General procedure for preparation of compounds 4.14a-r 
The thiolactone azide 4.8 (0.822 mmol, 1.0 eq) was added to a stirred solution of the 
appropriate acetylene 4.10a-i, 4.13a-i (0.905 mmol, 1.1 eq), CuSO4.5H2O (0.0411 mmol, 
0.05 eq) and sodium ascorbate (0.123 mmol, 0.15 eq) in 3 mL CH2Cl2/H2O (1:1). The 
resulting mixture was vigorously stirred for 16 hours at 25°C. The precipitated product was 
extracted with EtOAc and the combined organic layer washed with water, brine and dried 
over anhydrous NaSO4. Evaporation of the solvent under reduced pressure afforded a residue 
which was purified by column chromatography (MeOH:DCM 1:4). 
 
4-[2-Hydroxy-3-(4-{2-[3-(4-methoxy-phenyl)-3-oxo-propenyl]-phenoxymethyl}-
[1,2,3]triazol-1-yl)-propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.11a (RHH138E) 
 
Yellow gum (84.9 mg, 19%); Rf (MeOH:DCM 1:39) 0.18; 
IRνmax(KBr)/cm
-1
 3400 (OH), 1625 (C2=O), 1600 (αβ-unsat 
C=O); δH (400MHz, CDCl3) 7.98 (1H, d, J 15.6, βH), 7.93 
(2H, d, J 8.0, H-2B, H-6B), 7.87 (1H, s, H-8’), 7.60 (1H, dd, J 
1.6 and 7.6, H-6A), 7.55 (1H, d, J 16, αH), 7.34 (1H, m, H-
4A), 6.98-7.06 (2H, m, H-3A, H-5A), 6.92 (2H, d, J 8.8, H-
3B, H-5B), 5.21 (2H, s, H-9’), 4.63 (1H, dd, J 3.2 and 14.0, 
H-1’a/b), 4.47 (1H, m, H-1’a/b), 4.36 (1H, m, H-2’), 4.26 (1H, m, H-3’a/b), 4.17 (2H, m, H-
5, H-3’a/b), 3.84 (3H, s, OMe), 1.75 (3H, dd
‡
, J 1.2 and 4.8, H-7), 1.51 (3H, d, J 6.8, H-6); 
δC (100MHz, CDCl3) 195.8, 189.6, 177.4, 163.6, 157.4, 143.7, 139.4, 134.6, 131.8, 131.4, 
130.9(x2), 128.9, 124.8, 122.7, 121.7, 113.9(x2), 113.6, 113.3, 71.8, 69.0(x2), 62.9, 52.8, 
41.8, 19.6, 8.9; HRMS(ESI) found m/z 536.18485 [M+H]
+
 for C28H29N3O6S requires 
535.17771; Anal Calc. for C28H29N3O6S C, 62.79%; H, 5.46%; N, 7.85%; S, 5.99%. Found: 
C, 62.39%; H, 5.55%; N, 7.51%; S, 5.78%. 
                                               
‡
 The expected multiplicity of H-7 is a doublet, however, a doublet of doublets and in some cases (4.11f) a 
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4-[3-(4-{2-[3-(2,4-Dimethoxy-phenyl)-3-oxo-propenyl]-phenoxymethyl}-[1,2,3] triazol-1-
yl)-2-hydroxy-propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.11b (RHH138M) 
 
Yellow gum (179.0 mg, 38%); Rf (MeOH:DCM 1:39) 0.31; 
IRνmax(KBr)/cm
-1
 3413 (OH), 1629 (C2=O), 1603 (αβ-unsat 
C=O); δH (300MHz, CDCl3) 7.92 (1H, d, J 15.6, βH), 7.89 
(1H, s, H-8’), 7.66 (1H, d, J 8.4, H-6B), 7.59 (1H, br.d, J 8.1, 
H-6A), 7.48 (1H, d, J 16.2, αH), 7.34 (1H, m, H-4A), 7.08-
6.98 (2H, m, H-3A, H-5A), 6.53 (1H, dd, J 2.7 and 8.8, H-
5B), 6.47 (1H, d, J 2.4, H-3B), 5.24 (2H, s, H-9’), 4.49 (1H, 
dd, J 3.0 and 13.8, H-1’a/b), 4.47 (1H, m, H-1’a/b), 4.35 (1H, m, H-2’), 4.28 (1H, m, H-
3’a/b), 4.18 (2H, m, H-5, H-3’a/b), 3.80 (3H, s, OMe), 3.77 (3H, s, OMe), 1.79 (3H, dd, J 0.9 
and 3.3, H-7), 1.54 (3H, d, J 7.2, H-6); δC (75MHz, CDCl3) 195.8, 191.4, 177.4, 164.4, 
160.5, 157.4, 137.5, 133.4, 132.8, 131.6, 128.3, 127.6, 124.7, 121.7, 121.0, 113.5, 112.6, 
105.4, 98.8, 98.4, 71.8, 69.0, 63.1, 55.8, 55.6, 52.7, 41.8, 19.7, 8.9; HRMS(ESI) found m/z 
566.19528 [M+H]
+
 for C29H31N3O7S requires 565.18827; Anal Calc. for C29H31N3O7S: C, 
61.58%; H, 5.52%; N, 7.43%; S, 5.67%. Found: C, 61.09%; H, 5.34%; N, 6.98%; S, 5.27%. 
 
2-[2-Hydroxy-3-(4-{4-[3-(2,3,4-trimethoxy-phenyl)-propenyl]-phenoxymethyl}-
[1,2,3]triazol-1-yl)-propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.11c (RHH138SA) 
 
Yellow foam (156.2 mg, 32%); Rf (MeOH:DCM 1:39) 0.14; 
IRνmax(KBr)/cm
-1
 3401 (OH), 1630 (C2=O), 1601(αβ-unsat 
C=O); δH (300MHz, CDCl3) 7.91 (1H, s, H-8’), 7.89 (1H, d, 
J 16.2, βH), 7.60 (1H, dd, J 2.1 and 7.8, H-6A), 7.44-7.50 
(2H, m, αH, H-6B), 7.37 (1H, m, H-4A), 7.08-6.99 (2H, m, 
H-3A, H-5A), 6.74 (1H, d, J 8.7, H-5B), 5.26 (2H, s, H-9’), 
4.67 (1H, dd, J 3.3 and 14.1, H-1’a/b), 4.17-4.54 (5H, m, H-
1’a/b, H-2’, H-3’, H-5), 3.91 (3H, s, OMe), 3.89 (3H, s, 
OMe), 3.86, (3H, s, OMe), 1.81 (3H, dd, J 1.5 and 3.6, H-7), 1.56, (3H, d, J 7.2, H-6); δC 
(75MHz, CDCl3) 195.6, 192. 1, 177.2, 157.4, 156.8, 153.4, 139.2, 131.8, 131.6 129.3, 128.4, 
127.2, 126.8, 125.8, 124.5, 124.3, 121.7, 121.6, 113.1 107.5, 71.8, 69.1, 63.1, 62.2, 61.1, 
56.1, 52.7, 41.7, 19.6, 8.9; HRMS(ESI) found m/z 596.20614 [M+H]
+
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requires 595.19884; Anal Calc. for C30H33N3O8S: C, 60.49%; H, 5.58%; N, 7.05%; S, 5.38%. 
Found: C, 60.12%; H, 5.24%; N, 7.04%; S, 5.30%. 
 
4-[2-Hydroxy-3-(4-{3-[3-(4-methoxy-phenyl)-3-oxo-propenyl]-phenoxymethyl}-
[1,2,3]triazol-1-yl)propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.11d (RHH138F) 
 
Yellow gum (90.1 mg, 20%); Rf (MeOH:DCM 1:39) 0.19; 
IRνmax(KBr)/cm
-1
 3338 (OH), 1629 (C2=O), 1610 (αβ-unsat C=O); δH 
(400MHz, CDCl3) 7.98 (2H, d, J 9.2, H-2B, H-6B), 7.79 (1H, s, H-8’), 
7.65 (1H, d, J 15.6, βH), 7.46 (1H, d, J 15.6, αH), 7.27 (1H, t, J 8.0, H-
5A), 7.21-7.17 (2H, m, H-2A, H-6A), 6.97-6.92 (3H, m, H-4A, H-3B, 
H-5B), 5.15 (2H, s, H-9’), 4.62 (1H, dd, J 3.6 and 14.0, H-1’a/b), 4.48 
(1H, m, H-1’a/b), 4.38 (1H, m, H-2’), 4.27 (1H, m, H-3’a/b), 4.18 (2H, 
m, H-5, H-3’a/b), 3.84 (3H, s, OMe), 1.75 (3H, dd, J 1.2 and 6.8, H-7), 
1.52 (3H, d, J 7.2, H-6); δC (100MHz, CDCl3) 195.9, 188.9, 177.5, 
163.6, 158.5, 143.8, 143.6, 136.6, 131.4, 130.9(x2), 130.1, 124.7, 122.5, 
121.6, 116.8, 114.5, 114.0(x3), 71.8, 68.9, 61.9, 55.5, 52.8, 41.8, 19.6, 
8.9; HRMS(ESI) found m/z 536.18555 for C28H29N3O6S requires 535.17771; Anal Calc. for 
C28H29N3O6S: C, 62.79%; H, 5.46%; N, 7.85%; S, 5.99%. Found: C, 62.43%; H, 5.42%; N, 
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4-[3-(4-{3-[3-(2,4-Dimethoxy-phenyl)-3-oxo-propenyl]-phenoxymethyl}-[1,2,3] triazol-1-
yl)-2-hydroxy-propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.11e (RHH138U) 
 
Yellow gum (120.7 mg, 26%); Rf (MeOH:DCM 1:39) 0.17; 
IRνmax((KBr)/cm
-1
 3400 (OH), 1630 (C2=O), 1601 (αβ-unsat 
C=O); δH (300MHz, CDCl3) 7.79 (1H, s, H-8’), 7.71 (1H, d, J 8.4, 
H-6B), 7.57 (1H, d, J 15.6, βH), 7.45 (1H, d, J 15.6, αH), 7.28 
(1H, t, J 8.1, H-5A), 7.20-7.14 (2H, m, H-2A, H-6A), 6.97 (1H, m, 
H-4A), 6.54 (1H, dd, J 2.4 and 9.0, H-5B), 6.48 (1H, d, J 2.4, H-
3B), 5.18 (2H, s, H-9’), 4.62 (1H, dd, J 3.6 and 13.8, H-1’a/b), 
4.48 (1H, m, H-1’a/b), 4.37 (1H, m, H-2’), 4.26 (1H, m, H-3’a/b), 
4.18 (2H, m, H-5, H-3’a/b), 3.88 (3H, s, OMe), 3.85 (3H, s, OMe), 
1.77 (3H, dd, J 1.2 and 4.2, H-7), 1.53 (3H, d, J 6.9, H-6); δC 
(75MHz, CDCl3) 195.8, 190.5, 177.4, 165.0, 164.4, 160.5, 158.4, 
143.8, 141.7, 136.9, 132.8, 129.9, 127.6, 124.6, 121.4, 116.4, 114.4, 105.4,  98.6, 98.4, 71.7, 
68.8, 61.8, 55.8,  55.5, 52.6, 41.7, 19.7, 8.9; HRMS(ESI) found m/z 566.21003 [M+H]
+
 for 
C29H31N3O7S requires 565.18827; Anal Calc. for C29H31N3O7S: C, 61.58%; H, 5.52%; N, 
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3-[2-Hydroxy-3-(4-{4-[3-(2,3,4-trimethoxy-phenyl)-propenyl]-phenoxymethyl}-
[1,2,3]triazol-1-yl)-propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.11f (RHH138N) 
 
Yellow foam (108.8 mg, 22%); Rf (MeOH:DCM 1:39) 0.15; 
IRνmax(KBr)/cm
-1
 3401 (OH), 1629 (C2=O), 1603 (αβ-unsat C=O); 
δH (300MHz, CDCl3) 7.80 (1H, s, H-8’), 7.57 (1H, d, J 16.2, βH), 
7.46-7.40 (2H, m, H-6B, αH), 7.29-7.16 (3H, m, H-2A, H-5A, H-
6A), 6.98 (1H, m, H-4A), 6.74 (1H, d, J 8.7, H-5B), 5.18 (2H, s, H-
9’), 4.63 (1H, dd, J 3.3 and 14.1, H-1’a/b), 4.51-4.14 (5H, m, H-
1’a/b, H-2’, H-3’, H-5), 3.88 (3H, s, OMe), 3.89 (3H, s, OMe), 3.91 
(3H, s, OMe), 1.78 (3H, br. d, J 4.5, H-7), 1.54 (3H, d, J 7.2, H-6); 
δC (75MHz, CDCl3) 195.7, 190.9, 177.3, 158.4, 157.2, 153.7, 
143.7, 142.6, 136.6, 130.3, 130.0, 129.3, 127.0, 125.8, 124.6, 
121.5, 116.6, 115.9, 114.4, 107.4, 71.7, 68.9, 62.1, 61.8, 61.0, 56.1, 
52.6, 41.7, 19.6, 8.9; HRMS(ESI) found m/z 596.20647 [M+H]
+
 for C30H33N3O8S requires 
595.19884; Anal Calc. for C30H33N3O8S: C, 60.49%; H, 5.58%; N, 7.05%; S, 5.38%. Found: 
C, 60.76%; H, 5.41%; N, 7.23%; S, 5.58% 
 
4-[2-Hydroxy-3-(4-{4-[3-(4-methoxy-phenyl)-3-oxo-propenyl]-phenoxymethyl}-
[1,2,3]triazol-1-yl)propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.11g (RHH138O) 
 
Yellow gum (101.1 mg, 23%); Rf (MeOH:DCM 1:39) 0.31; 
IRνmax(KBr)/cm
-1
 3393 (OH), 1628 (C2=O), 1600 (αβ-unsat 
C=O); δH (300MHz, CDCl3) 8.00 (2H, d, J 8.7, H-2B, H-6B), 
7.79 (1H, s, H-8’), 7.71 (1H, d, J 15.6, βH), 7.56 (2H, d, J 8.7, H-
2A, H-6A), 7.40 (1H, d, J 15.6, αH ), 6.99-6.94 (4H, m, H-3A, H-
5A, 3B, H-5B), 5.19 (2H, s, H-9’), 4.64 (1H, dd, J 3.3 and 14.1, 
H-1’a/b), 4.50 (1H, m, H-1’a/b), 4.47 (1H, m, H-2’), 4.28 (1H, m, 
H-3’a/b), 4.20 (2H, m, H-5, H-3’a/b), 3.87 (3H, s, OMe), 1.79 
(3H, dd, J 0.9 and 4.8, H-7), 1.55 (3H, d, J 7.2, H-6); δC (75MHz, 
CDCl3) 195.8, 188.9, 177.3, 163.5, 160.0, 143.6, 131.2, 
130.8(x2), 130.2(x2), 128.4, 124.6, 120.0, 115.2(x2), 114.6, 113.9(x2), 73.1, 71.7, 68.9, 61.9, 
55.5, 52.7, 41.8, 19.6, 8.9; HRMS(ESI) found m/z 536.18482 [M+H]
+


































































































































requires 535.17771; Anal Calc. for C28H29N3O6S: C, 62.79%; H, 5.46%; N, 7.85%; S, 5.99%. 
Found: C, 62.37%; H, 5.58%; N, 7.33%; S, 5.78%. 
 
4-[3-(4-{4-[3-(2,4-Dimethoxy-phenyl)-3-oxo-propenyl]-phenoxymethyl}-[1,2,3] triazol-1-
yl)-2-hydroxy-propoxy]-3,5-dimethyl-5H-thiophen-2-one 4.11h (RHH138T) 
 
Yellow gum (90.6 mg, 19%); Rf (MeOH:DCM 1:39) 0.31; 
IRνmax(KBr)/cm
-1
 3402 (OH), 1630 (C2=O), 1600 (αβ-unsat C=O); 
δH (300MHz, CDCl3) 7.77 (1H, s, H-8’), 7.72 (1H, d, J 8.1, H-6B), 
7.61 (1H, d, J 15.6, βH), 7.52 (2H, d, J 8.7, H-2A, H-6A), 7.38 
(1H, d, J 15.6, αH), 6.98 (2H, d, J 8.7, H-3A, H-5A), 6.55 (1H, dd, 
J 2.4 and 9.0, H-5B), 6.49 (1H, d, J 1.8, H-3B), 5.22 (2H, s, H-9’), 
4.64 (1H, dd, J 3.3 and 14.4, H-1’a/b), 4.51 (1H, m, H-1’a/b), 4.41 
(1H, m, H-2’), 4.27 (1H, m, H-3’a/b), 4.19 (2H, m, H-5, H-3’a/b), 
3.89 (3H, s, OMe), 3.86 (3H, s, OMe), 1.81 (3H, dd, J 0.9 and 3.3, 
H-7), 1.56 (3H, d, J 6.9, H-6); δC (75MHz, CDCl3) 195.6, 190.7, 
177.1, 164.2, 164.1, 160.4, 159.7, 143.9, 141.8, 132.8, 130.0(x2), 
128.8, 125.5, 124.5, 122.3, 115.2(x2), 105.4, 98.8, 71.6, 69.0, 61.9, 55.8, 55.6, 52.6, 41.7, 
19.7, 9.0; HRMS(ESI) found m/z 566.19568 [M+H]
+ 
for C29H31N3O7S requires 565.18827; 
Anal Calc. for C29H31N3O7S: C, 61.58%; H, 5.52%; N, 7.43%; S, 5.67%. Found: C, 61.48%; 






















































[1,2,3]triazol-1-yl)-propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.11i (RHH96A) 
 
Yellow gum (208.9 mg, 43%); Rf (MeOH:DCM 1:39) 0.32; 
IRνmax(KBr)/cm
-1
 3420 (OH), 1630 (C2=O), 1600 (αβ-unsat C=O); 
δH (400MHz, CDCl3) 7.78 (1H, s, H-8’), 7.59 (1H, d, J 16, βH), 
7.53 (2H, d, J 8.8, H-2A, H-6A), 7.43 (1H, d, J 8.8, H-6B), 7.34 
(1H, d, J 15.6, αH), 6.97 (2H, d, J 8.8, H-3A, H-5A), 6.73 (1H, d, 
J 8.8, H-5B), 5.19 (2H, s, H-9’), 4.64 (1H, dd, J 3.6 and 14.0, H-
1’a/b), 4.50 (1H, m, H-1’a/b), 4.40 (1H, m, H-2’), 4.29 (1H, m, H-
3’a/b), 4.19 (2H, m, H-5, H-3’a/b), 3.91 (3H, s, OMe), 3.90 (3H, s, 
OMe), 3.89 (3H, s, OMe), 1.78 (3H, dd, J 0.8 and 6.0, H-7), 1.55 
(3H, d, J 7.2, H-6); δC (100MHz, CDCl3) 195.7, 191.1, 177.2, 
159.9, 157.0, 153.6, 143.7, 142.8, 142.2, 130.1(x2), 128.5, 126.9, 
125.6, 124.8, 124.6, 115.2(x2), 113.2, 107.4, 71.7, 69.0, 62.1, 61.9, 61.0, 56.1, 52.7, 41.8, 
19.6, 8.9; HRMS(EI) found m/z 595.1993 for C30H33N3O8S requires 595.19884; Anal Calc. 
for C30H33N3O8S: C, 60.49%; H, 5.58%; N, 7.05%; S, 5.38%. Found: C, 60.42%; H, 5.86%; 
N, 6.92%; S, 5.20% 
 
4-[2-Hydroxy-3-(4-{2-[3-(4-methoxy-phenyl)-acryloyl]-phenoxymethyl}-[1,2,3]triazol-1-
yl)-propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.14a (RHH138Q) 
 
Yellow gum (138.7 mg, 32%); Rf (MeOH:DCM 1:39) 
0.15; IRνmax(KBr)/cm
-1
 3400 (OH), 1627 (C2=O), 1602 
(αβ-unsat C=O); δH (300MHz, CDCl3) 7.59 (1H, s, H-
8’),7.51 (1H, dd, J 1.8 and 7.5, H-6B), 7.46 (1H, d, J 15.9, 
Hβ), 7.45-7.42 (3H, m, H-4B, H-2A, H-6A), 7.15 (1H, d, J 
15.9, αH), 7.10-7.02 (2H, m, H-3B, H-5B), 6.97 (2H, d, J 
8.7, H-3A, H-5A), 5.21 (2H, s, H-9’), 4.43 (1H, dd, J 3.3 
and 14.1, H-1’a/b), 4.29-4.06 (5H, m, H-1’a/b, H-2’, H-3’, 
H-5), 3.80 (3H, s, OMe), 1.74 (3H, dd, J 0.9 and 2.4, H-7), 1.51 (3H, d, J 7.2, H-6); δC 
(75MHz, CDCl3) 195.9, 193.4, 177.5, 161.7, 156.4, 143.7, 143.5, 132.9, 131.9, 130.3(x2), 
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19.6, 8.9; HRMS(ESI) found m/z 536.18492 [M+H]
+
 for C28H29N3O6S requires 535.17771; 
Anal Calc. for C28H29N3O6S: C, 62.79%; H, 5.46%; N, 7.85%; S, 5.99%. Found: C, 62.49%; 
H, 5.43%; N, 7.49%; S, 5.86%. 
 
4-[3-(4-{2-[3-(2,4-Dimethoxy-phenyl)-acryloyl]-phenoxymethyl}-[1,2,3]triazol-1-yl)-2-
hydroxy-propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.14b (RHH138A) 
 
Yellow foam (168.9 mg, 36%); Rf (MeOH:DCM 1:39) 
0.42; IRνmax(KBr)/cm
-1
 3412 (OH), 1633 (C2=O), 1600 
(αβ-unsat C=O); δH (300MHz, CDCl3) 7.79 (1H, d, J 16.2, 
βH), 7.57 (1H, s, H-8’), 7.48 (2H, m, H-4B, H-6B), 7.44 
(1H, d, J 8.4, H-6A), 7.23 (1H, d, J 16.6, αH), 7.14-7.04 
(2H, m, H-3B, H-5B), 6.49 (1H, dd, J 2.4 and 8.4, H-5A), 
6.42 (1H, d, J 2.4, H-3A), 5.24 (2H, s, H-9’), 4.62 (1H, dd, 
J 3.2 and 14.1, H-1’a/b), 4.29-4.13 (5H, m, H-5, H-3’, H-
2’, H-1’a/b), 3.82 (3H, s, OMe), 3.80 (3H, s, OMe), 1.77 (3H, br. d, J 1.2, H-7), 1.54 (3H, d, 
J 7.5, H-6); δC (75MHz, CDCl3) 194.1, 191.5, 177.2, 163.2, 160.3, 156.2, 143.7, 139.6, 
132.6, 130.5, 130.0, 125.3, 124.6, 122.0, 116.9, 114.6, 105.6, 104.3, 98.4, 97.9, 71.6, 69.0, 
63.8, 55.6, 55.5, 52.6, 41.8, 19.6, 8.9; HRMS(ESI) found m/z 566.19536 [M+H]
+
 for 
C29H31N3O7S requires 565.18827; Anal Calc. for C29H31N3O7S: C 61.58%, H 5.52%, N 
7.43%, S 5.67%. Found: C, 61.17%; H, 5.63%; N, 7.11%; S, 5.26%. 
 
4-[2-Hydroxy-3-(4-{2-[3-(2,3,4-trimethoxy-phenyl)-acryloyl]-phenoxymethyl}-
[1,2,3]triazol-1-yl)-propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.14c (RHH138H) 
 
Yellow foam (160.7 mg, 33%); Rf (MeOH:DCM 1:39) 
0.33; IRνmax(KBr)/cm
-1
 3415 (OH), 1631 (C2=O), 1600 
(αβ-unsat C=O); δH (300MHz, CDCl3) 7.71 (1H, d, J 15.9, 
βH), 7.59 (1H, s, H-8’), 7.52 (1H, dd, J 2.1 and 7.8, H-
6B), 7.47 (1H, m, H-4B), 7.26 (1H, d, J 8.7 H-6A), 7.24 ( 
1H, d, J 15.9, αH), 7.14 (1H, d, J 7.8, H-3B), 7.08 (1H, 
ddd, J 1.2, 7.2 and 7.5, H-5B), 6.69 (1H, d, J 9.3, H-5A), 
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4.31-4.10 (5H, m, H-1’a/b, H-2’, H-3’, H-5), 3.88 (3H, s, OMe), 3.87 (3H, s, OMe), 3.86, 
(3H, s, OMe), 1.79 (3H, dd, J 1.8 and 2.4, H-7), 1.55, (3H, d, J 6.9, H-6); δC (75MHz, 
CDCl3) 195.9, 194.0, 177.4, 156.3, 155.8, 153.5, 143.6, 142.3, 139.2, 132.9, 130.9 130.1, 
126.4, 124.7, 123.8, 122.0, 121.8, 115.5, 114.6, 107.8, 71.6, 69.0, 63.7, 61.7, 61.1, 56.1, 52.7, 
41.8, 19.7, 9.0; HRMS(ESI) found m/z 596.20609 [M+H]
+
 for C30H33N3O8S requires 
595.19884; Anal Calc. for C30H33N3O8S: C, 60.49%; H, 5.58%; N, 7.05%; S, 5.38%. Found: 
C, 60.28%; H, 5.90%; N, 6.68%; S, 5.21%. 
 
4-[2-Hydroxy-3-(4-{3-[3-(4-methoxy-phenyl)-acryloyl]-phenoxymethyl}-[1,2,3]triazol-1-
yl)-propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.14d (RHH138KA) 
 
Yellow gum (99.8 mg, 23%); Rf (MeOH:DCM 1:39) 0.30; 
IRνmax(KBr)/cm
-1
 3401 (OH), 1629 (C2=O), 1601 (αβ-unsat C=O); δH 
(300MHz, CDCl3) 7.82 (1H, s, H-8’), 7.73 (1H, d, J 15.6, βH), 7.54 – 
7.58 (4H, m, H-2A, H-6A, H-6B, H-2B), 7.36 (1H, t, J 8.7, H-5B), 7.34 
(1H, d, J 15.6, αH), 7.14 (1H, ddd, J 2.4, 2.8 and 8.4, H-4B), 6.91 (2H, 
d, J 9.0, H-3A, H-5A), 5.19 (2H, s, H-9’), 4.64 (1H, dd, J 3.0 and 13.6, 
H-1’a/b), 4.49 (1H, m, H-1’a/b), 4.41 (1H, m, H-2’), 4.28 (1H, m, H-
3’a/b), 4.20 (2H, m, H-5, H-3’a/b), 3.83 (3H, s, OMe), 1.77 (3H, dd, J 
1.2 and 6.8, H-7), 1.54 (3H, d, J 6.9, H-6); δC (75MHz, CDCl3) 195.9, 
190.4, 177.5, 161.9, 158.4, 145.2, 143.6, 139.9, 131.8, 130.4(x2), 129.8, 
127.4, 121.6, 119.7, 119.6, 114.5(x2), 114.1, 113.7, 71.8, 68.9, 62.0, 
55.4, 52.8, 41.8, 19.6, 8.9; HRMS(ESI) found m/z 536.18510 [M+H]
+
for C28H29N3O6S 
requires 535.17771; Anal Calc. for C28H29N3O6S: C, 62.79%; H, 5.46%; N, 7.85%; S, 5.99%. 
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4-[3-(4-{3-[3-(2,4-Dimethoxy-phenyl)-acryloyl]-phenoxymethyl}-[1,2,3]triazol-1-yl)-2-
hydroxy-propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.14e (RHH138J) 
 
Yellow foam (168.9 mg, 36%); Rf (MeOH:DCM 1:39), 0.15; 
IRνmax(KBr)/cm
-1
 3401 (OH), 1629 (C2=O), 1604 (αβ-unsat C=O); 
δH (400MHz, CDCl3) 8.03 (1H, d, J 16.2, βH), 7.83 (1H, s, H-8’), 
7.57-7.55 (3H, m, H-2B, H-6B, H-6A), 7.48 (1H, d, J 15.6, αH), 
7.38 (1H, t, J 8.0, H-5B), 7.16 (1H, ddd, J 2.4, 2.7 and 8.4, H-4B), 
6.52 (1H, dd, J 2.0 and 8.8, H-5A), 6.47 (1H, d, J 2.0, H-3A), 5.22 
(2H, s, H-9’), 4.64 (1H, m, H-1’a/b), 4.29-4.13 (5H, m, H-5, H-3’, 
H-2’, H-1’a/b), 3.89 (3H, s, OMe), 3.85 (3H, s, OMe), 1.79 (3H, 
dd, J 1.7 and 4.0, H-7), 1.55 (3H, d, J 6.8, H-6); δC (100MHz, 
CDCl3) 191 (x2), 177.5, 163.3, 160.5, 158.4, 143.7, 141.1, 140.2, 
131.9, 131.0, 129.7, 124.8, 121.6, 120.1, 119.6, 116.9, 114.1, 
105.6, 98.5, 71.8, 68.9, 62.0, 55.6, 55.5, 52.7, 41.8, 19.7, 8.9; HRMS(ESI) found m/z 
566.19536 [M+H]
+
 for C29H31N3O7S requires 565.18827; Anal Calc. for C29H31N3O7S: C 
61.58%, H 5.52%, N 7.43%, S 5.67%. Found: C, 61.11%; H, 5.63%; N, 7.11%; S, 5.26%. 
 
4-[2-Hydroxy-3-(4-{3-[3-(2,3,4-trimethoxy-phenyl)-acryloyl]-phenoxymethyl}-
[1,2,3]triazol-1-yl)-propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.14f (RHH138D) 
 
Yellow gum (89.4 mg, 18%); Rf (MeOH:DCM 1:39) 0.33; 
IRνmax(KBr)/cm
-1
 3400 (OH), 1628 (C2=O), 1600 (αβ-unsat C=O); 
δH (300MHz, CDCl3) 7.96 (1H, d, J 16, βH), 7.82 (1H, s, H-8’), 
7.55 (2H, m, H-2B, H-6B), 7.48 (1H, d, J 15.6, αH), 7.39-7.34 
(2H, m, H-6A, H-5B), 7.14 (1H, ddd, J 2.4, 2.8 and 8.7, H-4B), 
6.70 (1H, d, J 9.0, H-5A), 5.19 (2H, s, H-9’), 4.64 (1H, dd, J 2.7 
and 14.1, H-1’a/b), 4.49 (1H, m, H-1’a/b), 4.38 (1H, m, H-2’), 
4.29 (1H, m, H-3’a/b), 4.21 (2H, m, H-5, H-3’a/b), 3.92 (3H, s, 
OMe), 3.88 (3H, s, OMe), 3.86 (3H, s, OMe), 1.76 (3H, dd, J 1.2 
and 3.9, H-7), 1.53 (3H, d, J 6.9, H-6); δC (75MHz, CDCl3) 195.8, 
190.6, 177.4, 158.3, 156.0, 153.8, 143.5, 142.4, 140.6, 139.9, 
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60.8, 56.0, 52.6, 41.7, 19.6, 8.8; HRMS(ESI) found m/z 596.20684 [M+H]
+
 for C30H33N3O8S 
requires 595.19884; Anal Calc. for C30H33N3O8S: C, 60.49%; H, 5.58%; N, 7.05%; S, 5.38%. 
Found: C, 60.19%; H, 5.56%; N, 6.58%; S, 5.08% 
 
4-[2-Hydroxy-3-(4-{4-[3-(4-methoxy-phenyl)-acryloyl]-phenoxymethyl}-[1,2,3]triazol-1-
yl)-propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.14g (RHH138G) 
 
Yellow gum (86 mg, 20%); Rf (MeOH:DCM 1:39) 0.12; IRνmax 
(KBr)/cm
-1
 3400 (OH), 1628 (C2=O), 1600 (αβ-unsat C=O); δH 
(300MHz, CDCl3) 7.96 (2H, d, J 8.7, H-2B and H-6B), 7.81 (1H, 
s, H-8’), 7.72 (1H, d, J 15.6, βH), 7.57 (2H, d, J 9.0, H-2A, H-
6A), 7.37 (1H, d, J 15.6, αH), 7.01 (2H, d, J 8.7, H-3A, H-5A), 
6.91 (2H, d, J 8.7, H-3B, H-5B), 5.21 (2H, s, H-9’), 4.64 (1H, dd, 
J 3.0 and 14.1, H-1’a/b), 4.50 (1H, m, H-1’a/b), 4.39 (1H, m, H-
2’), 4.28 (1H, m, H-3’a/b), 4.19 (2H, m, H-5, H-3’a/b), 3.83 (3H, 
s, OMe), 1.77 (3H, dd, J 1.5 and 5.7, H-7), 1.54 (3H, d, J 6.9, H-
6); δC (75MHz, CDCl3) 195.9, 189.0, 177.4, 161.8, 161.7, 144.3, 
143.4, 131.5, 130.7(x2), 130.2(x2), 127.6, 124.7, 119.4, 114.6(x2), 114.5(x2), 113.7, 71.8, 
68.9, 61.9, 55.4, 52.8, 41.8, 19.6, 8.9; HRMS(ESI) found m/z 536.18526 [M+H]
+
 for 
C28H29N3O6S requires 535.17771; Anal Calc. for C28H29N3O6S: C, 62.79%; H, 5.46%; N, 
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4-[3-(4-{4-[3-(2,4-Dimethoxy-phenyl)-acryloyl]-phenoxymethyl}-[1,2,3]triazol-1-yl)-2-
hydroxy-propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.14h (RHH138B) 
 
Yellow foam (91.4 mg, 20%); Rf (MeOH:DCM 1:39) 0.34; 
IRνmax(CHCl3)/cm
-1
 3413 (OH), 1630 (C2=O), 1600 (αβ-unsat 
C=O); δH (400MHz, CDCl3) 7.99 (1H, d, J 15.6, βH), 7.95 (2H, d, 
J 8.8, H-2B and H-6B), 7.78 (1H, s, H-8’), 7.53 (1H, d, J 8.8, H-
6A), 7.50 (1H, d, J 15.6, αH), 7.00 (2H, d, J 8.8, H-3B, H-5B), 
6.51 (1H, dd, J 2.4 and 8.4, H-5A), 6.45 (1H, d, J 2.4, H-3A), 5.22 
(2H, s, H-9’), 4.62 (1H, dd, J 3.2 and 14.1, H-1’a/b), 4.48 (1H, m, 
H-1’a/b), 4.38 (1H, m, H-2’), 4.27 (1H, m, H-3’a/b), 4.17 (2H, m, 
H-5, H-3’a/b), 3.87 (3H, s, OMe), 3.83 (3H, s, OMe), 1.77 (3H, dd, 
J 1.2 and 6.4, H-7), 1.54 (3H, d, J 6.8, H-6); δC (100MHz, CDCl3) 
194.6, 189.6, 177.2, 163.1, 161.6, 160.4, 143.6, 140.2, 132.2, 131.2, 130.9, 130.7(x2), 124.6, 
120.0, 117.1, 114.5(x2), 105.5, 98.5, 71.7, 69.0, 61.9, 55.6, 55.5, 52.6, 41.7, 19.7, 8.9; 
HRMS(ESI) found m/z 566.19509 [M+H]
+
 for C29H31N3O7S requires 565.18827; Anal Calc. 
for C29H31N3O7S: C, 61.58%; H, 5.52%; N, 7.43%; S, 5.67%. Found: C, 61.17%; H, 5.58%; 
N, 7.33%; S, 5.78%.  
 
4-[2-Hydroxy-3-(4-{4-[3-(2,3,4-trimethoxy-phenyl)-acryloyl]-phenoxymethyl}-
[1,2,3]triazol-1-yl)-propoxy]-3,5-dimethyl-5H-thiophen-2-one, 4.14i (RHH138C) 
 
Yellow gum (84.2 mg, 17%); Rf (MeOH:DCM 1:39) 0.30; 
IRνmax(KBr)/cm
-1
 3418 (OH), 1630 (C2=O), 1601 (αβ-unsat C=O); 
δH (300MHz, CDCl3) 7.95 (1H, d, J 16, Hβ), 7.93 (2H, d, J 8.7, H-
2B, H-6B), 7.78 (1H, s, H-8’), 7.50 (1H, d, J 15.6, αH), 7.35 (1H, 
d, J 8.7, H-6A), 7.00 (2H, d, J 8.7, H-3B, H-5B), 6.69 (1H, d, J 
8.7, H-5A), 5.19 (2H, s, H-9’), 4.64 (1H, dd, J 3.0 and 14.1, H-
1’a/b), 4.50 (1H, m, H-1’a/b), 4.38 (1H, m, H-2’), 4.29 (1H, m, H-
3’a/b), 4.20 (2H, m, H-5, H-3’a/b), 3.91 (3H, s, OMe), 3.87 (3H, s, 
OMe), 3.85 (3H, s, OMe), 1.75 (3H, dd, J 0.9 and 4.5, H-7), 1.52 
(3H, d, J 6.9, H-6); δC (75MHz, CDCl3) 195.8, 189.3, 177.4, 
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123.8, 121.8, 120.8, 114.5(x2), 114.3, 107.6, 71.7, 68.8, 61.8, 61.4, 60.8, 56.0, 52.6, 41.8, 
19.6, 8.8; HRMS(ESI) found m/z 596.20590 [M+H]
+
 for C30H33N3O8S requires 595.19884; 
Anal Calc. for C30H33N3O8S: C, 60.49%; H, 5.58%; N, 7.05%; S, 5.38%. Found: C, 60.29%; 
H, 5.54%; N, 7.07%; S, 4.98%. 
 
I. General procedure for preparation of compounds 4.19a-f 
A mixture of the isatin/5-substituted isatin (11.0 mmol, 1.0 eq), a catalytic amount of PTSA 
and trimethyl orthoformate (330 mmol, 30 eq) in 30 mL of anhydrous MeOH was refluxed 
for 48 hours under an inert atmosphere. Upon completion the product mixture was 
neutralized with 5% aqueous sodium bicarbonate and the resulting mixture extracted with 
EtOAc. The combined organic layer was washed with H2O, brine, dried over anhydrous 
Na2SO4 and concentrated under reduced pressure to afford a crude residue. The latter was 
purified with column chromatography (eluent EtOAc:Hex, 2:3) to yield the pure product.  
 
5-Chloro-3,3-dimethoxyindolin-2-one, 4.19a  
 
The conditions employed for the preparation and purification of this 
compound is the same as the conditions described in General Procedure 
I, which gave 4.19a as a light yellow-orange crystalline solid (1.63 g, 
65%). m. p. 152°C; Rf (EtOAc:Hex 2:3) 0.47; IRνmax(KBr)/cm
-1
 3327 (N-H), 1625 (C=O), 
1480 (Ar C=C); δH (400MHz, CDCl3) 8.66 (1H, s, NH), 7.39 (1H, d, J 2.4, H-4), 7.31 (1H, 
dd, J 2.0 and 8.0, H-6), 6.85, (1H, d, J 8.4, H-7), 3.58 (6H, s, OMe); δC (100MHz, CDCl3) 
172.7, 139.0, 130.6, 128.3, 126.9, 125.6, 111.9, 97.2, 50.9(x2); LRMS(EI) found m/z 226.8 
(49%, M
+
) for C10H10ClNO3 requires 227.0 
 
5-Bromo-3,3-dimethoxyindolin-2-one, 4.19b  
 
The conditions employed for the preparation and purification of this 
compound is the same as the conditions described in General 
Procedure I. However, 8.85 mmol of 5-bromoisatin and 265 mmol of 
trimethyl orthoformate were used, which gave 4.19b as a light yellow crystalline solid (1.08 
g, 45%). m. p. 156-157°C; Rf (EtOAc:Hex 2:3) 0.55; IRνmax(KBr)/cm
-1
 3332 (N-H), 1621 
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(1H, dd, J 2.0 and 8.4, H-6), 6.81, (1H, d, J 8.4, H-7), 3.58 (6H, s, OMe); δC (100MHz, 
CDCl3) 172.5, 139.4, 133.5, 128.3, 127.2, 115.5, 112.4, 96.6, 50.9(x2); LRMS(EI) found m/z 
270.5 for C10H10BrNO3 requires 271.0  
 
5-Fluoro-3,3-dimethoxyindolin-2-one, 4.19c  
 
The conditions employed for the preparation and purification of this 
compound is the same as the conditions described in General Procedure 
I. However, 12.1 mmol of the 5-fluoroisatin and 363 mmol of trimethyl 
orthoformate were used, which gave 4.19c as an orange crystalline solid (1.22 g, 48%). m. p. 
101-103°C; Rf (EtOAc:Hex 2:3) 0.51; IRνmax(KBr)/cm
-1
 3188 (N-H), 1633 (C=O), 1485 (Ar 
C=C); δH (400MHz, CDCl3) 8.86 (1H, s, NH), 7.15 (1H, dd, J 2.8 and 7.6, H-4), 7.03 (1H, 
ddd, J 2.8, 8.0 and 8.8, H-6), 6.86 (1H, dd, J 4.0 and 8.8, H-7), 3.55 (6H, s, OMe); δC 
(100MHz, CDCl3) 173.2, 160.2, 136.4, 126.7, 117.2, 113.2, 111.7, 97.4, 50.9(x2); LRMS(EI) 
found m/z 211.4 for C10H10FNO3 requires 211.1 
 
5-Iodo-3,3-dimethoxyindolin-2-one, 4.19d  
 
The conditions employed for the preparation and purification of this 
compound is the same as the conditions described in General Procedure 
I. However, 7.32 mmol of the 5-iodoisatin and 220 mmol of trimethyl 
orthoformate were used, which gave 4.19d as a yellow-orange crystalline solid (1.18 g, 
51%). m. p. 155°C; Rf (EtOAc:Hex 2:3) 0.57; IRνmax(KBr)/cm
-1
 3321 (N-H), 1615 (C=O), 
1475 (Ar C=C); δH (300MHz, CDCl3) 8.42 (1H, s, NH), 7.68 (1H, d, J 1.8, H-4), 7.63 (1H, 
dd, J 2.0 and 8.4, H-6), 6.68 (1H, d, J 8.4, H-7), 3.56 (6H, s, OMe); δC (75MHz, CDCl3) 
170.1, 140.0, 139.4, 133.9, 127.5, 112.8, 96.5, 85.2, 50.9(x2); LRMS(EI) found m/z 318.8 
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3,3-Dimethoxy-5-methylindolin-2-one, 4.19e  
 
The conditions employed for the preparation and purification of this 
compound is the same as the conditions described in General 
Procedure I. However, 12.4 mmol of the 5-methylisatin and 372 
mmol of trimethyl orthoformate were used, which gave 4.19e as off-white needles (1.41 g, 
55%). m. p. 106°C; Rf (EtOAc:Hex 2:3) 0.52; IRνmax(KBr)/cm
-1
 3310 (N-H), 1626 (C=O), 
1495 (Ar C=C); δH (400MHz, CDCl3) 8.53 (1H, s, NH), 7.23 (1H, d, J 1.2, H-4), 7.11 (1H, 
dd, J 1.2 and 8.0, H-6), 6.80, (1H, d, J 8.0, H-7), 3.58 (6H, s, OMe), 2.35 (3H, s, H-8); δC 
(100MHz, CDCl3) 173.1, 139.1, 132.4, 131.0, 125.8, 112.3, 110.6, 97.5, 50.9(x2), 21.1; 
LRMS(EI) found m/z 207.5 for C11H13NO3 requires 207.1  
 
3,3-Dimethoxyindolin-2-one, 4.19f  
 
The conditions employed for the preparation and purification of this 
compound is the same as the conditions described in General Procedure 
I. However, 13.6 mmol of isatin and 408 mmol of trimethyl 
orthoformate were used, which gave 4.19f as colourless prisms (1.42 g, 54%); m. p. 90°C; Rf 
(EtOAc:Hex 2:3) 0.43; IRνmax(KBr)/cm
-1
 3165 (N-H), 1623 (C=O), 1474 (Ar C=C); δH 
(400MHz, CDCl3) 9.00 (1H, s, NH), 7.40 (1H, dd, J 1.2 and 8.0, H-4), 7.31 (1H, td, J 1.2 and 
7.6, H-6), 7.07, (1H, td, J 0.8 and 8.4, H-5), 6.92 (1H, d, J 7.6, H-7), 3.58 (6H, s, OMe); δC 
(100MHz, CDCl3) 173.3, 140.6, 130.7, 125.1, 122.7, 112.6, 111.0, 97.4, 50.9 (x2); 
LRMS(EI) found m/z 193.4 for C10H11NO3 requires 193.1  
 
J. General procedure for preparation of compounds 4.20a-f 
The ketal 4.19 (4.39 mmol, 1.0 eq), and KF-Al2O3 (22.0 mol, 5.0 eq) was suspended in 10 ml 
anhydrous CH2Cl2. (±)-Epichlorohydrin (22.0 mmol, 5.0 eq) was added and the reaction 
mixture stirred for 20 hours at 25°C. When the reaction was completed, as indicated by tlc, 
the product mixture was filtered, dried over anhydrous Na2SO4 and concentrated to afforded 
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5-Chloro-3,3-dimethoxy-1-(oxiran-2-ylmethyl)indolin-2-one, 4.20a  
The conditions employed for the preparation and purification of this 
compound is the same as the conditions described in General 
Procedure J; the ketal 4.19a gave 4.20a as a colourless oil (1.05 g, 
85%). Rf (MeOH:DCM 1:99) 0.42; IRνmax(film)/cm
-1
 1612 (C=O), 
1481 (Ar C=C), 1069 (C-O); δH (400MHz, CDCl3) 7.38 (1H, d, J 2.0, H-4), 7.33 (1H, dd, J 
2.0 and 8.4, H-6), 6.99 (1H, d, J 8.4, H-7), 4.23 (1H, dd, J 2.8 and 15.2, H-1’a/b), 3.56 (3H, 
s, OMe), 3.55 (3H, s, OMe), 3.48 (1H, dd, J 5.6 and 15.2, H-1’a/b), 3.15 (1H, m, H-2’), 2.81 
(1H, dd, J 4.0 and 4.4, H-3’a/b), 2.62 (1H, dd, J 2.4 and 4.8, H-3’a/b); δC (100MHz, CDCl3) 
170.4, 141.2, 130.6, 128.4, 126.3, 125.2, 111.1, 96.7, 50.9(x2), 49.8, 44.8, 41.8; LRMS(EI) 
found m/z 283.5 for C13H14ClNO4 requires 283.1  
 
5-Bromo-3,3-dimethoxy-1-(oxiran-2-ylmethyl)indolin-2-one, 4.20b  
The conditions employed for the preparation and purification of this 
compound is the same as the conditions described in General 
Procedure J. However, 3.40 mmol of the ketal 4.19b and 17.0 mmol 
each of KF-Al2O3 and (±)-epichlorohydrin were used, which gave 
4.20b as a colourless oil (1.28 g, 89%). Rf (DCM) 0.29; IRνmax(film)/cm
-1
 1610 (C=O), 1484 
(Ar C=C), 1070 (C-O); δH (300MHz, CDCl3) 7.50 (1H, d, J 1.8, H-4), 7.47 (1H, dd, J 2.1 and 
8.4, H-6), 6.93 (1H, d, J 8.4, H-7), 4.21 (1H, dd, J 3.0 and 15.0, H-1’a/b), 3.55 (3H, s, OMe), 
3.54 (3H, s, OMe), 3.46 (1H, dd, J 6.0 and 15.0, H-1’a/b), 3.13 (1H, m, H-2’), 2.80 (1H, dd, 
J 4.1 and 4.5, H-3’a/b), 2.60 (1H, dd, J 2.4 and 4.8, H-3’a/b); δC (75MHz, CDCl3) 170.2, 
141.7, 133.4, 127.8, 126.6, 115.6, 111.5, 96.6, 50.8(x2), 49.7, 44.7, 41.7; LRMS(EI) found 
m/z 327.2 for C13H14BrNO4 requires 327.0  
 
5-Fluoro-3,3-dimethoxy-1-(oxiran-2-ylmethyl)indolin-2-one, 4.20c  
 
The conditions employed for the preparation and purification of this 
compound is the same as the conditions described in General 
Procedure J. However, 4.99 mmol of the ketal 4.19c and 24.9 mmol 
each of KF-Al2O3 and (±)-epichlorohydrin were used, which gave 4.20c as a colourless oil 
(1.02 g, 87%). Rf (DCM) 0.29; IRνmax(film)/cm
-1
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δH (300MHz, CDCl3) 7.12 (1H, dd, J 2.4 and 7.2, H-4), 7.04 (1H, ddd, J 2.4, 8.7 and 9.0, H-
6), 6.95 (1H, dd, J 4.2 and 8.7, H-7), 4.22 (1H, dd, J 2.4 and 15.0, H-1’a/b), 3.54 (3H, s, 
OMe), 3.53 (3H, s, OMe), 3.45 (1H, dd, J 6.0 and 15.3, H-1’a/b), 3.13 (1H, m, H-2’), 2.79 
(1H, dd, J 4.1 and 4.5, H-3’a/b), 2.61 (1H, dd, J 2.4 and 4.8, H-3’a/b); δC (75MHz, CDCl3) 
170.7, 160.3, 138.6, 126.2, 117.0, 112.8, 110.8, 96.8, 50.8(x2), 49.9, 44.8, 41.9; LRMS(EI) 
found m/z 267.9 for C13H14FNO4 requires 267.1 
 
5-Iodo-3,3-dimethoxy-1-(oxiran-2-ylmethyl)indolin-2-one, 4.20d  
 
The conditions employed for the preparation and purification of this 
compound is the same as the conditions described in General 
Procedure J. However, 3.37 mmol of the ketal 4.19d and 16.8 mmol 
each of KF-Al2O3 and (±)-epichlorohydrin were used, which gave 
4.20d as a colourless oil (1.33 g, 81%). Rf (DCM) 0.36; IRνmax(film)/cm
-1
 1607 (C=O), 1481 
(Ar C=C), 1070 (C-O); δH (400MHz, CDCl3) 7.69 (1H, d, J 2.0, H-4), 7.68 (1H, dd, J 2.0 and 
8.4, H-6), 6.85 (1H, d, J 8.8, H-7), 4.22 (1H, dd, J 2.8 and 15.2, H-1’a/b), 3.57 (3H, s, OMe), 
3.56 (3H, s, OMe), 3.48 (1H, dd, J 6.0 and 15.2, H-1’a/b), 3.16 (1H, m, H-2’), 2.82 (1H, dd, 
J 4.0 and 4.4, H-3’a/b), 2.62 (1H, dd, J 2.8 and 4.8, H-3’a/b); δC (100MHz, CDCl3) 170.2, 
142.4, 139.5, 133.4, 127.0, 112.1, 96.5, 85.4, 50.9(x2), 49.8, 44.8, 41.8; LRMS(EI) found 
m/z 375.1 for C13H14INO4 requires 375.0 
 
3,3-Dimethoxy-5-methyl-1-(oxiran-2-ylmethyl)indolin-2-one, 4.20e  
 
The conditions employed for the preparation and purification of this 
compound is the same as the conditions described in General 
Procedure J. However 6.29 mmol of the ketal 4.19e and 31.5 mmol 
each of KF-Al2O3 and (±)-epichlorohydrin were used, which gave 
4.20e as a colourless oil (1.10 g, 95%). Rf (DCM) 0.28; IRνmax(film)/cm
-1
 1623 (C=O), 1499 
(Ar C=C), 1069 (C-O); δH (300MHz, CDCl3) 7.21 (1H, d, J 1.2, H-4), 7.14 (1H, dd, J 1.2 and 
8.4, H-6), 6.91 (1H, d, J 8.8, H-7), 4.14 (1H, dd, J 3.0 and 15.0, H-1’a/b), 3.55 (3H, s, OMe), 
3.54 (3H, s, OMe), 3.52 (1H, dd, J 6.0 and 15.0, H-1’a/b), 3.14 (1H, m, H-2’), 2.78 (1H, dd, 
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CDCl3) 170.9, 140.3, 132.6, 131.0, 125.5, 124.7, 109.7, 97.1, 50.9(x2), 49.8, 45.0, 41.7, 21.0 
LRMS(EI) found m/z 263.6 for C14H17NO4 requires 263.1  
 
3,3-Dimethoxy-1-(oxiran-2-ylmethyl)indolin-2-one, 4.20f  
 
The conditions employed for the preparation and purification of this 
compound is the same as the conditions described in General 
Procedure J. However, 6.59 mmol of the ketal 4.19f and 32.9 mmol 
each of KF-Al2O3 and (±)-epichlorohydrin were used, which gave 
4.20f as a colourless oil (1.02 g, 93%). Rf (DCM) 0.28; IRνmax(film)/cm
-1
 1615 (C=O), 1489 
(Ar C=C), 1068 (C-O); δH (300MHz, CDCl3) 7.31-7.39 (2H, m, H-4, H-6), 7.06 (1H, td, J 
0.8 and 7.8, H-5), 7.00 (1H, d, J 7.8, H-7), 4.16 (1H, dd, J 3.0 and 15.0, H-1’a/b), 3.54 (3, s, 
OMe), 3.53 (3H, s, OMe), 3.52 (1H, dd, J 6.0 and 15.0, H-1’a/b), 3.13 (1H, m, H-2’), 2.78 
(1H, dd, J 3.0 and 3.3, H-3’a/b), 2.62 (1H, dd, J 3.0 and 6.0, H-3’a/b); δC (75MHz, CDCl3) 
170.8, 142.6, 130.6, 124.6, 124.5, 122.7, 109.8, 96.8, 50.7(x2), 49.6, 44.9, 41.5; LRMS(EI) 
found m/z 249.4 for C13H15NO4 requires 249.1  
 
K. General procedure for preparation of compounds 4.21a-f 
Sodium azide (34.0 mmol, 5.0 eq) was added to a mixture of the epoxide 4.20 (6.79 mmol, 
1.0 eq) and NH4Cl (20.4 mmol, 3.0 eq) in 6 mL MeOH-H2O (8:1). The resulting mixture was 
stirred at 25°C for 16 hours. The product mixture was diluted with deionized water and 
extracted with EtOAc. The combined organic extracted was washed with 10% aqueous 
NaHCO3, H2O and brine and dried over anhydrous Na2SO4. Concentration of the organic 
layer under reduced pressure afforded the azide. 
 
1-(3-Azido-2-hydroxypropoyl)-5-chloro-3,3-dimethoxyindolin-2-one, 4.21a  
 
The conditions employed for the preparation of this compound is 
the same as the conditions described in General Procedure K; the 
epoxide 4.20a gave 4.21a as a colourless oil (2.06 g, 93%). Rf 
(MeOH:DCM 1:99) 0.12; IRνmax(film)/cm
-1
 3457 (OH), 2105 (N3), 
1613 (C=O); δH (400MHz, CDCl3) 7.38 (1H, d, J 2.0, H-4), 7.34 (1H, dd, J 2.4 and 8.0, H-6), 
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(3H, s, OMe), 3.45 (1H, dd, J 4.4 and 12.4, H-1’a/b), 3.36 (1H, dd, J 6.4 and 12.8, H-1’a/b), 
2.84 (1H, br. s, OH); δC (100MHz, CDCl3) 171.5, 141.3, 130.6, 128.6, 126.4, 125.3, 110.8, 
96.5, 70.0, 54.4, 50.9 (x2), 43.7; LRMS(EI) found m/z 326.5 (42%, M
+
) for C13H15ClN4O4 
requires 326.1  
 
1-(3-Azido-2-hydroxypropoyl)-5-bromo-3,3-dimethoxyindolin-2-one, 4.21b  
 
The conditions employed for the preparation of this compound is the 
same as the conditions described in General Procedure K. However, 
5.99 mmol of the epoxide 4.20b, 29.9 mmol of NaN3 and 18.0 mmol 
of NH4Cl were used, which gave 4.21b as a colourless oil (1.02g, 
50%). Rf (MeOH:DCM 1:99) 0.18; IRνmax(thin film)/cm
-1
 3457 (OH), 2105 (N3), 1610 
(C=O); δH (400MHz, CDCl3) 7.53 (1H, d, J 2.0, H-4), 7.50 (1H, dd, J 2.0 and 8.4, H-6), 6.91 
(1H, d, J 8.4, H-7), 4.08 (1H, m, H-2’), 3.76 (2H, m, H-3’), 3.56 (3H, s, OMe), 3.55 (3H, s, 
OMe), 3.46 (1H, dd, J 4.4 and 12.8, H-1’a/b), 3.37 (1H, dd, J 6.4 and 12.8, H-1’a/b), 2.79 
(1H, br. s, OH); δC (100MHz, CDCl3) 166.1, 136.5, 128.2, 122.7, 121.5, 110.5, 106.0, 91.2, 
63.7, 49.1, 45.6, 45.5, 38.3; LRMS(EI) found m/z 370.5 (10%, M
+
) for C13H15BrN4O4 
requires 370.0 
 
1-(3-Azido-2-hydroxypropoyl)-5-fluoro-3,3-dimethoxyindolin-2-one, 4.21c   
The conditions employed for the preparation of this compound is 
the same as the conditions described in General Procedure K. 
However, 5.26 mmol of the epoxide 4.20c, 26.3 mmol of NaN3 and 
15.8 mmol of NH4Cl were used, which gave 4.21c as a colourless 
oil (1.02 g, 50%). Rf (MeOH:DCM 1:99) 0.24; IRνmax(thin 
film)/cm
-1
 3456 (OH), 2106 (N3), 1622 (C=O); δH (400MHz, CDCl3) 7.16 (1H, dd, J 2.0 and 
7.6, H-4), 7.08 (1H, ddd, J 2.4, 8.4 and 8.8, H-6), 6.96 (1H, dd, J 4.0 and 8.8, H-7), 4.09 (1H, 
m, H-2’), 3.77 (2H, m, H-3’), 3.56 (3H, s, OMe), 3.55 (3H, s, OMe), 3.46 (1H, dd, J 4.4 and 
12.8, H-1’a/b), 3.37 (1H, dd, J 6.0 and 12.4, H-1’a/b), 2.82 (1H, br. s, OH); δC (100MHz, 
CDCl3) 166.5, 155.0, 133.3, 121.0, 111.6, 107.7, 105.2, 91.3, 63.7, 49.1,45.5(x2), 38.4; 
LRMS(EI) found m/z  310.6 (19%, M
+
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1-(3-Azido-2-hydroxypropoyl)-5-iodo-3,3-dimethoxyindolin-2-one, 4.21d   
 
The conditions employed for the preparation of this compound is the 
same as the conditions described in General Procedure K. However, 
3.67 mmol of the epoxide 4.20d, 18.3 mmol of NaN3 and 11.0 mmol 
of NH4Cl were used, which gave 4.21d as a colourless oil (1.17 g, 
88%). Rf (MeOH:DCM 1:99) 0.19; IRνmax(film)/cm
-1
 3454 (OH), 2104 (N3), 1607 (C=O); δH 
(400MHz, CDCl3) 7.70 (1H, d, J 2.0, H-4), 7.69 (1H, dd, J 1.8 and 8.0, H-6), 6.81 (1H, d, J 
8.4, H-7), 4.07 (1H, m, H-2’), 3.74 (2H, m, H-3’), 3.55 (3H, s, OMe), 3.54 (3H, s, OMe), 
3.46 (1H, dd, J 4.8 and 12.8, H-1’a/b), 3.36 (1H, dd, J 6.4 and 12.8, H-1’a/b), 2.65 (1H, br. s, 
OH); δC (100MHz, CDCl3) 171.2, 142.5, 139.5, 133.6, 127.1, 111.8, 96.4, 85.6, 69.0, 54.4, 
50.8, 50.9, 43.6; LRMS(EI) found m/z 418.4 (9%, M
+
) for C13H15IN4O4 requires 418.0  
 
1-(3-Azido-2-hydroxypropyl)-3,3-dimethoxy-5-methylindolin-2-one, 4.21e   
The conditions employed for the preparation of this compound is 
the same as the conditions described in General Procedure K. 
However, 7.46 mmol of the epoxide 4.20e, 37.3 mmol of NaN3 and 
22.4 mmol of NH4Cl were used, which gave 4.21e as a colourless 
oil (1.90 g, 90%). Rf (MeOH:DCM 1:99) 0.15; IRνmax(film)/cm
-1
 
3454 (OH), 2104 (N3), 1622 (C=O); δH (400 MHz, CDCl3) 7.24 (1H, d, J 2.0, H-4), 7.16 
(1H, dd, J 2.0 and 8.0, H-6), 6.88 (1H, d, J 8.0, H-7), 4.09 (1H, m, H-2’), 3.76 (2H, m, H-3’), 
3.56 (3H, s, OMe), 3.55 (3H, s, OMe), 3.45 (1H, dd, J 4.4 and 12.8, H-1’a/b), 3.41 (1H, dd, J 
5.6 and 12.8, H-1’a/b), 2.81 (1H, br. s OH), 2.36 (3H, s, H-8); δC (100 MHz, CDCl3) 166.8, 
134.9, 127.5, 125.7, 120.4, 119.6, 104.0, 91.7, 63.8, 49.1, 45.6, 45.5, 38.4, 15.7; LRMS(EI) 
found m/z 305.9 (55%, M
+
) for C14H18N4O4 requires 306.1 
 
1-(3-Azido-2-hydroxypropyl)-3,3-dimethoxyindolin-2-one, 4.21f  
 
The conditions employed for the preparation of this compound is the 
same as the conditions described in General Procedure K. However, 
7.46 mmol of the epoxide 4.20f, 37.3 mmol of NaN3 and 22.4 mmol of 
NH4Cl were used, which gave 4.21f as a colourless oil (1.84 g, 92%). Rf 
(MeOH:DCM 1:99) 0.14; IRνmax(thin film)/cm
-1
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(400MHz, CDCl3) 7.42 (1H, d, J 0.8 and 7.6, H-4), 7.38 (1H, td, J 1.2 and 8.0, H-6), 7.12 
(1H, td, J 0.8 and 7.6, H-5), 7.00 (1H, d, J 8.0, H-7), 4.10 (1H, m, H-2’), 3.79 (2H, m, H-3’), 
3.57 (3H, s, OMe), 3.56 (3H, s, OMe), 3.45 (1H, dd, J 4.4 and 12.0, H-1’a/b), 3.39 (1H, dd, J 
6.4 and 12.8, H-1’a/b); 2.78 (1H, br. s, OH); δC (100MHz, CDCl3) 166.8, 137.3, 125.5, 
119.7, 119.6, 117.7, 104.2, 91.5, 63.8, 49.1, 45.5(x2), 38.3; LRMS(EI) found m/z 292.6 
(19%, M
+
) for C13H16N4O4 requires 292.1  
 
L. General procedure for preparation of compounds 4.22a-f 
A solution of the azide 4.21 (500 mg, 1.53 mmol) in 9 ml acetone was treated with 1 mL of 
concentrated HCl. The resulting solution was stirred for 3 hours at 25°C. The product 
mixture was then neutralized with 2M Na2CO3. Extraction with EtOAc afforded the organic 
layer which was washed with water, brine and dried over anhydrous Na2SO4. Removal of the 
solvent under reduced pressure afforded a crude residue which was recrystallized from 
methanol. 
 
1-(3-Azido-2-hydroxypropyl)-5-chloroindoline-2,3-dione, 4.22a  
 
The conditions employed for the preparation and purification of this 
compound is the same as the conditions described in General 
Procedure L; the azide 4.21a gave 4.22a as a red crystalline solid 
(429 mg, 97%). m. p. 86°C; Rf (MeOH:DCM 1:39) 0.44; 
IRνmax(KBr)/cm
-1
 3470 (OH), 2100 (N3), 1744 (C3=O), 1608 (C2=O); δH (400MHz, CDCl3) 
7.55 (1H, dd, J 2.4 and 8.4, H-6), 7.51 (1H, d, J 2.4, H-4), 7.09 (1H, d, J 8.4, H-7), 4.14 (1H, 
m, H-2’), 3.80 (2H, m, H-1’), 3.53 (1H, J 4.4 and 12.8, H-3’a/b), 3.41 (1H, dd, J 6.0 and 
12.4, H-3’a/b), 2.80 (1H, br. s, OH); δC (100MHz, CDCl3) 182.0, 158.6, 149.5, 137.8, 129.8, 
125.7, 118.3, 112.6, 68.8, 54.4, 44.0; LRMS(EI) found m/z 279.8 (41%, M
+
) for 
C11H9ClN4O3 requires 280.0  
 
1-(3-Azido-2-hydroxypropyl)-5-bromoindoline-2,3-dione, 4.22b  
 
The conditions employed for the preparation and purification of 
this compound is the same as the conditions described in General 
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used, which gave 4.22b as a red crystalline solid (773.0 mg, 86%). m. p. 85°C; Rf 
(EtOAc:Hex 2:3) 0.42; IRνmax(KBr)/cm
-1
 3453 (OH), 2104 (N3), 1734 (C3=O), 1617 (C2=O); 
δH (300MHz, CDCl3) 7.70 (1H, dd, J 2.1 and 8.4, H-6), 7.66 (1H, d, J 2.1, H-4), 7.02 (1H, d, 
J 8.4, H-7), 4.13 (1H, m, H-2’), 3.79 (2H, m, H-3’), 3.53 (1H, dd, J 4.2 and 12.6, H-1’a/b), 
3.40 (1H, dd, J 6.0 and 12.3, H-1’a/b), 2.98 (1H, br. s, OH); δC (75MHz, CDCl3) 181.8, 
158.4, 150.0, 140.7, 128.0, 118.7, 116.8, 113.0, 68.8, 54.4, 44.0; LRMS(EI) found m/z 323.8 
(31%, M
+
) for C11H9BrN4O3 requires 324.0  
 
1-(3-Azido-2-hydroxypropyl)-5-fluoroindoline-2,3-dione, 4.22c   
 
The conditions employed for the preparation and purification of 
this compound is the same as the conditions described in General 
Procedure L. However, 4.30 mmol (1.33 g) of the azide 4.21c was 
used, which gave 4.22c as an orange crystalline solid (1.11 g, 
98%). m. p. 104°C, Rf (EtOAc:Hex 2:3) 0.30; IRνmax(KBr)/cm
-1
) 3444 (OH), 2090 (N3), 
1730 (C3=O), 1612 (C2=O); δH (400MHz, CDCl3) 7.28-7.35 (2H, m, H-4, H-6), 7.10 (1H, dd, 
J 3.6 and 8.8, H-7), 4.15 (1H, m, H-2’), 3.82 (2H, m, H-3’), 3.54 (1H, dd, J 4.4 and 12.8, H-
1’a/b), 3.42 (1H, dd, J 6.4 and 12.8, H-1’a/b), 3.07 (1H, br. s, OH); δC (100MHz, CDCl3) 
182.4, 160.7, 158.6, 147.4, 124.8, 118.2, 112.6, 112.3, 68.9, 54.5, 44.1; LRMS(EI) found m/z 
263.7 (45%, M
+
) for C11H9FN4O3 requires 264.1  
 
1-(3-Azido-2-hydroxypropyl)-5-iodoindoline-2,3-dione, 4.22d   
 
The conditions employed for the preparation and purification of this 
compound is the same as the conditions described in General 
Procedure L. However, 2.81 mmol (1.17 g) of the azide 4.21d was 
used, which gave 4.22d as a red crystalline solid (974.5 mg, 93%). 
m. p. 92-93°C; Rf (EtOAc:Hex 2:3) 0.46; IRνmax(KBr)/cm
-1
 3460 (OH), 2091 (N3), 1740 
(C3=O), 1619 (C2=O); δH (400MHz, CDCl3) 7.91 (1H, dd, J 2.0 and 8.4, H-6), 7.88 (1H, d, J 
1.6, H-4), 6.93 (1H, d, J 8.4, H-7), 4.14 (1H, m, H-2’), 3.82 (2H, m, H-3’), 3.56 (1H, dd, J 
4.4 and 12.4, H-1’a/b), 3.42 (1H, dd, J 6.0 and 12.8, H-1’a/b), 2.64 (1H, br. s, OH); δC 
(100MHz, CDCl3) 181.5, 158.1, 150.6, 146.5, 133.8, 119.1, 113.4, 86.3, 69.0, 54.5, 43.9; 
LRMS(EI) found m/z 371.8 (45%, M
+





































The conditions employed for the preparation and purification of this 
compound is the same as the conditions described in General 
Procedure L. However, 6.19 mmol (1.90 g) of the azide 4.21e was 
used, which gave 4.22e as a red crystalline solid (1.45 g, 90%). m. 
p. 97ºC; Rf (EtOAc:Hex 2:3) 0.28; IRνmax(KBr)/cm
-1
 3473 (OH), 2094 (N3), 1736 (C3=O), 
1619 (C2=O); δH (300MHz, CDCl3) 7.40-7.37 (2H, m, H-4, H-6), 6.96 (1H, d, J 8.7, H-7), 
4.14 (1H, m, H-2’), 3.78 (2H, m, H-3’), 3.51 (1H, dd, J 4.2 and 12.9, H-1’a/b), 3.40 (1H, dd, 
J 6.3 and 12.6, H-1’a/b), 3.05 (1H, br. s, OH), 2.31 (3H, s, H-8); δC (75MHz, CDCl3) 183.1, 
159.3, 149.0, 138.9, 134.0, 125.7, 117.7, 110.8, 68.9, 54.5, 44.0, 20.6; LRMS(EI) found m/z 
260.6 (11%, M
+
) for C12H12N4O3 requires 260.1  
 
1-(3-Azido-2-hydroxypropyl)indoline-2,3-dione, 4.22f  
 
The conditions employed for the preparation and purification of this 
compound is the same as the conditions described in General Procedure 
L. However, 6.29 mmol (1.84 g) of the azide 4.21f was used, which 
gave 4.22f as a red needles (1.72 g, quant). m. p. 96-97ºC; Rf 
(EtOAc:Hex 2:3) 0.29; IRνmax(KBr)/cm
-1
 3453 (OH), 2093 (N3), 1734 (C3=O), 1610 (C2=O); 
δH (400MHz, CDCl3) 7.63-7.59 (2H, m, H-4, H-6), 7.14 (1H, td, J 0.8 and 7.6, H-5), 7.09 
(1H, d, J 8.8, H-7), 4.16 (1H, m, H-2’), 3.83 (2H, m, H-3’), 3.54 (1H, dd, J 4.4 and 12.4, H-
1’a/b), 3.43 (1H, dd, J 6.4 and 12.8, H-1’a/b), 3.15 (1H, br. s, OH); δC (100MHz, CDCl3) 
182.8, 159.2, 151.2, 138.5, 125.4, 124.1, 117.7, 111.0, 68.3, 54.5, 44.0; LRMS(EI) found m/z 
246.6 (3%, M
+
) for C11H10N4O3 requires 246.1  
 
M. General procedure for preparation of compounds 4.23 a-i and 4.24 a-i  
The azide 4.22a (0.356 mmol, 1.0 eq) and the appropriate acetylene 4.10a-i, 4.13a-i (0.392 
mmol, 1.1 eq) was dissolved in 3 mL of CH2Cl2:H2O (1:1). Copper(II) sulphate pentahydrate 
(0.0178 mmol, 5 mol%) and sodium ascorbate (0.0534 mmol, 15 mol%) was added and the 
resulting mixture stirred for 3 hours at 25°C. The precipitated product was filtered and 
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(E)-5-chloro-1-(2-hydroxy-3-(4-((2-(3-(4-methoxyphenyl)-3-oxoprop-1-
enyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)propyl)indoline-2,3-dione, 4.23a (EXP60A) 
 
Orange amorphous solid (118.4 mg, 
58%); m. p. 178-180°C; Rf 
(MeOH:DCM 1:39) 0.13; 
IRνmax(KBr)/cm
-1
 3470 (OH), 1753 
(C3=O), 1662 (αβ-unsat C=O), 1607 
(C2=O); δH (400MHz, DMSO-d6) 
8.24 (1H, s, H-8’), 8.02 (2H, d, J 8.8, 
H-2B, H-6B), 7.90 (3H, m, Hα, Hβ, 
H-6A), 7.68 (1H, dd, J 2.0 and 8.4, H-6), 7.59 (1H, d, J 2.0, H-4), 7.44 (1H, m, H-4A), 7.33 
(1H, br. d, J 8.0, H-3A), 7.23 (1H, d, J 8.4, H-7), 7.06-7.02 (3H, m, H-5A, H-3B, H-5B), 
5.51 (1H, d, J 5.2, OH), 5.29 (2H, s, H-9’), 4.64 (1H, dd, J 3.2 and 13.6, H-3’a/b), 4.45 (1H, 
dd, J 8.8 and 13.6, H-3’a/b), 4.24 (1H, m, H-2’), 3.84 (3H, s, OMe), 3.76 (2H, m, H-1’); δC 
(100MHz, DMSO-d6) 188.1, 182.9, 163.8, 159.0, 158.0, 150.4, 142.8, 138.7, 137.5, 132.6, 
131.4(x2), 131.2, 130.2, 128.0, 126.2, 124.4, 124.1, 122.9, 121.8, 119.7, 114.7(x2), 113.8, 
113.6, 67.5, 62.3, 56.2, 53.7, 44.7; HRMS(ESI) found m/z 573.1542 [M+H]
+
 for 
C30H25ClN4O6 requires 572.14626; Anal Calc. for C30H25ClN4O6: C, 62.88%; H, 4.40%; N, 
9.78%. Found: C, 62.74%; H, 4.48%; N, 9.62%. 
 
(E)-5-chloro-1-(3-(4-((2-(3-(2,4-dimethoxyphenyl)-3-oxoprop-1-enyl)phenoxy) methyl)-
1H-1,2,3-triazol-1-yl)-2-hydroxypropyl)indoline-2,3-dione, 4.23b (EXP60B) 
Orange amorphous solid (130.2 mg, 
61%); m. p. 189°C; Rf (MeOH:DCM 
1:39)  0.15; IRνmax(KBr)/cm
-1
 3429 
(OH), 1748 (C3=O), 1658 (αβ-unsat 
C=O), 1607 (C2=O); δH (400MHz, 
DMSO-d6) 8.18 (1H, s, H-8’), 7.76 
(1H, d, J 15.6, Hβ), 7.71-7.67 (2H, 
m, H-6, H-6A), 7.59 (1H, d, J 2.0, H-
4), 7.54 (1H, d, J 8.4, H-6B), 7.52 (1H, d, J 15.6, Hα), 7.41 (1H, m, H-4A), 7.31 (1H, br. d, J 
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6.59 (1H, dd, J 2.0 and 8.8, H-5B), 5.51 (1H, d, J 5.2, OH), 5.27 (2H, s, H-9’), 4.61 (1H, dd, 
J 3.2 and 13.6, H-3’a/b), 4.42 (1H, dd, J 8.4 and 13.6, H-3’a/b), 4.22 (1H, m, H-2’), 3.83 
(6H, s, 2xOMe), 3.74 (2H, m, H-1’); δC (100MHz, DMSO-d6) 190.1, 183.0, 164.6, 160.8, 
159.0, 157.6, 150.4, 142.8, 137.5, 136.7, 132.7, 132.3, 129.1(x2), 128.0, 126.2, 124.4, 124.3, 
122.2, 121.9, 119.7, 113.8, 113.6, 106.7, 99.3, 67.4, 62.3, 56.6, 56.3, 53.7, 44.7; HRMS(ESI) 
found m/z 603.1639 [M+H]
+
 for C31H27ClN4O7 requires 602.15683; Anal Calc. for 
C31H27ClN4O7: C, 61.74%; H, 4.51%; N, 9.29%. Found: C, 61.63%; H, 4.85%; N, 8.99%. 
 
(E)-5-chloro-1-(2-hydroxy-3-(4-((2-(3-oxo-3-(2,3,4-trimethoxyphenyl)prop-1-
enyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)propyl)indoline-2,3-dione, 4.23c (EXP60C) 
 
Orange amorphous solid (143.6 mg, 




(OH), 1744 (C3=O), 1649 (αβ-unsat 
C=O), 1608 (C2=O); δH (300MHz, 
CDCl3) 7.93 (1H, s, H-8’), 7.84 (1H, 
d, J 15.9, Hβ), 7.57 (1H, dd, J 1.5 
and 7.8, H-6), 7.45-7.39 (3H, m Hα, H-4, H-6B), 7.34 (1H, m, H-4A), 7.28 (1H, d, J 8.7, H-
6A), 7.06-6.96 (3H, m, H-3A, H-5A, H-7), 6.70 (1H, d, J 9.0, H-5B), 5.17 (2H, s, H-9’), 4.37 
– 4.74 (3H, m, H-2’, H-3’), 3.89 (3H, s, OMe), 3.85 (3H, s, OMe), 3.80 (3H, s, OMe), 3.79 
(2H, m, H-1’); δC (75MHz, CDCl3) 191.7, 182.0, 158.6, 157.3, 156.9, 153.5, 149.6, 143.6, 
141.8, 138.7, 137.7, 131.8, 130.6, 129.5, 128.9, 127.0, 126.5, 125.8, 124.8, 124.3, 121.6, 
118.5, 113.0, 112.9, 107.4, 68.6, 62.8, 62.2, 61.1, 56.1, 53.8, 44.4; HRMS(EI) found m/z 
633.04956 for C32H29ClN4O8 requires 633.04766; Anal Calc. for C32H29ClN4O8: C, 60.71%; 
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(E)-5-chloro-1-(2-hydroxy-3-(4-((3-(3-(4-methoxyphenyl)-3-oxoprop-1-enyl) 
phenoxy)methyl)-1H-1,2,3-triazol-1-yl)propyl)indoline-2,3-dione, 4.23d (EXP10/08) 
 
Orange amorphous solid (142.9 mg, 
70%); m. p. 149-150°C; Rf 
(MeOH:DCM 1:39) 0.12; 
IRνmax(KBr)/cm
-1
 3367 (OH), 1747 
(C3=O), 1659 (αβ-unsat C=O), 1608 
(C2=O); δH (400MHz, DMSO-d6) 8.12-
8.15 (3H, m, H-2B, H-6B, H-8’), 7.87 
(1H, d, J 15.6, Hβ), 7.68-7.62 (2H, m, Hα, H-6), 7.56 (2H, m, H-2A, H-4), 7.41-7.33 (2H, m, 
H-5A, H-6A), 7.22 (1H, d, J 8.4, H-7), 7.10 (1H, m, H-4A), 7.06 (2H, d, J 8.8, H-3B, H-5B), 
5.44 (1H, br. s, OH), 5.23 (2H, s, H-9’), 4.59 (1H, dd, J 3.6 and 13.6, H-3’a/b), 4.42 (1H, dd, 
J 8.0 and 13.6, H-3’a/b), 4.24 (1H, m, H-2’), 3.86 (3H, s, OMe), 3.74 (2H, m, H-1’); δC 
(100MHz, DMSO-d6) 187.3, 182.2, 163.2, 158.4, 158.2, 149.7, 142.9, 142.2, 136.7, 136.2, 
130.9(x2), 130.4, 129.9, 127.2, 125.4, 123.6, 122.3, 121.9, 118.9, 117.1, 115.0, 114.0(x2), 
112.9, 66.7, 61.2, 55.5, 45.9, 43.9; HRMS(EI) found m/z 572.14574 for C30H25ClN4O6 
requires 572.14626; Anal Calc. for C30H25ClN4O6: C, 62.88%; H, 4.40%; N, 9.78%. Found: 
C, 62.84%; H, 4.38%; N, 9.70%. 
 
(E)-5-chloro-1-(3-(4-((3-(3-(2,4-dimethoxyphenyl)-3-oxoprop-1-enyl)phenoxy) methyl)-
1H-1,2,3-triazo-1-yl)-2-hydroxypropyl)indoline-2,3-dione, 4.23e (EXP9/08) 
 
Orange amorphous solid (115.9 mg, 
54%); m.p. 76°C; Rf (MeOH:DCM 1:39) 
0.22; IRνmax(KBr)/cm
-1
 3400 (OH), 1744 
(C3=O), 1651 (αβ-unsat C=O), 1608 
(amide C2=O); δH(400MHz, DMSO-d6) 
8.15 (1H, s, H-8’), 7.68 (1H, dd, J 2.1 and 
8.4, H-6), 7.61-7.48 (3H, m, Hβ, H-6B, 
H-4), 7.26-7.38 (4H, m, Hα, H-2A, H-5A, 
H-6A), 7.23 (1H, d, J 8.4, H-7), 7.08 (1H, ddd, J 2.4, 2.7 and 7.8, H-4A), 6.72 (1H, d, J 2.7, 
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(1H, dd, J 3.6 and 13.8, H-3’a/b), 4.13 (1H, dd, J 8.4 and 13.8, H-3’a/b), 4.24 (1H, m, H-2’), 
3.90 (3H, s, OMe), 3.85 (3H, s, OMe), 3.75 (2H, m, H-1’); δC (100MHz, DMSO-d6) 189.2, 
182.0, 163.8, 160.1, 158.3, 158.0, 149.6, 142.2, 140.8, 136.6, 136.2, 131.7, 129.8, 127.4, 
127.2, 125.1, 123.4, 121.3, 120.9, 118.7, 116.7, 113.9, 112.8, 105.9, 98.6, 66.6, 61.1, 55.8, 
55.4, 52.8, 43.9; HRMS(EI) found m/z 602.15624 for C31H27ClN4O7 requires 602.15683; 
Anal Calc. for C31H27ClN4O7: C, 61.74%; H, 4.51%; N, 9.29%. Found: C, 61.72%; H, 
4.55%; N, 8.96%. 
 
(E)-5-chloro-1-(2-hydroxy-3-(4-((3-(3-oxo-3-(2,3,4-trimethoxyphenyl)prop-1-
enyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)propyl)indoline-2,3-dione, 4.23f (EXP7/08) 
 
Orange amorphous solid (117.2 mg, 
52%); m.p. 127-128°C; Rf 
(MeOH:DCM 1:39) 0.17; 
IRνmax(KBr)/cm
-1
 3487 (OH), 1749 
(C3=O), 1654 (αβ-unsat C=O), 1603 
(amide C2=O); δH (300MHz, CDCl3) 
7.85 (1H, s, H-8’), 7.54 (1H, d, J 
15.6, Hβ), 7.48-7.36 (4H, m, H-6B, 
H-4, H-6, Hα), 7.27 (1H, t, J 7.8, H-5A), 7.20-7.13 (2H, m, H-2A, H-6A), 7.05 (1H, d, J 8.7, 
H-7), 6.95 (1H, m, H-4A), 6.73 (1H, d, J 8.7, H-5B), 5.13 (2H, s, H-9’), 4.58 (1H, m, H-
3’a/b), 4.50 (1H, m, H-2’), 4.40 (1H, dd, J 6.9, 13.2, H-3’a/b), 3.91 (3H, s, OMe), 3.89 (3H, 
s, OMe), 3.88 (3H, s, OMe), 3.75-3.94 (2H, m, H-1’), 2.75 (1H, br. s, OH); δC (75MHz, 
CDCl3) 190.9, 181.9, 158.7, 158.4, 157.2, 153.8, 149.5, 142.6, 137.8, 136.5, 130.0, 129.7, 
127.0, 126.5, 125.8, 124.9, 121.5, 118.4, 116.8, 114.5, 112.9, 107.4, 68.5, 62.1, 61.8, 61.0, 
56.1, 53.9, 44.4; HRMS(EI) found m/z 632.16686 for C32H29ClN4O8 requires 632.16739; 
Anal Calc. for C32H29ClN4O8: C, 60.71%; H, 4.62%; N, 8.85%. Found: C, 60.76%; H, 




























































Orange amorphous solid (142.4 mg, 70%); m. p. 
202-205°C; Rf (MeOH:DCM 1:39) 0.10; 
IRνmax(KBr)/cm
-1
 3488 (OH), 1750 (C3=O), 1657 
(αβ-unsat C=O), 1602 (C2=O); δH (300MHz, 
DMSO-d6) 8.17 (1H, s, H-8’), 8.12 (2H, d, J 8.1, 
H-2B, H-6B), 7.83-7.58 (6H, m, Hα, Hβ, H-4, H-6, 
H-2A, H-6A), 7.24 (1H, d, J 8.1, H-7), 7.12 (2H, d, 
J 8.4, H-3B, H-5B), 7.07 (2H, d, J 8.4, H-3A, H-
5A), 5.44 (1H, br. s, OH), 5.24 (2H, s, H-9’), 4.60 
(1H, br. d, J 13.0, H-3’a/b), 4.44 (1H, dd, J 7.8 and 
13.8, H-3’a/b), 4.25 (1H, m, H-2’), 3.87 (3H, s, 
OMe), 3.77 (2H, m, H-1’); δC (75MHz, DMSO-d6) 187.2, 182.1, 162.9, 159.8, 158.1, 149.6, 
142.7, 142.0, 136.7, 130.5(x2), 130.4(x2), 127.6, 127.2, 125.2, 123.5, 120.0, 119.7, 118.8, 
115.0(x2), 113.8(x2), 112.8, 66.6, 61.2, 55.4, 52.9, 43.8; HRMS(ESI) found m/z 573.1550 
[M+H]
+
 for C30H25ClN4O6 requires 572.14626; Anal Calc. for C30H25ClN4O6: C, 62.88%; H, 
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(E)-5-chloro-1-(3-(4-((4-(3-(2,4-dimethoxyphenyl)-3-oxoprop-1-enyl)phenoxy) methyl)-
1H-1,2,3-triazol-1-yl)-2-hydroxypropyl)indoline-2,3-dione, 4.23h (EXP59B) 
 
Orange amorphous solid (102.6 mg, 48%); m. p. 
126-128°C; Rf (MeOH:DCM 1:39) 0.13; 
IRνmax(KBr)/cm
-1
 3488 (OH), 1750 (C3=O), 
1649 (αβ-unsat C=O), 1610 (C2=O); δH 
(300MHz, DMSO-d6) 8.17 (1H, s, H-8’), 7.56-
7.71 (5H, m, H-4, H-6, H-2A, H-6A, H-6B), 
7.50 (1H, d, J 15.6, Hβ), 7.38 (1H, d, J 15.6, 
Hα), 7.24 (1H, d, J 8.4, H-7), 7.10 (2H, d, J 8.7, 
H-3A, H-5A), 6.67 (1H, d, J 2.0, H-3B), 6.63 
(1H, dd, J 2.1 and 8.7, H-5B), 5.46 (1H, d, J 4.8, 
OH), 5.22 (2H, s, H-9’), 4.60 (1H, dd, J 3.3 and 
13.5, H-3’a/b), 4.42 (1H, dd, J 7.8 and 13.5, H-3’a/b), 4.24 (1H, m, H-2’), 3.89 (3H, s, OMe), 
3.85 (3H, s, OMe), 3.76 (2H, m, H-1’); δC (75MHz, DMSO-d6) 189.2, 182.1, 163.6, 159.9, 
159.7, 158.1, 149.6, 142.0, 141.0, 136.6, 131.6, 129.8(x2), 127.6, 127.2, 125.2, 124.9, 123.5, 
121.6, 118.8, 115.1(x2), 112.8, 105.8, 98.6, 66.6, 61.2, 55.8, 55.4, 52.8, 43.9; HRMS(ESI) 
found m/z 603.1675 [M+H]
+
 for C31H27ClN4O7 requires 602.15683; Anal Calc. for 






























































Orange amorphous solid (134.6 mg, 
60%); m. p. 143-145°C; Rf 
(MeOH:DCM 1:39) 0.10; 
IRνmax(KBr)/cm
-1
 3487 (OH), 1749 
(C3=O), 1655 (αβ-unsat C=O), 1608 
(C2=O); δH (300MHz, DMSO-d6) 8.16 
(1H, s, H-8’), 7.69-7.58 (4H, m, H-4, H-
6, H-2A, H-6A), 7.50 (1H, d, J 16.2, 
Hβ), 7.34-7.22 (3H, m, H-6B, H-7, Hα), 
7.10 (2H, d, J 8.4, H-3A, H-5A), 6.91 
(1H, d, J 8.7, H-5B), 5.47 (1H, d, J 4.8, 
OH), 5.22 (2H, s, H-9’), 4.59 (1H, br. d, J 13.2, H-3’a/b), 4.40 (1H, dd, J 8.4 and 13.2, H-
3’a/b), 4.23 (1H, m, H-2’), 3.87 (3H, s, OMe), 3.83 (3H, s, OMe), 3.79 (3H, s, OMe), 3.76 
(2H, m, H-1’); δC (75MHz, DMSO-d6) 190.0 182.1, 159.9, 158.2., 156.3, 152.5, 149.6, 
142.4, 142.3, 142.0, 136.7, 130.0(x2), 127.4, 127.2, 126.4, 125.3, 124.7, 124.4, 123.5, 118.8, 
115.2(x2), 112.8, 107.8, 66.6, 61.5, 61.2, 60.3, 56.0, 53.0, 43.9; HRMS(ESI) found m/z 
633.1747 [M+H]
+
 for C32H29ClN4O8 requires 632.16739; Anal Calc. for C32H29ClN4O8: C, 
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(E)-5-chloro-1-(2-hydroxy-3-(4-((2-(3-(4-methoxyphenyl)acryloyl)phenoxy) methyl)-1H-
1,2,3-triazol-1-yl)propyl)indoline-2,3-dione, 4.24a (EXP54A) 
 
Orange amorphous solid (171.0 
mg, 84%); m. p. 93-94°C; Rf 
(MeOH:DCM 1:39) 0.24; 
IRνmax(KBr)/cm
-1
 3435 (OH), 
1744 (C3=O), 1650 (αβ-unsat 
C=O), 1598 (C2=O); δH (300MHz, 
CDCl3)) 7.62 (1H, s, H-8’), 7.48 
(1H, dd, J 1.5 and 7.2, H-6), 7.47-
7.35 (5H, m, Hβ, H-4, H-2A, H-6A, H-6B), 7.12-6.95 (5H, m, Hα, H-3B, H-4B, H-5B, H-7), 
6.80 (2H, d, J 8.7, H-3A, H-5A), 5.14 (2H, s, H-9’), 4.36 (1H, dd, J 3.0 and 13.5, H-3’a/b), 
4.27 (1H, m, H-2’), 4.16 (1H, dd, J 7.2 and 13.2, H-3’a/b), 3.77 (3H, s, OMe), 3.54-3.72 (2H, 
m, H-1’); δC (100MHz, CDCl3) 193.2, 182.0, 161.6, 158.6, 156.4, 149.6, 143.6, 143.4, 137.7, 
132.9, 130.2(x3), 129.6, 127.4, 126.2, 124.9, 124.8, 122.8, 121.8, 118.5, 114.4(x2), 113.8, 
112.9, 68.5, 63.1, 55.4, 53.8, 44.2; HRMS(ESI) found m/z 573.1561 [M+H]
+
 for 
C30H25ClN4O6 requires 572.14626; Anal Calc. for C30H25ClN4O6: C, 62.88%; H, 4.40%; N, 
9.78%. Found: C, 62.55%; H, 4.12%; N, 9.66%. 
 
(E)-5-chloro-1-(3-(4-((2-(3-(2,4-dimethoxyphenyl)acryloyl)phenoxy)methyl)-1H-1,2,3-
triazol-1-yl)-2-hydroxypropyl)indoline-2,3-dione, 4.24b (EXP54B) 
 
 
Orange amorphous solid (116.3 
mg, 54%); m. p. 97-98°C; Rf 
(MeOH:DCM 1:39) 0.13; 
IRνmax(KBr)/cm
-1
 3423 (OH), 
1744 (C3=O), 1646 (αβ-unsat 
C=O), 1598 (C2=O); δH (300MHz, 
CDCl3) 7.70 (1H, d, J 15.6, Hβ), 
7.64 (1H, s, H-8’), 7.48-7.40 (4H, m, H-4, H-6, H-4B, H-6B), 7.32 (1H, d, J 8.4, H-6A), 7.16 
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6.31 (1H, d, J 1.8, H-3A), 5.12 (2H, s, H-9’), 4.37 (1H, dd, J 2.4 and 13.2, H-3’a/b), 4.26 
(1H, m, H-2’), 4.17 (1H, dd, J 7.2 and 13.2, H-3’a/b), 3.75 (3H, s, OMe), 3.72 (3H, s, OMe), 
3.56 (2H, m, H-1’); δC (100MHz, CDCl3) 193.8, 182.0, 163.1, 160.2, 158.5, 156.3, 149.6, 
143.5, 139.2, 137.7, 132.6, 130.5, 130.3, 130.2, 129.5, 125.0, 124.8, 124.7, 121.7, 118.4, 
116.7, 113.7, 113.0, 105.6, 98.4, 68.5, 63.1, 55.5(x2), 53.8, 44.2; HRMS(ESI) found m/z 
603.1644 [M+H]
+
 for C31H27ClN4O7 requires 602.15683; Anal Calc. for C31H27ClN4O7: C, 
61.74%; H, 4.51%; N, 9.29%. Found: C, 61.63%; H, 4.55%; N, 8.90%. 
 
(E)-5-chloro-1-(2-hydroxy-3-(4-((2-(3-(2,3,4-trimethoxyphenyl)acryloyl)phenoxy) 
methyl)-1H-1,2,3-triazol-1-yl)propyl)indoline-2,3-dione, 4.24c (EXP54C) 
 
Orange amorphous solid (187.8 
mg, 83%); m. p. 96°C; Rf 
(MeOH:DCM 1:39) 0.12; 
IRνmax(KBr)/cm
-1
 3428 (OH), 
1744 (C3=O), 1649 (αβ-unsat 
C=O), 1608 (C2=O); δH (300MHz, 
CDCl3) 7.65 (1H, d, J 15.9, Hβ), 
7.64 (1H, s, H-8’), 7.49 (1H, dd, J 
1.5 and 7.8, H-6), 7.46 (1H, d, J 1.8, H-4), 7.44-7.40 (2H, m, H-4B, H-6B), 7.19 (1H, d, J 
9.3, H-6A), 7.18 (1H, d, J 16.2, Hα), 6.97-7.09 (3H, m, H-7, H-3B, H-5B), 6.64 (1H, d, J 8.7, 
H-5A), 5.14 (2H, s, H-9’), 4.41 (1H, dd, J 3.0 and 13.5, H-3’a/b), 4.30 (1H, m, H-2’), 4.19 
(1H, dd, J 7.2 and 13.5, H-3’a/b), 3.85 (3H, s, OMe), 3.81 (3H, s, OMe), 3.79 (3H, s, OMe), 
3.62-3.83 (2H, m, H-1’); δC (100MHz, CDCl3) 193.7, 182.0, 158.6, 156.4, 155.8, 153.4, 
149.6, 143.4, 142.3, 139.1, 137.7, 132.8, 130.4, 130.2, 129.6, 126.2, 124.8(x2), 123.7, 121.8, 
121.7, 118.5, 114.0, 112.9, 107.8, 68.6, 63.2, 61.6, 60.9, 56.1, 53.9, 44.3; HRMS(EI) found 
m/z 633.04645 for C32H29ClN4O8 requires 633.04766; Anal Calc. for C32H29ClN4O8: C, 
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(E)-5-chloro-1-(2-hydroxy-3-(4-((3-(3-(4-methoxyphenyl)acryloyl)phenoxy) methyl)-1H-
1,2,3-triazol-1-yl)propyl)indoline-2,3-dione, 4.24d (EXP13/08) 
 
Orange amorphous solid (122.4 mg, 




(OH), 1752 (C3=O), 1661 (αβ-unsat 
C=O), 1611 (amide C2=O); δH 
(400MHz, DMSO-d6) 8.18 (1H, s, H-
8’), 7.84 (2H, d, J 8.6, H-2A, H-6A), 
7.76 (1H, d, J 15.6, Hβ), 7.72-7.68 (4H, 
m, Hα, H-2B, H-6B, H-6), 7.59 (1H, d, J 2.0, H-4), 7.47 (1H, t, J 8.0, H-5B), 7.31 (1H, m, H-
4B), 7.24 (1H, d, J 8.4, H-7), 7.00 (2H, d, J 8.8, H-3A, H-5A), 5.49 (1H, d, J 4.6, OH), 5.25 
(2H, s, H-9’), 4.60 (1H, dd, J 3.2 and 13.6, H-3’a/b), 4.42 (1H, dd, J 8.0 and 13.6, H-3’a/b), 
4.22 (1H, m, H-2’), 3.81 (3H, s, OMe), 3.74 (2H, m, H-1’); δC (100MHz, DMSO-d6) 188.6, 
182.2, 161.3, 158.2 (x2), 149.7, 144.0, 139.3, 136.7, 136.2, 130.8(x2), 129.8, 127.2, 125.4, 
123.6, 121.0, 119.5, 119.4, 118.9, 114.3(x2), 114.1, 112.9, 110.3, 66.7, 61.3, 55.3, 52.9, 43.9; 
HRMS(EI) found m/z 572.14569 for C30H25ClN4O6 requires 572.14626; Anal Calc. for 
C30H25ClN4O6: C, 62.88%; H, 4.40%; N, 9.78%. Found: C, 62.79%; H, 4.38%; N, 9.50%. 
 
(E)-5-chloro-1-(3-(4-((3-(3-(2,4-dimethoxyphenyl)acryloyl)phenoxy)methyl)-1H-1,2,3-
triazol-1-yl)-2-hydroxypropyl)indoline-2,3-dione, 4.24e (EXP12/08) 
 
Orange amorphous solid (109.5 mg, 




(OH), 1752 (C3=O), 1660 (αβ-unsat 
C=O), 1611 (amide C2=O); 
δH(400MHz, DMSO-d6) 8.18 (1H, s, 
H-8’), 7.97 (1H, d J 15.6, Hβ), 7.91 
(1H, d, J 8.8, H-6A), 7.72-7.66 (4H, m, 
Hα, H-2B, H-6B, H-6), 7.59 (1H, d, J 2.0, H-4), 7.46 (1H, t, J 8.0, H-5B), 7.30 (1H, m, H-
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(2H, s, H-9’), 4.60 (1H, dd, J 2.8 and 13.6, H-3’a/b), 4.41 (1H, dd, J 8.4 and 13.8, H-3’a/b), 
4.21 (1H, m, H-2’), 3.83 (3H, s, OMe), 3.88 (3H, s, OMe), 3.74 (2H, m, H-1’); δC (100MHz, 
CDCl3) 188.7, 182.2, 163.1, 159.9, 158.3, 149.7, 142.2, 139.5, 138.8, 136.7, 130.0, 129.8, 
127.2, 125.4, 123.6, 120.9, 119.3, 119.0, 118.9, 115.8, 113.9, 112.9, 106.3, 98.2, 94.9, 66.7, 
61.3, 55.8, 55.5, 52.9, 43.9; HRMS(EI) found m/z 602.15624 for C31H27ClN4O7 requires 
602.15683; Anal Calc. for C31H27ClN4O7: C, 61.74%; H, 4.51%; N, 9.29%. Found: C, 
61.73%; H, 4.55%; N, 9.26%. 
 
(E)-5-chloro-1-(2-hydroxy-3-(4-((3-(3-(2,3,4-trimethoxyphenyl)acryloyl) 
phenoxy)methyl)-1H-1,2,3-triazol-1-yl)propyl)indoline-2,3-dione, 4.24f (EXP11/08) 
 
Orange amorphous solid (121.8 mg, 
54%); m. p. 149-150°C; Rf 
(MeOH:DCM 1:39) 0.14, 
IRνmax(KBr)/cm
-1
 3478 (OH), 1751 
(C3=O), 1660 (αβ-unsat C=O), 1611 
(amide C2=O); δH (400MHz, DMSO-
d6) 8.18 (1H, s, H-8’), 7.90 (1H, d, J 
16.0, Hβ), 7.77 (1H, d, J 9.2, H-6A), 
7.76 (1H, d, J 16.0, Hα ), 7.70-7.68 ( 3H, m, H-6, H-2B, H-6B), 7.59 (1H, d, J 2.0, H-4), 7.48 
(1H, t, J 8.0, H-5B), 7.32 (1H, ddd, J 2.0, 2.4 and 8.0, H-4B), 7.24 (1H, d, J 8.4, H-7), 6.90 
(1H, d, J 8.8, H-5A), 5.49 (1H, d, J 4.8, OH), 5.25 (2H, s, H-9’), 4.60 (1H, dd, J 3.2 and 13.6, 
H-3’a/b), 4.41 (1H, dd, J 6.9, 13.2, H-3’a/b), 4.21 (1H, m, H-2’), 3.86 (3H, s, OMe), 3.85 
(3H, s, OMe), 3.76 (3H, s, OMe), 3.75 (2H, m, H-1’); δC (100MHz, DMSO-d6) 188.8, 182.2, 
158.3, 158.2, 155.8, 153.0, 149.7, 142.1, 141.80, 139.3, 138.5, 136.7, 129.8, 127.2, 125.4, 
123.6, 123.4, 121.0, 120.9, 120.4, 119.4, 118.9, 114.0, 112.9, 108.4, 66.7, 61.4, 61.3, 60.4, 
56.0, 52.9, 43.9; HRMS(EI) found m/z 632.16686 for C32H29ClN4O8 requires 632.16739; 
Anal Calc. for C32H29ClN4O8: C, 60.71%; H, 4.62%; N, 8.85%. Found: C, 60.64%; H, 
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(E)-5-chloro-1-(2-hydroxy-3-(4-((4-(3-(4-methoxyphenyl)acryloyl)phenoxy) methyl)-1H-
1,2,3-triazol-1-yl)propyl)indoline-2,3-dione, 4.24g (EXP53A) 
 
Orange amorphous solid (104.6 mg, 65%); m. p. 
199-202°C; Rf (MeOH:DCM 1:39) 0.10; 
IRνmax(KBr)/cm
-1
 3489 (OH), 1750 (C3=O), 1658 
(αβ-unsat C=O), 1601 (C2=O); δH (300MHz, 
DMSO-d6) 8.19 (1H, s, H-8’), 8.12 (2H, d, J 9.0, H-
2B, H-6B), 7.82-7.59 (6H, m, Hα, Hβ, H-4, H-6, H-
2A, H-6A), 7.24 (1H, d, J 8.1, H-7), 7.28 (2H, d, J 
8.7, H-3A, H-5A), 7.01 (2H, d, J 8.4, H-3B, H-5B), 
5.48 (1H, br. s, OH), 5.29 (2H, s, H-9’), 4.61 (1H, 
dd, J 2.1 and 13.2, H-3’a/b), 4.43 (1H, dd, J 8.4 and 
13.8, H-3’a/b), 4.24 (1H, m, H-2’), 3.82 (3H, s, 
OMe), 3.76 (2H, m, H-1’); δC (100MHz, DMSO-d6) 188.0, 183.0, 162.5, 161.9, 159.0, 150.4, 
143.8, 142.6, 137.5, 131.6, 131.4(x2), 131.3(x2), 128.2, 128.0, 126.3, 124.4, 120.2, 119.7, 
115.4(x2), 115.1(x2), 113.6, 67.4, 62.1, 56.1, 53.7, 44.7; HRMS(ESI) found m/z 573.1558 
[M+H]
+
 for C30H25ClN4O6 requires 572.14626; Anal Calc. for C30H25ClN4O6: C, 62.88%; H, 
4.40%; N, 9.78%. Found: C, 62.28%; H, 4.36%; N, 9.59%. 
 
(E)-5-chloro-1-(3-(4-((4-(3-(2,4-dimethoxyphenyl)acryloyl)phenoxy)methyl)-1H-1,2,3-
triazol-1-yl)-2-hydroxypropyl)indoline-2,3-dione, 4.24h (EXP53B) 
 
Orange amorphous solid (171.9 mg, 80%); m. 
p. 185-187°C; Rf (MeOH:DCM 1:39) 0.11; 
IRνmax(KBr)/cm
-1
 3488 (OH), 1750 (C3=O), 
1655 (αβ-unsat C=O), 1611 (C2=O); δH 
(300MHz, DMSO-d6) 8.18 (1H, s, H-8’), 8.07 
(2H, d, J 8.7, H-2B, H-6B), 7.94 (1H, d, J 15.6, 
Hβ), 7.85 (1H, d, J 8.4, H-6A), 7.70 (1H, d, J 
15.6, Hα), 7.68 (1H, dd, J 1.8 and 8.7, H-6), 
7.58 (1H, d, J 2.1, H-4), 7.23 (1H, d, J 8.7, H-
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(2H, m, H-3A, H-5A), 5.49 (1H, br. s, OH), 5.28 (2H, s, H-9’), 4.60 (1H, dd, J 3.3 and 14.1, 
H-3’a/b), 4.42 (1H, dd, J 8.4 and 14.1, H-3’a/b), 4.24 (1H, m, H-2’), 3.90 (3H, s, OMe), 3.84 
(3H, s, OMe), 3.75 (2H, m, H-1’); δC (75MHz, DMSO-d6) 187.1, 181.8, 162.5, 161.2, 159.4, 
157.8, 149.3, 141.5, 137.6, 137.4, 130.7, 130.0(x2), 129.6, 126.9, 125.0, 123.2, 118.8, 118.5, 
115.7, 114.3(x2), 112.5, 105.9, 97.9, 66.3, 61.0, 55.4, 55.1, 52.6, 43.6; HRMS(ESI) found 
m/z 603.1626 [M+H]
+
 for C31H27ClN4O7 requires 602.15683; Anal Calc. for C31H27ClN4O7: 
C, 61.74%; H, 4.51%; N, 9.29%. Found: C, 61.37%; H, 4.22%; N, 8.90.%. 
 
(E)-5-chloro-1-(2-hydroxy-3-(4-((4-(3-(2,3,4-trimethoxyphenyl)acryloyl)phenoxy) 
methyl)-1H-1,2,3-triazol-1-yl)propyl)indoline-2,3-dione, 4.24i (EXP53C) 
 
Orange amorphous solid (203 mg, 90%); 
m. p. 155-157°C; Rf (MeOH:DCM 1:39) 
0.10; IRνmax(KBr)/cm
-1
 3487 (OH), 1749 
(C3=O), 1652 (αβ-unsat C=O), 1603 
(C2=O); δH (300MHz, DMSO-d6) 8.18 
(1H, s, H-8’), 8.09 (2H, d, J 9.3, H-2B, 
H-6B), 7.86 (1H, d, J 16.0, Hβ), 7.74 
(1H, d, J 15.6, Hα), 7.72-7.67 (2H, m, H-
6, H-6A), 7.58 (1H, d, J 2.7, H-4), 7.23 
(1H, d, J 8.7, H-7), 7.19 (2H, d, J 8.7, H-
3B, H-5B), 6.90 (1H, d, J 8.7, H-5A), 
5.48 (1H, d, J 4.8, OH), 5.28 (2H, s, H-9’), 4.60 (1H, dd, J 3.3 and 13.5, H-3’a/b), 4.42 (1H, 
dd, J 8.4 and 13.5, H-3’a/b), 4.23 (1H, m, H-2’), 3.87 (3H, s, OMe), 3.86 (3H, s, OMe), 3.78 
(3H, s, OMe), 3.75 (2H, m, H-1’); δC (75MHz, DMSO-d6) 186.8, 181.5, 161.1, 157.5, 154.8, 
152.2, 149.0, 141.2(x2), 137.0, 136.1, 130.3, 129.9(x2), 126.6, 124.8, 122.9, 122.6, 120.4, 
119.9, 118.2, 114.0(x2), 112.2, 107.8, 66.0, 60.7(x2), 59.7, 55.4, 52.3, 43.3; HRMS(ESI) 
found m/z 633.1751 [M+H]
+
 for C32H29ClN4O8 requires 632.16739; Anal Calc. for 
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Compound 5.4 (EXP39) 
 
Boron trifluoride diethyl etherate complex (5 drops) was added 
slowly to a solution of dihydroartemisinin 1.15 (1.00 g, 3.54 
mmol, 1 eq) and propargyl alcohol (794 mg, 14.2 mmol, 4 eq) in 
10 mL of dry DCM at 0ºC under a nitrogen atmosphere. The 
resulting mixture was allowed to warm to 25ºC and stirred at this 
temperature for 10 hours. The product mixture, after dilution with DCM, was washed 
successively with 5% aqueous NaHCO3, water and brine. The organic layer was dried over 
anhydrous Na2SO4 and concentrated. Purification of the crude product using column 
chromatography (0-20% EtOAc:Hex) afforded the β-isomer as colourless needles (867.4 mg, 
76%); m. p. 116°C; Rf (EtOAc:Hex 1:4) 0.67; IRνmax(KBr)/cm
-1
 2113 (C≡C); δH (300MHz, 
CDCl3) 5.39 (1H, s, H-12), 4.95 (1H, d, J 3.3, H-10), 4.29 (2H, d, J 2.4, H-1’), 2.65 (1H, m, 
H-9), 2.40-2.30 (2H, m, H-3’ and a proton of the 
§
DHA nucleus), 2.05-1.17 (10H, m, protons 
of the DHA nucleus), 1.42 (3H, s, H-14), 0.93 (3H, d, J 6.0, H-16), 0.91 (3H, d, J 7.2, H-15); 
δC (75MHz, CDCl3) 104.1, 100.6, 88.0, 81.0, 79.7, 73.9, 54.9, 52.5, 44.3, 37.4, 36.4, 34.6, 
30.6, 26.1, 24.7, 24.4, 20.3, 12.7; HRMS(ESI) found m/z 323.1207 [M+H]
+
 for C18H26O5 
requires 322.17802; Anal Calc. for C18H26O5: C, 67.06%; H, 8.13%. Found: C, 66.70%; H, 
8.10%. 
 
M. General procedure for preparation of compounds 5.5a-f 
The azide 4.22 (0.356 mmol, 1.0 eq) and acetylene 5.4 (0.392 mmol, 1.1 eq) was dissolved in 
3 mL of CH2Cl2:H2O (1:1). Copper (II) sulphate pentahydrate (0.0178 mmol, 5 mol%) and 
sodium ascorbate (0.0534 mmol, 15 mol%) was added and the resulting mixture stirred for 6 
hours at 25°C. The product mixture was diluted with water and extracted with EtOAc. The 
combined organic layer was washed with water and brine, dried over anhydrous Na2SO4 and 
concentrated. The crude product mixture was then subjected to column chromatography (0.5-
10% MeOH/DCM).  
                                               
§
 Apart from H-9, H-10, H-12 and the methyl protons H-14, H-15 and H-16, assignment of the remaining 11 
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Compound 5.5a (EXP57AA) 
 
The conditions employed for the preparation and purification 
of this compound is the same as the conditions described in 
General Procedure M; the azide 4.22a was used, which gave 
5.5a as an orange foam (112 mg, 52%). m. p. 99-101°C; Rf 
(EtOAc:Hex 3:2) 0.13; IRνmax(KBr)/cm
-1
 3463 (OH), 1747 
(C3’=O), 1611 (C2’=O), 1475 (Ar C=C); δH (400MHz, 
DMSO-d6) 8.05 (1H, s, H-8”), 7.74 (1H, dd, J 2.0 and 8.4, H-
6’), 7.64 (1H, d, J 2.0, H-4’), 7.29 (1H, d, J 8.4, H-7’), 5.50 
(1H, d, J 4.4, OH), 5.44 (1H, d, J 5.6, H-12), 4.85 (1H, br. s, 
**
H-10), 4.79 (1H, d, J 12.4, H-9”a/b), 4.61 (1H, dd, J 3.2 and 14.0, H-3”a/b), 4.56 (1H, d, J 
12.8, H-9”a/b), 4.43 (1H, dd, J 8.4 and 14.0, H-3”a/b), 4.25 (1H, m, H-2”), 3.77 (2H, m, H-
1”), 2.45 (1H, m, H-9), 2.29-1.14 (11H, m, protons of the DHA nucleus), 1.34 (3H, s, H-14), 
0.91 (3H, br. d, J 6.0, H-16), 0.82 (3H, d, J 7.2, H-15); δC (100MHz, DMSO-d6) 183.0, 
159.0, 150.5, 144.3, 137.5, 128.0, 125.2, 124.4, 119.6, 113.7, 104.0, 100.6, 87.7, 81.2, 67.5, 
61.1, 53.6, 52.8, 44.7, 44.5, 37.3, 36.7, 34.8, 31.0, 26.3, 24.9, 24.7, 20.8, 13.4; HRMS(ESI) 
found m/z 603.2201 [M+H]
+
 for C29H35ClN4O8 requires 602.21434; Anal Calc. for 
C29H35ClN4O8: C, 57.76%; H, 5.85%; N, 9.29%. Found: C, 57.56%; H, 5.70%; N, 8.93%; 
 
Compound 5.5b (EXP57BA) 
 
The conditions employed for the preparation and purification 
of this compound is the same as the conditions described in 
General Procedure M. However, 0.380 mmol of the azide 
4.22c was used, which gave 5.5b as an orange foam (69.1 mg, 
31%). m. p. 101-103°C; Rf (EtOAc:Hex 3:2) 0.11; 
IRνmax(KBr)/cm
-1
 3464 (OH), 1743 (C3’=O), 1623 (C2’=O), 
1487 (Ar C=C); δH (400MHz, DMSO-d6) 8.06 (1H, s, H-8”), 
7.57 (1H, ddd, J 2.4, 8.8 and 9.2, H-6’), 7.49 (1H, dd, J 2.4 
and 6.8, H-4’), 7.28 (1H, dd, J 4.0 and 8.4, H-7’), 5.51 (1H, d, 
J 4.8, OH), 5.44 (1H, d, J 6.0, H-12), 4.85 (1H, br. s, H-10), 4.79 (1H, d, J 12.4, H-9”a/b), 
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4.61 (1H, dd, J 3.6 and 14.0, H-3”a/b), 4.56 (1H, d, J 12.4, H-9”a/b), 4.43 (1H, dd, J 8.0 and 
14.0, H-3”a/b), 4.26 (1H, m, H-2”), 3.77 (2H, m, H-1”), 2.45 (1H, m, H-9), 2.25-1.14 (11H, 
m, protons of the DHA nucleus), 1.33 (3H, s, H-14), 0.91 (3H, dd, J 2.0 and 6.0, H-16), 0.82 
(3H, d, J 7.2, H-15); δC (100MHz, DMSO-d6) 184.2, 160.3, 148.2, 144.3, 129.4, 125.3, 
124.4, 113.4, 111.7, 104.1, 100.6, 87.7, 81.2, 67.4, 61.1, 55.6, 53.6, 52.8, 44.6, 44.5, 37.3, 
36.7, 34.8, 31.0, 26.3, 24.9, 24.7, 20.8, 13.4; HRMS(ESI) found m/z 587.2512 [M+H]
+
 for 
C29H35FN4O8 requires 586.24389; Anal Calc. for C29H35FN4O8: C, 59.38%; H, 6.01%; N, 
9.55%. Found: C, 59.10%; H, 6.00%; N, 9.10%; 
 
Compound 5.5c (EXP57CC) 
 
The conditions employed for the preparation and purification 
of this compound is the same as the conditions described in 
General Procedure M. However, 0.404 mmol of the azide 
4.22f was used, which gave 5.5c as an orange foam (110.3 
mg, 48%); m. p. 92°C; Rf (EtOAc:Hex 3:2) 0.10; 
IRνmax(KBr)/cm
-1
 3463 (OH), 1741 (C3’=O), 1612 (C2’=O), 
1472 (Ar C=C); δH (400MHz, DMSO-d6) 8.02 (1H, s, H-8”), 
7.65 (1H, br. t, J 7.5, H-6’), 7.55 (1H, br. d, J 6.9, H-4’), 7.19 
(1H, d, J 7.8, H-7’), 7.13 (1H, br. t, J 7.2, H-5’), 5.39-5.45 
(2H, m, H-12 and OH), 4.82 (1H, br. s, H-10), 4.76 (1H, d, J 12.3, H-9”a/b), 4.52-4.60 (2H, 
m, H-3”a/b, H-9”a/b), 4.41 (1H, dd, J 7.8 and 13.5, H-3”a/b), 4.25 (1H, m, H-2”), 3.73 (2H, 
m, H-1”), 2.43 (1H, m, H-9), 2.24-1.09 (11H, m, protons of the DHA nucleus), 1.30 (3H, s, 
H-14), 0.88 (3H, d, J 4.8, H-16), 0.79 (3H, d, J 7.2, H-15); δC (100MHz, DMSO-d6) 183.2, 
158.3, 151.1, 143.5, 137.8, 124.3, 124.0, 122.9, 117.5, 111.0, 103.2, 99.9, 86.9, 80.3, 66.6, 
60.3, 52.8, 52.0, 43.8, 43.7, 36.5, 35.9, 33.9, 30.2, 25.4, 24.1, 23.8, 19.9, 12.4; HRMS(ESI) 
found m/z 569.2589 [M+H]
+
 for C29H36N4O8 requires 568.25331; Anal Calc. for 
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Compound 5.5d (EXP57D) 
 
The conditions employed for the preparation and purification 
of this compound is the same as the conditions described in 
General Procedure M. However, 0.387 mmol of the azide 
4.22e was used, which gave 5.5d as an orange foam (101.4 
mg, 45%). m. p. 103-105°C; Rf (EtOAc:Hex 3:2) 0.12; 
IRνmax(KBr)/cm
-1
 3464 (OH), 1736 (C3’=O), 1622 (C2’=O), 
1492 (Ar C=C); δH (400MHz, DMSO-d6) 8.06 (1H, s, H-8”), 
7.51 (1H, br. d, J 8.4, H-6’), 7.41 (1H, br s, H-4’), 7.13 (1H, 
d, J 8.0, H-7’), 5.51 (1H, d, J 7.2, OH), 5.44 (1H, d, J 3.6, H-
12), 4.85 (1H, br. s, H-10), 4.79 (1H, d, J 12.4, H-9”a/b), 4.61 (dd, J 3.6 and 14.0, H-3”a/b), 
4.56 (1H, d, J 12.8, H-9”a/b), 4.43 (1H, dd, J 8.4 and 14.0, H-3”a/b), 4.25 (1H, m, H-2”), 
3.74 (2H, d, J 6.0, H-1”), 2.45 (1H, m, H-9), 2.32 (3H, s, H-8’), 2.25-1.16 (11H, m, protons 
of the DHA nucleus), 1.33 (3H, s, H-14), 0.91 (3H, dd, J 2.8 and 6.0, H-16), 0.82 (3H, d, J 
7.2, H-15); δC (100MHz, DMSO-d6) 184.3, 159.3, 149.8, 144.3, 138.9, 133.1, 125.3, 125.1, 
118.3, 111.7, 104.1, 100.6, 87.7, 81.2, 67.4, 61.1, 53.7, 52.8, 44.6, 44.5, 37.3, 36.7, 34.8, 
31.1, 26.3, 24.9, 24.7, 20.8, 20.7, 13.4; HRMS(ESI) found m/z 583.2747 [M+H]
+
 for 
C30H38N4O8 requires 582.26896; Anal Calc. for C30H38N4O8: C, 61.84%; H, 6.57%; N, 
9.62%. Found: C, 61.67%; H, 6.56%; N, 9.32%; 
 
Compound 5.5e (EXP57E) 
 
The conditions employed for the preparation and purification 
of this compound is the same as the conditions described in 
General Procedure M. However, 0.308 mmol of the azide 
4.22d was used, which gave 5.5e as an orange foam (138.3 
mg, 42%). m. p. 112-115°C; Rf (EtOAc:Hex 3:2) 0.13; 
IRνmax(KBr)/cm
-1
 3458 (OH), 1743 (C3’=O), 1605 (C2’=O), 
1470 (Ar C=C); δH (400MHz, DMSO-d6) 8.05 (1H, s, H-8”), 
8.01 (1H, dd, J 1.6 and 8.4, H-6’), 7.85 (1H, d, J 1.6, H-4’), 
7.11 (1H, d, J 8.8, H-7’), 5.50 (1H, d, J 3.2, OH), 5.44 (1H, d, 
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H-3”a/b), 4.56 (1H, d, J 12.4, H-9”a/b), 4.42 (1H, dd, J 8.0 and 14.0, H-3”a/b), 4.24 (1H, m, 
H-2”), 3.75 (2H, d, J 6.8, H-1”), 2.45 (1H, m, H-9), 2.25-1.17 (11H, m, protons of the DHA 
nucleus), 1.34 (3H, s, H-14), 0.91 (3H, dd, J 2.0 and 6.4, H-16), 0.82 (3H, d, J 7.2, H-15); δC 
(100MHz, DMSO-d6) 182.5, 158.5, 151.3, 146.1, 144.3, 132.6, 125.3, 120.4, 114.4, 104.0, 
100.6, 87.7, 86.5, 81.2, 67.4, 61.1, 60.4, 53.6, 52.8, 44.5, 37.3, 36.7, 34.8, 31.0, 26.3, 24.9, 
24.7, 20.8, 13.4; HRMS(ESI) found m/z 695.1567 [M+H]
+
 for C29H35IN4O8 requires 
694.14996; Anal Calc. for C29H35IN4O8: C, 50.15%; H, 5.08%; N, 8.07%. Found: C, 50.11%; 
H, 5.01%; N, 7.90%; 
 
Compound 5.5f (EXP57FB) 
 
The conditions employed for the preparation and purification 
of this compound is the same as the conditions described in 
General Procedure M. However, 0.474 mmol of the azide 
4.22b was used, which gave 5.5f as an orange foam (103.8 
mg, 52%); m. p. 104°C; Rf (EtOAc:Hex 3:2) 0.16; 
IRνmax(KBr)/cm
-1
 3464 (OH), 1744 (C3’=O), 1609 (C2’=O), 
1472 (Ar C=C); δH (400MHz, DMSO-d6) 8.06 (1H, s, H-8”), 
7.87 (1H, dd, J 2.0 and 8.8, H-6’), 7.74 (1H, d, J 2.0, H-4’), 
7.24 (1H, d, J 8.8, H-7’), 5.50 (1H, d, J 3.6, OH), 5.44 (1H, d, 
J 5.6, H-12), 4.85 (1H, br. s, H-10), 4.79 (1H, d, J 12.4, H-9”a/b), 4.61 (1H, dd, J 3.2 and 
13.6, H-3”a/b), 4.55 (1H, d, J 12.0, H-9” a/b), 4.43 (1H, dd, J 8.0 and 13.6, H-3”a/b), 4.24 
(1H, m, H-2”), 3.76 (2H, d, J 6.8, H-1”), 2.45 (1H, m, H-9), 2.25-1.14 (11H, m, protons of 
the DHA nucleus), 1.34 (3H, s, H-14), 0.91 (3H, d, J 6.4, H-16), 0.82 (3H, d, J 6.8, H-15); δC 
(100MHz, DMSO-d6) 182.8, 158.8, 150.8, 144.3, 140.3, 127.1, 125.3, 120.1, 115.5, 114.1, 
104.1, 100.6, 87.7, 81.2, 67.4, 61.1, 53.6, 52.8, 44.6, 44.5, 37.3, 36.7, 34.8, 31.0, 26.3, 24.9, 
24.7, 20.8, 13.4; HRMS(ESI) found m/z 5647.1719 [M+H]
+
 for C29H35BrN4O8 requires 
646.16383; Anal Calc. for C29H35BrN4O8: C, 53.79%; H, 5.45%; N, 8.65%. Found: C, 
53.40%; H, 5.35%; N, 8.28%; 
 
N. General procedure for preparation of compounds 5.6a-c 
Anhydrous K2CO3 (44.0 mmol, 2.0 eq) was added to hydroxyacetophenone (22.0 mmol, 1.0 
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was added and the resulting mixture stirred for 48 hours at 25°C. The product mixture was 
extracted with DCM and the combined organic layer washed several times with water to 
remove DMF before being dried over anhydrous Na2SO4. Concentration of the organic layer 
in vacuo afforded a residue which was purified using column chromatography (0-30% 
EtOAc:Hex). 
 
1-(4-(2-bromoethoxy)phenyl)ethanone, 5.6a  
 
Colourless crystalline solid (3.90g, 73%); m. p. 58°C; Rf (EtOAc:Hex 
1:4) 0.32; δH (400MHz, CDCl3) 7.95 (2H, d, J 8.8, H-2 and H-6), 6.95 
(2H, d, J 9.2, H-3 and H-5), 4.36 (2H, t, J 6.0, H-1’), 3.66 (2H, t, J 6.4, 
H-2’), 2.56 (3H, s, H-8); δC (100MHz, CDCl3) 196.6, 161.9, 131.0, 
130.6(x2), 114.3(x2), 67.9, 28.5, 26.3 
 
1-(4-(3-bromopropoxy)phenyl)ethanone, 5.6b  
 
Colourless liquid (3.84g, 68%); Rf (EtOAc:Hex 1:4) 0.43; δH (400MHz, 
CDCl3) 7.92 (2H, d, J 9.2, H-2 and H-6), 6.94 (2H, d, J 8.4, H-3 and H-5), 
4.18 (2H, t, J 6.0, H-1’), 3.59 (2H, t, J 6.4, H-3’), 2.54 (3H, s, H-8), 2.34 
(2H, quint, J 6.4, H-2’); δC (100MHz, CDCl3) 196.6, 162.6, 130.6(x2), 
130.6, 114.2(x2), 65.6, 32.2, 29.6, 26.3 
 
1-(4-(4-bromobutoxy)phenyl)ethanone, 5.6c 
Colourless liquid (3.89g, 65%); Rf (EtOAc:Hex 1:4) 0.45; δH (400MHz, 
CDCl3) 7.90 (2H, d, J 8.4, H-2 and H-6), 6.90 (2H, d, J 8.4, H-3 and H-
5), 4.06 (2H, t, J 5.6, H-1’), 3.47 (2H, t, J 6.4, H-4’), 2.52 (3H, s, H-8), 
2.06 (2H, quint, J 6.8, H-2’), 1.96 (2H, quint, J 6.4, H-3’); δC (100MHz, 
CDCl3) 196.6, 162.8, 130.6(x2), 130.4, 114.1(x2), 67.1, 33.2, 29.4, 27.8, 
26.3 
 
O. General procedure for preparation of compounds 5.7a-c 
To the O-alkylated acetophenone 5.6 (2.06 mmol, 1.0 eq) in 5 mL MeOH was added 5 mL of 
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methanolic solution of the commercially available, 4-methoxybenzaldehyde (2.06 mmol, 1.0 
eq) was added drop-wise and the mixture stirred for another 8 hours. A precipitate formed 
which was filtered and washed with cold MeOH. Recrystallization from MeOH afforded the 
pure product.  
 
(E)-1-(4-(2-bromoethoxy)phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one, 5.7a  
 
The conditions employed for the preparation and 
purification of this compound is the same as the 
conditions described in General Procedure O. However 
5.6a was used which gave 5.7a as a white powder (563.2 
mg, 76%); m. p. 90°C; Rf (EtOAc:Hex 3:7) 0.21; δH (400MHz, CDCl3) 8.04 (2H, d, J 9.2, H-
2B, H-6B), 7.90 (1H, d, J 15.6, Hβ), 7.61 (2H, d, J 8.4, H-2A, H-6A), 7.42 (1H, d, J 15.6, 
Hα), 7.00 (2H, d, J 8.8, H-3B, H-5B), 6.95 (2H, d, J 8.8, H-3A, H-5A), 4.38 (2H, t, J 6.4, H-
1’), 3.87 (3H, s, OMe), 3.68 (2H, t, J 6.4, H-2’); δC (100MHz, CDCl3) 188.7, 161.7, 161.6, 
144.0, 132.1, 130.2(x2), 130.1(x2), 127.8, 119.6, 114.4(x4), 67.9, 55.4, 28.6 
 
(E)-1-(4-(3-bromopropoxy)phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one, 5.7b  
 
The conditions employed for the preparation and 
purification of this compound is the same as the 
conditions described in General Procedure O. However 
1.94 mmol each of 5.6b and 4-methoxybenzaldehyde 
were used which gave 5.7b as a light yellow powder 
(510.4 mg, 70%); m. p. 51-52ºC; Rf (EtOAc:Hex 3:7) 0.28; δH (300MHz, CDCl3) 8.03 (2H, 
d, J 9.0, H-2B, H-6B), 7.77 (1H, d, J 15.6, Hβ), 7.60 (2H, d, J 8.7, H-2A, H-6A), 7.42 (1H, d, 
J 15.6, Hα), 6.98 (2H, d, J 9.3, H-3B, H-5B), 6.93 (2H, d, J 8.7, H-3A, H-5A), 4.20 (2H, t, J 
6.0, H-1’), 3.86 (3H, s, OMe), 3.61 (2H, t, J 6.3, H-3’), 2.36 (2H, quint., J 6.3, H-2’); δC 
(75MHz, CDCl3) 188.7, 162.3, 161.6, 143.9, 131.6, 130.7(x2), 130.1(x2), 127.8, 119.6, 
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(E)-1-(4-(4-bromobutoxy)phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one, 5.7c  
 
The conditions employed for the preparation and 
purification of this compound is the same as the 
conditions described in General Procedure O. However 
1.84 mmol each of 5.6c and 4-methoxybenzaldehyde 
were used which gave 5.7c as a light yellow solid (852.6 
mg, quant); m. p. 91-92ºC; Rf (EtOAc:Hex 3:7) 0.29; δH (400MHz, CDCl3) 8.03 (2H, d, J 
8.8, H-2B, H-6B), 7.78 (1H, d, J 15.6, Hβ), 7.61 (2H, d, J 8.8, H-2A, H-6A), 7.43 (1H, d, J 
15.6, Hα), 6.93-6.98 (4H, m, H-3A, H-5A, H-3B, H-5B), 4.09 (2H, t, J 6.0, H-1’), 3.86 (3H, 
s, OMe), 3.51 (2H, t, J 6.4, H-4’), 2.09 (2H, quint., J 6.4, H-2’), 2.01 (2H, quint., J 5.6, H-
3’); δC (100MHz, CDCl3) 188.8, 162.6, 161.6, 143.8, 131.5, 130.7(x2), 130.1(x2), 127.9, 
119.6, 114.4(x2), 114.3(x2), 67.1, 55.4, 33.2, 29.4, 27.8 
 
P. General procedure for preparation of compounds 5.8a-c 
Sodium azide (2.78 mmol, 2.0 eq) was added to a solution of 5.11 (1.39 mmol, 1.0 eq) in 3 
mL of anhydrous DMF. The reaction mixture was stirred at 25ºC for 18 hours. The addition 
of ice-cold water to the product mixture resulted in the formation of a precipitate which was 
filtered and washed with copious amounts of water. Recrystallization from MeOH afforded 




The conditions employed for the preparation and 
purification of this compound is the same as the 
conditions described in General Procedure P. However 
5.7a was used which gave 5.8a as a light yellow solid 
(448.4 mg, quant); m. p. 97-98°C; Rf (EtOAc:Hex 3:7) 0.19; δH (400MHz, CDCl3) 8.04 (2H, 
d, J 9.2, H-2B, H-6B), 7.79 (1H, d, J 15.6, Hβ), 7.60 (2H, d, J 8.4, H-2A, H-6A), 7.42 (1H, d, 
J 15.6, Hα), 7.00 (2H, d, J 9.2, H-3B, H-5B), 6.94 (2H, d, J 8.8, H-3A, H-5A), 4.23 (2H, t, J 
5.2, H-1’), 3.86 (3H, s, OMe), 3.64 (2H, t, J 5.2, H-2’); δC (100MHz, CDCl3) 188.8, 161.8, 
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(E)-1-(4-(3-azidopropoxy)phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one, 5.8b  
 
The conditions employed for the preparation and 
purification of this compound is the same as the 
conditions described in General Procedure P. However 
1.33 mmol of 5.7b and 2.66 mmol of sodium azide were 
used which gave 5.8b as a light yellow solid (335.3 mg, 
74%); m. p. 56°C; Rf (EtOAc:Hex 3:7) 0.30; δH (400MHz, CDCl3) 8.04 (2H, d, J 9.2, H-2B 
and H-6B), 7.79 (1H, d, J 15.6, Hβ), 7.61 (2H, d, J 8.4, H-2A, H-6A), 7.43 (1H, d, J 15.6, 
Hα), 6.99 (2H, d, J 9.2, H-3B, H-5B), 6.95 (2H, d, J 8.8, H-3A, H-5A), 4.15 (2H, t, J 6.0, H-
1’), 3.87 (3H, s, OMe), 3.55 (2H, t, J 6.4, H-3’), 2.10 (2H, quint, J 6.0, H-2’); δC (100MHz, 
CDCl3) 188.8, 162.4, 161.6, 143.9, 131.6, 130.7(x2), 130.1(x2), 127.9, 119.6, 114.4(x2), 
114.3(x2), 64.8, 55.4, 48.2, 28.7 
 
(E)-1-(4-(4-azidobutoxy)phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one, 5.8c  
 
The conditions employed for the preparation and 
purification of this compound is the same as the 
conditions described in General Procedure P. However 
1.28 mmol of 5.7c and 2.57 mmol of sodium azide were 
used which gave 5.8c as an off-white solid (461.0 mg, 
quant); m. p. 61ºC; Rf (EtOAc:Hex 3:7) 0.45; δH 
(300MHz, CDCl3) 8.01 (2H, d, J 8.7, H-2B, H-6B), 7.77 (1H, d, J 15.6, Hβ), 7.59 (2H, d, J 
8.7, H-2A, H-6A), 7.41 (1H, d, J 15.6, Hα), 6.91-6.97 (4H, m, H-3A, H-5A, H-3B, H-5B), 
4.07 (2H, t, J 5.7, H-1’), 3.84 (3H, s, OMe), 3.37 (2H, t, J 6.3, H-4’), 1.89 (2H, quint, J 5.7, 
H-2’), 1.78 (2H, quint, J 6.3, H-3’); δC(75MHz, CDCl3) 188.7, 162.5, 161.5, 143.8, 131.4, 
130.7(x2), 130.1(x2), 127.8, 119.6, 114.4(x2), 114.2(x2), 67.4, 55.4, 51.1, 26.4, 25.7 
 
Q. General procedure for preparation of compounds 5.9a-c 
The azide 5.8 (0.464 mmol, 1.0 eq) and acetylene 5.4 (0.510 mmol, 1.1 eq) were dissolved in 
3 mL of CH2Cl2:H2O (1:1). Copper (II) sulphate pentahydrate (0.0232 mmol, 5 mol%) and 
sodium ascorbate (0.0696 mmol, 15 mol%) was added to the mixture. The resulting mixture 
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and extracted with EtOAc. The combined organic layer was washed with water and brine, 
dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product so 
obtained was subjected to column chromatography (0.5-10% MeOH:DCM).  
 
Compound 5.9a (EXP66A) 
 
The conditions employed for the preparation and 
purification of this compound is the same as the conditions 
described in General Procedure Q. However 5.8a was used 
which gave 5.9a as a light brown gel (113.6 mg, 38%); Rf 
(MeOH:DCM 1:39) 0.13; δH (300MHz, CDCl3) 7.99 (2H, 
d, J 8.7, H-2B, H-6B), 7.74 (1H, d, J 15.6, Hβ), 7.69 (1H, 
s, H-7’), 7.57 (2H, d, J 8.7, H-2A, H-6A), 7.37 (1H, d, J 
15.6, Hα), 6.92 (2H, d, J 8.7, H-3B, H-5B), 6.91 (2H, d, J 
9.0, H-3A, H-5A), 5.40 (1H, s, H-12), 4.93 (1H, d, J 12.9, 
H-8’a/b), 4.89 (1H, d, J 3.9, H-10), 4.78 (2H, t, J 5.4, H-1’), 4.66 (1H, d, J 12.6, H-8’a/b), 
4.43 (2H, t, J 5.7, H-2’), 3.83 (3H, s, OMe), 2.62 (1H, m, H-9), 2.39-1.12 (11H, m, protons 
of the DHA nucleus), 1.41 (3H, s, H-14), 0.90 (3H, d, J 6.3, H-16), 0.85 (3H, d, J 7.5, H-15); 
δC (100MHz, CDCl3) 188.6, 161.7, 161.3, 145.2, 144.2, 132.3, 130.8(x2), 130.2(x2), 127.7, 
123.5, 119.4, 114.4(x2), 114.2(x2), 104.1, 101.6, 88.0, 81.1, 66.6, 61.7, 55.4, 52.6, 49.5, 
44.4, 37.4, 36.4, 34.6, 30.8, 26.2, 24.7, 24.5, 20.3, 13.0; HRMS(ESI) found m/z 646.3151 
[M+H]
+
 for C36H43O8 requires 645.30502; Anal Calc. for C36H43O8: C, 66.96%; H, 6.71%; N, 
6.51%. Found: C, 66.99%; H, 6.71%; N, 6.44%; 
 
Compound 5.9b (EXP66B) 
 
The conditions employed for the preparation 
and purification of this compound is the 
same as the conditions described in General 
Procedure Q. However 0.445 mmol of 5.8b, 
0.489 mmol of 5.4, 0.0223 mmol of copper 
(II) sulphate pentahydrate and 0.0667 mmol 
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5.9b as a light yellow solid (186.1 mg, 65%); m. p. 145-146ºC; Rf (MeOH:DCM 1:39) 0.15; 
δH (300MHz, CDCl3) 8.00 (2H, d, J 9.0, H-2B, H-6B), 7.76 (1H, d, J 15.6, Hβ), 7.58 (2H, d, 
J 9.0, H-2A, H-6A), 7.50 (1H, s, H-8’), 7.39 (1H, d, J 15.6, Hα), 6.94 (2H, d, J 9.3, H-3B, H-
5B), 6.92 (2H, d, J 8.7, H-3A, H-5A), 5.37 (1H, s, H-12), 4.90 (1H, d, J 12.3, H-9’a/b), 4.88 
(1H, br. s, H-10), 4.66 (1H, d, J 12.6, H-9’a/b), 4.58 (2H, t, J 6.3, H-1’), 4.04 (2H, t, J 6.0, H-
3’), 3.83 (3H, s, OMe), 2.61 (1H, m, H-9), 2.47-2.28 (3H, m, H-2’ and a proton of the DHA 
nucleus), 2.08-1.12 (10H, m, protons of the DHA nucleus), 1.41 (3H, s, H-14), 0.89 (3H, d, J 
5.7, H-16), 0.83 (3H, d, J 7.5, H-15); δC (75MHz, CDCl3) 188.6, 162.0, 161.5, 145.2, 143.9, 
131.8, 130.7(x2), 130.1(x2), 127.7, 122.8, 119.4, 114.4(x2), 114.1(x2), 104.0, 101.7, 88.0, 
81.0, 64.3, 61.7, 55.3, 52.4, 46.8, 44.3, 37.3, 36.3, 34.5, 30.7, 29.7, 26.1, 24.6, 24.3, 20.2, 
12.9; HRMS(ESI) found m/z 660.3258 [M+H]
+
 for C37H45O8 requires 659.32067; Anal Calc. 
for C37H45O8: C, 67.36%; H, 6.87%; N, 6.37%. Found: C, 67.26%; H, 6.85%; N, 6.35%; 
 
Compound 5.9c (EXP66C) 
 
The conditions employed for the preparation and 
purification of this compound is the same as the conditions 
described in General Procedure Q. However 0.427 mmol of 
5.8c, 0.470 mmol of 5.4, 0.0235 mmol of copper (II) 
sulphate pentahydrate and 0.0704 mmol of sodium 
ascorbate were used which gave 5.9c as a light brown gel 
(161.4 mg, 55%); Rf (MeOH:DCM 1:39) 0.21; δH 
(300MHz, CDCl3) 8.00 (2H, d, J 9.3, H-2B, H-6B), 7.75 
(1H, d, J 15.6, Hβ), 7.58 (2H, d, J 8.4, H-2A, H-6A), 7.53 
(1H, s, H-9’), 7.40 (1H, d, J 15.6, Hα), 6.92 (2H, d, J 8.7, H-3B, H-5B), 6.91 (2H, d, J 8.7, 
H-3A, H-5A), 5.39 (1H, s, H-12), 4.91 (1H, d, J 12.0, H-10’a/b), 4.90 (1H, d, J 4.8, H-10), 
4.67 (1H, d, J 12.3, H-10’a/b), 4.44 (2H, t, J 7.2, H-1’), 4.05 (2H, t, J 5.7, H-4’), 3.83 (3H, s, 
OMe), 2.63 (1H, m, H-9), 2.34 (1H, m, proton of the DHA nucleus), 2.12 (1H, quint, J 7.2, 
H-2’), 1.99 (1H, m, proton of the DHA nucleus), 1.88-1.76 (3H, m, H-3’and a proton of the 
DHA nucleus), 1.75-1.13 (7H, m, protons of the DHA nucleus), 1.42 (3H, s, H-14), 0.90 (3H, 
d, J 5.7, H-16), 0.86 (3H, d, J 7.5, H-15); δC (100MHz, CDCl3) 188.7, 162.4, 161.6, 143.9, 
143.7, 131.6, 130.7(x2), 130.1(x2), 127.8, 122.4, 119.6, 114.4(x2), 114.2(x2), 104.1, 101.7, 
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24.5, 20.3, 13.0; HRMS(ESI) found m/z 674.3444 [M+H]
+
 for C38H47O8 requires 673.33632; 
Anal Calc. for C38H47O8: C, 67.74%; H, 7.03%; N, 6.24%. Found: C, 67.57%; H, 7.00%; N, 
6.11%; 
 
Compound 5.10  
 
Boron trifluoride etherate (5 drops) was added to a solution of 
dihydroartemisinin 1.15 (1.00 g, 3.54 mmol, 1 eq) and ethylene 
glycol (439.0 mg, 7.08 mmol, 2 eq) in 10 mL of anhydrous 
DCM at 0ºC. The resulting mixture was allowed to warm to 
25ºC and allowed to stir at this temperature for 19 hours. The 
product mixture was washed with saturated NaHCO3, water and brine. The organic layer was 
dried over anhydrous Na2SO4 and concentrated. Purification of the crude product using 
column chromatography (0-20% EtOAc:Hex) afforded the 10β-isomer as light green prisms 
(860.6 mg, 74%); m. p. 72-73°C; Rf (EtOAc:Hex 2:3) 0.4; IRνmax(KBr)/cm
-1
 3501 (OH); δH 
(400MHz, CDCl3) 5.39 (1H, s, H-12), 4.95 (1H, d, J 3.3, H-10), 4.29 (2H, d, J 2.4, H-1’), 
2.65 (1H, m, H-9), 2.41-1.20 (11H, m, protons of the DHA nucleus), 1.42 (3H, s, H-14), 0.93 
(3H, d, J 6.0, H-16), 0.91 (3H, d, J 7.2, H-15); δC (100MHz, CDCl3) 104.2, 102.6, 88.0, 81.0, 
70.7, 62.3, 52.5, 44.4, 37.4, 36.4, 34.6, 30.9, 26.1, 24.7, 24.6, 20.3, 13.0; HRMS(ESI) found 
m/z 351.1784 [M+Na]
+
for C17H28O6 requires 328.18859 
 
Compound 5.11  
 
To a solution of the alcohol 5.11 (643.7 mg, 1.96 mmol, 1 
eq) in anhydrous DCM (3 mL) at 0ºC under nitrogen was 
added Et3N (218.2 mg, 2.16 mmol, 1.1 eq) and 
methanesulfonylchloride (336.8 mg, 2.94 mmol, 1.5 eq). 
The resulting mixture was stirred for two hours at 0ºC. The 
reaction mixture was then quenched with water and extracted with DCM. The combine 
organic layer was dried over anhydrous MgSO4 and concentrated. The crude colourless 
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Compound 5.12 (EXP51D) 
 
The potassium salt of thiolactone 3.5 (140.0 mg, 0.768 
mmol, 1 eq) was added to a solution of 5.11 (375.0 mg, 
0.922 mmol, 1.2 eq) in anhydrous DMF (2 mL). The 
resulting mixture was stirred at 60ºC under a nitrogen 
atmosphere. Thin layer chromatography signalled the 
completion of the reaction after 20 hours whereupon 
water was added to the reaction mixture followed by extraction with ethyl acetate. The 
combined organic layer was washed with copious amounts of water to remove DMF before 
being dried over anhydrous MgSO4. Concentration in vacuo afforded the crude product 
which was subjected to column chromatography (5-40% EtOAc:Hex) to yield the pure 
product as a light yellow oil (175.5 mg, 49%); Rf (EtOAc:Hex 3:7) 0.28; δH (400MHz, 
CDCl3) 5.36 (1H, s, H-12), 4.80 (1H, d, J 3.2, H-10), 4.33-4.41 (2H, m, H-2’), 4.20 (1H, qd, 
J 1.2 and 6.8, H-5”), 4.10 (1H, m, H-1’a/b ), 3.66 (1H, m, H-1’a/b), 2.62 (1H, m, H-9), 2.34–
1.23 (11H, m, protons of the DHA nucleus), 1.79/1.80 (3H, d, J 1.2, H-7”), 1.56/1.58 (3H, d, 
J 6.8, H-6”), 1.40 (3H, s, H-14), 0.88 (3H, d, J 7.2, H-16), 0.86 (3H, d, J 7.6, H-15); δC 
(100MHz, CDCl3) 195.3 (195.5), 178.1, 114.7 (114.8), 104.1, 102.5 (102.6), 87.9, 80.8 
(80.9), 70.0 (70.2), 67.5 (67.6), 60.3, 52.5, 44.3, 41.4 (41.6), 37.5 (37.6), 36.4, 34.5, 30.7, 
26.1, 24.4 (24.7), 20.2 (20.3), 19.7 (19.8), 12.8 (12.9), 8.8 (8.9) Chemical shift values given 
in brackets represent those of the other diastereomer.  
 
4-Azido-7-chloroquine, 5.13  
 
Sodium azide (1.33 g, 20.5 mmol, 2.0 eq) was added to a solution of 
4,7-dichloroquinoline (2.00 g, 10. 1 mmol, 1.0 eq) in 3 mL of 
anhydrous DMF. The reaction mixture was stirred at 60ºC for 10 
hours. The addition of ice-cold water to the product mixture resulted in the formation of a 
precipitate which was filtered and washed with copious amounts of water. Recrystallization 
from hot DCM afforded the product as light green needles (1.90 g, 92%); m. p. 115-116ºC; 
Rf (EtOAc:Hex 1:4) 0.26; δH (400MHz, CDCl3) 7.09 (1H, d, J 5.2, H-3), 7.45 (1H, dd, J 2.0 
and 8.8, H-6), 7.96 (1H, d, J 8.8, H-5), 8.04 (1H, d, J 2.0, H-8), 8.80 (1H, d, J 5.2, H-2); δC 
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Compound 5.14 (EXP61C/08) 
 
Brown gel (258.2 mg, 50%); Rf (MeOH:DCM 1:19) 0.16; δH 
(300MHz, CDCl3) 9.03 (1H, d, J 4.5, H-2”), 8.21 (1H, d, J 
1.5, H-8”), 7.96 (1H, s, H-5’), 7.97 (1H, d, J 9.3, H-5”), 7.56 
(1H, dd, J 2.1 and 9.3, H-6”), 7.48 (1H, d, J 4.2, H-3”), 5.29 
(1H, s, H-12), 5.04 (1H, d, J 13.2, H-6’a/b), 4.97 (1H, d, J 4.5, 
H-10), 4.80 (1H, d, J 13.2, H-6’a/b), 2.52 (1H, m, H-9), 2.26-
1.19 (11H, m, protons of the DHA nucleus), 1.54 (3H, s, H-
14), 0.94 (3H, d, J 7.8, H-16), 0.84 (3H, d, J 6.3, H-15); δC 
(100MHz, CDCl3) 151.4, 150.2, 146.2, 141.0, 136.9, 129.4, 129.0, 124.6, 124.2, 120.7, 
116.0, 108.1, 99.8, 93.9, 84.1, 69.5, 61.7, 42.4, 40.7, 34.9, 34.7, 30.4(x2), 25.1, 21.0, 18.8, 
12.3; HRMS(ESI) found m/z 527.2083 [M+H]
+
 for C27H31ClN4O5 requires 526.1983; Anal 
Calc. for C27H31ClN4O5: C, 61.53%; H, 5.93%; N, 10.63%. Found: C, 61.03%; H, 5.34%; N, 
10.13% 
 
Compound 5.15 (Exp62A/08) 
 
Light green foam (199.9 mg, 45%); m. p. 122ºC; Rf 
(MeOH:DCM 1:19) 0.11; δH (400MHz, CDCl3) 9.27 (1H, s, 
H-3”’), 7.68 (1H, s, H-3’), 7.46 (1H, s, H-6”’), 6.24 (1H, br. 
s, H-1”’), 5.46 (1H, s, H-12), 4.93 (1H, br. s, H-10), 4.91 
(1H, d, J 12.8, H-1’a/b), 4.71 (1H, d, J 12.8, H-1’a/b), 4.43 
(1H, br. s, H-3”), 4.03 (1H, br. d, J 11.2, H-5”a/b), 3.81 
(1H, br. d, J 11.6, H-5”a/b), 3.57 (1H, br. s, OH), 3.00 (2H, 
br. s, H-2”), 2.65 (1H, m, H-9), 2.40-1.16 (11H, m, protons 
of the DHA nucleus), 1.93 (3H, s, H-7’”), 1.44 (3H, s, H-
14), 0.94 (3H, d, J 5.6, H-16), 0.90 (3H, d, J 7.2, H-15); δC 
(100MHz, CDCl3) 163.8, 150.5, 145.6, 137.9, 122.8, 111.3, 104.2, 102.1, 88.8, 88.0, 85.4, 
81.1, 61.8, 61.6, 59.3, 52.5, 44.4, 37.5, 37.4, 36.4, 34.6, 30.9, 26.1, 24.7, 24.5, 20.3, 12.3, 
12.4; HRMS(ESI) found m/z 590.2811 [M+H]
+
 for C28H39N5O9 requires 589.27478; Anal 
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7.4. Single Crystal X-ray Diffraction 
X-ray single crystal intensity data were collected on a Nonius Kappa-CCD diffractometer 
using graphite monochromated MoKα radiation. Temperature was controlled by an Oxford 
Cryostream cooling system (Oxford Cryostat). The strategy for the data collections was 
evaluated using the Bruker Nonius "Collect” program. Data were scaled and reduced using 
DENZO-SMN software.
3
 Absorption correction was made empirically by utilizing SADABS 
program.
4
 The structure was solved by direct methods and refined employing full-matrix 
least-squares with the program SHELXL-97
4
 refining on F
2
. Packing diagrams were 




7.5. Procedures for Biological Assays 
7.5.1. In vitro Antiplasmodial Assay: D10 strain of P. falciparum 
The test compounds were tested in duplicate against the chloroquine sensitive (CQS) strain 
of P. falciparum (D10). Continuous in vitro cultures of asexual erythrocyte stages of P. 
falciparum were maintained using a modified method of Trager and Jensen.
6
 Quantitative 
assessment of antiplasmodial activity in vitro was determined via the parasite lactate 




The compounds were prepared to a 2mg/ml stock solution in 10% DMSO or 10% methanol 
and were sonicated to enhance solubility. All compounds were tested as a suspension. Stock 
solutions were stored at -20ºC. Further dilutions were prepared on the day of the experiment. 
Chloroquine (CQ) was used as the reference drug in all experiments. A full dose-response 
was performed for all compounds to determine the concentration inhibiting 50% of parasite 
growth (IC50 – value). Test compounds were tested at a starting concentration of 100 µg/ml, 
which was then serially diluted 2-fold in complete medium to give 10 concentrations; with 
the lowest concentration being 0.2 µg/ml. The same dilution technique was used for all 
samples. CQ was tested at a starting concentration of 100 ng/ml. The highest concentration of 
solvent to which the parasites were exposed to, had no measurable effect on the parasite 
viability (data not shown). The IC50-values were obtained using a non-linear dose-response 
curve fitting analysis via Graph Pad Prism v.4.0 software. 
 
7.5.2. In vitro Antiplasmodial Assay: W2 strain of P. falciparum 
Ring stage, W2-strain P. falciparum parasites (1% parasitaemia, 2% haematocrit) were 
cultured in 0.5 mL of medium in 48-well culture dishes.
8
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DMSO were added to cultured parasites to give a final concentration of 20 µM. From 48-well 
plates, 125 µM of culture was transferred to two 96 well plates (duplicates). Serial dilutions 
(1:5) of inhibitors were made to final concentrations of 10 µM, 2 µM, 0.4 µM, 80 nM, 16 nM 
and 3.2 nM. Cultures were maintained at 37ºC for 2 days after which the parasites were 
washed and fixed with 1% formaldehyde in PBS. After two days, parasitaemia was measured 




7.5.3. Assay of Enzyme Inhibition: Falcipain-2 of P. falciparum 
IC50s against falcipain-2 were determined as described previously.
8
 Briefly, an equal amounts 
of recombinant falcipain-2 were incubated with different concentrations of inhibitors (added 
from 100x stocks in DMSO) in 100 mM sodium acetate (pH 5.5), –10 mM dithiothreitol for 
30 min at room temperature before addition of the substrate benzoxycarbonyl-Leu-Arg-7-
amino-4-methyl-coumarin (final concentration = 25 µM). Fluorescence was continuously 
monitored for 30 min at room temperature in a labsystem Fluoroskan
®
 II spectrofluorometer. 
IC50s were determined from plots of activity over enzyme concentration with GraphPrism 
software. 
 
7.5.4. BACTEC Assay: H37Rv strain of M. tuberculosis  
All work was carried out in the Biosafety Level 3 laboratory of the Division of Molecular 
Biology and Human Genetics of the University of Stellenbosch. A clinical isolate of M. 
tuberculosis was selected from a bank of genetically well-characterized (according to their 
IS6110 fingerprint profile) strains located in the Division of Molecular Biology and Human 
Genetics of the University of Stellenbosch for the evaluations.
9
 The strain was drug sensitive 
to isoniazid and rifampicin. Compounds to be tested for antimycobacterial activity were 
filtered and sterilized through 0.22 micron syringe filters (millex LG). The M. tuberculosis 
clinical isolate was grown on Lowenstein-Jensen culture medium for 4 weeks.
10
 After 
incubation at 37ºC, bacteria were collected, suspended in 7H9 mycobacterial growth medium 
(Middlebrook) and the bacterial suspension added to a BACTEC vial containing BACTEC 
12B growth medium (Becton Dickinson, USA). Growth was monitored every 24 hours until 
a growth index (GI) value of 500 was reached. From this culture, 0.1 mL was added to a new 
BACTEC vial and the growth monitored every 24 hours until a GI value of 500 was 
reached.
11
 This culture was the primary culture and was used for testing bacterial viability 
against a variety of inhibitors. The test compound was disssolved in DMSO and 0.1ml of this 
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10.0µg/ml. BACTEC vials were incubated at 37ºC and the growth index (GI) was monitored 
every 24 hours in a BACTEC 460TB system. A growth index below 10 was considered as 
negative growth and above 10 as positive growth. The growth index of the treated samples, 
were compared to a control culture containing sterile DMSO. 
 
7.5.5. MABA Assay: H37Rv strain of M. tuberculosis 
In brief, the MICs of the test compounds were determined by the microplate Alamar blue 
assay (MABA).
12
 Stock solutions were prepared in DMSO at a final concentration of 12.8 
mM and the final testing concentrations ranged from 128 to 0.5 µM. M. tuberculosis H37Rv 
(ATCC 27294, Rockville, Md.) was grown to late log phase (70 to 100 Klett units) in a 
Middlebrook 7H9 broth supplemented with 0.2% v/v glycerol, 0.05% Tween 80 and 10% v/v 
oleic acid-albumin-dextrose-catalase. Cultures were centrifuged for 15 min at 4ºC at 3.150 x 
g, washed twice and resuspended in phosphate-buffered saline. Suspensions were then passed 
through an 8 µm-pore-size filter to remove clumps and aliquots were frozen at -80ºC. The 
number of CFU was determined by plating on 7H11 agar plates. Two-fold dilutions of 
compounds were prepared in Middlebrook 7H12 medium (7H9 broth containing 0.1% w/v 
casitone, 5.6 µg/mL palmitic acid, 5 mg/mL bovine serum albumin and 4 mg/mL catalase, 
filter-sterilized) in a volume of 100 µL in 96-well, black, clear-bottom microplates (BD 
Bioscience, Franklin Lakes, N.J.). M. tuberculosis H37Rv (100 µL inoculum of 2 x 10
4
 CFU) 
was added, yielding a final testing volume of 200 µL. The plates were incubated at 37ºC. On 
the 7
th
 day of incubation 12.5 µL of 20% Tween 80 and 20 µL of Alamar blue were added to 
all wells. After incubation at 37ºC for 16-24 hours, fluorescence of the wells was measured at 
an excitation of 530 nm and emission of 590 nm. The MICs were defined as the lowest 
concentration effecting a reduction in fluorescence of ≥90% relative to the mean of replicate 
bacteria-only controls. 
 
7.5.6. LORA Assay: H37Rv strain of M. tuberculosis 
Recombinant H37Rv (pFCA-luxAB) was grown to NRP phase 2 in 300 mL Dubos Tweem 
albumin broth (Becton Dickson) in a BiostatQ fermentor (B. Braun Biotech) to mimic the 
Wayne oxygen-limited culture with a headspace ratio of 0.5. The culture was agitated at a stir 
rate of 120 rpm with no detectable perturbation of the surface medium.
13
 The fermentor 
culture was operated and maintained within a biosafety level 3 laboratory. The dissolved 
oxygen concentration (DOC) was continuously monitored with an Ingold oxygen sensor 
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light units (RLUs) and the CFU levels were determined at 3-day intervals. Bacterial samples 
were removed through a silicone septum with a syringe in order to preclude the introduction 
of oxygen. The number of CFU was estimated by plating dilutions of aliquots on Dubos 
oleic-albumin agar plates in triplicate and incubating the cultures at 37ºC. The colonies were 
enumerated every week for 5 weeks. The cells were harvested on the 22
nd
 day, i.e. a time 
when the A570 and DOC readings indicated achievement of the desired growth phase (NRP-
2). Fifty millilitre aliquots of bacterial culture samples were centrifuged (2.700 x g, 30 min, 
4ºC), washed once with prechilled phosphate-buffered saline (PBS: pH 7.4) suspended in 1 
mL of PBS and stored at -80ºC.  
 
Prior to use, the cultures were thawed, diluted in Middlebrook 7H12 broth and sonicated for 
15s. The cultures were diluted to obtain an A570 of 0.03-0.05 and 3000-7000 RLUs per 100 




 CFU/mL. Two-fold serial dilution of test compounds 
were prepared in a volume 100 µL in black 96-well microtiter plates and 100 µL of the cell 
suspension was added. The microplate cultures were placed under anaerobic conditions by 
using an Anoxomat model WS-8080 (MART Microbiology) and three cycles of evacuation 
and filling with a mixture of 10% H2, 5% CO2 and the balance N2 (7.32). An anaerobic 
indicator strip was placed inside the chamber to visually confirm the removal of oxygen. The 
plates were incubated at 37ºC for 10 days and then transferred to an ambient gaseous 
condition (5% CO2-enriched air) incubator for a 28 h “recovery”. Luminescence readings 
were obtained following the 28 h aerobic recovery. The data were analyzed graphically and 
the lowest concentration of test compound preventing metabolic recovery (90% reduction 
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